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Abstract  
Early onset retinal dystrophies (EORD) are a group of disorders presenting in 
childhood with degenerative abnormalities in photoreceptor cells. They are one of the 
leading causes of sight impairment in the United Kingdom. Since the initial discovery of 
Rho causing dominant retinitis pigmentosa in 1990, more than 160 genes have been 
associated with retinal dystrophy. Many, including CRB1, CRX, and RPE65 exhibit 
phenotypic heterogeneity and have been associated with more than one retinal 
disorder. Increasingly, with the advent of next generation sequencing, the association 
of non-syndromic retinal dystrophy with mutations in syndromic genes has been 
reported including CEP290, CLN3, and BBS1.  
In this thesis, a large cohort of patients with EORD underwent both detailed 
phenotyping to characterise their condition and molecular genetic investigations to 
identify and investigate the underlying causative variants. Many areas of the presented 
research were driven by novel findings on whole-exome sequencing such as the 
association of IFT140 with non-syndromic retinal dystrophy or CRX with macular 
dystrophy. Other areas were driven by unusual groups of patients with limited 
published data on their condition such as COL18A1 and Knobloch syndrome, with 
novel phenotypic features of cone-rod dysfunction and pigmentary glaucoma. Sanger 
sequencing was performed for confirmation and segregation of identified variants but in 
addition, for investigation of phenotypically similar patient panels for unusual gene 
associations. This included systemically mild Hermansky-Pudlak syndrome due to 
HPS6, juvenile macular dystrophy and CDH3, macular dystrophy and CRX and 
microcephaly with familial exudative vitreoretinopathy due to LRP5. Functional 
investigation of missense variants in IFT140 related retinal dystrophy was performed 
with transient cell transfection. This thesis highlights the vast heterogeneity of rare 
forms of EORD, presents novel clinical and molecular data and describes the key 
features of conditions to aid diagnosis and opportunities for future research. 
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1 Introduction 
Early-onset retinal dystrophies (EORD) are inherited disorders presenting in childhood 
with visual impairment due to degenerative abnormalities of photoreceptors. EORD is 
an important cause of visual impairment registration in the United Kingdom.1 The 
reported prevalence of both isolated and syndromic retinal dystrophy in children from a 
Danish population study was 13 in 100,000 with the majority of affected patients having 
Leber congenital amaurosis (LCA) or rod-cone dystrophy (RCD).2  Approximately 57% 
of cases are non-syndromic with the most common syndromic cause being Usher 
syndrome in which RCD and sensorineural hearing impairment coincide.2 Prevalence 
and genetic aetiology vary geographically with more isolated or consanguineous 
communities demonstrating a greater burden of disease.3  
Since the initial discovery of Rho causing dominant RCD in 1990, more than 160 genes 
have been associated with retinal dystrophy.4, 5 Many, including CRB1, CRX, GUCY2D 
and RPE65 exhibit phenotypic heterogeneity and have been associated with more than 
one retinal disorder.6-9 Increasingly, with the advent of next generation sequencing 
(NGS), the association of non-syndromic retinal dystrophy with mutations in syndromic 
genes has been reported including CEP290, CLN3, and BBS1.10-12 This clinical and 
molecular heterogeneity presents a diagnostic challenge. 
NGS techniques including whole-exome screening (WES), allow parallel screening of 
multiple genes. Approximately 55% of non-syndromic retinal dystrophies and 80% of 
syndromic retinal dystrophies can achieve molecular diagnosis by WES.13-15 The 
remaining unsolved cases can be explained by missed variants on exome due to poor 
coverage, for instance the ORF15 region of RPGR, variants assumed to be non-
pathogenic but in fact important for splicing, novel genes, copy number variants and 
non-coding region variants.10 These non-coding region variants can arise within 
promoters such as the locus control region of opsin genes and within introns creating 
alternate splice sites such as the common intronic variant in CEP290 related disease, 
c.2991+1655A>G.12, 16, 17 Whole genome sequencing (WGS), has better coverage of 
regions that may not be covered well in WES.15 In addition, WGS will help identify copy 
number variants and non-coding region variants that may be responsible for disease.18 
Ultimately, combined approaches with WGS and RNA analysis may be needed to 
solve undiagnosed cases. 
Introduction 
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1.1 The neurosensory retina 
The neuroretina is the light sensitive structure within the eye responsible for 
transducing photons of incident light in to electrical signals to be interpreted by the 
brain as images. Light enters the eye through the cornea, aqueous humour, pupillary 
aperture of the iris, lens and vitreous humour, with the cornea and lens the refractive 
structures that focus the light on to the retina. The laminated neuroretina comprises 
multiple different cell types to interpret and perform initial processing of these signals 
supported by the underlying retinal pigment epithelium (RPE, figure 1-1). 
 
Figure 1-1: Retinal layers 
Layers of the retina with superimposed basic cone photoreceptor cell circuitry (adapted from 
Fariss 2000
19
 and Busskamp 2010
20
). RPE, retinal pigment epithelium; OS, outer segment; 
ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner 
plexiform layer; GCL, ganglion cell layer; cPR, cone photoreceptor; ON and OFF bipolar cells in 
the INL and GCL layers. Scale bar 20µm. 
The neurosensory retina comprises 6 broad types of neural cells, rod and cone 
photoreceptors, bipolar, horizontal, amacrine and ganglion cells as well as one main 
type of glial cell, the Müller glial cell. There are actually more than 60 diverse sub-types 
of neural cells reflecting the complex processing of the retina.21 Rod and cone 
photoreceptors comprise an inner segment containing the cell body, a connecting 
cilium and an outer segment. The outer segments are highly modified, photosensitive 
cilia, containing the membranous discs for phototransduction. They lack any capability 
Introduction 
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for protein production and rely on the intraflagellar transport (IFT) system, which 
comprises large protein complexes for transport from the cell body to cilium tip and 
back.22 23 There are an estimated one thousand stacked discs in the rod outer segment 
which are discrete from the plasma membrane and extracellular space, whereas in the 
cone outer segment there are a series of membrane evaginations exposed to the 
extracellular space.24 Ten percent of the discs in rods undergo distal shedding and 
phagocytosis by the RPE at daily onset of light, whilst new discs are formed at the 
base of the outer segment with an analogous process occurring in the cone outer 
segment.24, 25 There are approximately 4.6 million cones which comprise 3 types, long-
wavelength sensitive (L), medium-wavelength sensitive (M) and short-wavelength 
sensitive (S).26 Colour vision arises from two cone-opponent systems, the red-green 
system from compared responses between L- and M-cones and the blue-yellow 
system in which S-cone responses are compared to a combined L- and M-cone 
response.27 There are 92 million rod photoreceptors with the highest density in a ring at 
the eccentricity of the optic disc and an absence of rods from the central fovea which is 
populated exclusively by cones.26 Photoreceptor outer segments interdigitate with the 
underlying RPE, their cell bodies are located in the outer nuclear layer and their axonal 
processes form synapses in the outer plexiform layer with bipolar and horizontal cells.                                    
There are approximately 12 types of bipolar cell, 11 of which are cone specific and 
each connect to multiple cone photoreceptors.21 Responses can be broadly classified 
in to ON and OFF channels which respond differently to light input and synapse with 
ganglion ON and OFF bipolar cells directly or via amacrine cells.21 Rod photoreceptors 
synapse with rod bipolar cells and then to amacrine cells. Amacrine cells, of which 
there are approximately 30 types, act as modifiers of bipolar and ganglion cell 
responses. The axonal processes of ganglion cells radiate across the retina, become 
the optic nerve, and then decussate in the optic chiasm before synapsing 
predominantly in the lateral geniculate nucleus. An additional photosensitive pigment, 
melanopsin also known as opsin 4, is found within a small subset of intrinsically 
photosensitive retinal ganglion cells with non-visual roles in circadian rhythm and the 
pupillary light reflex.28 The major target of intrinsically photosensitive retinal ganglion 
cells is the suprachiasmatic nuclei, in which the main circadian clock in mammals is 
found.29  
The main non-neuronal cell of the retina, the Müller glia extend from the 
photoreceptors to the inner limiting membrane and have roles in retinal development, 
the visual cycle of cones and retinal neuron cell metabolism.30, 31 There are outer and 
inner plexi of retinal vessels throughout the retina except for a central foveal avascular 
zone of approximate diameter 450µm, essential for clear vision by reducing light 
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scatter due to blood vessels.32 The RPE comprises a single pigmented layer of cells 
essential in retinal metabolism and retinal structure. Underneath the RPE lies the 
choroid comprising Bruch’s membrane, a capillary network, the choriocapillaris and the 
large choroidal vessels.  
1.1.1 Retinal development 
Multi-potential retinal progenitor cells can form any of the 6 retinal neurons or 1 retinal 
glial cell dependent on the temporal and spatial expression of transcription factors 
including PAX6, SOX2 and VSX2.33, 34 Ganglion cells are the initial cell type to appear. 
In humans, differentiation arises first in the fovea with the peripheral retina laminated 
by week 30 of gestation.35 The foveal pit is created by displacement of inner retinal 
layers out of the centre. Photoreceptor maturation, in particular the lengthening of outer 
segments, continues after birth, is initially most developed in non-foveal regions and 
continues up until the age of approximately 13 years.36 In addition, the ONL thickens in 
the fovea from approximately 3 weeks of age onwards due to central cone packing. 
This developmental process has implications on visual function, with infants having 
poor central vision.  
Retinal vasculogenesis begins in the inner retina at the optic nerve head and radiates 
outwards, reaching the peripheral retina just before birth.32 The deeper retinal capillary 
networks arise by angiogenic sprouting from the inner retinal vessels. The process is 
regulated by pro and inhibitory angiogenic factors such as vascular endothelial growth 
factor (VEGF). Components of the Wnt signalling pathway, including FZD4, Norrin and 
LRP5 are central regulators of vascular endothelial cell development and are essential 
for normal retinal vascular growth and organisation.37 
1.1.2 Phototransduction and the visual cycle 
Phototransduction is the process by which a photon of light is absorbed by light 
sensitive pigment in rods (rhodopsin) and cones (cone opsins) and converted in to an 
electrical signal (figure 1-2). Rhodopsin and the cone opsins comprise an opsin protein 
covalently bound to a light sensitive chromophore, 11-cis-retinaldehyde.38 Upon light 
stimulation, this is isomerised to all-trans-retinaldehyde which induces conformational 
changes within the protein to an activated state.38 The activated opsin binds to a G-
protein, transducin, with subsequent activation of cGMP phosphodiesterase (PDE) 
resulting in decreased cGMP concentration and a consequent decrease of intra-discal 
calcium concentration by closure of cation gated channels. Reduced calcium leads to 
hyperpolarisation of the membrane forming the basis of generation of an electrical 
signal from a photon of light. Opsins are inactivated by phosphorylation and arrestin 
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binding. Restoration to the dark-adapted state relies on the function of guanylate 
cyclase to restore cGMP levels and re-open the cGMP gated cation channels. 
Recycling of chromophores to regenerate 11-cis-retinaldehyde is an enzymatic process 
known as the visual cycle and arises in the RPE (figure 1-2).38 All-trans-retinal diffuses 
from the disc membrane in to the cytoplasm or is transported via the transmembrane 
ATP-binding cassette, subfamily A, member 4 (ABCA4) in to the cytoplasm where it is 
reduced to all-trans-retinol by retinal dehydrogenases (RDH) including RDH12.39 It then 
diffuses bound to binding proteins including interstitial retinol-binding protein (IRBP) in 
to the RPE where lecithin retinol acyltransferase (LRAT) esterification forms fatty acid 
retinal esters. The esters undergo isomerisation by retinal pigment epithelium-specific 
protein, 65kDa (RPE65) to form 11-cis-retinol which is oxidised to the 11-cis-retinal 
form by 11-cis-RDHs including RDH5.40-42 The 11-cis-retinal diffuses back in to the 
outer segment again bound to IRBP to reform the stable opsin (or rhodopsin) pigment.  
Mutations in genes encoding the key proteins involved in phototransduction and the 
visual cycle are associated with a range of inherited retinal dystrophies. This includes 
GUCY2D related LCA, RPE65 related LCA and RCD, LRAT related LCA, RDH5 
related fundus albipunctatus, RBP3 (encoding IRBP) related retinal dystrophy, RDH12 
related LCA, ABCA4 related cone-rod dystrophy (CORD) and macular dystrophy (MD) 
and achromatopsia due to mutations in cone specific phototransduction genes GNAT2, 
PDE6C, CNGA3, CNGB3 and PDE6H .43-50 
There is an alternative cone-specific second pathway present in Müller cells in which 
11-cis-retinol is generated which cones but not rods can use to regenerate their 
chromophores.31 The enzyme that catalyses the production of 11-cis-retinol is thought 
to be multifunctional O-acyltransferase (MFAT).31 
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Figure 1-2: Schematic representation of transduction and the visual cycle 
Image based on Palczewski 2014.
38
 Opsin in the outer segment disc membrane is activated by 
a photon of light. All-trans-retinal is converted in the photoreceptor cytoplasm to all-trans-retinol 
by all-trans retinal dehydrogenase (atRDH). This is transported by IRBP in to the RPE where 
LRAT converts it to all-trans-retinyl esters. RPE65 isomerises this to 11-cis-retinol, RDH5 
dehydrogenases this to 11-cis-retinal which IRBP transports back in to the photoreceptor outer 
segment for re-association with opsin.  
1.2 Clinical assessment 
Assessment of visual function and examination of ocular pathology are readily 
achieved in the clinical setting. Visual acuity, colour vision and fields are objective 
measurements of visual deficit. Slit lamp biomicroscopy through a dilated pupil permits 
direct visualisation of fundus changes which may be more apparent on retinal imaging. 
1.2.1 Visual function 
Visual acuity is a measurement of the ability to discriminate 2 points at a distance. The 
greatest acuity is found in the central fovea where the resolving power can reach 14 
seconds of arc, greater than the angle subtended by a single cone partly due to 
complex retinal neuron processing and higher cortical processing.51 In infancy, visual 
acuity is reduced due to a lack of foveal maturation with foveal cone density rapidly 
increasing over the first 8 months of life.52 In addition, infants are hypermetropic due to 
the relatively small eyeball size with the process of emmetropisation occurring as the 
eye grows. High refractive errors are frequently found in retinal dystrophies possibly 
reflecting abnormal emmetropisation due to reduced vision.53 
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Methods for assessing visual acuity are dependent on age and the presence of 
developmental delay. Optotypes are standardised pictures or letters for testing vision 
that represent the minimum distance between 2 points that the average person can 
resolve, specifically 1 minute of arc which is the thickness of the lines used in each 
optotype when viewed at a fixed distance.54  
In infants, forced-choice preferential looking cards are used which have a black and 
white grating pattern.52 The Cardiff acuity test, employ a similar preferential looking 
system but with vanishing optotypes using recognisable shapes such as a fish or a 
ship and are used from 6 months up to 2 years of age (figure 1-3). Once children are 
verbal and able to recognise pictures, usually from the age of 2 years, Kay pictures are 
used of varying size to represent specific visual acuity levels.55 Once able to read, 
Snellen or logarithm of the Minimum Angle of Resolution (logMAR) visual acuity charts 
are used with decreasing sizes of optotypes. Patients are tested uniocularly with 
refractive correction and additionally with a pinhole. Snellen charts have a number of 
limitations including non-uniform progression in letter size and a different number of 
letters per line, the logMAR chart is more accurate in this regard.56 Within this thesis, 
variable methods of visual acuity measurements over time were frequently found. To 
enable comparison, all acuities were converted between Snellen and logMAR using a 
conversion table (table 1-1). 
 
Figure 1-3: Examples of visual acuity tests 
Adapted from www.kaypictures.co.uk and www.haagstreituk.com. From left to right; the Cardiff 
acuity test, Kay picture test, logMAR chart. 
Colour vision is routinely tested with either the Ishihara or Hardy-Rand-Rittler (HRR) 
tests, which are both pseudoisochromatic. The latter is the most accurate in identifying 
colour defects consistent with cone abnormalities as it tests all 3 components of colour 
vision including tritan function and can be performed in young children.57 Reduced 
visual acuity can limit testing but only once worse than 0.72 logMAR for Ishihara plates 
and 1.10 logMAR for HRR plates.58 
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Snellen visual acuity log MAR visual acuity 
6/3.8 -0.2 
6/4.8 -0.1 
6/6 0.0 
6/7.5 0.1 
6/9 0.18 
6/9.5 0.20 
6/12 0.3 
6/15 0.4 
6/18 0.48 
6/19 0.50 
6/24 0.60 
6/30 0.70 
6/38 0.80 
6/48 0.90 
6/60 1.00 
6/75 1.10 
6/90 1.18 
6/95 1.20 
6/120 1.30 
6/150 1.40 
6/190 1.50 
6/240 1.60 
6/600 2.00 
Table 1-1: Conversion between Snellen and logMAR visual acuity 
Adapted from Gregori 2010
59
 
Visual field testing permits an assessment of central regions of missing vision 
(scotomas) or of peripheral field defects. Visual fields to confrontation are also used as 
a rapid screening method for deficits. Formal visual fields are an objective method for 
monitoring progression over time and in addition are used to assess eligibility to drive. 
Within the clinic two main types of testing are used; the first a type of kinetic uniocular 
visual field (Goldmann, Haag Streit, Bern, Switzerland) with a moving stimulus of 
varying brightness and size; the second with a static stimulus using the Humphrey 
Field Analyzer II (Carl Zeiss Meditec AG, Oberkochen, Germany) to produce uniocular 
Humphrey 24-2 and 30-2 threshold visual fields or suprathreshold binocular (driving) 
Esterman visual fields. Goldmann visual field defects have been shown to correlate 
with wide-field autofluorescence imaging defects in patients with retinal dystrophy.60 
1.2.2 Ophthalmoscopy and retinal imaging 
Binocular biomicroscopy with a slit lamp permits a stereoscopic, magnified examination 
of the eye with a double aspheric high-power positive lens used to focus on the fundus. 
Colour fundus photography allows accurate documentation of fundus changes and can 
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be performed in cooperative young children with a variety of cameras as described in 
methods. Particularly useful in the assessment of retinal dystrophy patients are fundus 
autofluorescence (FAF) imaging and optical coherence tomography (OCT). FAF can 
demonstrate areas of retinal dysfunction or atrophy not necessarily apparent on colour 
images. OCT provides a high resolution cross-sectional image of the retinal layers to 
allow quantifiable assessment of any changes in thickness or atrophy, as well as any 
intraretinal cystoid macular oedema, a frequent complication of RCD.61 These imaging 
techniques are further described in methods. 
1.3 Molecular genetics 
The human mitochondrial genome was first deciphered in 1981 but it was only in 2004 
that a near complete human nuclear genome was published.62, 63 The Human Genome 
Project involved more than 20 groups across 6 countries from 1990 to 2004 at an 
estimated cost of 3 billion dollars.64 Approximately 99% of the 3.1 gigabase genome 
was covered with the remainder consisting mainly of heterochromatin, a permanently 
condensed, transcriptionally inactive and highly repetitive DNA that is particularly 
challenging to sequence.65 With the development of new sequencing technologies, the 
cost of a whole genome is now available for less than £1000.64 
The emergence of new sequencing technology has greatly changed the approach to 
the molecular investigation of patients with parallel sequencing of multiple copies of 
fragmented DNA allowing a rapid and cost-effective approach to investigation. 
Previously Sanger sequencing of candidate genes, linkage analysis and arrayed primer 
extension (APEX) microarray screening were the only investigative options. 
Subsequently, NGS became routinely available with a large number of patients 
investigated by gene panels (Manchester Centre for Genomic Medicine), WES and 
WGS. In the research setting, we have performed WES on >100 patients with EORD. 
We have been able to recruit patients in to national research projects employing NGS 
techniques thus providing a funded route for investigating patients. This has included 
the National Institute for Health Research (NIHR) BioResource funded Specialist 
Pathology: Evaluating Exomes in Diagnostics (SPEED) study based at the Cambridge 
Biomedical Centre to which >500 patients have been contributed from Moorfields. 
Initially WES was performed but the majority of patients have undergone WGS as the 
cost difference became minimal. A second project to which large numbers of patients 
are being recruited is the 100,000 Genomes Project. This was devised in 2012 to 
sequence 100,000 whole genomes from 70,000 people with rare diseases and cancer 
with the aim of driving research, developing a genomic medicine service for the NHS 
and improving diagnosis and treatment (www.genomicsengland.co.uk). I was involved 
in running the pilot phase of this project in November 2013. 
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Within this thesis, patients have been molecularly solved by a variety of methods 
including Sanger sequencing, a tool which still provides a rapid and cheap screening 
approach for panels of unsolved patients and for confirmation of variants found by 
other methods. 
1.3.1 Mendelian inheritance 
The approach to the investigation of the majority of EORD patients relies on the 
assumption of Mendelian or monogenic inheritance in which an alteration in the genetic 
code at a single locus leads to an abnormal phenotypic expression. A trait or condition 
that follows Mendelian inheritance may demonstrate a recognisable pedigree pattern to 
determine likely inheritance. There are a number of caveats to this. An autosomal 
dominant pedigree may not be apparent if there is variable expressivity or de novo 
disease, features found in CRX related retinal dystrophy, or if there is variable 
penetrance as found in PRPF31 related RCD (figure 1-4).7, 66 In autosomal recessive 
inheritance, a pedigree may appear pseudo-dominant if the condition is common in the 
population or if there is extended consanguinity within the family. X-linked dominant 
disease may resemble a dominant pedigree except that there can be no male to male 
transmission. The pedigree may resemble that of mitochondrial inheritance with only 
female transmission possible but both males and females affected. If the condition is 
fatal in utero to males then only females within the pedigree will be affected as typically 
found in conditions such as incontinentia pigmenti.67 In X-linked recessive disease, 
there is also no male to male transmission and in theory only males should be affected. 
However, female carriers can have phenotypic manifestations of disease due to 
skewed X-inactivation. This is apparent in conditions such as X-linked RCD.68 
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Figure 1-4: Pedigree examples 
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1.4 Types of retinal dystrophy 
1.4.1 Leber congenital amaurosis 
At the most severe end of the spectrum is Leber Congenital Amaurosis (LCA, MIM# 
204000), a clinically and genetically heterogeneous condition characterised by onset at 
birth or in infancy, nystagmus and an absence of photoreceptor responses on ERG.69 It 
was first described by Theodore Leber a German Ophthalmologist in 1869.70 It 
accounts for at least 5% of all retinal dystrophies and 20% of children attending 
schools for the visually impaired with an estimated incidence of 1 in 81000 to 1 in 
30000 live births.71 LCA may be isolated to ocular involvement or arise as part of a 
syndrome. The prognosis depends on the underlying genetic defect. For instance, 
patients with RPE65 related disease have a better prognosis than GUCY2D.69, 72 
In LCA, at least 17 genes have been identified to date. All are recessively inherited 
apart from CRX which is predominantly dominant with a high rate of de novo mutations 
and 3 reports of sporadic heterozygous IMPDH1 related LCA.73-75 Disease manifests 
by variable mechanisms (table 1-2). The regulation of phototransduction by intracellular 
cGMP is abnormal in LCA due to mutations in GUCY2D which encodes a membrane 
bound guanylate cyclase in photoreceptor outer segments.50 Phototransduction is also 
affected by mutations in RPE65, RDH12 and LRAT which encode enzymes essential in 
the retinol metabolism pathway.43, 45, 76 Abnormal photoreceptor development and 
survival arises in CRX related disease.77 Abnormal cilia metabolism or protein 
trafficking is found in AIPL1, LCA5, RPGRIP1, CEP290, SPATA7, TULP1, RD3 and 
IQCB1 disease.12, 78-85 Abnormal function of the RPE inwardly rectifying potassium 
channel Kir7.1 is found in KCNJ13 related disease leading to an abnormal membrane 
resting potential.86 Mutations in IMPDH1 may be pathogenic by impairing regulation of 
translation at polyribosomes.87 
Patients with LCA present with profound visual loss from birth or within the first few 
months of life, with a typical final visual acuity of 3/60 Snellen to perception of light.69, 72 
Other features include pendular nystagmus, roving eye movements, sluggish or absent 
pupillary responses, high refractive error and the oculodigital sign where repetitive eye 
poking leads to loss of orbital fat, enophthalmos and eventually cataract and 
keratoconus. Photoattraction may be noted and conversely, although less commonly 
photodysphoria (extreme photophobia), a feature of GUCY2D related disease.72 Of 
note, visual function (acuity and fields) can vary significantly between visits and this is 
of particular relevance when considering clinical trials as the inter-test variability needs 
to be taken in to account.88  
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Pheno-
type, 
MIM # 
Gene 
symbol, 
MIM 
Chromo
somal 
locus 
Protein name (and 
function) 
Key defining clinical 
features 
First 
published 
LCA1 
204000 
GUCY2D 
600179 
17p13.1 Guanylate cyclase 2D 
(hydrolysis cGMP) 
Very poor vision, severe 
photoaversion, normal 
fundus early on 
Perrault 
1996
50
 
LCA2 
204100 
RPE65 
180069 
1p31.3-
1p31.2 
Retinoid isomerohydrolase 
(phototransduction) 
Relatively good early vision 
early on, featureless fundus, 
low autofluorescence 
Marlhens 
1997
43
 
LCA3 
604232 
SPATA7 
609868 
14q31.3 Spermatogenesis-associated 
protein 7 (cilial protein 
trafficking) 
Retinal atrophy, attenuated 
vessels 
Wang 2009
89
 
LCA4 
604393 
AIPL1 
604392 
17p13.2 Aryl-hydrocarbon-interacting 
protein-like 1 (PDE6 
chaperone) 
Atrophic maculopathy, 
severe early visual loss 
Sohocki 
2000
90
 
LCA5 
604537 
LCA5 
611408 
6q14.1 Lebercilin 
(cilial transport) 
Macula dysplasia/atrophy den 
Hollander 
2007
78
 
LCA6 
613826 
RPGRIP1 
605446 
14q11.2 Retinitis pigmentosa GTPase 
regulator-interacting protein 
(cilial transport) 
Severe vision loss, initial 
normal fundus progresses to 
pigmentary retinopathy 
Dryja 2001
79
 
LCA7 
613829 
CRX 
602225 
19q13.33 Cone-rod homeobox protein 
(photoreceptor development 
and survival) 
Severe vision loss, macula 
atrophy, AD or sporadic 
Freund 
1998
77
 
LCA8 
613835 
CRB1 
604210 
1q31.3 Crumbs homolog 1 
(Müller cell photoreceptor 
interaction and 
photoreceptor cell structure) 
Nummular pigmentation, 
para-arteriolar RPE sparing, 
thickened and disorganised 
retina, Coat’s like response 
Lotery 
2001
91
 
LCA9 
608553 
NMNAT1 
608700 
1p36.22 Nicotinomide 
mononucleotide 
adenylytransferases 1 
(NAD+ biosynthesis and 
neuroprotection) 
Atrophic macular lesions Falk 
92
 
Perrault 
93
, 
Chiang 
94
, 
Koenekoop 
95
, all 2012 
LCA10 
611755 
CEP290 
610142 
12q21.32 Centrosomal protein of 290 
kDa (cilial transport) 
Minimal fundus abnormalities 
in infancy 
den 
Hollander 
2006
12
 
LCA11 
146690 
IMPDH1 
146690 
7q32.1 Inosine-5’-monophosphate 
dehydrogenase 1 (guanine 
synthesis and translation 
regulation) 
Diffuse RPE mottling, no 
pigmentary deposits 
Bowne 
2006
74
 
LCA12
610612 
RD3 
180040 
1q32.3 Protein RD3 (trafficking of 
guanylate cyclase 1) 
Atrophic macular lesion Friedman 
2006
96
 
LCA13
612712 
RDH12 
608830 
14q24.1 Retinol dehydrogenase 12 
(phototransduction) 
Bone spicule pigmentation 
and maculopathy, may get 
Coats like response 
Janecke 
2004
76
 
LCA14 
613341 
LRAT 
604863 
4q32.1 Lecithin retinal 
acyltransferase 
(phototransduction) 
Low autofluorescence Thompson 
2001
45
 
LCA15 
613843 
TULP1 
602280 
6p21.31 Tubby-related protein 1 
(cilial transport) 
Pigmentary retinopathy, 
reading vision in early stages 
Hagstrom 
1998 
97
 
Banerjee 
1998
98
 
LCA16 
614186 
KCNJ13 
603208 
2q37.1 Inward rectifier potassium 
channel 13 (RPE potassium 
channel) 
Early poor vision, gradual 
progression, posterior pole 
dense nummular RPE 
pigmentation  
Sergouniotis 
2011
86
 
SLSN5 
609254 
IQCB1 
609237 
3q13.33 IQ motif-containing protein 
B1 (ciliary protein) 
Relatively preserved central 
RPE and photoreceptors, 
peripheral granular RPE 
change 
Estrada-
Cuzcano 
2011
85
 
Stone 2011
84
 
Table 1-2: Reported LCA genes, protein function and key features 
SLSN5, Senior-Loken syndrome 5 
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The fundus appearance may initially be normal or show macular atrophic change with 
a pigmentary retinopathy tending to develop over time. Other reported changes include 
disc pallor, vessel attenuation, optic disc drusen, optic disc oedema, flecked retina and 
nummular pigmentation. Fundus appearances vary by genetic cause (table 1-2). 
Fundus imaging may be limited in LCA from poor fixation due to young age, low vision, 
nystagmus or photophobia or poor image quality from nystagmus. Imaging as part of 
an examination under anaesthesia can be achieved using handheld instruments for 
fundus photography, FAF imaging and OCT. FAF imaging may be normal in LCA, or 
more commonly show a ring of increased autofluorescence parafoveally indicating 
abnormal accumulation of lipofuscin in the post mitotic RPE cell, with reduced 
autofluorescence around the arcades indicating RPE atrophy.99, 100 In RPE65 related 
disease, the fundus appearance is usually normal in childhood but the FAF is 
universally severely reduced throughout the retina due to a lack of lipofuscin production 
from abnormal retinol metabolism.101 Patients with LCA, poor vision and undetectable 
ERG may still have normal or minimally decreased autofluorescence. This suggests 
that the RPE–photoreceptor complex is, at least in part, functionally and anatomically 
intact. This finding would have implications for future treatment, indicating that 
photoreceptor function may still be rescuable in such patients. 
Electrodiagnostic testing although technically difficult in early childhood, is a key 
investigation to distinguish LCA from other early onset inherited retinal dystrophies 
presenting with nystagmus and poor vision such as congenital stationery night 
blindness and achromatopsia.102 The ERG in LCA for both photopic and scotopic 
responses is undetectable or severely abnormal. In congenital stationery night 
blindness the ERG shows a diminished scotopic b wave in the presence of a normal a 
wave. In achromatopsia (which may present very similarly to GUCY2D related LCA 
with photoaversion) the photopic responses are generally non-recordable with 
preserved scotopic (rod specific) responses. 
Systemic assessment and relevant investigations are necessary for all LCA patients to 
exclude an underlying syndromic diagnosis or potential associated systemic findings. 
These include learning difficulties, found in 19.8% of LCA patients, neurological 
disorders including epilepsy, cerebellar vermis hypoplasia, renal impairment and 
cardiomyopathy.12, 103-105 Syndromic features may not be present at diagnosis but may 
develop later. For instance, Senior-Loken syndrome characterised by nephronophthisis 
and LCA and linked to 5 genes, usually presents in the first decade, but renal failure 
may not present until the second decade, if at all.84, 85, 106 The advent of molecular 
diagnosis via NGS may impact on the approach to systemic investigation of patients. A 
molecular diagnosis of non-syndromic retinal dystrophy may indicate no further 
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investigations are needed but conversely the identification of a syndromic cause such 
as a gene causing Joubert syndrome would allow targeted systemic investigation.  
1.4.2 Rod cone dystrophy 
In RCD, also known as retinitis pigmentosa, patients generally present in childhood or 
adolescence with symptoms of nyctalopia, a pigmentary retinopathy often described as 
bone spicules from intra-retinal pigmentary migration and ERG abnormalities 
predominantly affecting rod function first.107, 108 Retinal degeneration starts in the mid-
periphery with loss of photoreceptors and mid-peripheral field loss. As the condition 
progresses, degeneration advances anteriorly and posteriorly reducing the visual field 
and ultimately affecting the central vision. Loss of vision occurs in adult life at an age 
depending on the underlying genetic cause.109 Age of onset and visual prognosis are 
very variable. Other features include vascular attenuation, waxy disc pallor, cataract 
and cystoid macular oedema.  
From a large series, dominant disease accounted for 20% of cases, recessive 
(classified based on consanguinity or more than 1 affected sibling) for 15%, X-linked 
for 7%, with 43% sporadic/simplex cases.110 Sporadic cases are often assumed to be 
recessive in origin although a significant minority will represent de novo dominant 
disease, X-linked (for males), mitochondrial or uniparental isodisomy.107 WES 
investigations of sporadic cases have identified mutations in dominant genes in 10-
19%, which may result from de novo mutations or incomplete penetrance in parents.10, 
13 The first reported genetic cause of any RCD was of a mutation in the RHO gene 
which encodes the visual pigment for rod photoreceptors and is associated with 
dominantly and recessively inherited RCD.4, 111  
Non-syndromic recessive RCD has been associated with more than 60 genes.107, 112, 113 
Dominantly inherited RCD is most commonly found to be due to RHO in 25% of 
cases.107 Incomplete penetrance in dominant disease (which may initially mask the true 
inheritance pattern when analysing the pedigree) has been reported with RP1 and pre-
mRNA splicing factors such as PRPF31.114, 115 X-linked RCD presents earlier, is 
associated with childhood myopia and progresses more rapidly than other forms of 
RCD.109 It usually manifests severe disease only in males. The phenotype in carrier 
females can be very variable from no abnormalities through to severe disease 
presumed to be related to random X-inactivation. In most families, the examination of 
carrier females is informative with abnormalities of the retina including a tapetal reflex 
and sectoral peripheral bone spicule pigmentation.68 Three genes have been 
associated with X-linked RCD, RPGR, RP2 and OFD1 although the latter has only 
been found in 1 family to date.116 73% of cases are due to mutations in RPGR with 
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66% of these clustered in the ORF15 region.117 Mutations within the ORF15 region of 
RPGR have also been shown to cause X-linked CORD.118 
1.4.3 Cone rod dystrophy 
CORD is less common than RCD arising in 1 in 80,000 from one large population 
study.108 Patients present in childhood at a mean age of 11 years with disturbance of 
central visual function manifesting with reduced visual acuity, symptoms of blur, 
reduced colour vision and central scotoma.119, 120 Bulls-eye maculopathy is an early 
finding with retinal thinning on OCT. As the disease progresses, nyctalopia occurs and 
peripheral pigmentation increases. Severe sight impairment occurs by a mean age of 
35 years.120 Recessive mutations account for 90% of CORD cases with ABCA4 the 
most commonly identified gene.120 119  
1.4.4 Macular dystrophy 
Childhood onset macular dystrophies arise less frequently than pigmentary 
retinopathies. Most common are Stargardt disease and Best’s disease with several 
other less common types including pattern dystrophy from PRPH2 and X-linked 
retinoschisis from mutations in RS1.110, 121 Recessive mutations in ABCA4 can cause 
CORD or RCD but most commonly cause Stargardt disease, a juvenile onset macular 
dystrophy characterised by yellow pisciform fleck deposits in the posterior pole. In 
Stargardt approximately half of patients have full field ERG abnormalities which 
represent peripheral photoreceptor dysfunction and are used as a marker of severity of 
disease.122 Best’s vitelliform macular dystrophy presents in the 2nd decade with reduced 
visual acuity, yellow macular lesions and an abnormal electroculogram due to BEST1 
mutations.123 There is significant intra-familial variability in severity. Rarely, bi-allelic 
mutations in BEST1 cause a vitelliform dystrophy which is multifocal and has ERG 
abnormalities in adulthood.124 
1.4.5 Abnormal retinal vasculogenesis 
Inherited disorders of retinal vascular development include familial exudative 
vitreoretinopathy (FEVR) and incontinentia pigmenti (IP). FEVR presents in infancy or 
early childhood with reduced vision and photoreceptor dysfunction as a consequence 
of complications including macular ectopia, retinal detachment and exudation.125, 126 
Mutations in genes of the Wnt signalling pathway NDP, LRP5, TSPAN12 and FZD4, 
which regulate normal retinal vascular growth in utero, are associated with 
approximately 50% of familial exudative vitreoretinopathy (FEVR) cases.125 FEVR is 
characterised by variable expression and inheritance patterns.126  IP is a systemic 
disorder of ectodermal cells due to mutations in IKBKG important in inflammatory and 
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apoptotic pathways.67 Retinal vascular abnormalities may be present from birth and 
can lead to retinal detachment and vision loss.127   
1.4.6 Syndromic retinal dystrophies 
Children presenting to the ophthalmologist may have a known syndromic manifestation 
of disease or may develop syndromic manifestations. As such, routine paediatric 
assessment of EORD patients is important. Syndromic manifestations may be 
apparent at presentation, for instance sensorineural hearing loss in Ushers syndrome, 
polydactylyl in Bardet-Biedl syndrome and lack of cutaneous pigmentation in 
oculocutaneous albinism. Systemic associations may develop later, for instance in 
juvenile neuronal ceroid lipofuscinosis due to mutations in CLN3, a rapidly progressive 
retinal dystrophy presenting age 6-8 years precedes the onset of neurological 
decline.128  
1.5 Thesis aims 
Detailed phenotypic and molecular analysis is incomplete for many sub-groups of 
EORD. This clinical characterisation is important for an accurate and timely diagnosis; 
appropriate and selective investigations; family counselling of prognosis and 
recurrence risks and options for pre-implantation diagnosis or pre-natal diagnosis; 
understanding of rate and degree of degeneration to target potential treatments to 
effective treatment windows; understanding of disease pathways to identify potential 
novel treatment targets; and selection of molecularly confirmed patients for treatment 
trials. By investigating groups of similar patients both molecularly and clinically, using 
the latest techniques available, insight in to phenotypes and novel molecular 
aetiologies should be achieved.  
The main aims of this thesis are to: 
- Phenotypically characterise cohorts of patients defined by molecular cause (proven 
or likely) by detailed history, examination, retinal imaging, electrophysiology and 
where appropriate systemic investigations in conjunction with paediatricians and 
clinical geneticists 
- Develop practical skills to enable molecular investigation including Sanger 
sequencing, cell studies and zebrafish studies 
- Perform targeted molecular screening of patients and family segregation  
- Investigate identified variants from WES 
- Develop the skills to interrogate databases and utilise bioinformatic tools to 
interpret and investigate molecular data 
- Investigate potential phenotype-genotype correlation
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2 Methods 
2.1 Clinical methods 
Ethical approval was obtained from the Research Ethics Committee, Moorfields Eye 
Hospital (reference MOOA1014). The study protocol adhered to the tenets of the 
Declaration of Helsinki. Written, informed consent was obtained from all participants 
prior to their inclusion in this study with parental written consent provided on behalf of 
the children involved in this study.  
Patients and their relatives were examined and investigated within the inherited retinal 
eye disease clinics at Moorfields Eye Hospital, London and Great Ormond Street 
Hospital, London. I examined the majority of patients reported in this thesis. When this 
was not possible, for instance the patients were no longer under the care of the 
hospital or lived too far away for further review to be logistically possible, the prior 
assessment by one of my 2 supervisors was used. Within each chapter, the role of the 
examiner is made clear.  
When relevant, relatives would be examined and investigated. Examination of available 
relatives is particularly useful in retinal genetics clinics, where clues to the diagnosis 
and inheritance pattern may be found. For instance, in a male patient presenting in the 
first decade with nyctalopia, high myopia and fundus signs consistent with a rod-cone 
dystrophy, examination of his mother may be informative. Carrier females in X-linked 
RCD may have abnormalities of the retina including a tapetal reflex and sectoral 
peripheral bone spicule pigmentation.68  
2.1.1 History and examination 
A detailed history provides vital information as to the possible type of retinal disease, 
its potential inheritance and its impact on the patient and their family. In taking a 
medical history I enquired about specific ocular presenting symptoms including: 
nyctalopia, field loss (difficulty on stairs, bumping in to things), central vision 
disturbance (reading, faces, colours), photophobia, photoattraction, eye poking, 
glasses, and previous ocular surgery (eg cataract). I also enquired about any signs or 
symptoms of syndromic disease such as extra digits/skin tags on hands or feet (or 
scars if removed), renal impairment, deafness, anosmia, learning difficulties, 
developmental delay, obesity, skeletal abnormalities (such as hip dysplasia, shortened 
ribs), poor balance, cardiomyopathy, peripheral neuropathy, pituitary failure and 
bleeding diathesis. Some syndromic features may not be apparent at presentation but 
develop later, such as LCA with renal failure due to nephronophthsis which usually 
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develops in the first decade but may not present until the second decade.84 Additionally 
for children I enquired about birth history, development, schooling and support in place. 
For adults it was important to note employment and difficulties working, driving and 
support. When visual deterioration met the criteria, registration as sight impaired or 
severely sight impaired was discussed. A detailed family history was taken and a 
pedigree drawn. This was helpful in determining likely inheritance pattern. 
Consanguinity was always documented. 
Ocular examination of the patient included best corrected visual acuity, colour vision, 
and visual fields (as described above). Slit lamp biomicroscopy of the anterior segment 
was performed specifically looking for any relevant signs such as keratoconus, iris 
transillumination, anterior segment dysgenesis, cataract or raised intra-ocular pressure. 
A dilated fundus examination permitted assessment of the appearance of the optic disc 
and vessels and the distribution, type and pattern of any pigmentary change. Additional 
features included macular lesions such as vitelliform lesions or flecks, exudation, 
telangiectasia, haemorrhage, and schisis. In children too young for slit lamp 
examination, a hand-held slit lamp and an indirect ophthalmoscope were used. 
Systemic assessment included external examination of the patient for any apparent 
dysmorphic features such as saddle-nose, microcephaly, short stature, scars on 
hands/feet, extra digits or sparse scalp hair. Growth parameters in children were 
measured when relevant. 
2.1.2 Retinal imaging 
All patients, age permitting underwent retinal imaging which is useful for documentation 
of findings and for objective monitoring of progression. Colour fundus images were 
obtained by 35 degree (Topcon Great Britain Ltd, Berkshire, UK), ultra-widefield 
confocal scanning laser imaging (Optos plc, Dunfermline, UK), or RetCam imaging 
(Clarity Medical Systems Inc, California, USA).  
Conventional Topcon white-light 35 degree images would typically be obtained in 9 
positions of gaze to cover the entire fundus through a dilated pupil (figure 2-1). An 
Optos image covers 200 degrees and encompasses the peripheral retina, particularly 
useful in the paediatric setting and for patients with limited cooperation as a single 
image may be sufficient once the dilated pupil is properly aligned. Optos images were 
acquired by laser scanning ophthalmoscopy using 2 lasers, 532nm green (to image 
retina) and 633nm red (to image RPE and choroid, www.optos.com). The RetCam was 
used for examination of supine patients, most typically during examination under 
anaesthesia in theatre again through a dilated pupil. Images were acquired using a 
corneal contact probe with white light and a field of approximately 130 degrees. 
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Figure 2-1: Example colour fundus imaging  
Left eye of a 12 year boy with enhanced S-cone syndrome. Due to the wavelength of laser 
used, Optos images have an artificial appearance which can be altered to more realistic retinal 
colours using the product software. There are frequently artefacts from eyelashes (seen 
superiorly and inferiorly) and from fingers holding up eyelids (top right). 
Fundus autofluorescence (FAF) imaging may highlight abnormalities in retinal 
dystrophy not visible ophthalmoscopically and can be a useful parameter for monitoring 
disease progression (figure 2-2). The RPE phagocytoses shed outer segments of 
photoreceptors with lipofuscin accumulating in lysosomes in the RPE as a by-product 
of this process.129 When stimulated by blue light, the lipofuscin pigments naturally 
fluoresce. Normally, the optic disc and retinal vessels appear dark, the AF signal is 
most intense 5-15 degrees temporal to the fovea and the fovea itself appears dark due 
to the absorption of 488nm light by the macular pigments with some absorption by 
melanin granules in the RPE.130 In early stages of retinal dystrophy, increased 
autofluorescence is indicative of RPE dysfunction prior to atrophy and in RCD is 
classically seen as a ring in the macula.131 Regions of reduced AF may be seen prior to 
any visible atrophic changes ophthalmoscopically. This loss of AF is indicative of 
severe damage to the retinal pigment epithelium (RPE) and subsequent atrophy of the 
overlying neurosensory retina. In this study, FAF imaging was most frequently 
performed using 30 or 55 degree imaging (Spectralis, Heidelberg Engineering Ltd, 
Heidelberg, Germany). The Spectralis is a confocal scanning laser ophthalmoscope 
which continually scans the retina. Laser excitation of 488nm was used with an 
emission detection filter of 500nm. The Optos ultra wide-field was also used for FAF 
imaging and these images can be used to estimate the visual field.60 
 
Figure 2-2: Examples of FAF imaging  
Left eye of a 12 year boy with enhanced S-cone syndrome demonstrating different sizes of 
fields with different imaging modalities. 
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Spectral domain OCT scans (Spectralis) were used to create cross-sectional images of 
retinal layers, RPE and choroid (figure 2-3). An 870nm superluminescent diode was 
used across a 30 degree field with reflected light from a spectrum of wavelengths then 
measured. The speed of reflection and wavelength were processed to build up an 
image of the reflective surfaces. Images were measured at 40,000 A-scans per second 
giving a high axial resolution of 7 µm to a depth of 1.9mm 
(www.heidelbergengineering.com). OCT images demonstrate a number of features in 
retinal dystrophy, including loss of retinal layers, RPE or choroid, disorganised 
lamination, macular oedema and outer retinal tubulations (ORTs).132 In RCD, the inner 
segment ellipsoid (ISe) band is typically lost in the peripheral macula with progressive 
loss towards the fovea a marker of progression.133 
 
Figure 2-3: Example of OCT imaging with layer segmentation 
Left OCT of patient with enhanced S-cone syndrome with individual layers labelled. Infrared 
image on left represents multiple scan positions with the highlighted arrow corresponding to the 
OCT image illustrated on the right. The outer segment/RPE band can be differentiated from the 
RPE in high quality scans only. Note, subfoveally the increased black space representing the 
increased outer segments in this region. Also note, nasally disrupted ISe band. 
Fundus fluorescein angiography (FFA) is a technique to visualise retinal vessels and to 
a lesser extent the choroidal circulation (figure 2-4). Intravenous fluorescein is injected 
and consecutive fundus images taken with a blue excitation light of 488nm and a 
500nm filter to isolate the fluorescence only. This technique is particularly useful in 
conditions where there may be abnormal vascular development such as familial 
exudative vitreoretinopathy, in telangiectasia and exudation and in choroidal 
neovascular membranes of the macula. FFAs can be performed using the Topcon 
system, Optos, RetCam or Spectralis. Optos FFA is particularly useful if peripheral 
images are needed. However, limited normative data can make interpreting these 
images challenging. Peripheral vascular abnormalities have been found in normal 
patients and areas of non-perfusion have been found in patients with high myopia.134 
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Figure 2-4: Examples of fundus fluorescein angiograms 
Top, 31 year old untreated familial exudative vitreoretinopathy (FEVR); Optos image of left eye 
with temporal incomplete vascularisation and abnormal vascular malformations. Middle, 7 
weeks old boy, poor eye contact, nystagmus and microcephaly; RetCam image of right retinal 
fold, incomplete peripheral vascularisation evident on FFA. Bottom, 11 year old with PNPLA6 
related chorioretinopathy and a secondary right choroidal neovascular membrane (CNVM); 
Optos colour image of right eye, Spectralis FFA of posterior pole, no leak from CNVM. 
2.1.3 Electrophysiology 
The majority of patients presenting with symptoms related to retinal dystrophy undergo 
electrophysiological testing to objectively assess the function of the visual pathways, 
localise disease and estimate visual disability. The interpretation of reporting of these is 
performed by Prof Graham Holder and Dr Anthony Robson, and the ERG figures and 
interpretations within this thesis have been provided by them.  
Electrodiagnostic tests (EDTs) comprise the electroretinogram (ERG) which measures 
the mass response from photoreceptors and the inner retina; the pattern ERG (PERG) 
which measures the macula photoreceptor and retinal ganglion cell responses; the 
electrooculogram (EOG) for examining RPE function; and the visual evoked potential 
(VEP) which assesses intracranial pathways. In this thesis the main investigative 
Methods 
 
 33 
methods of relevance were the ERG, PERG and VEP. The ERG can be particularly 
useful in infants presenting with nystagmus and poor visual responses, to readily 
distinguish between LCA or less severe conditions such as achromatopsia. ERG 
responses can be pathognomonic of certain conditions including enhanced S-cone 
syndrome due to NR2E3 mutations and cone dystrophy with supernormal rod ERG due 
to KCNV2 mutations.135  
Recordings were performed to standards published by the International Society for 
Clinical Electrophysiology of Vision (ISCEV) to ensure the stimulus parameters and 
adaptive state of the eye at recording (dark or light adapted duration) were comparable 
and meaningful.136, 137 Recordings were performed with gold foil corneal electrodes but 
in infants and young children these were not usually tolerated and skin electrodes were 
used with modified protocols.138 Abnormal retinal function was determined by reduced 
(or less commonly abnormally increased) amplitude and by delayed timing of 
responses. 
The basic protocols for ERG recordings are broadly divided in to 4 categories: dark 
adapted (DA) 0.01, DA 10.0, light adapted (LA) 30Hz and LA 3.0 (figure 2-5). Dark 
adaptation was performed by patching the eye for 20 minutes to obtain maximal 
information about rod-driven responses. Flash stimuli were delivered by a Ganzfeld 
bowl to achieve whole field, uniform illumination with units of candela-seconds per 
meter squared (cd.s.m-2). DA 0.01 comprised a 0.01 cd.s.m-2 dim stimulus generating a 
b-wave that reflects rod pathways. DA 10.0 comprised a 10.0 cd.s.m-2 stimulus  
generating an a-wave which reflects combined photoreceptor responses and ON 
pathways, and a b-wave that reflects predominantly rod ON bipolar cells. In practice 
the DA 10.0 was predominantly used for interpreting rod and inner retinal cell 
dysfunction. Depending on the machine used, some recordings were with a 11 cd.s.m-2 
stimulus. Light adaptation was performed using a 30 cd m-2 stimulus from the Ganzfeld 
bowl for at least 10 minutes. LA 30Hz flicker was a 3.0 cd.s.m-2 stimulus delivered at a 
frequency of approximately 30Hz, which generates a cone isolated response due to the 
poor temporal resolution of rods and rod-saturating background. LA 3.0 was a single 
flash 3.0 cd.s.m-2 stimulus generating an a-wave reflecting predominantly cone function 
and a b-wave that reflects ON and OFF bipolar cells. Further specific testing was 
performed when indicated for instance S-cone specific ERG or ON and OFF bipolar 
cell recordings. ERGs were recorded with the pupil dilated except in young 
children/infants. 
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Figure 2-5: Electroretinogram and pattern electroretinogram examples  
All patients shown have CRX mutations. Patient with macular dystrophy demonstrates 
subnormal PERG with normal ERGs for age (53 years at ERG). Patient with CORD, 
demonstrates subnormal rod and bright flash ERGs (DA 0.01; DA 11.0), delayed and subnormal 
cone flicker ERGs (LA 3.0 30Hz) and markedly subnormal single flash ERG (LA 3.0 2Hz) with 
undetectable PERG. Patient with RCD, demonstrates undetectable rod ERG (DA 0.01), severe 
reduction in the bright flash ERGs (DA 11.0) and markedly delayed and subnormal cone flicker 
and single flash ERGs (LA 3.0 30Hz; LA 3.0). PERG was unrecordable due to nystagmus. 
PERG recordings were performed with a black and white checkerboard of constant 
mean luminance with an undilated pupil and refractive correction. The test required 
central fixation for good quality recordings. Recordings measured the response of the 
retina stimulated by this contrasting image reflecting function of the central macula. It is 
useful for assessing macular involvement in a retinal dystrophy (figure 2-5) and in 
differentiating macula or ganglion cell related visual loss.139 Two main components 
were measured, the P50 at approximately 50msec which reflects the function of the 
macula and the N95 component reflecting retinal ganglion cell function. 
The VEP was recorded using occipitally placed skin electrodes with monocular 
stimulation from a black and white checkerboard.140 Relevant applications include; 
investigating demyelinating optic nerve disease in which the pattern VEP is delayed in 
the presence of a normal PERG; assessing chiasmal misrouting in oculocutaneous 
albinism in which the majority of optic nerve fibres decussate contralaterally; and 
demonstrating normal responses and objective visual acuity in non-organic visual 
loss.141, 142  
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2.2 Molecular genetic methods 
For the majority of patients reported within this thesis, I performed molecular 
investigations with Sanger sequencing. Patients were either undiagnosed and for 
candidate gene screening or they had undergone NGS and were for further 
investigation and co-segregation. Within each chapter, my role in the genetic 
investigations is detailed. 
2.2.1 DNA isolation and quantification 
Genomic DNA was isolated from peripheral blood lymphocytes, saliva or buccal swabs, 
using the Puregene kit (Gentra Puregene Blood and Tissue Extraction Kit, QIAGEN, 
Manchester, UK) by colleagues within the Institute (Beverley Scott and Naushin 
Waseem). DNA samples may have already been obtained. Otherwise patients and 
relatives were contacted for samples or recruited within clinic. I performed the majority 
of this additional sampling.  
Extracted DNA was quantified using a spectrophotometer (NanoDrop 2000, Thermo 
Fisher Scientific, Waltham, MA, USA) and 1µl of the DNA sample. The 
spectrophotometer uses a wide spectral range of light stimulation from ultraviolet to 
visible light (190-840nm) and a photodetector to measure the absorbance of a sample. 
DNA has a peak absorbance at 260nm, protein at 280nm. The transmittance of a 
substance is related to its optical depth and its absorbance; this is known as the Beer-
Lambert law and this principle is used to calculate the concentration of a sample based 
on a 50µg/ml DNA sample at 260nm absorbance having an optical density of 1. The 
quality of DNA was also assessed using a purity ratio, A260/A280 with an optimal ratio 
of 1.8 indicating low amounts of contaminating protein and values below 1.6 indicating 
high protein contamination. DNA was diluted to 50ng/µl for use in reactions. 
2.2.2 Polymerase chain reaction 
In vitro cloning of DNA fragments by polymerase chain reaction (PCR) is a rapid, and 
sensitive method of amplifying even tiny amounts of DNA.65 Within the laboratory, PCR 
was performed to selectively amplify a region of DNA under investigation using 
specifically designed oligonucleotide sequences (primers) acting at target sequences 
surrounding an exon. Primers were designed in a 5’ to 3’ direction to direct synthesis of 
a complementary DNA strand towards the other primer binding site. Each newly 
synthesised strand thus acting as a template for further reactions, creating an 
exponential reaction for DNA production.  
There are 3 steps to the PCR process (figure 2-6): 
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1) Denaturation: DNA is heated to a temperature sufficient to break the hydrogen 
bonds and separate the double-stranded DNA in to 2 complementary strands 
2) Primer annealing: primers bind to complementary sequences on the single-
stranded DNA 
3) DNA synthesis: DNA polymerase initiates the synthesis of new DNA strands by 
the addition of synthetic deoxynucleoside triphosphates (dNTPs), specifically 
dATP, dCTP, dGTP and dTTP. 
 
Figure 2-6: Polymerase chain reaction 
The process was repeated for approximately 30 cycles to generate sufficient DNA to 
sequence (table 2-1). PCR was performed in a thermal cycler (Bio-Rad C1000, Bio-
Rad Laboratories, California, USA). The reagents comprised DNA, Taq DNA 
polymerase, reaction buffer, magnesium chloride (MgCl2), dNTPs and primers.  
Standard PCR reaction, 20 μl vol 
Step Condition 
1 95°C 300 secs 
2 95°C 30 secs 
3 X°C 30 secs 
4 72°C 60 secs 
Go to  step 2, 34 times 
5 72°C 420 secs 
6 4°C 120 secs 
Table 2-1: PCR protocol 
X is the PCR specific temperature 
Taq polymerases are heat resistant DNA polymerases derived from a microorganism, 
Thermus aquaticus that exists in naturally hot environments. These enzymes can 
withstand the initial 95°C denaturation step. The standard Taq polymerase used in the 
lab was BIOTAQ (BIOTAQ™ DNA Polymerase, Bioline, London, UK, table 2-2). In 
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cases where PCR reactions were weak or sub-optimal, MyTaq (MyTaq™ DNA 
Polymerase, Bioline) was used (table 2-2). MyTaq has increased affinity for DNA.  
BIOTAQ mix, total vol 
20μl 
Final 
concentration 
 MyTaq mix, total vol 
20μl 
Final 
concentration 
10x reaction 
buffer 
2μl 1x  5x reaction 
buffer 
4μl 1x 
Primer forward 
(10μM) 
0.8μl 0.4μM  Primer forward 
(10μM) 
0.8μl 0.4μM 
Primer reverse 
(10μM) 
0.8μl 0.4μM  Primer reverse 
(10μM) 
0.8μl 0.4μM 
BIOTAQ          
(5 units/μl) 
0.2μl 1 unit/reaction  MyTaq  
(5 units/μl) 
0.2μl 1 unit/reaction 
dNTPs  
(2mM) 
2μl 0.2mM  DNA  50ng - 
MgCl2  
(50mM) 
0.6μl 1.5mM  Water 13.2μl  - 
DNA  50ng -     
Water 12.6μl  -    
Table 2-2: BIOTAQ and MyTaq protocols for PCR 
The ammonium based reaction buffers (containing ammonium sulphate and Tris-
hydrochloride) and MgCl2 provided optimal reaction conditions. The MyTaq 5x reaction 
buffer contains dNTPs and MgCl2. For those PCR products with an unavoidably high 
GC content (typically >60%), 8% dimethyl sulphoxide (DMSO) was added to the 
protocol. DMSO is thought to reduce the formation of secondary structures by binding 
the major and minor grooves of DNA strands.143 
Primers (typical 18-25 nucleotides) were designed using open-source software at 
Primer3plus.com with gene sequences from Ensembl accessed at 
http://www.ensembl.org.144 Primer pairs were selected based on similar predicted 
melting temperatures, an optimal GC content (<60%) and an amplicon size <1000 
base pair (bp) to avoid difficulties in amplification and sequencing. Primers with high 
GC content would be more likely to dimerise or form secondary structures. Primer pairs 
were run through in silico PCR software at UCSC genome browser 
(https://genome.ucsc.edu/cgi-bin/hgPcr) to ensure they would specifically anneal only 
to the area of interest without any other alternative binding sites in the genome. 
Lyophilised primers were re-suspended in sterile water at 100mM and stored at -20ºC 
with a working stock of 200µl of 10mM primer stored at 4ºC.  
PCR reactions were first optimised using a temperature gradient protocol to determine 
the optimal primer annealing temperature to minimise non-specific amplification and 
ensure a high yield of PCR product. The temperature gradient would typically be run 
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from 50-65°C (figure 2-7). The resulting PCR products were separated by size using 
agarose gel electrophoresis. 4µl of PCR product was mixed with 1µl of loading buffer 
(bromophenol blue/xylene cyanol/Ficoll) and electrophoresed for 30-40 minutes at 
150V constant voltage through a 2% agarose gel containing 5µl/100ml of SafeView 
reagent (Applied Biological Materials Inc, Richmond, BC, Canada) in TBE 
(Tris/borate/EDTA, Thermo Fisher Scientific) buffer. An appropriate molecular weight 
marker was used, most typically HyperLadder IV (Bioline Reagents Limited, London, 
UK). The gel was imaged using an ultraviolet transilluminator and photographed using 
an orange filter.  
 
Figure 2-7: Temperature gradient optimisation example 
Agarose gel electrophoresis image of RDH12 exon 7 run with BIOTAQ. 65°C was the optimal 
temperature chosen from this experiment as it was the highest temperature with a clear band. 
2.2.3 Sanger sequencing 
Dye-terminator dideoxynucleotide DNA sequencing, more commonly known as Sanger 
sequencing, is an enzymatic process for interpreting the nucleotide order within a 
specific length of DNA.65 The original method as described in the 1970s generated 
newly synthesised DNA strands of sequential lengths depending on the incorporation 
of a dideoxynucleotide chain terminator in to the new strand, that could be separated 
on a polyacrylamide gel.145 Automated sequencing machines are now used with 4 
fluorescent labels of differing emission wavelengths that are detected as the DNA 
sample migrates past a laser and camera at a fixed point during electrophoresis 
through a polyacrylamide gel capillary.146 
The PCR product was sequenced in a number of steps. Prior to sequencing, 
unincorporated primers and nucleotides were removed to avoid contamination of 
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downstream sequencing reactions or alteration of the dNTP:dye-terminator ratio. The 
product was cleaned up of primers and free dNTPs using a combination of 
Exonuclease I (ThermoFisher Scientific) and FastAP shrimp alkaline phosphatase 
(ThermoFisher Scientific). The former removes primers and acts on single stranded 
DNA such that the double stranded PCR product is not digested; the latter inactivates 
the dNTPs by dephosphorylating them. 3.2µl of enzyme mix containing 2 units of Exo I 
and 2 units of FastAP was added per PCR reaction and incubated for 60 minutes at 
37°C followed by inactivation for 20 minutes at 80°C then cooled to 4°C for 5 minutes. 
Sequencing of the amplified product was performed using BigDye terminator chemistry 
(table 2-3, BigDye Terminator Cycle Sequencing Kit, v.3.1; Thermo Fisher Scientific). 
This kit contains a DNA polymerase and fluorescently labelled dNTPs. 
BigDye reaction     
   Step Condition 
   1 96°C 120 secs 
Mix, total 10μl   2 96°C 10 secs 
BigDye 1μl  3 50°C 5 secs 
Template 1.5μl  4 60°C 240 secs 
Primer  0.5μl   Go to step 2, 24 times 
Water  7μl  5 4°C 120 secs 
Table 2-3: BigDye reaction 
Free nucleotides and enzyme were then cleaned up by using sequencing clean-up 
filter plates (Montage SEQ96, Millipore Ltd, Watford, UK) with a vacuum pump 
according to manufacturer instructions and then re-suspended in 12µl of sterile water. 
Finally, the samples were loaded on to an automated capillary sequencer (Applied 
Biosystems 3730 DNA Analyzer) run by colleagues within the Institute (Naushin 
Waseem and Beverley Scott). 
2.2.4 Next generation sequencing 
2.2.4.1 Massively parallel sequencing 
Patients were selected for WES based on prior molecular investigations including 
candidate gene screening, APEX microarray, single nucleotide polymorphism (SNP) 
microarray, homozygosity mapping and NGS gene panel screening. WES was 
predominantly performed at AROS Applied Biotechnology (Aarhus, Denmark), with 
alignment and variant calling performed by a colleague (Vincent Plagnol) at the UCL 
Genetics Institute. Further variant filtering and interpretation was predominantly 
performed by the post-doctoral fellow within the laboratory, Dr Gavin Arno as well as by 
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Prof Andrew Webster. WES was performed using SureSelect XT Human All Exon 
capture (Agilent Technologies Inc., Santa Clara, USA). In brief, for this type of massive 
parallel sequencing, patient DNA was digested in to randomly sheared, adaptor-ligated 
and PCR-amplified fragments.147 These were mixed with a pool of biotinylated RNA 
capture probes (designed to cover the whole exome) that then attached to streptavidin-
coated magnetic beads. These were then selectively PCR amplified with paired-end 
sequencing performed using the Illumina HiSeq2500 sequencer (Illumina, San Diego, 
CA). The fluorescence emitted for each incorporated dNTP was recorded to determine 
the sequence. Approximate read-depths and coverage were 30x minimum for 75% of 
the exome and 10x minimum for 90% of the exome. 
2.2.4.2 Variant call alignment and analysis 
The resulting raw data required extensive processing. The raw FASTQ files containing 
FASTA formatted text-based sequence and quality data for each read were aligned to 
the Genome Reference Consortium human genome build 37 (GRCh37) using 
Novoalign (Novocraft Technologies, Selangor, Malaysia) version 2.08.03. Duplicate 
reads were identified using Markduplicates (Picard Tools, Broad Institute, Cambridge, 
Ma, USA, http://broadinstitute.github.io/picard). The Haplotype Caller module of the 
Genome Analysis ToolKit (GATK, version 3.3-0, Broad Institute, 
www.broadinstitute.org/GATK) was used to identify sequence variants. The resulting 
genomic variant call format (VCF) file was further analysed using the GenotypeGVCFs 
module (of GATK) for final variant calling. Variant quality scores were recalibrated 
according to GATK best practice separately for single nucleotide variants and 
insertions/deletions. Finally, the resulting variants were annotated using ANNOVAR 
(www.openbioinformatics.org) based on Ensembl gene and transcript definitions. 
Candidate variants were filtered based on function (non-synonymous missense, 
presumed loss of function, splicing defined as intronic sites within 5 bp of exon-intron 
junction) and a minor allele frequency (MAF) <0.5% (as compared with an internal 
control group of 3000 clinical exomes, UCL-exomes consortium and the NHLBI GO 
Exome Sequencing Project dataset, EVS, Seattle, WA available at 
http://evs.gs.washington.edu/EVS/). Variants in know retinal dystrophy genes would be 
investigated first with this analysis predominantly performed by Dr Arno and Prof 
Webster and to a lesser extent by myself. If potentially pathogenic variants in known 
retinal dystrophy genes were not found, the other variants were investigated to try and 
identify candidate genes. This approach would involve investigating known reports of 
protein function, animal models, orthologues and human paralogues. 
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2.2.4.3 Whole genome sequencing 
In WGS, there is no targeted capture of regions of interest and no PCR step. This 
results in less bias, improved coverage of regions difficult to PCR such as repetitive 
regions or GC rich first exons, allows investigation of deep intronic variants and 
regulatory regions that may not be covered with other methods and better identifies 
copy number variants (CNVs).148 In practice, the coverage is approximately 95% of the 
genome with a lower read-depth than WES at 15x. 
WGS was performed as part of the NIHR BioResource Rare-diseases SPEED study 
using the Illumina TruSeq DNA PCR-Free Sample preparation kit (Illumina Inc.) and 
sequenced using an Illumina HiSeq 2500. Alignment and variant calling was performed 
by Dr Keren Carss (NIHR BioResource - Rare Diseases, Department of Haematology, 
University of Cambridge, Cambridge, UK). Reads were aligned to the Genome 
Reference Consortium human genome build 37 (GRCh37) using Isaac Genome 
Alignment Software (version 01.14, Illumina Inc.).149 Single nucleotide variations and 
small insertion deletions were identified using Isaac Variant Caller (version 2.0.17).149  
2.2.5 Other molecular investigations 
NGS of the coding regions of 105 retinal genes (table 2-4) and subsequently 176 
retinal genes (table 2-5) was performed at the Manchester Centre for Genomic 
Medicine (Manchester, UK) with enrichment using a SureSelect Target Enrichment Kit 
(Agilent Technologies Inc., Santa Clara, USA) then sequenced on the HiSeq 2500 
(Illumina Inc., San Diego, CA).14 Sequenced reads were aligned to the human 
reference sequence hg19 (build GRCh37) with the Burrows-Wheeler aligner (BWA 
v0.6.2).150 The genome analysis tool kit (GATKlite v2.0.39) was used for base quality 
score recalibration and indel realignment prior to variant calling using the 
UnifiedGenotyper.151 This gene panel was frequently used for screening undiagnosed 
patients as a rapid and cost-effective method from clinic with variant interpretation 
performed by the Manchester Centre providing a variant list from their analysis and 
most likely causative candidates. 
Autozygosity mapping has frequently been used within the department for 
consanguineous families. The underlying principle is that non-random mating leads to 
inheritance of identical ancestral alleles. Regions of homozygous DNA >5Mb are 
generally not seen in non-consanguineous mating; larger homozygous tracts are 
identical by descent, and indicate parental consanguinity.152 For recessive disease, the 
degree of consanguinity is directly correlated to the risk of disease. Homozygosity 
mapping of multiple family members can highlight a candidate gene for sequence 
analysis. This investigation of homozygous regions was performed using a SNP 
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microarray containing 730,525 SNPs (OmniExpress, Illumina Inc., San Diego, Ca, 
USA) at the Institute of Child Health (London, UK) and was additionally performed on 
exome data. 
ABCA4  CEP290  GNAT2  NDP  RBP3  SAG  
ADAM9  CERKL  GPR98  NR2E3  RD3  SEMA4A  
AIPL1  CHM  GUCA1A  NRL  RDH12  SNRNP200  
ARL6  CLRN1  GUCA1B  OTX2  RDH5  SPATA7  
BBS1  CNGA1  GUCY2D  PCDH15  RGR  TEAD1  
BBS10  CNGA3  IDH3B  PDE6A  RGS9  TIMP3  
BBS12  CNGB1  IDH3B  PDE6B  RHO  TOPORS  
BBS2  CNGB3  IMPDH1  PDE6C  RIMS1  TRIM32  
BBS4  CRB1  IMPG2  PDE6G  RLBP1  TTC8  
BBS5  CRX  KCNV2  PITPNM3  ROM1  TULP1  
BBS7  DFNB31  KLHL7  PRCD  RP1  UNC119  
BBS9  DHDDS  LCA5  PROM1  RP1L1  USH1C  
BEST1  EFEMP1  LRAT  PRPF3  RP2  USH1G  
C1QTNF5  ELOVL4  LRP5  PRPF31  RP9  USH2A  
CA4  EYS  MERTK  PRPF6  RPE65  ZNF513  
CACNA2D4  FAM161A  MKKS  PRPF8  RPGR 
 CDH23  FSCN2  MKS1  PRPH2  RPGRIP1  
 CDHR1  FZD4  MYO7A  RAX2  RS1  
 
Table 2-4: List of 105 retinal genes in Manchester panel  
Note, ORF15 region of RPGR poorly covered 
ABHD12 CDH3 GPR179 LZTFL1 PEX1 TSPAN12 
ACBD5 CEP164 GRM6 MFRP PEX2 TUB 
ADAMTS18 CIB2 HARS MVK PEX7 VCAN 
AHI1 CLN3 HMX1 NEK2 PHYH VPS13B 
ARL2BP CNNM4 IFT140 NMNAT1 PLA2G5 WDR19 
BB1P1 CSPP1 IMPG1 NPHP1 PRPF4 ZNF423 
C21orf2 CYP4V2 INPP5E NPHP3 RAB28  
C2ORF86 DTHD1 INVS NPHP4 RBP4  
C8ORF37 EMC1 IQCB1 NYX RPGRIP1L  
CABP4 FLVCR1 ITM2B OAT SDCCAG8  
CACNA1F GNAT1 KCNJ13 OFD1 SLC24A1  
CAPN5 GNPTG KIAA1549 PANK2 TMEM237  
CC2D2A GPR125 KIF11 PCYT1A TRPM1  
Table 2-5: List of additional retinal genes in 176 gene panel 
APEX microarray screening (Asper Biotech Ltd.), was performed on patients prior to 
my study using a genotyping microarray containing specific disease causing variants 
and common polymorphisms. For LCA this comprised >300 variants for 8 retinal 
dystrophy genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, RPGRIP1, LRAT and 
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MERTK) with an autosomal recessive RCD screen containing >700 disease causing 
variants for 28 retinal dystrophy genes (ABCA4, AIPL1, CERKL, CNGA1, CNGA3, 
CNGB3, CRB1, EYS, GRK1, IMPG2, LRAT, MERTK, PDE6A, PDE6B, NR2E3, 
PROM1, RBP3, RDH12, RGR, RHO, RLBP1, RP1, RPE65, SAG, TULP1, CLRN1 and 
USH2A).153, 154 
2.2.6 Variant analysis and functional predictive tools 
Variants were interrogated using the GenBank accession number from the National 
Institute for Health publically available genetic sequence database with nucleotide 
position 1 corresponding to the A of the ATG translation initiation codon.155 
2.2.6.1 Determining novelty  
Variants were identified as novel if not previously reported in the literature and if absent 
from open-source variant databases namely dbSNP available at 
http://www.ncbi.nlm.nih.gov/projects/SNP/, EVS, 1000 genomes project available at 
http://www.1000genomes.org/ and the Exome Aggregation Consortium (ExAC, 
Cambridge, MA) available at http://exac.broadinstitute.org.156 The ExAC database 
became publically available in late 2014 and comprises >60,000 exomes collated to 
determine MAF of a variant. Frequently, a pathogenic variant not previously reported in 
an affected patient, would be identified in the ExAC database but at a very low 
frequency (<0.0001) consistent with rare disease.  
2.2.6.2 Predicting pathogenicity  
Various in silico tools were used to estimate the pathogenicity of novel variants. These 
included the open-source predictive algorithms for missense variant of ‘Sorting 
Intolerant from Tolerant’ (SIFT) available at http://sift.jcvi.org and Polymorphism 
Phenotyping v2 (PolyPhen2) available at http://genetics.bwh.harvard.edu/pph2 with a 
score <0.05 indicating pathogenicity for SIFT and a score of ≥0.90-<0.95 indicating 
possibly damaging and ≥0.95 probably damaging for Polyphen2.157, 158 For splice site 
variants, Splice Site Prediction by Neural Network at 
http://www.fruitfly.org/seq_tools/splice.html and Human Splicing Finder (HSF) at 
www.umd.be/HSF3 were used.159, 160 Conservation of residues between orthologues 
and between human paralogues was analysed using Clustal Omega accessed at 
http://www.ebi.ac.uk/Tools/msa/clustalo/ with protein sequences to be aligned identified 
from Ensembl.161 Conservation across species indicates importance of that residue in 
protein function. Both SIFT and Polyphen2 work in part by analysing conservation. 
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2.2.6.3 Protein modelling 
A polypeptide may be subject to post-translational modification such as the methylation 
of cone transducin.162 The secondary structure motifs such as the α-helix may be 
partially predicted from the amino acid sequence but the three-dimensional tertiary 
structure of a protein may only be deduced experimentally. This includes X-ray 
crystallography or nuclear magnetic resonance spectroscopy with this information 
curated, annotated and made freely available within the Protein Data Bank 
(www.pdb.org).163 The UniProt Knowledgebase (www.uniprot.org) is an open-source 
resource of protein sequence and functional information with manual curation of the 
Swiss-Prot section.164 For proteins without experimental data, modelling of the 
crystalline structure can be performed using tools such as Visual Molecular Dynamics 
(VMD accessed at http://www.ks.uiuc.edu/Research/vmd/) based on paralogues and 
sequence information. VMD is developed with NIH support by the Theoretical and 
Computational Biophysics group at the Beckman Institute, University of Illinois at 
Urbana-Champaign, USA. 
Complex structural motifs form protein domains essential for protein function and 
interactions. Mutations leading to altered residues within these domains may introduce 
structural change to the shape of the protein, may alter protein interactions or may be 
tolerated.  
2.3 Cell studies 
Under supervision by a colleague (Nicholas Owen) within our lab at the Institute of 
Ophthalmology, an in vitro experiment was designed to perform transient plasmid 
transfection of hTERT-RPE1 cells. I performed all experiments. This necessitated 
learning how to first transform XL1-Blue Supercompetent cells to synthesis plasmid 
DNA; perform Maxiprep, site directed mutagenesis and Miniprep; grow, split, freeze, 
resurrect and transfect cells using a class II biological safety cabinet; immunostain; and 
use a confocal microscope. 
2.3.1.1 Plasmid transformation of cells 
The initial experiment required transforming XL1-Blue Supercompetent cells (#200236, 
Agilent Technologies, Santa Clara, Ca, USA) with a WT and mutated (E664K) pCMV-
IFT140-Myc-DDK plasmid (#RC207528, Origene, Rockville, MD, USA, both gifted from 
a colleague in France) in order to make large quantities of plasmid DNA. All 
procedures were performed using sterile plasticware on the laboratory bench using a 
Bunsen burner to minimise contamination.  
Transformation was performed according to the following protocol: 
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1. LB agar plates: 400ml water and 16g LB agar was autoclaved in a 500ml conical 
flask, once cooled slightly antibiotic was added (100 µg/µl, ampicillin for pUC18 
control, kanamycin for IFT140 plasmid), poured in to plates, stored agar side up  
2. XL1-blue cells (from -80 °C freezer) were rapidly thawed by hand and added to 
labelled microcentrifuge tubes on ice, 50µl per experiment (plus 2 controls, pUC18 
plasmid, known efficiency of ≥1.0 x 109 colony forming units/µg, and no DNA) 
3. 0.85µl of β-mercaptoethanol was added to each tube and gently swirled 
4. This was placed on ice for 10 minutes and swirled gently every 2 minutes 
5. 50ng DNA plasmid (at 100ng/µl) was added (or 0.1ng (1µl) of pUC18), and swirled 
gently 
6. Ice 30 minutes 
7. Samples were heat pulsed at 42°C for 45 seconds exactly (water bath used) 
8. Ice for 2 minutes 
9. 200µl S.O.C. medium was added 
10. Incubated for 1 hour at 37°C with shaking at 225-250rpm 
11. Plated on LB agar plates using sterile technique with Bunsen burner, glass rod and 
100% ethanol, 50µl and 150µl volumes both used per experiment 
12. Incubated at 37°C overnight 
13. Colonies counted next day- efficiency assessed by counting pUC18, expect >100 
colonies per 1µl plated 
This resulted in <10 colonies per plate, with no colonies on the control negative DNA 
plate and initially, <10 on the pUC18 plate indicating low efficiency. This markedly 
improved with practice until there were >100 colonies on the pUC18 plate.  
2.3.1.2 Culture of single colonies 
Due to the low numbers of colonies, all were cultured and sequenced: 
1. Under sterile conditions 3-4ml of sterile LB broth + 3-4 µl kanamycin were added to 
a 50ml conical centrifuge tube 
2. A single colony, was picked using a 10µl pipette tip with the whole tip placed in to 
the conical tube 
3. Incubated at 37°C at 225rpm for 6 hours minimum 
4. Under sterile conditions, 1.5ml was taken from the tube and added to a 50ml LB 
broth bottle, 2 made per experiment 
5. Incubated overnight at 37°C at 225rpm 
6. A glycerol stock was made of the resulting mix for storage in -80°C freezer for 
future source of original clone: 0.5ml of overnight mix + 0.5ml 8% sterile glycerol in 
a 1.5 ml microcentrifuge tubes 
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Maxiprep was then performed on the overnight culture using the EndoFree plasmid 
Maxi kit (QIAGEN, Dusseldorf, Germany) and an adapted manufacturer’s protocol. This 
resulted in >900ng/µl of plasmid DNA per plasmid type with an overall approximate 
volume of 0.7ml per plasmid. 
2.3.1.3 Sequencing of plasmid open reading frame 
Primer pairs were designed to sequence the open reading frame (ORF) of the plasmid 
(table 2-6). Gradient optimisation of primer pairs was performed with template at 
100ng/µl. VP1.5 and XL39 are plasmid specific primer sequences located before and 
after the ORF respectively. 
Name Primer forward 5’ → 3’ Primer reverse 5’ → 3’ 
VP1.5/IFTORF1R GGACTTTCCAAAATGTCG AGTGCCTCCCTCTTCTCCAT 
IFTORF 2 GAAGGGCAAGACCACTCAGG TCCACTGATGTGCATGTCGG 
IFTORF 3 TGTCGTCACACTTCCACCAG CTTCGCATACAAACAGCCGG 
IFTORF 4 GCAAGAGACTAATAAGAGCCACC CATGTTCCCCAGGCACACC 
IFTORF 5 TCAAAAGTGAGGCCGTCTGG CTCCTCCTGGCTCTCGTACT 
IFTORF 6 CTTCTCCCTGGTCCGCATC CGTGTACTTCTTGGTGGCCA 
IFTORF 7F/XL39 GAGCATCACCGAGGAGATGG ATTAGGACAAGGCTGGTGGG 
Table 2-6: Primer pairs for sequencing plasmid open reading frame  
All reactions were performed with BIOTAQ DNA polymerase at 68°C. Both WT and 
E664K plasmids were checked for the correct sequence. This identified 2 additional 
variants in the E664K plasmid; both were synonymous. 
2.3.1.4 Site directed mutagenesis 
Four plasmid clones were generated by site directed mutagenesis (SDM) using a PCR 
based method. Primer pairs were designed to be complementary, 25-40bp length with 
the desired mutation central to the primer sequence, terminating with either a G or C 
and a total GC content not more than 40% (table 2-7). Primers were PAGE 
(Polyacrylamide gel purification) purified to give the highest percentage of mutagenized 
clones. The melting temperature (Tm) was checked to be approximately 10°C above 
the extension temperature where Tm=81.5+0.41(%GC)-675/N-%mismatch (N, primer 
length, bps). 
SDM was performed using Turbo DNA polymerase (Agilent Technologies, table 2-8 
and 2-9, figure 2-8). 
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Plasmid 
mutant 
Primer forward 5’ → 3’ Primer reverse 5’ → 3’ 
c.1319 T>C 
(p.Leu440Pro) 
CATGTCGGTGCGCGGGCTGTGT
GCGAC 
GTCGCACACAGCCCGCGCACCGA
CATG 
c.1451C>T 
(p.Thr484Met) 
GGACCTTCTTGTGTGAGATGCC
TGTGTTAGCAATGC 
GCATTGCTAACACAGGCATCTCAC
ACAAGAAGGTCC 
c.2330T>G 
(p.Leu777Arg) 
GAAGCTGAAGTGGCGCATGGCG
TCCCG 
CGGGACGCCATGCGCCACTTCAG
CTTC 
c.2815T>C 
(p.Ser939Pro) 
GCAGGTCCTCCGGCAGCATCCT
GGG 
CCCAGGATGCTGCCGGAGGACCT
GC 
Table 2-7: Primer pairs for site directed mutagenesis 
Component Volume Final concentration 
10x PCR Buffer 5 µl 1x 
10mM dNTP 1 µl 0.2mM 
DNA template 1/2/8 µl (5/10/40ng) - 
Turbo DNA polymerase 2.5 units/µl 1 µl 2.5 units/reaction 
Primer forward, 10µM 1.1 µl  0.22µM 
Primer reverse, 10µM 1.1 µl  0.22µM 
Water 39.8/38.8/32.8 µl - 
Total volume 50 µl  
Table 2-8: Reaction mix for SDM  
SDM procedure: 
Step Temperature Time  
1 Denature 95°C 30 seconds  
2  
3 Annealing/extension 
4 
95°C 
50°C 
68°C 
30 seconds 
1 minute 
2 minutes/kb of plasmid 
 
Go to step 2, 11 times    
5 Terminate Ice 2 minutes  
Table 2-9: Reaction steps for SDM 
From each sample, 10 µl of PCR product was reserved. To the PCR reaction mix 1 µl 
of DpnI restriction enzyme (10 units/ µl, Thermo Fisher Scientific, Waltham, MA, USA) 
was added and incubated at 37°C for 1 hour to cleave the parental dsDNA. Samples 
were then run on an agarose gel, with each quantity of DNA template (10 µl product 
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with 2 µl dye) both digested and undigested, aiming to see a difference between the 
two to select the DNA quantity that optimally worked.  
 
Figure 2-8: Agarose gel of PCR site directed mutagenesis  
For each generated mutant, samples were run with undigested and digested products for each 
of 5ng, 10ng, 40ng, no polymerase and no template giving a total of 10 wells per mutant. 
Following this XL1-blue cells were transformed with the PCR product using the same 
procedure as above, but using 5 µl of the digested product. The initial attempt at 
transformation failed for all products. SDM was repeated for the L440P and L777R. 
Repeat transformation worked for all products with 2-5 colonies grown per plate (figure 
2-9, example of the 5ng S939P agar plate with 2 colonies grown). For large numbers of 
colonies, colony PCR using restriction enzymes would have been used to identify 
correctly mutated colonies. However, given the small number of colonies, each colony 
was cultured. Single colony culture was performed as above followed by Miniprep of 
each colony for DNA extraction and sequencing. Miniprep was performed using the 
(QIAprep Spin Miniprep Kit (QIAGEN) and an adapted manufacturer’s protocol with the 
resulting isolated DNA sequenced (table 2-6). 
 
Figure 2-9: Overnight LB agar plate culture of XL1-blue supercompetent cells  
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From sequence results, the colony with successful mutagenesis was identified and an 
overnight culture performed from the glycerol stock (all under sterile technique): 
1. 50ml flat bottomed tube with 4ml LB broth and 4µl kanamycin was prepared 
2. Using a 10µl pipette tip, a sample was scraped from the top of the glycerol stock 
and dropped in to the tube 
3. Incubated at 37°C, 220rpm for 6 hours 
4. 1.5ml of started culture was added to each of 2 conical flasks with 50ml LB broth + 
50µl kanamycin 
5. Incubated at 37°C, 220rpm overnight 
Maxiprep was then performed to again yield >900ng/µl of plasmid DNA per plasmid 
type with an overall approximate volume of 0.7ml per plasmid. 
2.3.1.5 Culture of hTERT-RPE1 cells  
Cultured hTERT-RPE1 cells (gifted from colleague in lab) were stored in an incubator 
at 37°C with 5% CO2. To work with cells, a class II biological safety cabinet was used, 
with all equipment sterilized with 70% alcohol prior to use. Cells were used at passage 
16 (p16) to p28, therefore a frozen stock was made at an early passage of p16. 
Cell culture protocol: 
1. DMEM (DMEM/F12 GlutaMAX, Thermo Fisher Scientific) containing 50ml FBS 
(foetal bovine serum, Labtech, Uckfield, UK) was warmed in a 37°C incubator, a 
5ml trypsin (trypsin-EDTA, phenol red, Thermo Fisher Scientific) aliquot was taken 
out of the -20ºC freezer to thaw 
2. Cells were inspected under microscope 
3. In hood, DMEM+FBS was removed 
4. Cells were washed with 10ml HBSS (Thermo Fisher Scientific), wash was removed 
5. 5ml trypsin was added to lift cells off flask surface 
6. Incubated 5-10 minutes at 37°C, ensuring minimum time was used 
7. 5-6ml DMEM+FBS was added to flask then all contents were removed to 15ml tube 
8. Cells were counted with a haemocytometer: 25µl of sample were added to top and 
bottom, central 5x5 grids counted with top and right-sided lines only counted for 
cells touching sides of boxes, average number from 2 central grids were counted 
eg 200 equivalent to 200 x 104 (20 x 105). 
9. A new flask containing 20ml DMEM+FBS was then re-seeded at cell concentration 
required, typically 1 x105 to allow twice weekly splitting, eg from count above 1ml 
was added to give an approximate 1 in 20 ratio, cell confluence was required 
quicker, 1.5ml was added etc. 
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10. The flask was labelled with passage, sprayed with 70% ethanol and placed in 
incubator 
11. Confluency, debris and infection check were performed daily 
12. Remainder of cells were used to seed cover slips/ frozen 
Freezing of cells: 
1. From cell splitting, cells were pelleted in a 15ml tube in a centrifuge at high speed, 
for 5 minutes 
2. Resuspended in freeze medium (table 2-10), volume to make 1 x106 concentration 
3. Frozen in 1ml aliquots in cryogenic tubes, 3 hours in -20°C then moved to -80°C 
Component Volume 
10% DMSO 1ml 
60% FBS  6ml 
DMEM+FBS 3ml 
Total 10ml (scale as appropriate) 
Table 2-10: Freeze medium components 
Resurrecting cells: 
1. DMEM+FBS medium was warmed and 10ml added to a 15ml tube 
2. Cells were removed from -80 freezer, rapidly thawed in hand  
3. 1ml cells was added to 10ml medium 
4. Spun at 1000rpm for 8 minutes 
5. Medium was tipped off and pellet flicked to re-suspend 
6. 10ml medium was added and pipetted to mix 
7. Added to a flask already containing 10ml medium 
2.3.1.6 Transient transfection of hTERT-RPE1 cells 
Transient transfection was achieved using Lipofectamine® LTX Reagent with PLUS™ 
(Thermo Fisher Scientific). A 12 well plate was used for which the surface area per well 
is 4cm2 requiring 1ml volume of plating medium. The experiments were designed to 
include each plasmid under investigation with 2 control wells per plasmid; the first 
control contained no DNA, the second control contained both no DNA and no primary 
antibody.  
1. In a class II biological safety cabinet, single round cover slips were sterilised (using 
100% ethanol and flame) and placed in to each well  
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2. Cultured hTERT-RPE1 cells were seeded at 1x105/well in 1ml of DMEM+FBS 
medium and incubated in a sterile incubator at 37°C with 5% CO2 
3. 50-80% confluency was required before transfection (approx. 24 hours) 
4. The medium was removed and 800 µl warmed OptiMEM-I reduced serum medium 
(Thermo Fisher Scientific) added per well 
5. For each experiment, in a 1.5ml microcentrifuge tube, plasmid DNA was diluted in 
200 µl OptiMEM-I reduced serum medium, and mixed gently 
6. PLUS reagent was added to the diluted DNA 
7. This was mixed gently, then incubated for 5 minutes at room temperature 
8. Lipofectamine LTX was added (avoiding tube sides), and mixed thoroughly, then 
incubated for 30 minutes at room temperature 
9. DNA-lipid complexes were added drop-wise to the wells, mixed by gently rocking 
10. Wells were incubated in 5% CO2 incubator at 37°C 
11. After 4-6 hours if cells dying then the medium was changed to DMEM+FBS 
12. After 24 hours serum starvation was performed in order to ciliate cells, by removing 
OptiMEM-I, washing with 1ml DMEM (no FBS) and then adding 1ml DMEM (no 
FBS) and incubating for 24 hours 
Fixation/permeabilisation 
1. All steps were performed at room temperature, culture media was removed and 
each well washed with 1ml phosphate buffered saline (PBS, Sigma-Aldrich) 3 x 10 
minutes 
2. Fixed for 10 minutes using 4% fresh/thawed paraformaldehyde (PFA, Sigma-
Aldrich) in PBS 
3. Washed with PBS 3 x 10 minutes 
4. Permeablised with 0.5% Triton X-100(Sigma-Aldrich) in PBS, 15 minutes 
5. Washed with PBS 3 x 10 minutes  
Immunostaining 
1. Cells were blocked with 400µl 5% normal donkey serum (NDS, Abcam, Cambridge, 
UK) diluted in PBS for 1 hour at room temperature 
2. Primary antibodies were prepared in 1% NDS + PBS, 300 µl per well 
3. Blocking solution was removed and replaced with antibody dilutions 
4. The 12-well plate was sealed and incubated overnight at 4°C 
5. Next day, solutions were removed and washed with PBS 3 x 10 minutes  
6. The following steps were all performed in dim lighting at room temperature 
7. Secondary antibodies were prepared in 1% NDS + PBS, typically at 1:300  
8. Final wash solution was removed and secondaries added 
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9. If low on antibody stock, cover slips were removed from the well and 140 µl solution 
dropped carefully on to each slip 
10. Incubated 1 hour 
11. Washed with PBS 3 x 10 minutes 
12. Mounted with Prolong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific)  
13. Allowed to dry minimum 2 hours, preferably overnight before imaging 
Cells were immunostained with primary antibodies to the C-terminal Myc-DDK tag of 
the plasmid (1:5000 rat Anti-DYKDDDDK Tag Antibody, 200473, Agilent 
Technologies), basal body (1:1000 rabbit anti-pericentrin, Sigma-Aldrich, Dorset, UK) 
and secondarily stained with 1:300 donkey Alexa Fluor® 488 conjugated anti-rat 
(Thermo Fisher Technologies) and 1:300 donkey Alexa Fluor® 647 conjugated anti-
rabbit (Thermo Fisher Technologies). In addition, primary antibody to cilia was initially 
used (1:1000 mouse  anti-acetylated tubulin, Sigma-Aldrich) with secondary 1:300 
donkey Alexa Fluor® 594 conjugated anti-mouse (Thermo Fisher Technologies). 
Optimisation experiments were performed initially with 1µg of WT plasmid to determine 
optimal dilution of anti-FLAG antibody, then the amount of plasmid DNA was further 
optimised based on transfection efficiency (tables 2-11, 2-12).  
Well Plasmid 
name 
Plasmid amount, 
µg  
LTX amount, 
µl 
PLUS amount, 
µl 
Anti-FLAG 
antibody dilution 
1 WT 1 2 1 1:1000 
2 WT 1 2 1 1:2000 
3 WT 1 4 1 1:5000 
4 WT 1 4 1 1:10000 
5 WT 0 2 1 1:1000 
6 WT 0 2 1 No primary 
Table 2-11: Optimisation of anti-FLAG antibody 
Well Plasmid name Plasmid amount, µg  LTX amount, µl PLUS amount, µl 
1 WT 0.25 2 1 
2 WT 0.5 2 1 
3 WT 1 2 1 
5 WT 0 2 1 
6 WT 0 2 1 
Table 2-12: Optimisation of wild-type IFT140 plasmid quantity 
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This determined that 1µg plasmid DNA was optimal for transfection. Ciliation was 
successful for the control sample without plasmid DNA (figure 2-10) and was observed 
with 0.25 µg and to a lesser extent with 0.50 µg of DNA. However transfection 
efficiency was low for these amounts. At 1 µg, ciliation was inhibited but transfection 
efficiency was reasonable (approximately 38%). Therefore the ciliation step and anti-
acetylated tubulin antibody primary were removed from the transfection procedure.  
 
Figure 2-10: hTERT-RPE1 ciliated cells 
Cells were imaged with confocal pinhole laser-scanning microscopy (Zeiss LSM 700, 
Carl Zeiss Microscopy GmbH, Jena, Germany) using 4 solid-state excitation lasers 
(405/444, 488, 555 and 633 nm) with 2 reflection channels simultaneously detected. 
Image processing was performed with ZEN software (2012, Carl Zeiss Microscopy 
GnbH). The percentage of transfected cells with localisation of IFT140 to the basal 
body was calculated from a mean of 3 independent experiments with >100 cells 
counted per experiment (statistical analysis with a one-way analysis of variance and 
post hoc comparison using a Bonferroni correction, IBM© SPSS© Statistics version 22). 
It was noted that a large degree of non-specific cytoplasmic staining was present for 
the majority of transfected cells with a minority of cells expressing IFT140 at a low level 
that was focal and could be localised. This low level expression was counted in the 
experiment and this approach double checked with French colleagues who had initially 
published the experiment.  
Further clarification of observed IFT140 staining was achieved by investigating 
endogenous IFT140 staining in these cells with 1:50 and 1:200 anti-IFT140 antibody 
and 1:300 donkey Alexa Fluor® 647 conjugated anti-rabbit as above. This identified 
non-specific endogenous nuclear staining which would have precluded interpretation of 
expression differences. 
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2.4 Zebrafish studies 
Colleagues within the laboratory already working with zebrafish helped with the 
investigation of an ift140 zebrafish morphant; their roles were in breeding and 
maintaining the zebrafish, performing the microinjections, fixing and embedding, retinal 
histology and Western blots. I designed the experiments, performed retinal 
cryosections, immunohistochemistry, tunel assay and embryo length measurements.  
Wild type (wt) AB zebrafish were bred and maintained in the University College London 
animal facility according to standard protocols and the guidelines of the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research.165 
Microinjection of 3ng ATG start site translation blocking 
(ATCAAAATACACAGCCATGAGCTAC, GeneTools, Philomath, OR, USA) and 
mismatch (MM, ATAAAAATAAACAACCATAAGATAC) morpholino, both modified with 
a 3’ end with carboxyfluorescein, was performed into the yolk sac of 1-2 cell stage wt 
embryos. The morphant embryos were grown at 28.5°C, observed for morphological 
changes at 3 and 5 days post-fertilisation (dpf) with wholemount alcian blue (Sigma-
Aldrich) staining to highlight cartilage structure.166 Successful knockdown of ift140 was 
confirmed by western blot of morphant (both ATG and MM) and wt fish (n=20 per 
group, 30ug total protein) using an IFT140 antibody (1:500 rabbit polyclonal IFT140 
antibody, 17460-1-AP, Proteintech, Manchester, UK) with a beta-actin positive 
antibody control (Sigma-Aldrich). In addition, simultaneous knock-down of both Tp53 
and ift140 were performed to ensure that any observed phenotype was not an off-
target apoptotic effect.167  
For histological analysis, embryos were fixed in 4% PFA, embedded, sectioned and 
stained with toluidine blue (Sigma-Aldrich) according to previously published 
protocols.168  
2.4.1.1 Retinal immunohistochemistry 
Immunohistochemistry was performed on 12 µm retinal cryosections that had been 
fixed in 4% PFA, cryo-protected with 30% sucrose (Sigma) and embedded in Tissue-
Tek® O.C.T. Compound (Sakura Finitek Europe, Alphen aan den Rijn, The 
Netherlands).  
A cryostat (Leica Biosystems, Nussloch, Germany) was used to make the retinal 
cryosections for immunohistochemistry. Separate experiments were performed to test 
primary antibodies against green/red double cones (1:500 mouse anti-zpr-1, ZIRC, 
Oregon, USA) and axons to demonstrate inner retinal layers (1:400 mouse anti-
acetylated tubulin, Sigma-Aldrich). Sections were secondarily stained with donkey 
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Alexa Fluor® 488 conjugated anti-mouse (Thermo Fisher Scientific). Immunostaining 
procedure was as follows: 
1. Slides of retinal cryosections either used fresh or if from -80°C freezer, allowed to 
dry for 1-2 hours 
2. Washed with PBS for 10 minutes x 3 
3. Blocked at room temperature for 1 hr using 20% NDS in PBS with 0.5% Triton x100 
4. Removed block and covered with primary antibodies diluted in 1% NDS (in PBS 
with 0.5% Triton x100) and incubated at 4°C overnight 
5. Washed with PBS for 10 minutes x 3 
6. Covered with secondary antibody (in dark), incubated room temperature 2-4 hours 
7. Washed with PBS for 10 minutes x 3 
8. Dried at room temperature 
9. Mounted with ProLong Gold Antifade Mountant with DAPI and coverslips 
10. Imaged with confocal microscopy (Zeiss LSM 700).  
2.4.1.2 Tunel assay 
For investigation of apoptosis levels, 12 µm cryosections were stained according to 
manufacturer instructions using the ApopTag® Fluorescein In Situ Apoptosis Detection 
Kit (Merck Millipore, Billerica, USA) and then mounted with ProLong Gold Antifade 
Mountant with DAPI and imaged with confocal microscopy (Zeiss LSM 700). 
2.4.1.3 Rescue experiments 
For the rescue experiments, embryos were co-injected with ift140 ATG MO and 0.1 
µg/µl of wt RNA or mutant mRNAs (L440P, T484M) and compared with both wt fish 
and a control group injected with ift140 ATG MO only (n≥100 live embryos counted per 
experiment). The mRNA was generated from plasmid constructs, linearized by SfoI 
restriction enzyme digest (New England Biolabs, Inc., Hitchin, UK) followed by T7 
driven in vitro transcription (mMESSAGE, mMACHINE T7 transcription kit, Life 
Technologies) according to manufacturer protocols. Phenotypes were quantified at 
5dpf based on morpholino length measured from snout to end of notochord using 
ImageJ (statistical analysis with a 2-tailed, paired t-test, IBM© SPSS© Statistics version 
22) and as a secondary measure the vertical eye diameter was also measured.169, 170 
The fish were anaesthetised with 0.003% tricaine before imaging (Nikon stereoscopic 
microscope). The E664K plasmid repeatedly failed transcription and so rescue was 
attempted with wt, L440P and T484M RNAs only.  
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3 Retinal dystrophy due to mutations in the cone-rod 
homeobox gene 
3.1 Introduction 
The cone-rod homeobox gene CRX (MIM #602225) encodes a transcription factor vital 
for both the development and survival of photoreceptors.171-173 It is expressed 
predominantly in photoreceptors and the pineal gland and has a high homology to the 
OTX family of homeobox genes.171, 173 It acts by binding to promoter enhancer regions 
of specific retinal genes; this role is particularly important in retinal development.  It is 
co-expressed in the retina with other transcription factors including NRL and NR2E3.173, 
174   
A locus for autosomal dominant CORD (CORD2, MIM #120970) was identified in 1994 
and mapped to 19q13.175 The gene responsible for CORD at this locus was identified 
as CRX.171 Subsequently it became evident that mutations in CRX may be associated 
with a range of different retinal phenotypes including CORD, LCA, RCD and COD.77, 176, 
177  
CRX mutations are rare with the majority of mutations arising de novo.73 Prior to the 
research outlined in this thesis, 42 probable disease causing mutations and 1 whole 
exon deletion had been reported, all in the heterozygous state except for 3 case 
reports of homozygous disease in LCA and severe RCD.16, 73, 75, 77, 171, 176-199   
In this study of CRX related retinal dystrophy, the phenotypic heterogeneity was 
investigated. This identified a previously unreported association with adult-onset ‘bulls-
eye’ macular dystrophy.  
3.2 Methods 
3.2.1 Ascertainment of patients 
WES in a cohort of unsolved macular dystrophy patients identified 2 patients with 
heterozygous CRX mutations, with this novel finding prompting further study of this 
gene. From interrogation of the genetic database, I identified 65 unsolved probands 
with adult-onset macular dystrophy or CORD and performed targeted Sanger 
sequencing of all exons and intron-exon boundaries of CRX. CORD was included to 
ensure all macular involving dystrophies were investigated. This identified 3 families. In 
addition, from the database, 6 further molecularly solved families with LCA or childhood 
onset retinal dystrophy were identified.  
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3.2.2 Clinical assessment 
Each patient with a CRX mutation underwent a full clinical examination including visual 
acuity and dilated fundus examination. The majority of examinations were performed 
by myself, but in a few patients were performed by one of my supervisors. Age 
permitting, retinal fundus imaging was obtained with electrophysiology performed in all 
patients. 
3.2.3 Molecular investigations 
In total, 11 families were solved by a combination of candidate gene Sanger 
sequencing of all exons and intron-exon boundaries (5 families), APEX microarray (2 
families), Manchester 105 retinal gene panel (1 family) and WES (3 families). 
Confirmatory bi-directional Sanger sequencing of affected exons was performed by 
myself on all 11 identified probands with segregation in available relatives. DNA was 
amplified using specifically designed primers (table 3-1).   
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2 TCACATACCTAAGAGGAGAAGGAGG TGACATACATTTCAGATGAACCC BIOTAQ 64 389 
3 TGAGGTGTAGAAGGGCAGGG TCCAGATAGAGGAAACTGAGTGC MyTaq 64 564 
4.1 TGCAAAGTAGACAGATGTGAACCC TGAAATAGGAGCTCGGAGACCC BIOTAQ 64 518 
4.2 TGGAGCCCAGCCTCAGAGTCC TCTCTGTAAGCTGAACACCGAGC MyTaq 64 564 
Table 3-1: Primer pairs for sequencing of CRX 
Mutation nomenclature was assigned in accordance with GenBank Accession number 
NM_000554.4.  
Phenotype-genotype correlation 
Age of presentation was used as a surrogate and approximate metric of severity in 
order to test associations between mutation position and phenotype severity. First, a 
quantitative analysis was performed of the mutations by plotting the mutation position 
against age of presentation. Using the same data, the hypothesis that mutations 
affecting residues earlier in the gene are generally more severe than others was tested 
by computing the non-parametric Spearman correlation coefficient. Second, a 
qualitative comparison was performed by dividing the mutations into two mutually 
exclusive groups: missense variants affecting the homeodomain, and those that were 
premature termination codons (PTCs) in the carboxyl end of the gene. A comparison of 
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the median age of the two groups was made, and tested for significance using the 
Mann-Whitney test. Statistical analysis was performed using IBM© SPSS© Statistics 
version 22. 
Conservation of CRX homeodomain residues between species and between 
paralogues within humans was analysed using Clustal Omega. The locations of 
mutations arising within the homeodomain were plotted against the consensus 
sequences.  
3.3 Results 
The clinical data are summarized in table 3-2 with pedigrees shown in figure 3-1. From 
the screened cohorts, 11 affected patients were ascertained with a further 7 affected 
relatives from 5 families recruited giving a total of 18 affected patients from 11 families.  
There were 6 simplex cases of which de novo disease could be confirmed in 3 (19090, 
19512 and 20046). A dominant pedigree was evident in 4 families.   
Twelve patients had generalized photoreceptor dysfunction with clinical diagnoses of 
LCA (n=4), RCD (n=2), CORD (n=5) and COD (n=1). An unexpected group of adult 
onset macular dystrophy in 6 patients was identified with initial identification of this 
phenotype from WES of 2 patients. Two were asymptomatic with their disease 
identified incidentally. One (patient 17489.2) was identified after all family members of 
patient 17489.1 were examined in the clinic and the other (patient 19161.1) was 
identified after routine visual field testing at the optometrist showed centrocaecal 
scotomas. This patient still had acuity of 0.0 logMAR (6/6 Snellen) after 6 years of 
follow-up. Deterioration of acuity with time was documented in 3 cases. Patient 4663, 
the most severely affected of the macular dystrophy group, deteriorated from 0.2 
logMAR (20/32 Snellen) each eye to right 1.3 logMAR (20/400 Snellen) and left 1.5 
logMAR (20/630 Snellen) during 16 years follow up. Patient 16711 had incidental 
peripapillary changes similar to angioid streaks without any other identifiable features 
in the fundus or systemically (figure 3-2); this was thought to be an incidental finding 
unrelated to his macular dystrophy. 
A common fundus feature in all phenotypes was that of macular atrophy, present in 14 
of 18 cases. It was not present in 2 LCA patients (examined at a young age), nor in 
both members of family 17489, although these latter cases did have ISe band 
disruption at the maculae on OCT (figure 3-2). Three of the 4 LCA cases had 
noticeably blonde fundi at presentation.  
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Family, 
gender 
Age 
ons-
et 
Age  
last 
rv 
Diagn-
osis 
Fundus Age at last 
electrophysiology, 
key findings 
Latest VA, 
logMAR, (Snellen), 
refraction if known 
19090   
(f) 
Birth 2  
yrs 
LCA Blonde  11 mths: probably 
undetectable 
R NPL L NPL 
19512 
(m) 
3 
mths 
2.5 
yrs 
LCA Blonde fundus, central 
macular atrophy, thin 
peripheral retina 
9 mths: undetectable R&L NPL  
R&L +3.00 DS  
20046   
(f) 
Birth 7 
mths 
LCA Blonde fundus 7 mths: markedly 
attenuated 
R&L PL  
R&L +3.50 DS 
5126.1 
(m) 
12  
yrs 
50  
yrs 
CORD Macular & peripheral 
atrophy, bone spicules, 
attenuated arterioles, 
pale optic discs 
47 yrs: very severe 
generalized retinal 
dysfunction  
R HM L CF  
R +3.25/-2.00x165 
L +3.75/-3.50 x5 
5126.2 
(m) 
12  
yrs 
27  
yrs 
CORD Macular atrophy, subtle 
peripheral RPE mottling 
25 yrs: undetectable 
PERG, generalized 
retinal dysfunction, 
cone deterioration 
R 1.0 (6/60)        
L 1.1 (6/75)  
R +1.25/-2.75 x29  
L +1.25/-3.00 x174 
5126.3  
(f) 
14  
yrs 
25  
yrs 
CORD Macular atrophy, 
peripheral retinal RPE 
pigment change 
15 yrs: undetectable 
PERG, subnormal rod, 
moderately severe 
reduction cone  
R 1.0 (6/60)            
L 0.8 (6/38)  
R +6.5/-3.50 x 175   
L +6.00/-3.50 x 20 
17489.1 
(m) 
3.5 
yrs 
16  
yrs 
RCD Yellow spots R macula, 
pale optic discs, 
attenuated arterioles, 
mid peripheral 
hypopigmentation 
11 yrs: Undetectable 
PERG and rod ERG, 
markedly subnormal 
cone specific ERG 
R 1.0 (6/60)        
L 1.2 (6/95)  
R +0.50 DS  
L +0.50 DS 
17489.2 
(f) 
53 
yrs 
53  
yrs 
MD Mild disc pallor only 53 yrs: Bilateral 
macular dysfunction, 
normal ERGs 
R 0.3 (6/12)      
L 0.5 (6/19) 
18280.1 
(f) 
49 
yrs 
56  
yrs 
MD Ring of RPE atrophy in 
maculae 
52 yrs: PERG not 
definitely detectable, 
normal ERGs 
R 0.2 (6/9.5)      
L 0.3 (6/12)  
R +0.25/0.25 x180 
L +0.25/0.25 x45 
18280.2 
(f) 
50  
yrs 
56  
yrs 
MD Ring of RPE atrophy in 
maculae 
51 yrs: Undetectable 
PERG, normal ERGs 
R 0.6 (6/24)  
L 0.3 (6/12)  
R +1.00/-0.75 x90   
L +0.50 DS 
18280.3 
(m) 
32  
yrs 
42  
yrs 
CORD Ring RPE atrophy in 
maculae with peripheral 
RPE pigmentary 
change 
35 yrs: Undetectable 
PERG, subnormal rod, 
markedly subnormal 
cone ERG 
R&L 1.0 (6/60)        
R -2.50/-0.50 x180  
L -3.50/-0.50 x180 
19161.1 
(f) 
50  
yrs 
56  
yrs 
MD Mild RPE mottling 
maculae 
52 yrs: Markedly 
reduced PERG, normal 
ERGs 
R&L 0.0 (6/6)  
Hyperopic 
19161.2 
(f) 
45  
yrs 
52  
yrs 
CD Ring of RPE atrophy in 
maculae 
48 yrs: Severely 
reduced PERG, cone 
ERGs reduced/delayed  
R 0.5 (6/19)      
L 0.2 (6/9.5)  
R&L +1.75 DS 
19990.1 
(f) 
6  
yrs 
27  
yrs 
RCD Macular atrophy, 
peripheral extensive 
pigmentary retinopathy 
26 yrs: Severe 
generalised loss of 
photoreceptor function  
R&L PL 
19990.2 
(f) 
Birth 2  
yrs 
LCA Ring of RPE atrophy in 
maculae, mottled 
peripheral RPE change 
20 mths: undetectable 
PERG and ERG 
R&L HM  
R +6.00/-2.00x180 
L +2.00/-1.25 x180 
712       
(f) 
11  
yrs 
73  
yrs 
CORD Pale discs, blonde 
posterior pole, 
attenuated arterioles, 
peripheral pigmentary 
clumps 
60 yrs: PERG 
undetectable on L, 
residual on R, severe 
cone dysfunction with 
rod involvement 
R 0.8 (6/38)  
L 1.0 (6/60)  
R -11.00/-1.00 x10 
L -9.50/-2.00 x175 
4663     
(f) 
42  
yrs 
67  
yrs 
MD Macular atrophy 67 yrs: extinguished 
PERG, normal ERGs 
R 1.3 (6/120)  
L 1.5 (6/190) 
Hyperopic 
16711 
(m) 
35  
yrs 
63  
yrs 
MD Macular atrophy 54 yrs: undetectable 
PERG, normal ERGs 
R&L 1.0 (6/60) 
 
Table 3-2: Key phenotypic features of patients 
NPL, no perception of light; DS, dioptre sphere; PL, perception of light; HM, hand movements; 
CF, counting fingers  
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Figure 3-1: Pedigrees 
FAF imaging and OCT scans were available in 12 of 18 patients; the LCA patients 
were all too young for imaging and FAF and Spectralis OCT was unavailable in the 
COD patient. FAF imaging demonstrated a reduced ring of autofluorescence para-
foveally in the CORD patients, an extensive loss of autofluorescence in the RCD 
patients and a ring of increased autofluorescence at the macula with loss of 
autofluorescence within the ring in all macular dystrophy patients.  
On OCT, 4 of the CORD patients had loss of the ISe band with outer retinal thinning at 
the macula on OCT, with patient 9 showing disruption of the ISe band but no macular 
thinning. The 2 patients with RCD had loss of outer retina and ISe band at the maculae 
on OCT. The macular dystrophy patients had disruption of the ISe band at the maculae 
on OCT with patient 17489.2 the least affected. 
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Figure 3-2: Retinal imaging in CRX related retinal dystrophy 
Fundus imaging of patients 5126.2, 17489.1, 17489.2, 19161.1, 18280.1, 18280.3, 16711, 
4663: (a) right fundus photograph, (b) right 30 or 55 degree FAF imaging, (c) right OCT. Patient 
4663, (a.1) fundus photograph from 1998, (a.2) fundus photograph from 2014 
Electrophysiology was performed in all patients (figure 3-3, table 3-2). Patients with 
LCA had an undetectable ERG, whereas those with later onset generalised 
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photoreceptor dystrophy had subnormal and delayed full field ERGs. The PERG was 
universally reduced in the macular dystrophy patients, with normal full field ERGs. 
 
Figure 3-3: Electroretinography features  
One eye of patients 19161.1, 18280.3, 17489.1 and normal control (age 24). Patient 19161.1, 
macular dystrophy, demonstrates subnormal PERG with normal ERGs for age (53 years at 
ERG).
200, 201
 Patient 18280.3, cone-rod dystrophy, demonstrates subnormal rod and bright flash 
ERGs (DA 0.01; DA 11.0), delayed and subnormal cone flicker ERGs (LA 3.0 30Hz) and 
markedly subnormal single flash ERG (LA 3.0 2Hz) with undetectable PERG. Patient 17489.1, 
rod-cone dystrophy, demonstrates undetectable rod ERG (DA 0.01); severe reduction in the 
bright flash ERGs (DA 11.0) and markedly delayed and subnormal cone flicker and single flash 
ERGs (LA 3.0 30Hz; LA 3.0 2Hz). PERG was unrecordable due to nystagmus. 
Four families demonstrated intra-familial phenotypic heterogeneity (figure 3-1). Family 
17489 segregated macular dystrophy and RCD; family 18280 macular dystrophy and 
CORD; family 19161 macular dystrophy and cone dystrophy; and family 19990 RCD 
and LCA. Family 17489 is particularly unusual as the son had early onset retinal 
dystrophy with rod-cone dysfunction, the mother a mild, asymptomatic macular 
dystrophy and the daughter optic atrophy with normal ERGs that presented age 3. Both 
she and her father screened negative for mutations in CRX. The identified 
heterozygous mutation in this family has previously been reported.178 Phenotypic 
homogeneity was present in only 1 family (5126), all affected members having CORD. 
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Molecular analysis was performed on all patients and available family members (table 
3-3). Seven novel mutations were identified, 6 PTCs in exon 4, and 1 missense 
mutation in exon 3. The novel missense mutation is predicted to be pathogenic based 
on SIFT and Polyphen2 scores. Segregation analysis confirmed de novo mutations in 3 
of the LCA cases. 
Table 3-3: Mutations in CRX found in this patient series 
Nine further missense variants in 11 patients were identified (table 3-4). Based on 
predictive algorithms, previous reports and the presence of the variant in control 
population databases, 8 of these most likely represent benign changes with the ninth 
predicted to be damaging but not segregating with known disease within the family. 
Four of these 9 variants are novel and include 2 synonymous changes, c.355A>C 
(p.Arg119Arg) and c.561C>T (p.Thr187Thr), and 2 non-synonymous changes, 
c.127C>T (p.Arg43Cys) and c.526C>T (p.Arg176Trp). The novel synonymous changes 
Family Diagn-
osis 
Variant: nucleotide, 
protein 
Predicted effect Segregation First 
report 
19090 LCA c.570delC 
(p.Tyr191Metfs*3)  
PTC Both parents negative This paper 
19512 LCA c.571delT 
(p.Tyr191Metfs*3) 
PTC Both parents negative Rivolta 
2001
194
 
20046 LCA c.570delC 
(p.Tyr191Metfs*3) 
PTC Both parents negative As above  
5126 CORD c.568_590del 
(p.Pro190Glyfs*38) 
PTC Present in all 3 affected 
patients, other family DNA 
unavailable 
This paper 
17489 RCD, 
MD 
c.121C>T 
(p.Arg41Trp) 
Pathogenic  
SIFT 0,      
Polyphen2 1.0 
Present in affected patient 
and affected mother, 
absent in father and sister 
Swain 
1997
178
 
18280 MD, 
CORD 
c.774T>A 
(p.Tyr258*) 
PTC Present in all 3 affected 
patients, further family 
DNA unavailable 
This paper 
19161 MD, 
CD 
c.605delG 
(p.Cys202Sfs*17) 
PTC Present in both affected 
patients, further family 
DNA unavailable 
This paper 
19990 RCD, 
LCA 
c.624T>G 
(p.Tyr208*) 
PTC Present in affected patient 
and daughter, further 
family DNA unavailable 
Stone 
2007
73
 
712 CORD c.821delG 
(p.Gly274Alafs*97) 
PTC No other DNA available This paper 
4663 MD c.582delC 
(p.Tyr195Thrfs*23) 
PTC No other DNA available This paper 
16711 MD c.272G>A 
(p.Arg91Lys) 
Pathogenic  
SIFT 0,       
Polyphen2 0.992 
No other DNA available This paper 
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are predicted to be tolerated on SIFT analysis, arise more than 100 base pairs from 
any intron-exon boundary and are not predicted to affect splicing in silico. Variant 
c.365G>A, found in 2 patients with macular dystrophy and cone dystrophy, onset 
childhood and early 30’s respectively, has been previously reported as an apparently 
benign variant.202 Variants c.472G>A and c.101-12A>G were found in 2 patients both 
with predominantly macular dystrophy and mild full field ERG abnormalities. Both 
variants have been previously reported in normal controls.178 The c.526C>T variant 
was identified in a RCD patient hemizygous for a novel RPGR splice site mutation 
(identified in the same exome sequencing experiment) and segregation analysis found 
the same heterozygous CRX change in the mother, who had normal acuity, fundus 
examination and electrophysiology at the age of 35. The c.127C>T variant predicted to 
be damaging was identified in a macular dystrophy patient on exome-analysis and 
subsequently also identified in her older brother and mother, both of whom are 
asymptomatic but unavailable for further examination. Age of onset in this patient was 
22 years old with visual acuity at last review age 27 of 1.0 logMAR each eye (20/200 
Snellen) 
Patient details Variation SIFT Polyphen2 ExAC database First 
reported 
Family 19090, father c.355A>C 
(p.Arg119Arg) 
0.43 N/A N/A This paper 
Family 20046, patient and 
mother 
c.196G>A 
(p.Val66Ile) 
1.0 0.033  358 in 121402 Vallespin 
2007
203
 
Family 17489, patient 17489.1 ,  c.100+12C>T N/A N/A 17164 in 114812 Swain 
1997
178
 
Patient with CORD c.561C>T 
(p.Thr187Thr) 
0.75 N/A N/A This paper 
Two patients cone dystrophy 
and macular dystrophy 
c.365G>A 
(p.Gly122Asp) 
0.35 0.080 1092 in 119584 Sohocki 
2001
202
 
Patient macular dystrophy with 
mild cone and rod involvement 
c.472G>A 
(p.Ala158Thr) 
0.62 0.012 981 in 119300 Swain 
1997
178
 
Patient macular dystrophy with 
mild rod and cone involvement  
c.101-12A>G N/A N/A 358 in 121402 rs73941294 
Patient with rod cone dystrophy c.526C>T 
(p.Arg176Trp) 
0.22 0.974 4 in 119782 ExAC 
Patient with macular dystrophy c.127C>T, 
p.Arg43Cys 
0.03 1.000 N/A This paper 
Table 3-4: Identified CRX variants of uncertain pathogenicity 
A quantitative analysis was performed of the mutations by plotting the mutation position 
against age of presentation. A more severely affected subset of patients could be 
expected to have a lower median age of presentation than the remainder of the cohort. 
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Such an analysis would be expected to demonstrate critical gene regions after which 
severity might change thus exposing clinically significant functional domains.204 On 
plotting the position of mutation against age of presentation (figure 3-4) there was no 
evident position after which severity differed, nor was there a correlation between 
position and severity (Spearman correlation coefficient rs= 0.093, p=0.787). A 
comparison of median age of presentation in those with homeodomain missense 
versus PTC mutations showed no statistical difference (Mann-Whitney test, U = 7.00. 
p=0.634). 
 
Figure 3-4: Mutation codon position against age of onset 
Forty three mutations of possible pathogenicity have been previously reported (table 3-
5). A further 4 variants were excluded from further analysis for the following reasons: 
the first was from a single report of a mutation in exon 2, c.24dupG (p.Pro9Alafs*61) in 
a patient with LCA but the mutation did not segregate with disease and the patient in 
question also had severe bilateral sensorineural hearing loss, a feature not otherwise 
reported with CRX mutations196; 2 mutations, c.720_742dup23 (p.Gln248Profs*19) and 
c.753delC (p.Ser252Profs*119), are part of a screen on a microarray are also excluded 
as they are unpublished and no further information is provided as to patient 
phenotype153; the fourth, c.351dupC (p.Lys118Glnfs*56) is also unpublished.183  
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Mutation- heterozygous 
unless specified 
Protein SIFT score Polyphen2 score First report 
c.121C>T p.Arg41Trp 0 1.0 Swain 1997
178
 
c.122G>A p.Arg41Gln 0.04 0.998 Swain 1997
178
 
c.124G>A p.Glu42Lys 0.03 0.997 Li 2011
179
 
c.166G>A p.Ala56Thr 0.23 0.96 Lotery 2000
180
 
c.193G>C, homozygous p.Asp65His 0 0.999 Jin 2008
181
 
c.238G>A p.Glu80Lys 0 0.991 Sankila 2000 
182
 
c.239A>C p.Glu80Ala 0 0.991 Freund 1997 
171
 
c.239A>G p.Glu80Gly 0.03 0.997 Huang 2012
183
 
c.264G>T p.Lys88Asn  0 0.999 Nichols 2010
184
 
c.268C>T, homozygous  p.Arg90Trp 0 1.000 Swaroop 1999
185
 
c.344G>A p.Arg115Gln 0.58 0.999 Sohocki 2001
202
 
c.413delT p.Ile138Thrfs*48 N/A N/A Nichols 2010
184
 
c.421delT p.Ser141Profs*46 N/A N/A Zou 2013
186
 
c.429_430delTCinsA p.Ser143Argfs*44 N/A N/A Stone 2007
73
 
c.436_447del p.Leu146_Pro149del N/A N/A Sohocki 1998 
176
 
c.447dupC p.Ser150Leufs*24 N/A N/A Lines 2002
187
 
c.458delC p.Pro153Glnfs*34 N/A N/A Ziviello 2005
188
 
c.460delA p.Thr154Profs*33 N/A N/A Arcot Sadagepan 2013
199
 
c.463_464insGGCA p.Thr155ArgFs*20 N/A N/A Stone 2007
73
 
c.495delAinsTTT p.Ala166Leufs*22 N/A N/A Kohl 2012
189
 
c.502delG p.Glu168Serfs*19 N/A N/A Freund 1997
171
 
c.503_504delAG p.Glu168Valfs*6 N/A N/A Freund 1998
77
 
c. 512delT p.Leu171Cysfs*16 N/A N/A Perrault 2003
190
 
c.520delG p.Ala174Argfs*13 N/A N/A Nakamura 2002
191
 
c.529delG p.Ala177Leufs*10 N/A N/A Koenekoop 2002
192
 
c.541delG p.Ala181Profs*6 N/A N/A Zhang 2001
193
 
c.570dupC p.Tyr191Leu*45  N/A N/A Stone 2007
73
 
c.571delT p.Tyr191Met*3 N/A N/A Rivolta 2001
194
 
c.573T>A p.Tyr191* N/A N/A Chen 2013
75
 
c.585C>A p.Tyr195* N/A N/A Stone 2007
73
 
c.585dupC p.Ala196Argfs*40 N/A N/A Sohocki 1998
176
 
c.587-590delCCCC p.A196Gfs*22  N/A N/A Swain 1997
178
 
c.615delC p.Ser206Profs*13 N/A N/A Itabashi 2004
195
 
c.624T>G p.Tyr208* N/A N/A Stone 2007
73
 
c.636delC p.Ser213Profs*6 N/A N/A Kitiratschky 2008
177
 
c.650delG p.Gly217Alafs*2 N/A N/A Freund 1998
77
 
c.709dupC p.Leu237Profs*30 N/A N/A Stone 2007
73
 
c.709delC p.Leu237Serfs*134  N/A N/A Silva 2000
196
 
c.789delC p.Val264Trpfs*107  N/A N/A Rivolta 2001
194
 
c.816delCACinsAA p.Thr273Argfs*98 N/A N/A Paunescu 2007
197
 
c.887T>G p.Phe296Cys 0 0.999 Preising 2007
198
 
c.899A>G p.*300Trpext*118 N/A N/A Eisenberger 2013
16
 
c.85-?_299+?del Unknown N/A N/A Eisenberger 2013
16
 
Table 3-5: Previously reported mutations in CRX 
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Analysis of the 43 remaining likely pathogenic mutations indicates a pattern of 
missense mutations in exon 3 and PTCs in exon 4 (figure 3-5). There are 2 exceptions 
to this, c.344G>A (p.Arg115Gln) located early in exon 4 and reported in a single patient 
with limited phenotype and segregation data; and c.887T>G (p.Phe296Cys), located in 
the extreme C terminal and reported in a single family with CORD that is predicted to 
be damaging.198, 202 There is a single report of a whole exon deletion of CRX, identified 
in a sibling pair with LCA who had bi-allelic disease with a compound heterozygous 
missense mutation on the other allele.16  
 
Figure 3-5: Schematic diagram of CRX structure and mutations 
All published likely pathogenic mutations and 7 novel mutations from this series positioned 
along gene schematic. Mutations in bold with # for patients in this series. 
The CRX homeodomain is highly conserved throughout species (figure 3-6) with all 
reported homeodomain mutations arising within highly conserved residues. Analysis of 
the homeodomain between human paralogues reveals that 4 reported mutations arise 
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in residues that are not conserved (figure 3-7); p.Glu42Lys reported to cause LCA, 
p.Ala56Thr reported to cause LCA, p.Asp65His reported to cause RCD in a 
homozygous state and p.Lys88Asn reported to cause LCA. All mutations found within 
the homeodomain that are associated with LCA therefore alter amino acid residues 
that are not conserved between paralogue human proteins. 
 
Figure 3-6: Conservation of missense variants across species 
Affected residues in this study highlighted with residue change underneath. * (asterisk) indicates 
positions which have a single, fully conserved residue, a : (colon) indicates conservation 
between groups of strongly similar properties, a . (period) indicates conservation between 
groups of weakly similar properties. 
 
Figure 3-7: Conservation of missense variants across human paralogues 
3.4 Discussion 
This series of 18 patients with retinal dystrophy consequent on CRX mutations 
represents the largest series studied and identified a new associated macular 
dystrophy phenotype. A group of patients with an autosomal dominant macular 
dystrophy presenting in their 3rd to 5th decades is described. There was documented 
progression of the macular disease. Two cases were asymptomatic at presentation. 
At the severe end of the CRX disease spectrum are the LCA cases presenting in 
infancy with severe loss of vision. RCD presented within the first decade of life, CORD 
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in the 2nd-3rd decades and macular dystrophy in adulthood, with a range of 35 to 53 
years.  The macular dystrophy was characterized by a ‘bulls-eye’ appearance similar to 
that observed in other macular dystrophies including the autosomal dominant form 
associated with PROM1.205 Variable expressivity is also a feature of PROM1 with some 
patients manifesting generalized retinal dysfunction.  
Macular atrophy was present in 14 of 18 cases. Also commonly found was a disrupted 
ISe band on OCT, identified in all investigated patients. Electrophysiology further 
characterised the phenotypes demonstrating a normal ERG in all macular dystrophy 
cases confirming that the dysfunction was confined to the macula. Two cases with 
macula dystrophy have normal ERG age 60 and 67 years indicating no evidence for 
peripheral retinal dysfunction developing with time. In families 17489 and 18280 who 
co-segregate macular dystrophy with generalised retinal dysfunction, it is noted that the 
older affected family members have the mildest phenotype. 
There are 4 exons in CRX, the first non-coding, producing a 299 amino acid protein. 
The protein has strong homology to OTX1 and OTX2 in 3 regions; the homeodomain at 
residues 39-99 which binds to DNA, the 13 residue WSP motif at residues 158-170, 
which is of unknown function, and the OTX tail at residues 284-295, a specific carboxyl 
terminus motif, of unknown function.171 Broadly, the mutations that arise in the 
homeodomain are missense mutations; those in the remainder of the last exon, exon 4 
are PTCs with no mutation reported within the OTX tail (figure 3-5). In all cases, it is 
predicted that abnormal protein is produced, as avoidance of nonsense mediated 
decay (NMD) would be predicted for the premature terminations according to the 
classical rules for this phenomenon.206 The significance of the two distinct classes of 
mutation in the different protein regions is not clear.  As noted, no clear genotype-
phenotype association could be deduced from the complete data set or from the cases 
newly reported here.  
All but 1 reported homeodomain mutation arise within the alpha helices that are 
important in binding to the major groove of DNA via several hydrogen bonds, the 
exception being a homozygous mutation, c.193G>C (p.Asp65His).181, 184  One 
homeodomain mutation associated with LCA, c.264G>T (p.Lys74Asn) has been 
demonstrated to disrupt DNA binding in a molecular model as well as interfere with the 
normal function of co-expressed transcription factors such as NRL in vitro, by a 
postulated dominant-negative effect184. The homeodomain mutations arise in residues 
fully conserved in CRX between species but not fully conserved in human paralogues 
of the CRX protein. Interestingly, all LCA associated mutations were located in non-
conserved residues in these paralogues suggesting importance of these residues in 
CRX specific function. 
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There have been 3 reports of bi-allelic CRX disease. Two siblings with LCA have been 
reported with compound heterozygous mutations, the first a missense mutation that 
removes the normal translation termination codon, the second a deletion of exon 4.16 
The carrier parents were asymptomatic but not examined. Two homozygous, missense 
mutations have been reported, both in the homeodomain; c.193G>C (p.Asp65His) in a 
sporadic patient with severe RCD and asymptomatic parents unavailable for 
examination and c.268C>T (p.Arg90Trp) in a patient with LCA, his heterozygous carrier 
parents having subtle cone abnormalities on ERG.181 185 In vitro studies of DNA binding 
compared the p.Arg90Trp mutation to p.Arg41Trp which had been identified in CRX 
related CORD.185 DNA binding was more severely affected by p.Arg41Trp. This was 
thought to be consistent with the more severe symptoms found in heterozygous 
p.Arg41Trp related CORD compared to the heterozygous p.Arg90Trp asymptomatic 
carrier parents. However, in the series of patients reported in this thesis, affected 
members of family 17489 were heterozygous for p.Arg41Trp manifesting with severe 
RCD in the son and asymptomatic macular dystrophy in the mother which would not fit 
with this theory. The reason for the variable severity of mutations is still to be 
elucidated.  
Heterozygous knockout mice (+/-) have no retinal phenotype at 6 months of age 
whereas homozygous knockout mice (-/-) have severe loss of rod and cone function, 
but neither types model the dominant human disease.207 A spontaneous mouse 
mutant, CrxRip/+ was then identified in which a dominant PTC on one allele produced a 
truncated protein and a phenotype similar to congenital, blinding, dominant CRX retinal 
dystrophy in humans.208 There is a lack of normal photoreceptor differentiation in the 
CrxRip/+mouse, with arrested development at an early stage and inactive and immature 
photoreceptors identified histologically. There were 2 main mechanisms by which this 
mutant caused disease: firstly by a lack of normal DNA binding by the CRX mutant 
compared to wild type leading to loss of normal transactivation of photoreceptor genes 
and secondly by a dominant negative effect of this mutant allele whereby mutant CRX 
blocks the binding of wild type CRX to target genes and of OTX2 to the Nrl promoter 
preventing transactivation of Nrl and in turn the transactivation of essential rod and 
cone gene expression. Ectopic Nrl expression in the CrxRip/+ mouse partially rescued 
the poorly differentiated rod photoreceptor precursors. Reported knock-in mouse 
models have severely reduced retinal function and demonstrated the association of 
CRX expression level on disease severity as well as the ability of the mutant allele to 
interfere with wild type function.209 One model with a truncating mutation had more 
severe disease than another, with a missense mutation mirroring the reported human 
phenotypes for those specific mutations. These mouse models may provide excellent 
opportunities for further functional analysis of CRX related disease and the 
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investigation of potential treatments. The evidence to date, including this study and the 
mouse models, suggests that haploinsufficiency of CRX is not, in itself, disease-
causing. Instead, an allele has to be both non-functional and expressed (hence the 
lack of PTCs early in the gene), such that the abnormal protein partly abrogates the 
normal one expressed from the other allele. 
Seven novel mutations were identified; 1 missense in exon 3 with 6 PTCs in exon 4. 
Four families demonstrated the large degree of clinical variability that can occur 
between those sharing the same CRX mutant allele. This heterogeneity may be due to 
i) the influence of polymorphisms in the CRX promoter region; ii) polymorphisms in co-
expressed transcription factors such as Nrl; iii) the impact of environmental factors; iv) 
stochastic factors, that is small perturbations of CRX function causing larger and later 
effects on the degree of degeneration; v) variable levels of expression of the mutant 
allele which in a mouse model has been correlated with variable severity or vi) variable 
levels in expression of the wild-type allele which in PRPF31 related disease has been 
correlated with variable penetrance.114, 209 Study of the promoter region and of RNA 
transcripts may help to elucidate this further.  
A further novel mutation, c.127C>T, in a patient with macular dystrophy did not 
segregate with known eye disease in the family, with the asymptomatic mother and 
brother heterozygous for the variant. Given the examples in this series of 
asymptomatic presentation, it cannot be concluded that these other family members 
are not affected. Unfortunately, examination and retinal imaging was not possible in the 
family members to clarify this issue. The patient presented at age 22, younger than the 
other macular dystrophy patients in this series, and also has a more severe reduction 
in visual acuity than the other macular dystrophy patients. 
Only 3 of the 11 reported families had a family history of possible retinal dystrophy in 
antecedent generations prior to this study. Parental sequencing in 3 of the 8 other 
families confirmed de novo mutations. DNA was unavailable from antecedents in the 
remaining 5 families, although the observed pedigrees make it possible that these 
mutations may also have arisen de novo. Alternatively, given the relatively mild 
presentation of the macular dystrophy phenotype, disease in antecedents might have 
been unreported. These 8 families highlight the difficulties in genetic counselling in 
patients with apparent simplex retinal disease. The possibility of de novo mutation, or 
mild unreported disease in antecedents, suggests a greater risk in subsequent 
generations than if autosomal recessive inheritance was assumed. It would also affect 
the risk to other siblings. Clinicians should therefore have a low threshold for screening 
CRX in patients presenting with any of the phenotypes consistent with those presented 
here.    
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4 Enhanced S-cone syndrome in children 
4.1 Introduction 
Enhanced S-cone syndrome (ESCS, MIM 268100) is a rare, autosomal recessive 
retinal dystrophy first described in 1990.210 It is one of the few disorders in which the 
electrophysiological findings are pathognomonic.135, 210 Patients present with symptoms 
of nyctalopia from the first decade with or without reduced vision; the visual loss may 
be associated with foveal schisis.211, 212 The disorder is probably slowly progressive and 
deterioration of the ERG has been demonstrated.212, 213 Adults with the disorder 
characteristically show nummular pigmentary deposition at the level of the RPE outside 
of the vascular arcades with or without foveal schisis-like cystic changes.212 There are 
few reports of the presentation of ESCS in children: case reports of early findings 
describe a normal fundus or early changes of white dots at the level of the RPE. 214-216 
This prompted further investigation of a series of children with a diagnosis of ESCS 
from Moorfields. 
Defects in a nuclear receptor gene, NR2E3, were linked to ESCS in 2000. Mutations in 
NR2E3 leading to loss of function of the transcription factor are theorised to be 
pathogenic by the abnormal differentiation of post-mitotic photoreceptor precursor 
cells, so altering their cell fate from rod to S-cone.217 218 To date, at least 49 mutations 
have been reported with resultant phenotypes of ESCS, Goldmann-Favre syndrome 
and both autosomal dominant and autosomal recessive RCD.212, 218-239 An atypical form 
or ESCS due to bi-allelic NR2E3 variants has been reported in 3 patients with residual 
rod function.229, 233, 240 
4.2 Methods 
4.2.1 Patient ascertainment 
Nine patients (2 simplex cases, 2 sibling pairs and 1 sibling pair and half cousin) were 
ascertained from the inherited retinal disease clinics based on a clinical and molecular 
diagnosis of ESCS. 
4.2.2 Clinical assessment 
Each confirmed patient underwent a full clinical examination including visual acuity and 
dilated ophthalmoscopic examination. I examined all patients. One patient declined 
further investigations apart from molecular testing but their sibling had undergone full 
investigation. All other patients had electrophysiological testing and dilated fundus 
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imaging. Additional S-cone ERGs were recorded, when possible, to a 5ms blue 
stimulus (445 nm, 80 cd.m-2) on a bright orange background (620nm, 560 cd.m-2); ON-
OFF ERGs were recorded to an orange stimulus (duration 200ms) on a green 
background (530nm, 150 cd.m-2).241, 242  
4.2.3 Molecular investigations 
Patients identified as clinically typical for ESCS had already been screened by 
colleagues within the lab for disease causing mutations. Family 2 declined further 
molecular testing on the affected children, the father having already been identified as 
having a homozygous variant causing his Goldmann-Favre syndrome and the related 
mother being heterozygous for the same variant. This consanguineous family, who 
demonstrate pseudo-dominant inheritance, has been previously reported.211, 212, 243 I 
confirmed those parental mutations and performed segregation within all other families 
by direct sequencing of the relevant exons and intron/exon boundaries of NR2E3 (table 
4-1). Mutation nomenclature was assigned in accordance with GenBank Accession 
number NM_014249.3 with nucleotide position 1 corresponding to the A of the ATG 
initiation codon. The gene was not covered on the ExAC database. 
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1 TGGTAATGCTGCAGGTGTGGC TCCTTCCATGGTCCCTGCGAACC BIOTAQ 60 482 
2-3 GCGTGGGTTCGTTCAAATGCGG CTCTCCCACTCACCATCCTCT BIOTAQ 60 837 
4-5 TGACAAGAAATGGGCAGCGGGAC ATACTGGCGTGGGGATGTGTGTG BIOTAQ 60 712 
6-7 TCCTTGGGTGCCTGAGATGGTG TGGGAGAGTGTGGGAGAGGCAGA BIOTAQ 60 894 
8 AATTCCTCCTGACCCACTCTGG CTTTCGGTGGGCATTTCTGCTG BIOTAQ 60 393 
Table 4-1: Primer pairs for sequencing of NR2E3 
4.3 Results 
Clinical findings are summarized in table 4-2. Nine children (5 female, 4 male) from 5 
families were assessed. Mean age at last review was 10.8 years (median 11 years, 
range 7-15 years). Diagnostic ERG was performed in 8 patients at a mean age of 8.6 
years (median 8 years, range 3-14 years). Geographic/ethnic origin was white British in 
4 families and the Kashmir region of Pakistan in 1 family. 
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 Fundus FAF OCT Latest VA, 
log MAR 
Refraction 
1.1 (f) 
GC 
19824 
9 White dots and 
nummular 
pigmentation 
along arcades 
Diffuse paracentral 
hyperfluorescence, multiple 
small high density foci along 
arcades, hypofluorescence 
outside of the arcades  
Normal R 0.80         
L 0.90 
R +8.00/-3.50 x 5    
L +8.50/-3.50 x 160 
1.2(f) 9 White dots and 
nummular 
pigmentation 
along arcades 
Diffuse paracentral 
hyperfluorescence, multiple 
small high density foci along 
arcades, hypofluorescence 
outside of the arcades 
Foveal 
sparing 
cysts BE 
R 0.50         
L 0.36 
R +10.50/-1.00 x 70 
L +10.00/-1.00 x 80 
1.3(m) 12 Few white dots 
and RPE 
mottling along 
arcades 
Diffuse paracentral 
hyperfluorescence with 
multiple small high density 
foci along arcades 
Normal R 0.14         
L 0.74 (L 
amblyopia) 
R +3.00/-0.50 x 10  
L +4.50 DS 
2.1(f) 
GC 
15494 
15 Subtle RPE 
mottling along 
arcades 
Small foci of high density 
along arcades 
Foveal 
sparing 
cysts BE 
R 0.1           
L 0.1 
R +2.50/-1.25 x 180 
L +2.25/-1.25 x 180 
2.2(m) 11 Normal Small foci of high density 
along arcades 
Normal R 0.00          
L 0.08 
R +1.00/-1.00 x 15  
L +2.50/-2.25 x 170 
3.1(m) 
GC 
19784 
7 Few white dots 
along superior 
arcades 
- - R 0.05             
L 0.10 
R +2.25/-1.00 x 180 
L +3.00/-1.00 x 180 
3.2(m) 9 RPE mottling 
along arcades  
Diffuse paracentral 
hyperfluorescence with 
multiple small high density 
foci along arcades 
Normal R 0.14         
L 0.00 
R +3.50 DS             
L +2.50 DS 
4(f)    
GC 
19940 
14 White dots and 
nummular 
pigmentation 
along arcades 
Diffuse paracentral 
hyperfluorescence, multiple 
small high density foci along 
arcades, hypofluorescence 
outside of the arcades 
Foveal 
involving 
cysts BE 
R 0.86         
L 1.20 
R +3.50/-0.50 x 21  
L +3.50/-1.00 x 145 
5(f)    
GC 
16715 
11 Normal Small foci of high density 
along arcades 
Normal R 0.10      
L 0.125 
R +3.50/-1.50 x 20  
L +4.00/-1.50 x 165 
Table 4-2: Key clinical features  
Longitudinal data were available in 8 patients (mean follow up 3 years; range 1-10 
years). All patients reported nyctalopia although patient 3.1 only reported this from the 
age of 7. No patient had nystagmus. Visual acuity ranged from 0.0 to 1.2 logMAR. 
Reduced vision in both eyes (≥0.3 logMAR) with deterioration over time was recorded 
in patients 1.1, 1.2 and 4, the rest retaining good visual acuity with appropriate 
refractive correction. Only patient 4 had evidence of intra-retinal cysts involving the 
fovea. This patient was intolerant of both topical and oral carbonic anhydrase inhibitors. 
All patients had a hyperopic refractive error with mean spherical equivalent at 
presentation of +4.40 D (range +1.40 D to +11.75 D) and at last review a mean of 
+4.00 D (range +0.50 D to +10.00 D). 
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Figure 4-1: Fundal abnormalities in paediatric enhanced S-cone syndrome 
Patient 5, (a.i) and (a.ii) left normal fundal photographs, (b) abnormal fundus autofluorescence 
(FAF) imaging with high density foci; Patient 2.1, (a.i) right normal fundal photograph 2006 (a.ii) 
right fundal photograph 2011 with RPE mottling present (b) right FAF imaging with high density 
foci; Patient 1.3, (a) right Optos fundus photograph with RPE mottling and a few white dots, (b) 
FAF imaging showing diffuse paracentral hyperfluorescence and small high density foci along 
arcades; Patient 1.2, (a) right Optos fundus photograph demonstrating white dots and extensive 
nummular pigmentation, (b) FAF imaging demonstrating diffuse paracentral hyperfluorescence, 
small high density foci and a hypofluorescent ring outside of the arcades. 
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Figure 4-2: Optical coherence tomography scans 
Patient 5, left normal macular OCT; Patient 2.1, right abnormal macular OCT with intra-retinal 
cysts; Patient 1.2, right abnormal superior arcade OCT demonstrating disorganized architecture 
and multiple hyper-reflective lesions in the outer nuclear layer (white arrow).  
Two patients had a normal biomicroscopic appearance to their fundi although their FAF 
imaging demonstrated foci of high density around the arcades (figure 4-1). Two had 
RPE mottling only and 2 had RPE mottling with white dots. The typical adult ESCS 
feature of nummular pigmentary deposits along the arcades was present in 3 patients. 
There was phenotypic variability within family 1 which was independent of age; a 
female patient and her female half cousin (patients 1.1, 1.2) had extensive nummular 
pigmentation not present in her older male half cousin (patient 1.3, figure 4-1). 
Progression of ophthalmoscopic changes was recorded in 4 patients. Patient 2.1 who 
presented at age 6 years with a normal fundus appearance showed subtle RPE 
mottling along the arcades at age 11 years (figure 4-1). Patient 3.1 had subtle RPE 
mottling at presentation aged 4 years, and subsequently developed white dots along 
the arcades from age 6. Patients 1.1 and 1.2 had nummular pigmentary lesions along 
the arcades which increased during follow up periods of 2 and 3 years respectively.  
FAF imaging was abnormal in 8 of 8 patients. Three patients had multiple fine foci of 
increased autofluorescence associated with the arcades. Two of these patients had a 
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normal fundus appearance; the third had subtle RPE mottling only. Diffuse paracentral 
hyperfluorescence within the arcades in conjunction with multiple fine high density foci 
alongside the arcades, was present in 5 patients. In 3 of these patients with more 
severe disease, reduced autofluorescence was noted outside of the arcades in the mid 
peripheral retina. 
Eight patients underwent OCT; 5 had normal OCTs, 2 had evidence of macular intra-
retinal cysts without foveal involvement and 1 had fovea-involving cysts (figure 4-2). 
Extended OCT scanning, to include the superior arcades, was performed in 2 patients. 
There was loss of normal retinal architecture and small hyper-reflective lesions 
throughout the outer nuclear layer. 
ERGs demonstrated the characteristic features of ESCS (figure 4-3).  
 
Figure 4-3: Electrophysiology in enhanced S-cone syndrome  
a) Full-field and pattern ERGs in patient 2.1. b) Extended S-cone ERGs from the right eye of 
patient 2.1. N, normal. 
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The rod-specific DA 0.01 response was undetectable; brighter flash dark adapted 
ERGs (DA 3.0 and DA 11.0) were of simplified, delayed waveform (figure 4-3). The 
responses to the same stimuli under scotopic (DA 3.0) and photopic adaptation (LA 
3.0) were of similar waveform; the 30Hz flicker ERG was profoundly delayed and 
additionally was of lower amplitude than the single flash LA 3.0 ERG a-wave. S-cone 
specific testing was possible in 5 children, and showed high amplitude, delayed and 
simplified responses in keeping with origins in short wavelength sensitive cones, and of 
similar waveform to those obtained to white light stimulation. Extended S-cone ERGs 
from patient 2.1 is shown in figure 4-3b. The 200ms blue stimulus response shows 
some OFF- activity, as occurs in some but not all ESCS patients.212 The photopic ON- 
OFF- response in the patient (200ms orange flash) is markedly reduced, of simplified 
waveform, and shows delay in all components. 
The PERG P50 component, used to assess macular function, was within normal 
amplitude limits in 2 patients, subnormal without delay in 2, delayed without amplitude 
reduction in 1, and delayed and subnormal in 1 patient. PERG data from one patient 
was excluded due to high levels of physiological noise. One patient did not have 
electrodiagnostic testing due to parental preference but his brother has typical 
electrophysiology and both have genetically confirmed disease.  
Molecular genetic analysis 
Mutations identified and segregation are shown in table 4-3 and figure 4-4. 
Mutation  Family SIFT Polyphen2 First reported 
119-2A>C, aberrant splicing  1 and 3 N/A N/A Haider 2000
218
 
c.1194delT (p.Pro399Glnfs*44) 1 N/A N/A This series 
c.310C>T (p.Arg104Trp)  2 0.00  1.00  Haider 2000
218
 
c.1025T>C (p.Val342Ala) 3 0.00 0.996 This series 
c.305C>A (p.Ala102Asp) 4 0.00 0.999 This series 
c.767C>A (p.Ala256Glu) 4 and 5 0.02 0.998 Sharon 2003
244
 
c.994G>A (p.Glu332Lys) 5 0.04 0.912 This series 
Table 4-3: Identified mutations in NR2E3  
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Figure 4-4: Pedigrees and mutation distribution for the 5 affected families  
* presumed genotype, DNA unavailable for testing 
Family 1, a brother and sister pair and their cousin have the same compound 
heterozygous change; c.119-2A>C (paternal), predicted to cause aberrant splicing and 
the most common mutation reported in ESCS, and a novel PTC, c.1194delT 
(p.Pro399Glnfs*44, maternal). Additional novel mutations identified were all missense, 
c.1025T>C (p.Val342Ala), c.305C>A (p.Ala102Asp) and c.994G>A (p.Glu332Lys). All 
novel missense mutations are predicted be pathogenic in silico (table 4-3). They all 
arise in amino acids highly conserved throughout evolution as confirmed by Clustal 
Omega (figure 4-5). 
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Figure 4-5: Conservation of missense mutations 
4.4 Discussion 
In this study, the characteristic retinal features of ESCS in children was investigated 
and compared with adults with the disorder. Appropriate investigations, in particular 
ERG and FAF imaging, were found to be clinically most helpful in diagnosis. Variability 
of presentation and visual disability both across and within families was identified. 
Most children initially lack the deep nummular pigmentation typically seen in adults, 
and fundus examination may be normal at presentation in keeping with previous 
reports of the paediatric phenotype in ESCS.215, 216 Patient 2.1 in this series, previously 
reported to have a normal fundus appearance, now has subtle RPE mottling.211, 212 
Isolated, subtle RPE changes along the arcades are a finding not previously noted in 
ESCS but apparent in this series. Sub-retinal white dots without nummular 
pigmentation in children have been previously reported in a series of 3 patients.214 
Whilst the white dots are characteristic of ESCS, they are not diagnostic and have also 
been reported in NR2E3 related autosomal recessive RCD with clumped 
pigmentation.244 Previously reported complications in ESCS of choroidal neovascular 
membrane or sub-retinal fibrosis were not evident in any of the present series.210, 215, 245  
This series of children suggests a sequence of fundal change from normal appearance, 
followed by RPE mottling along the arcades, and then the development of white dots 
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followed by deep nummular pigmentary deposition. FAF imaging is particularly useful 
in highlighting subtle abnormalities along the arcades in children with a normal fundus 
appearance. High density foci along the arcades on FAF imaging with a normal fundal 
appearance has previously been reported in an 8 year old child.211, 215 A practical 
application is in determining whether other (younger) family members are affected. The 
high density foci on FAF imaging do not always correspond to white dots seen 
ophthalmoscopically.215 Four patients in the present series demonstrated high density 
foci on FAF without white dots. These foci have been shown in a murine model to 
originate from accumulations of microglial cells between the outer nuclear layer and the 
RPE.246 Microglial cells are known to play a central role in chronic degenerative 
conditions of the central nervous system. In adults, FAF imaging may demonstrate a 
ring of relatively increased hyperfluoresence within the arcades as seen in 5 cases in 
this series, a spoke-like hyperfluorescence in the macula in the presence of foveal 
schisis and/or a reduction in autofluorescence anterior to the arcades in the mid 
periphery of the retina.212 This latter sign was found in 3 cases in this series all of 
whom have more severe disease and is thought to represent loss of photoreceptor 
cells. It corresponds well to reported histology in advanced ESCS which demonstrated 
relative preservation of photoreceptors in the macula and the far periphery of the retina 
with loss of photoreceptors in the mid periphery.213 Monitoring of disease progression 
with FAF imaging in particular the loss of autofluorescence in the mid periphery can 
therefore be used as a marker of photoreceptor loss. 
Intra-retinal cysts in the macula similar to adult disease, can occur in children and can 
lead to loss of vision.211, 212 The majority of patients in the present series maintained 
good visual acuity in keeping with other reported ESCS cases, but in 3 patients vision 
deteriorated.210, 247 One case had intra-retinal cysts involving the fovea that could 
explain the reduction in acuity and one had para-foveal cysts. However, these 3 cases 
also had more advanced ophthalmoscopic changes with nummular pigmentation.  
Two patients underwent extended OCT outside of the macula. There were intra-retinal, 
hyper-reflective lesions in the outer nuclear layer, with a disorganized retinal 
architecture and loss of normal lamination. This has been previously described in a 
child with ESCS in the mid-periphery, and may be a useful adjunct in diagnosis and 
monitoring.215, 248 The OCT findings are consistent with the previously described 
histological data which found a loss of normal retinal lamination and disorganisation of 
the retina.213 The disorganised retinal lamination has been suggested not to be 
developmental but acquired either from ongoing proliferation in the NR2E3 deficient 
retina or as a secondary proliferative response to cell death.248 Extended OCT studies 
also identified thickening of the retina in particular the outer nuclear layer in a ring 
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around the arcades, with thinning evident in end-stage disease.248 In CRB1 related 
retinal dystrophy there is thickening and disorganisation evident throughout the retina 
including the macula, a finding thought most likely to be developmental.249 Although 
this has been observed at an early age it has not yet been proven to be developmental. 
Electrophysiology remains the most useful investigation in ESCS due to the 
pathognomonic ERG abnormalities. Additional non-standard ERG testing provides 
further evidence of the disorder with S-cone specific ERGs several times the 
magnitude of normal, also showing a waveform similar to that of the conventional 
Ganzfeld ERG.135 Pattern ERGs were abnormal in 4 of 6 cases but were generally 
better preserved than in affected adults; a previous study revealed abnormal pattern 
ERGs in 16 of 16 adults including 5 with undetectable responses.212 Pathognomonic 
ERGs facilitate targeted molecular diagnosis. 
NR2E3 encodes a 410 amino acid, 8 exon, ligand dependent transcription factor 
important in the determination of photoreceptor cell fate. NR2E3, in cell studies and the 
RD7 murine model, acts in tandem with CRX to promote rod photoreceptor 
differentiation and suppress the formation of cone cells.174, 250 Histopathological and 
immunocytochemical analysis of a post mortem eye of one elderly patient with ESCS 
showed a degenerate retina with no rods and approximately twice the number of 
cones, 92% of which were short-wavelength cones.213 The NR2E3 protein constitutes a 
DNA binding domain (DBD, amino acid residues 45-131) and a ligand binding domain 
(LBD, amino acid residues 222-410).251 The DBD is a highly conserved region 
comprising 2 ‘zinc finger’ -like structures that specifically bind to consensus sites in the 
promoter regions of target genes.251 Interaction of the DBD with the homeodomain of 
CRX enables NR2E3 transactivation of target genes.174, 251 Mutations in the DBD have 
been shown to abolish DNA binding.252 Some but not all mutations in the LBD have 
been shown to disrupt homo- and heterodimerisation.240 Reported mutations in NR2E3 
are evenly split between the DBD and the LBD without any obvious clustering. Four 
novel mutations are reported in this study, three of which are missense mutations 
predicted to be damaging in silico; p.Ala102Asp arising within the DBD and 
p.Glu332Lys and p.Val342Ala located within the LBD. The novel deletion, c.1194delT; 
p.Pro399Glnfs*44, also located in the LBD, is a PTC that creates an alternative reading 
frame predicted to result in a new 43 amino acid chain followed by a stop codon.  
All but 1 family in this series were found to be compound heterozygous for mutations in 
NR2E3, limiting the possible phenotype-genotype correlations that could be made 
based on a specific type or location of mutation. At present the prognosis related to a 
specific genotype is unknown and the molecular diagnosis does not alter the patient’s 
management.  
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5 Non-syndromic retinal dystrophy due to bi-allelic 
mutations in IFT140               
5.1 Introduction 
The outer segments of photoreceptors are highly modified, photosensitive cilia, which 
lack any capability for protein production.22 Thus, they are reliant on the intraflagellar 
transport (IFT) system, which comprises large protein complexes for transport from the 
cell body to cilium tip and back driven by the motors kinesin-2 and dynein-2 
respectively.23 The IFT-B complex is essential for cilium assembly and anterograde 
transport whereas the IFT-A complex is responsible for retrograde transport, with 
additional roles in anterograde transport by connecting kinesin to the IFT complex, and 
in facilitating entry of proteins in to the cilium.253, 254 IFT140, a subunit of IFT-A, is vital 
for both the development and the maintenance of outer segments, and has a specific 
role in opsin transport across the connecting cilium.23  
Mutations in IFT140 have been associated with Jeune asphyxiating thoracic dystrophy 
and Mainzer-Saldino syndrome, ciliopathies forming part of a spectrum of skeletal 
dysplasias now collectively termed short rib thoracic dysplasia 9 with or without 
polydactyly (SRTD9, MIM#266920).255-258 First described in 1970, patients have 
variable skeletal features including shortened ribs, short stature, cone-shaped 
phalangeal epiphyses (pre-pubertal), brachymesophalangy, and acetabular spurring or 
metaphyseal defect of the femoral head.259 Non-skeletal features in the majority of 
patients include a severe early-onset retinal dystrophy, and end stage renal failure 
secondary to nephronophthisis by teenage years with cerebellar ataxia, epilepsy, facial 
dysmorphism, learning difficulties and cholestasis also reported.255-257  
IFT140 mutations have now been identified in patients with isolated retinal 
dystrophy.260, 261 Prior to these reports, 2 families from this centre were identified from 
WES with non-syndromic RCD due to bi-allelic IFT140 variants and further functional 
investigation of this novel finding was then planned. A further 3 families were 
subsequently identified, 2 from the Manchester 176 retinal gene panel and 1 from 
WGS as part of the SPEED study. Detailed characterisation of the ocular phenotype 
was performed and functional analysis of 2 identified variants with protein localisation 
studies in hTERT-RPE1 cells performed to support their pathogenicity. In addition, 
characterisation of a zebrafish morpholino was performed as a potential animal model 
of the human disease. 
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5.2 Methods 
5.2.1 Patient ascertainment 
Two probands were initially identified by colleagues from whole exome sequencing. 
Variants in IFT140 were identified as the most likely cause of their retinal dystrophy 
with no other pathogenic variants in known retinal dystrophy genes. Both probands 
were assessed and examined by myself and their extended family in Pakistan and New 
Zealand contacted for DNA samples and segregation. All patients provided written, 
informed consent. A colleague in Pakistan was able to review 2 of the affected family 
members there. Three further probands were later identified, 2 from the Manchester 
NGS gene panel test and the fifth from WGS as part of the SPEED study.  
5.2.2 Clinical investigations 
A total of 8 affected patients were studied with full ophthalmic examination (2 by 
myself, 4 by my supervisors and 2 by a colleague in Pakistan) and retinal imaging. 
Seven of 8 patients underwent renal function testing, 5 of 8 patients had hand x-rays. 
One patient was no longer contactable despite multiple attempts and therefore 
unavailable for renal function testing. 
5.2.3 Molecular investigations 
Patient 1.1 had been previously investigated by a negative APEX microarray. He was 
then found negative by targeted NGS of the coding regions of 31 retinal dystrophy 
genes performed at Bioscientia Center for Human Genetics (Ingelheim, Germany). 
WES was then performed (AROS). Patient 2 was initially investigated as part of the UK 
National Collaborative Usher study due to the co-existence of hearing loss with retinal 
dystrophy with negative bidirectional Sanger sequencing of 9 Usher genes (MYO7A, 
CDH23, PCDH15, USH1C, USH1G, USH2A, GPR98, WHRN, CLRN1) and a 
candidate gene SLC4A7 as part of the UK National Collaborative Usher Study as 
previously described.262 WES was then performed as above. Patients 3.1 and 4 
underwent NGS of the coding regions of 176 retinal genes (Manchester). Patient 5 
underwent WGS as part of the SPEED study. 
Bi-directional Sanger sequencing of involved exons and intron-exon boundaries of 
IFT140 was performed by my colleague in the lab for family 1, by myself on family 2, by 
Manchester Genomics centre for families 3 and 4 and as part of the NIHR SPEED 
study on family 5. Segregation was confirmed in available relatives. I obtained blood 
samples on relatives from Pakistan and New Zealand to enable segregation. DNA was 
amplified using specifically designed primers by polymerase chain reaction (PCR) and 
the resulting fragments were sequenced using standard protocols (table 5-1).  
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13 CAGTTCCCTGTGCCTCAGAG ACCCGGTCTCAGGTAGTTCT BIOTAQ 65 409 
19 TCTGACCATTGCCAGTGACC TGGGCAGCATTTCATCGAGT BIOTAQ 65 548 
22 GTGCTCAGGGTCTGCAGAG TGGCTTTGTCCAAAGGGAGG BIOTAQ 65 423 
Table 5-1: Primer pairs for Sanger sequencing of IFT140 in families 1 and 2 
Nomenclature was assigned in accordance with GenBank Accession number 
NM_014714.3.  
5.2.4 Cell studies 
Under supervision by a colleague (Nicholas Owen) within our lab at the Institute of 
Ophthalmology, an in vitro experiment was designed to perform transient plasmid 
transfection of hTERT-RPE1 cells to further investigate missense variants identified in 
the original 2 families. I performed all experiments as described in methods section 2.3. 
5.2.5  Zebrafish studies 
Investigation of a zebrafish morphant was performed as described in methods section 
2.4. There was limited published data on this morphant, and we hypothesised that 
rescue experiments may provide further evidence of pathogenesis of the missense 
variants studied. 
5.3 Results 
Ophthalmological and systemic findings 
Five families were studied (figure 5-1). Clinical details are summarised in table 5-2. All 
patients had a retinal dystrophy characterised by nyctalopia and progressive field loss, 
with fundus features and electrophysiology (available in 3 patients) consistent with a 
rod-cone dystrophy. 
Non-syndromic retinal dystrophy due to mutations in IFT140 
 
 86 
 
Figure 5-1: Pedigrees of 5 families with mutation segregation 
Family 1 of Northern Pakistan origin was comprised of the proband (patient 1.1) and 
his 3 affected second cousins, 2 of whom (patients 1.2 and 1.3) were available for 
clinical examination. Patient 1.1 was born at full term to consanguineous parents. He 
was noted to have reduced night vision at 2 years of age. Fundus examination 
demonstrated mild mid-peripheral retinal changes only (figure 5-2). Electroretinography 
(ERG) performed age 8 demonstrated a relatively severe rod-cone dystrophy with 
marked bilateral macular involvement which had progressed when repeated age 13 
years. Systemically, patient 1.1 was well with no dysmorphic features and normal 
growth parameters (age 13, height 50th-75th centile, weight 75th centile, head 
circumference 25th centile). His fingers were noted to be long and he had no skeletal 
abnormalities. Hand and hip X-rays were normal (figure 5-3). He had a history of 
congenital right pelvico-ureteric junction obstruction and secondary hydronephrosis, 
which required surgical correction at 4 years of age. Renal and liver function blood 
tests were normal at age 13 years. Renal ultrasound demonstrated a normal left 
kidney, with global cortical thinning and loss of normal corticomedullary differentiation 
on the right consistent with the history of hydronephrosis.  
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1.1 
GC 
17830 
2 
years 
13 years              
R 0.0 (6/6)           
L 0.0 (6/6)  
R +0.25/-1.25 x40  
L -5.50/-0.50 x140 
Mid-peripheral 
hypopigmented dots, 
mild RPE atrophy  
 
Humphrey VF 24-
2: extensive loss 
periphery, central 
10° preserved 
Ishihara: 17/17 BE 
Age 13, residual 
PERG activity, 
severe loss both 
rod and cone 
systems 
N N 
1.2 <10 
years 
45 years              
R 0.7 (6/30)         
L 0.5 (6/19) 
Mid-peripheral RPE 
hypopigmentation with 
intra-retinal pigmentary 
migration, macular 
atrophy 
Early cataract RE, 
L cataract surgery 
age 44 
Not done N N 
1.3 <10 
years 
44 years              
R 0.3 (6/12)          
L 0.3 (6/12) 
Mid-peripheral RPE 
hypopigmentation, 
early macular atrophy 
Early lens opacity Not done N N 
2 
GC 
1558 
16 
years 
67 years 
R HM                   
L PL 
Posterior pole 
chorioretinal atrophy, 
extensive mid-
peripheral 
pigmentation, severely 
attenuated vessels 
Confrontation VF: 
<5° BE 
Cataract surgery 
BE late 40’s, 
myopic prior 
Not done 76 95 
3.1 
GC 
4303 
Late 
20’s 
53 years 
R 0.7 (6/30)         
L 1.8 (1/60) 
R cystoid macular 
oedema with epiretinal 
membrane, B macular 
atrophy, attenuated 
vessels extensive 
pigmentary change 
Confrontation VF: 
20° on R, 10° on L 
Early cataract 
 
Age 45, 
undetectable 
PERG and rod 
specific ERG, 
markedly 
subnormal cone 
115 61 
3.2 Early 
30’s 
57 years 
R 0.2 (6/9.5)         
L 0.2 (6/9.5) 
Marked vessel 
attenuation, nasally 
occluded vessels, 
extensive atrophy 
particularly posterior 
pole, mid-peripheral 
pigmentary change 
Early cataract BE 
Ishihara: R 2/17 L 
4/17 
 
Not done 91 56 
4 
GC 
21161 
28 
years 
31 years 
R 0.0 (6/6)           
L -0.1 (6/4.8) 
Attenuated vessels, 
mid-peripheral RPE 
mottling 
Confrontation VF: 
full 
Ishihara: 17/17 BE 
Not done 77 109 
5  
GC 
20552 
14 
years 
26 years 
R 0.3 (6/12)         
L 0.2 (6/9) 
R -2.50/-0.75 x15   
L -1.75/-1.25 x10 
Bilateral mild epiretinal 
membrane, mild RPE 
change in mid-
periphery 
Early subcapsular 
cataract 
Ishihara: R 7/17 L 
17/17 
Age 25, 
subnormal 
PERG, rod 
responses 
undetectable, 
subnormal cone 
NA NA 
Table 5-2: Clinical summary of patients with IFT140 related retinal dystrophy 
eGFR, estimated glomerular filtration rate; NA, not available 
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Both patients 1.2 and 1.3 developed visual symptoms in childhood with preservation of 
central vision until their 40’s. They had retinal changes of RCD with attenuated vessels, 
macular atrophy and mid-peripheral pigmentary change, worse in the older brother. 
Neither brother had any syndromic features. Specifically, hand X-rays did not 
demonstrate shortened phalanges, and renal and liver functions were normal.  
Patient 2, of Caucasian British origin, first noticed nyctalopia aged 16 years with 
peripheral field loss noted in his mid-20’s when he was diagnosed with RCD. Loss of 
central vision occurred by 50 years of age with fundus features of a severe and 
extensive pigmentary retinopathy. There was no history of skeletal or renal 
abnormalities. Hand X-ray did not identify shortened phalanges, and renal function 
blood tests were normal age 67 years. There was a history of progressive hearing loss 
noted at the age of 4 years, which required hearing aids. Audiometry revealed 
symmetrical bilateral high frequency loss and bilateral plateau loss of 25-30db in 250-
2000 kHz frequencies. The hearing loss was atypical for Usher syndrome. There was 
no other medical history of note. His younger sister also has RCD but without hearing 
loss. Clinical examination was not possible but a DNA sample was obtained. 
Family 3 are from the Gujarat region of India. The proband, 3.1, noted nyctalopia in his 
late 20’s and problems with glare. He noted reduced left vision at age 44 years. 
Fundus examination revealed extensive pigmentary change and vessel attenuation. 
ERG was consistent with severe generalised retinal dysfunction in both eyes. Patient 
3.2, presented with nyctalopia and progressive peripheral field loss in her early 30’s. 
When last reviewed age 57, visual acuity was still good at 0.2 logMAR each eye 
(Snellen 20/32) despite marked vessel attenuation and generalised atrophy of the 
posterior pole. Neither patient has any systemic manifestations. Both patients have 
normal serum creatinine but estimated glomerular filtration rates (eGFR) that are 
borderline and under review. Both are hypertensive on oral medications. Patient 3.2 
has had stable creatinine and eGFR over 6 years of monitoring. 
Family 4 are British Caucasian. The proband noted difficulty with dark and light 
adaptation in his late 20’s but otherwise remains without symptoms. At last review age 
31 years, visual acuity was excellent with mild retinal changes only. Systemically well, 
skeletal survey, renal function and renal ultrasound were all normal. 
Family 5 are from the Punjab region of Pakistan. The proband developed nyctalopia in 
early teenage years without any other noticeable symptoms. When last reviewed age 
26 years, the patient was systemically well with no clinically apparent syndromic 
features of disease. Further investigations were unfortunately not possible as the 
patient is no longer contactable. 
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Figure 5-2: Retinal imaging in IFT140 related rod-cone dystrophy 
(a) colour fundus photographs, (b) FAF imaging, (c) OCT.  
Patient 1.1, RE (a) diffuse, mid-peripheral white dots, para-foveal atrophy in macula, (b) ring of 
increased autofluorescence in macula, reduced mid-peripherally (c) centrally preserved ISe 
band. Patient 1.2, LE (a) central macula atrophy, peripheral intra-retinal pigmentary migration in 
regions of depigmentation. Patient 1.3, LE (a) central macular atrophy with mid-peripheral 
hypopigmentation. Patient 2, LE (a) posterior pole atrophy with heavy mid-peripheral 
pigmentation, (b) extensive loss of autofluorescence, (c) loss of outer retina and inner choroid. 
Patient 3.2, RE. (a) macular atrophy, mid-peripheral RPE atrophy and pigment change, marked 
vessel attenuation, nasal vessel occlusion, (b) reduced autofluorescence particularly in posterior 
pole, (c) disorganised retina with loss of outer retina and ORT (arrowed). Patient 4, RE. (a) 
attenuated vessels, mid-peripheral RPE hypopigmentation, (b) ring of increased 
autofluorescence in macula, speckled reduction mid-periphery (c) ISe band preserved centrally. 
Patient 5, RE. (a) mild mid-peripheral RPE atrophy, (b) ring of increased autofluorescence in 
macula with small dots of reduced autofluorescence nasally, (c) ISe band preserved centrally 
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Figure 5-3: Skeletal imaging in IFT140  
Patient 1.1 anteroposterior (AP) x-rays of left hand and pelvis, patient 2, AP and lateral x-rays of 
left and right hands. All x-rays normal. 
Molecular investigations 
In family 1, WES identified a homozygous variant, c.1451C>T (p.Thr484Met), with 
segregation in 5 unaffected and 3 affected family members supporting causality (figure 
5-1). This variant has now been reported.260 No other predicted pathogenic variants 
were identified in known retinal genes. In family 2, WES identified a splice site variant 
c.2399+1G>T, that has been previously reported in 4 syndromic patients and a novel 
missense variant, c.2815T>C (p.Ser939Pro) predicted to be tolerated in silico.255, 256 
Patient 2’s affected sister also carries both variants with his son carrying the missense 
variant only, confirming that the mutations are in trans.  
A targeted gene panel of 176 genes identified c.998G>A (p.Cys333Tyr) in the third 
proband. This was also present in 2 other affected family members with 1 unaffected 
sibling not harbouring the variant. It is therefore possible, in this non-consanguineous 
family, that the affected patients are hemizygous with a deletion on the other allele. 
This variant has not been reported in an affected patient before but is present in 2 of 
121,370 alleles on ExAC. 
Patient 4 also underwent targeted sequencing of 176 retinal genes identifying 2 
variants. The first, c.1021G>A (p.Ala341Thr) has an allele frequency of 10 in 119,692 
on ExAC and is predicted to be damaging in silico (SIFT 0.03, Polyphen2 1.00). The 
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second, is a novel frameshifting mutation, c.1422_1423insAA (p.Arg475Asnfs*14). 
Segregation in his parents confirmed the mutations to be in trans.  
WGS in patient 5 identified the same homozygous variant as found in family 3. Affected 
and unaffected family members overseas were unavailable for further testing.  
Conservation of the missense variants identified in this study was compared to 
syndromic missense variants across a diverse range of orthologues (figure 5-4). 
Ala341Thr, Thr484Met and Ser939Pro are not conserved, Cys333Tyr is fully 
conserved. Six of 9 syndromic missense mutations are fully conserved; 3 are not 
conserved. 
 
Figure 5-4: Conservation of missense variants 
Transient cell transfection studies 
Site directed mutagenesis using mutation specific complementary primer pairs 
generated 4 plasmid clones. A total of 6 plasmids were used in cell transfection 
experiments: 2 contained non-syndromic mutations c.1451C>T (p.Thr484Met, T484M) 
and c.2815T>C (p.Ser939Pro, S939P); one a previously unreported mutation, 
c.1319T>C (p.Leu440Pro, L440P), from a patient with Leber Congenital Amaurosis and 
renal failure (personal communication Isabelle Perrault); a previously reported plasmid 
with a syndromic mutation c.1990G>A (p.Glu664Lys,E664K);255 the WT plasmid; and a 
polymorphism, c.2330T>G (p.Leu777Arg, L777R), rs34535263. Following transient 
transfection of IFT140 and mutants in hTERT-RPE1 cells and subsequent 
immunostaining, analysis of aberrant IFT140 localisation with the basal body was 
performed (figure 5-5).  
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(A) Transient transfection was performed with 6 Myc-DDK-tagged IFT140 plasmid constructs. 
Cells were immunostained with primary antibodies to the IFT140 plasmid and basal body and 
secondarily stained. Expressed IFT140 (white arrow) and basal body localisation was reduced 
in all mutants compared with WT and L777R. Scale bar= 20µm.
 
Figure 5-5: Aberrant localisation of IFT140 with basal bodies in transiently 
transfected hTERT-RPE1 cells. 
(B) The percentage of transfected 
cells with localisation of IFT140 to 
the basal body was calculated from 
a mean of 3 independent 
experiments (n>100 cells).   
 
A statistically significant difference 
was found between WT and E664K, 
L440P, T484M and S939P          
(*** p<0.0001). There was no 
statistically significant difference 
found between WT and L777R, nor 
between the syndromic mutants, 
E664K and L440P and the non-
syndromic mutants T484M and 
S939P (p=1). 
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Transfection efficiency was 38% with generalised cytoplasmic staining frequently 
observed. Those cells with specific basal body labelling by IFT140 were counted. 
Statistically significant aberrant localisation was found for T484M, S939P, L440P and 
E664K compared to WT and L777R (p<0.0001). No significant difference was found 
between any of the 4 pathogenic mutations (T484M, S939P, L440P and E664K, p=1) 
nor between the syndromic mutants L440P and E664K when compared to the non-
syndromic mutants T484M and S939P (p=1). Two control experiments using 
secondary antibodies and either no plasmid DNA or no plasmid DNA and no primary 
antibodies were performed each time to check for contamination (figure 5-6). 
 
Figure 5-6: Control experiments 
No aberrant staining with secondary antibodies. Scale bar= 20µm. 
Characterisation of an ift140 zebrafish morphant 
Colleagues within the lab performed microinjection of an ift140 translation blocking 
morpholino (ift140 ATG MO) with embryos analysed at 3 and 5 dpf (figure 5-7). They 
identified changes in the gross morphology with normal body axis curvature but shorter 
length and smaller eyes for both ift140 ATG MO 3dpf and 5dpf morphants but with 
abnormalities most obvious in the 5dpf group. In addition, there was a variable lack of 
swim bladder for ift140 ATG MO at 5dpf. They performed Western blot to confirm 
successful knockdown of ift140. Simultaneous knock-down of both Tp53 and ift140 at 
3dpf demonstrated that the observed phenotype was still present indicating that this 
was not an off-target apoptotic effect. Alcian blue cartilaginous stain was similarly 
distributed between morphant and wt although development appeared either delayed 
or the cartilaginous structures reduced in size in morphants. Retinal histology 
demonstrated mild thickening of the inner plexiform and ganglion cells layers at 5dpf.  
Apoptosis assay found no apparent difference between wt and morphant at both 3dpf 
and 5dpf stages. Immunohistochemistry demonstrated reduced anti-zpr-1 (red-green 
double cone staining) for 5dpf MO. Anti-acetylated tubulin was similarly distributed and 
intense for wt and MO; an increased ganglion cell layer was occasionally found.  
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Figure 5-7: Characterisation of an ift140 zebrafish morphant 
(a) Gross morphology of 3 and 5 dpf wt ift140 ATG morphant MO, and ift140 MM MO 
demonstrating similar body axis curvature but shorter length, smaller eye and variable lack of a 
swimbladder (5dpf only) for the ATG MO compared to the wt and MM. Scale bar = 500µm.     
(b) Western blot analysis of wt, ift140 ATG MO and ift140 MM MO (n=20 for each, 30 µg) 
demonstrating successful knockdown of ift140 translation for the ATG MO.                               
(c) Retinal histological sections demonstrating thickening of both inner plexiform layer (IPL) and 
ganglion cell layer (GCL) in MO morphants at both 3 and 5 dpf (PR, photoreceptors; ONL, outer 
nuclear layer; ON, optic nerve; RPE, retinal pigment epithelium).                                               
(d) Apoptosis assay demonstrating similar numbers of TUNEL+ve cells between wt and MO. 
Scale bar= 20 µm.  
(e) Alcian blue stain of lateral and transverse whole-mount zebrafish demonstrating similar 
cartilage staining although structures are reduced in size for the ift140 MO (p1, pharyngeal arch 
1; p2, pharyngeal arch 2; M, Meckel’s cartilage; pq, palatoquadrate; ch, ceratohyal; cb1-5, 
ceratobranchials 1-5).  
(f) Transverse cryosections through wt and MO retina stained with either mouse anti-zpr-1 or 
mouse anti-acetylated tubulin. Mild thickening of IPL and GCL observed for anti-acetylated 
tubulin 5dpf ift140 MO. Scale bar= 20 µm.  
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Further investigation of missense variants was performed by attempted rescue of 
morphant phenotype. I generated wt, L440P and T484M mRNAs having first checked 
that there was no consensus between injected morpholino and the mRNAs using Blast. 
Colleagues performed co-injection of zebrafish embryos with ift140 ATG MO and wt or 
mutant mRNAs. I performed the analysis at 5dpf. As the previously described lack of 
swim bladder phenotype was not found on these repeat experiments, length of fish and 
vertical eye diameter were instead measured. This identified significantly smaller 
lengths of 5dpf morphant fish for all mRNA types compared to wt and failed to 
demonstrate rescue of phenotype with wt mRNA (figure 5-8). The eye diameter was 
significantly smaller for all mRNA types with the morphant also smaller but not reaching 
statistical significance (p=0.0641). However the numbers in the eye diameter group 
were much smaller than the length group as only those fish with full lateral orientation 
on photographs could be measured accurately. 
 
 
Figure 5-8: mRNA rescue experiments of morphant phenotype 
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5.4 Discussion 
This series of patients with IFT140 mutations and non-syndromic retinal dystrophy 
underwent detailed ophthalmic phenotyping. Systemic investigation was performed in 
all but 1 patient. Five patients were in their 5th-7th decades, far older than any 
previously reported patients. The patients have typical features of RCD presenting from 
early childhood to the 4th decade and all are developmentally normal, with no apparent 
skeletal or neurological abnormalities. Cone-shaped epiphyses are universally found 
pre-pubertally in IFT140 related disease. This abnormality is not apparent in adults, 
although shortening of the phalanges can still be detected.263 Hand X-rays in patients 
1.2, 1.3 and 2 did not identify shortened phalanges but it remains possible that X-rays 
during childhood could have revealed evidence of the cone shape abnormality. Renal 
function was normal in the tested patients except for patients 3.1 and 3.2 with 
borderline renal function age 53 and 57 years respectively. It is possible that this mild 
renal impairment is related to IFT140 but given their age and hypertension, it may be 
unrelated. Patient 1.1 had unilateral congenital pelvico-ureteric obstruction which has 
not been reported in IFT140 related disease; it is likely that this is an incidental finding. 
His 2 affected older second cousins have normal renal function in their 40s.  
All but one of the previously reported syndromic patients with IFT140 mutations had a 
severe, early-onset retinal dystrophy and undetectable or severely attenuated ERG.255-
257 The exception, a patient homozygous for c.699T>G (p.Ile233Met), had no evidence 
of retinal dystrophy age 2 years but did have skeletal and renal manifestations.255 Of 7 
patients recently reported with isolated retinal dystrophy due to IFT140, 5 have RCD 
with onset of nyctalopia ranging from 7 to 33 years old, and 2 have severe early-onset 
retinal dystrophy.260 There was no evidence of renal or skeletal involvement, but one 
patient had hypogonadism and fatty liver which have been reported in other 
ciliopathies.264, 265 It was not clear if all patients underwent systemic investigation and 
renal function. A further report of 12 patients, focused on the ophthalmic phenotype, 
describing it as severe with infantile onset, hyperopia and flat ERG (age <2 years-20 
years). The patients reported in this present series have milder and later onset retinal 
dystrophy than the majority of those previously reported with fundus features 
consistent with RCD. Refraction, available in 2 patients was myopic.    
All reported patients with syndromic IFT140 related ciliopathy, have developed end 
stage renal failure by their second decade with the exception of 10 families 
homozygous for p.Glu664Lys (reported ages 10 months -17 years).255-257, 261 The 
affected children in those families presented in infancy with severe EORD consistent 
with a diagnosis of LCA and with additional syndromic findings including epilepsy, 
hypotonia and developmental delay. In all patients in whom hand x-rays were 
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performed, cone-shaped epiphyses were identified. Systemic investigations were 
unavailable for 4 families.261 The lack of overt renal dysfunction suggests a possible 
genotype-phenotype correlation for this specific mutation.255, 257, 261  However, there has 
been 1 reported patient homozygous for this variant with renal failure and a kidney 
transplant age 17 years raising the possibility that renal dysfunction may still occur with 
this allele but perhaps later than with other syndromic disease alleles.261  
Phenotypic heterogeneity of several ciliopathy genes has been well established 
including CEP290, IQCB1, IFT172, BBS1 and BBS3.11, 12, 85, 266, 267 In the case of 
CEP290, there is evidence for a dosage-dependent phenotype with bi-allelic loss of 
function mutations associated with Joubert syndrome and the common 
c.2991+1655A>G splicing mutation in which a small amount of protein is still produced, 
associated with LCA.12 In addition, CEP290 mutations in functionally critical regions, 
despite predicted residual protein production, were associated with a more severe 
phenotype.268 Three non-syndromic families in this report have bi-allelic missense 
mutations, as do several of the previously reported syndromic families (table 5-3).255-257 
This would suggest that phenotypic variability is not related to the type of mutation. 
Only 1 patient with bi-allelic premature termination codons has been reported which 
may indicate an essential developmental role for IFT140.261 Mice homozygous for 
Ift140null1 die mid-gestation indicating embryonic lethality for a null phenotype.269 
IFT140 is a 1462 amino acid protein encoded by 31 exons and consists of 2 types of 
domain; 5 WD repeats and 9 tetratricopeptide repeats.164 Reported mutations arise 
throughout the gene with no clustering or domain preference (table 5-3). Of the 4 
missense variants in this report, p.Cys333Tyr and p.Ala341Thr arise within the WD5 
domain but the other 2 are not located within known functional domains. Of the 
previously reported syndromic mutations, 2 arise within functional domains 
(p.Val292Met and p.Tyr311Cys in WD4) and the remaining 7 do not. Conservation of 
missense amino acid residues in orthologues demonstrates a lack of conservation of 3 
of the non-syndromic residues, with 1 fully conserved. Three of 9 syndromic mutations 
are not conserved precluding any conclusion (figure 5-4). The Cys333Tyr allele was 
identified in 2 families and it would suggest that this may be a retina-specific allele. The 
variant Thr484Met was recently identified in conjunction with a 2nd missense variant in 
a patient with non-syndromic LCA indicating that this allele may also be retina-specific. 
The non-conserved Ala341Thr variant was identified in a patient with a novel 
frameshifting variant; neither have been reported in an affected patient before. The 
non-conserved Ser939Pro residue is predicted to be tolerated in silico and arises in 
conjunction with a splice site variant previously reported in syndromic disease. These 
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results may indicate that the Ala341Thr and Ser939Pro variants are less deleterious to 
protein function such that there is a non-syndromic manifestation of disease.  
Diagnosis Allele 1 Exon Allele 2 Exon 
Perrault 2012
255
 
MSS  c.2399+1G>T Intron 19 c.1990G>A ; p.Glu664Lys 17 
MSS  c.932A>G ; p.Tyr311Cys 9 c.857_860del ; p.Ile286Lysfs*6 8 
MSS c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
MSS c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
MSS c.634G>A ; p.Gly212Arg 7 c.3916dupG ; p.Ala1306Glyfs*56 29 
MSS c.699T>G ; p.Ile233Met 7 c.699T>G ; p.Ile233Met 7 
JATD c.2399+1G>T Intron 19 c.634G>A ; p.Gly212Arg and/or 
alteration exon 6 donor splice site 
7 
MSS c.1565G>A ; p.Gly522Glu 14 2
nd
 allele not found  
MSS c.874G>A ; p.Val292Met 8 2
nd
 allele not found  
MSS c.1727G>A ; p.Arg576Gln 15 2
nd
 allele not found  
MSS c.489C>T ; p.Gly163Gly, and c.488_491del 
(p.Glu164Thrfs*10) from creation donor splice site 
5 2
nd
 allele not found  
Schmidts 2013
256
 
JATD  c.1380delC ; p.Asn460Lysfs*28 12 c.874C>T ; p.V292M 8 
JATD c.1565G>A ; p.Gly522Glu 14 c.874C>T ; p.V292M  8 
JATD c.454C>T ; p.Leu152Phe 5 c.454C>T ; p.Leu152Phe 5 
JATD  c.1565G>A ; p.Gly522Glu 14 c.874C>T ; p.Val292Met 8 
JATD  c.2278C>T ; p.Arg759* 19 2
nd
 allele not found  
MSS  c. 2399+1G>T  Intron 19 c.4078T>C ; p.Cys1360Arg 30 
MSS  c.418G>A ; p.Gly140Arg and c.800A>G ; 
p.Glu267Gly 
5, 7 c.490G>T ; p.Glu164* 6 
JATD  c.2399 +1C>A  Intron 19 2
nd
 allele not found  
JATD  c. 4058 G>C ; p.Pro1353Arg  30 2
nd
 allele not found  
JATD  c.2360 T>C, ; p.Asp787Gly 19 2
nd
 allele not found  
JATD  c.1541 A>T ; p.Leu514His (rs150903791) 14 2
nd
 allele not found  
JATD  c.329G>A ; p.Arg110His 4 2
nd
 allele not found  
JATD  c. 481C>A ; p.Pro161Thr 5 2
nd
 allele not found  
JATD c. 481C>A ; p.Pro161Thr 5 2
nd
 allele not found  
Khan 2014
257
 
MSS c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
MSS c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
Xu 2015 
RP c.4196T>C (p.L1399P) 31 c.1898_1901delATAA (p.N633Sfs*10) 17 
RP c.3826G>A (p.G1276R) 28 c.1989C>G (p.C663W) 17 
RP c.650_651delTG (p.V217Gfs*2) 7 c.212C>T (p.P71L) 4 
RP c.2611C>T(p.R871C) 21 c.1377G>A (p.W459*) 12 
RP 
C.1252G>C (p.A418P) 
11 c.2921C>T (p.A974V) NB presumed in 
trans 
23 
LCA c.1452C>T (p.T484M) 13 c.985T>C (p.C329R) 9 
LCA c.2368G>A (p.E790K) 19 c.1655_1656delAG (p.E522Gfs*6) 14 
Bifari 2015 
MSS c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
EORD c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
EORD c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
EORD c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
MSS c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
EORD c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
MSS c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
EORD c.1541_1542delinsAA 14 c.1541_1542delinsAA 14 
MSS c.1990G>A ; p.Glu664Lys 17 c.1990G>A ; p.Glu664Lys 17 
Table 5-3: Previously reported mutations in IFT140  
JATD: Jeune asphyxiating thoracic dystrophy, MSS: Mainzer-Saldino syndrome, EORD: early-
onset retinal dystrophy 
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Transient expression of IFT140 in hTERT-RPE1 cells transfected with a Myc-DDK-
tagged IFT140 plasmid, demonstrated that localisation of IFT140 with the basal body 
was significantly reduced in mutant cells compared with WT and L777R cells 
(p<0.0001). No difference was found between the 2 missense variants from families in 
this report and the 2 reported syndromic missense variants indicating a deleterious 
effect on protein trafficking in vitro for all mutants studied. This supports causality of 
these 2 non-syndromic missense variants in vitro. 
Characterisation of an ift140 zebrafish morphant demonstrated mild abnormalities only, 
indicating that in early embryonic development Ift140 is not an essential component for 
cilial development in this specific model organism. Retinal characteristics of ift140 
morphant zebrafish have not previously been reported but other features consistent 
with a weak phenotype in particular a lack of abnormal body axis shape and olfactory 
cilial defects have been described for both translation-blocking and splice site ift140 
morphants.22 A more severe phenotype may present later than 5 dpf. There are limited 
other animal models. Homozygous knockout Ift140null/null mice are embryonically lethal 
with severe multi-system abnormalities including skeletal defects.270 Mice with selective 
knockout in the renal collecting ducts (from HoxB7-Cre-driven depletion) have very 
shortened or missing cilia at birth with subsequent cyst development and renal 
dysfunction.269 CRISPR/CAS or Talen generated transgenic animal models may be 
useful for future studies. Transgenic zebrafish generated by CRISPR/CAS would 
permit investigation of the phenotype in the adult fish.  
In this series, 5 families with apparently isolated RCD due to IFT140 mutations are 
characterised. Given the potential for systemic complications, children with apparently 
isolated retinal dystrophy due to IFT140 mutations, may need long-term systemic 
investigation and renal function monitoring. However it is likely that some patients will 
have isolated retinal disease and as more patients are reported, specific allele 
phenotypes may emerge. 
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6 Knobloch syndrome 
6.1 Introduction 
Knobloch syndrome is a rare, recessively inherited disorder first described in 1971 in a 
family with 5 of 10 children affected by vitreoretinal degeneration, retinal detachment, 
high myopia, occipital encephalocele and lens subluxation.271 The phenotypic 
description has subsequently evolved with additional ocular features of cataract, 
smooth irides and persistent foetal vasculature.272-274 Limited electrophysiological 
characterisation has been reported in 3 patients.275, 276 Neuroradiological imaging has 
revealed a variety of developmental brain anomalies including occipital skull defects 
with or without encephalocele, polymicrogyria, sub-ependymal nodules and cerebellar 
vermis atrophy.275, 277-280 Additional systemic findings include epilepsy, developmental 
delay, and renal abnormalities. 272-274, 277, 280-284  
The Knobloch locus was mapped to 21q22.3 in 1996 and COL18A1 was subsequently 
identified as the causative gene.285, 286 COL18A1 encodes Collagen alpha-1(XVIII) 
chain, ubiquitously expressed in vascular and epithelial basement membranes.287, 288 It 
has multiple functions in ocular and neurological development including angiogenesis, 
maintenance of basement membranes and in the Wnt/β-catenin signalling pathway.287 
Following identification of families with this rare syndrome in the retinal genetics clinics 
and review of the literature, the lack of complete published phenotypic data prompted 
further study. I ensured all had neuroradiological imaging and examined all families to 
ascertain key clinical, electrophysiological and molecular data. This identified novel 
features including pigment dispersion syndrome and glaucoma, and cone-rod 
dysfunction on electroretinography. Two patients had normal neuroradiology 
highlighting the fact that some affected individuals have isolated ocular disease. 
Patients may initially present to the ophthalmologist and awareness of the ocular 
phenotype will aid early diagnosis, appropriate genetic counselling and monitoring for 
potential complications. 
6.2 Methods 
6.2.1 Ascertainment of patients 
Five families were ascertained from inherited retinal clinics. Four were diagnosed with 
Knobloch syndrome based on clinical features and underwent COL18A1 Sanger 
sequencing by colleagues. The fifth, was diagnosed after WES identified a 
homozygous, previously reported variant in COL18A1 and re-examination of the 
Knobloch syndrome 
 
 101 
phenotype supported Knobloch syndrome. Investigation of patient phenotype and 
molecular results were conducted by myself. 
6.2.2 Clinical assessment 
All patients underwent retinal imaging, electrophysiology and radiological imaging of 
the brain, either Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) 
examinations. 
6.2.3 Molecular investigations 
Bi-directional Sanger sequencing by colleagues in the laboratory of all 41 exons and 
intron-exon boundaries of the medium isoform of COL18A1 (NM_030582.3) was 
performed in an affected proband from families 1-4 and segregation confirmed in the 
affected sibling and available relatives. Patients 1.1 and 5 had previously undergone 
APEX microarray. Patient 5 underwent WES (AROS) with identified variants then 
confirmed by Sanger sequencing in the affected proband and available relatives. A 
diagnosis of Knobloch syndrome had not been clinically suspected in patient 5 prior to 
WES. Two potentially pathogenic homozygous variants were identified in COL18A1 
and RPGRIP1. I segregated the RPGRIP1 variant (primers table 6-1) 
Exon Primer forward 5’ → 3’ Primer reverse 5’ → 3’ Enzyme 
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p
) 
18 GTTGTTAAACTACCAGCTTG GGGACACTACAACCCACAA MYTAQ 60 301 
Table 6-1: Primer pair for sequencing RPGRIP1 
Databases were interrogated for novel variants in COL18A1 using both the medium 
isoform (NM_030582.3) and the alternate short isoform, also reported in the literature 
(NM_130445.2). GenBank accession number NM_020366 was used for the RPGRIP1 
variant. 
6.3 Results 
Key clinical features are summarised in table 6-2. Nine patients from 5 families (figure 
6-1) were evaluated; ages at last review ranged from 2 to 38 years (mean 15.7, median 
14). The ethnic origins were Indian, British Caucasian (2 families), Slovak and Arab. All 
patients had presented in infancy with nystagmus and variable convergent or divergent 
squints except for patient 3.2 who was orthophoric. All patients had severe visual 
impairment with best corrected visual acuity in each eye at last review ranging from 
1.06 log MAR (Snellen 6/75) to no perception of light. Patient 1.2 had stable vision of 
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1.3 log MAR (Snellen 6/120) in the right eye from first review age 9 years to last review 
age 21 years; patient 5 also had stable vision of 1.0 log MAR each eye over a 36 year 
review period. All patients had high myopia (≥-6 dioptres) in at least 1 eye with high 
myopia reported in patients 4.2 and 5 prior to cataract extraction. Five patients were 
anisometropic with high myopia in 1 eye and hyperopia in the other. This was related to 
lens subluxation in 2 patients (2.2 and 3.1), unilateral retinal detachment with hyperopic 
shift in 1 patient (2.1) and unilateral high myopia in the right eye with near emmetropia 
in the left eye from infancy in two siblings unrelated to retinal detachment (1.1 and 1.2).  
These siblings had asymmetrical axial lengths as measured by B scan ultrasound age 
8 years for patient 1.1 and age 19 years for patient 1.2 when the length of the myopic 
eyes were 26.7mm and 27.9mm and the emmetropic 20.7mm and 21.1mm 
respectively. These siblings were previously reported when children; new data in this 
report, 15 years later, include visual acuity, repeat ERG, anterior segment and fundus 
features and neuroradiology.289 
 
Figure 6-1: Pedigrees and mutation segregation 
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Table 6-2: Key ophthalmic features in Knobloch syndrome 
C-R, chorioretinal 
Anterior segment abnormalities were present in all patients except patient 4.1, 
examined at age 4 years (figure 6-2). Abnormalities included poor pupillary dilatation (6 
patients), absence of crypts associated with a featureless iris (5 patients), iris 
transillumination (3 patients) and persistent pupillary membrane (3 patients). 
Patient 
No./ 
Gender/ 
Ethnic 
origin/ 
Genetic 
Database 
no. 
Age 
at 
last 
rv, 
yrs 
Visual acuity,    
logMAR 
(Snellen 
equivalent) 
Refraction, under 
cycloplegia unless 
otherwise stated 
Anterior 
segment 
features 
Posterior segment 
features 
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1.1/M  
Indian 
GC14449 
23 R NPL             
L CF 
R -17.50DS               
L +1.0 DS  
(atropine 1998) 
+  +    + R para-central, 
circumscribed C-R 
atrophy, L generalised 
retinal/RPE atrophy 
1.2/F 
 
21 R 1.3 (6/120)        
L PL 
R -13.5/-1.00 x180     
L +0.75/-1.00 x180 
(subjective 2002) 
+ + +     R para-central, 
circumscribed C-R 
atrophy,  L generalised 
retinal/RPE atrophy 
2.1/M 
British 
Caucasian 
GC19526 
14 R 1.9 (6/480)      
L NPL 
R -18.00/-2.00 x15    
L +9.00DS 
 + + +   + Generalized, ill-defined 
macular C-R atrophy 
BE 
2.2/M 
 
11 R 1.6 (6/240)     
L 1.4 (6/150) 
R -24.00/-2.00 x10    
L +3.00/-1.50 x15 
 + + +  +  Para-central well-
defined C-R atrophy BE 
3.1/M 
Slovak 
GC20422 
17 R 1.6 (6/240)      
L 1.4 (6/150) 
R +12.00/-2.00 x100 
L -10.00/-6.00 x110  
(subjective 2014) 
+  +  + +  Para central ill-defined 
retinal/RPE atrophy BE 
3.2/F 
 
11 R 1.2 (6/95)       
L 1.4 (6/150) 
R -20.00/-2.00 x100  
L -19.00/-2.00 x180 
+  +  + +  Para-central C-R 
atrophy, well-defined 
on R, ill-defined on L 
4.1/F         
Arab 
GC20693 
4 R 2.1 (<6/600)       
L 2.1 (<6/600) 
R -12.00/-2.00 x10    
L -12.50 DS 
       Central, ill-defined C-R 
atrophy BE 
4.2/M 
 
2 R PL               
L NPL 
Not performed     +  + Central, ill-defined C-R 
atrophy BE 
5/F     
British 
Caucasian 
GC18840 
38 R 1.06 (6/75)       
L 1.06 (6/75) 
R -35 DS                   
L -28 DS                 
(pre lens removal) 
  + + + +  Para-central well-
defined deep large C-R 
atrophy on R, smaller 
and ill-defined on L 
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Figure 6-2: Anterior segment and retinal imaging in Knobloch Syndrome.  
Patient 1.2, 21 year old female, (a) LE, featureless iris with ectropion uveae and persistent 
pupillary membranes, (b) RE and (c) LE colour fundus photographs, bilateral macular atrophy 
and hyperpigmentary change, R tessellated fundus; Patient 2.2, 14 year old male, (a) L 
inferotemporal lens subluxation (b) L Optos widefield colour and (C) L Optos autofluorescence 
imaging features of peripapillary atrophy, macula atrophy, tessellated blonde fundi, 
circumscribed loss of autofluorescence in posterior poles, inferotemporal artefact in fundus 
image from subluxated disc; Patient 3.2, age 11 years, RE (a) right featureless iris, cortical lens 
opacity with inferotemporal lens subluxation, (b) left Optos wide-field imaging demonstrating 
disc pallor, attenuated vessels, thin retina, abnormal collapsed vitreous, (c) R (d) L OCT 
demonstrating extensive atrophy of outer retina, RPE and choriocapillaris in both eyes; Patient 
5, 38 year old female, RE (a) pseudophakia with peripheral laser iridotomy, (b) Topcon fundus 
photograph demonstrating attenuated vessels, macular and peripapillary atrophy and increased 
retinal pigment, (c) autofluorescence imaging with reduced autofluorescence corresponding to 
atrophy and (d) loss of outer retina, RPE and choroid on OCT. 
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Five patients had cataract with 2 requiring cataract extraction. Three patients had lens 
subluxation in the inferotemporal direction with patient 5 reported to have lens 
subluxation prior to cataract extraction. All 3 patients of Northern European origin 
(families 2 and 5), had iris transillumination with all developing raised intraocular 
pressure. Glaucomatous disc cupping was identified in one eye of patient 2.1 at age 11 
years without lens subluxation. No increased pigment was noted on gonioscopy of 
patients 2.1 and 2.2. Patient 5, in addition to iris transillumination, had endothelial 
pigment (Krukenberg spindles), pigment on the lens capsule and heavily pigmented 
angles on gonioscopy, all consistent with a diagnosis of pigment dispersion syndrome.  
All highly myopic eyes had disc pallor, attenuated vessels, a markedly tessellated 
appearance with prominent choroidal vessels, peripapillary atrophy and occasional 
pigmented spots (figure 6-2); two eyes had staphylomas. The emmetropic left eyes of 
patients 1.1 and 1.2 were heavily pigmented. Abnormal vitreous condensations were 
noted in 6 patients. Macular atrophy was present in all eyes (table 6-2). The atrophy 
was chorioretinal in most patients, involving outer retina, RPE and choroid. In 10 eyes 
the atrophy was para-central being well-circumscribed in 6 of 10 eyes; in 8 eyes it was 
central and ill-defined (figure 6-2).  In those patients without central macular atrophy, 
poor foveal reflexes were noted. Patients 1.1 and 4.2 developed bilateral retinal 
detachments and patient 2.1 unilateral detachment. OCT scanning of the posterior pole 
was available in 6 patients. All showed lack of foveal pits, extensive loss of outer retinal 
structure and in 4 patients, additional atrophy of the RPE and choroid. Fundus 
autofluorescence imaging, available in 5 patients, demonstrated well-circumscribed 
loss of posterior pole autofluorescence. 
Electroretinography showed cone-rod dysfunction in 14 eyes of 8 patients, and 
severely reduced/undetectable responses in 4 eyes of 3 patients (figure 6-3). Patients 
1.1 and 1.2 at initial testing in 2002 had undetectable ERGs in their emmetropic left 
eyes with cone more than rod dysfunction in their myopic right eyes. Repeat ERG in 
2014 in patient 1.1 showed undetectable ERGs in both eyes, the right eye having 
developed a total retinal detachment and the left a peripheral shallow detachment only. 
Repeat ERG in patient 1.2 showed marked deterioration, particularly of cone 
responses in the right eye, but with stable visual acuity. ERG was undetectable in 
patient 4.2 who was tested under general anaesthesia with silicone oil in situ in both 
vitreous cavities.  
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Figure 6-3: Cone-rod dysfunction in Knobloch syndrome  
Left eye of patient 3.2 with normal (N) for comparison. Rod specific (DA 0.01) ERG is mildly 
subnormal; bright flash (DA 11.0) a-wave amplitude is subnormal; cone flicker (LA 30Hz) and 
single flash (LA 3.0) ERGs are markedly subnormal and delayed (note the differences in 
calibration compared to the normal); PERG is undetectable. 
Neuroradiology was performed in all patients (table 6-3, figure 6-4).  Imaging was 
normal in 2 patients. Four patients had occipital skull defects and only patient 2.2 had 
occipital encephalocele. Minor abnormalities in 2 patients comprised an occipital 
subgaleal fat pad and a corticated (covered in cortical bone) small channel in the 
occipital lobe, possibly representing an atretic encephalocele. Three patients had 
polymicrogyria. The imaging results differed between siblings in all families except 
family 4. 
Table 6-3: Neuroradiological and systemic features 
Pt no. Neurological features Systemic features 
1.1 Subgaleal fat pad, polymicrogyria Epilepsy, developmental delay 
1.2 Midline occipital defect, atretic 
encephalocele, polymicrogyria 
None 
2.1 Normal Hypermobile joints 
2.2 Resected occipital encephalocele, 
polymicrogyria 
Hypermobile joints 
3.1 Midline occipital defect Learning difficulties 
3.2 Occipital lobe corticated channel None 
4.1 Midline occipital defect Congenital hydronephrosis, hypermobile 
joints 
4.2 Midline occipital defect Hypermobile joints 
5 Normal Unilateral duplex kidney/bifid ureter, 
hamstring sarcoma 
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Figure 6-4: Neuroradiological findings in Knobloch syndrome 
Intracranial sagittal and coronal T1-and axial T2- weighted MRI acquisitions of patients 1.1, 1.2, 
2.1, 2.2, and 4.1 as well as CT of patient 3.2. Patient 1.1 (a), (b), subgaleal fat pad (arrowed) 
overlying occipital bone, (c) extensive bifrontal polymicrogyria (arrowed); Patient 1.2 (a) small 
occipital bone defect (arrowed) with atretic encephalocele/meningocele, (b) medial bifrontal 
polymicrogyria (arrowed); Patient 2.1 (a) and (b) no abnormalities; Patient 2.2 (a) MRI aged 6 
months with occipital encephalocele (arrowed), (b) MRI aged 11 years occipital scarring and 
retained retrocerebellar arachnoid cyst at site of previous surgery (arrowed), (c) MRI aged 11 
years bilateral inferior frontal polymicrogyria (arrowed); Patient 3.1, midline occipital bony defect 
above occipital protuberance (arrowed); Patient 3.2 (a) small, well corticated channel in the 
midline of the occipital lobe (arrowed); Patient 4.1 (a) small bony occipital defect (arrowed) with 
meningeal tissue communicating to subcutaneous tissue through the defect; Patient 4.2 (a), (b) 
small bony occipital defect (arrowed) with fibrous band extending from meningeal lining to 
subcutaneous tissue; Patient 5 (a) and (b) no abnormalities. 
Cutaneous occipital abnormalities were present in 4 patients including a palpable 
swelling, alopecia and a patch of white hair. Systemic abnormalities included learning 
difficulties, epilepsy, congenital hydronephrosis from a ureteric abnormality and duplex 
kidney with bifid ureters in patient 5 who additionally had undergone treatment for a 
hamstring sarcoma. 
Bi-allelic variants in COL18A1 predicted to be pathogenic were identified in all 5 
families. Segregation was confirmed in available family members (figure 6-1).  
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Two novel mutations were identified with a further 3 mutations not previously reported 
in an affected patient but found at a very low mean allele frequency in the ExAC 
database (figure 6-1). Six mutations, 5 that create PTCs and a splice site mutation 
were identified in total. The splice site mutation, c.2437-2 A>G, very rare on ExAC (1 in 
120452), disrupts the canonical acceptor site for exon 17. WES on patient 5 also 
identified a missense homozygous variant in RPGRIP1 c.3064C>T, p.Leu1022Phe 
(rs367899074) which also segregated with disease in the family. This was not thought 
to be causative based on predicted tolerance in silico (SIFT score 0.7, Polyphen2 
score 0.049), phenotype of the patient in particular the anterior segment abnormalities 
and due to the identified COL18A1 variant having been previously reported in 3 
families with Knobloch syndrome.290, 291 Variant c.3213delC (p.Gly1072Aspfs*17) 
identified in family 2 was reported at an all allele frequency of 0.004 on EVS, but this 
appears to be an artefact. It was absent in 1000genomes and dbSNP, and on 
contacting the EVS team, the area had poor coverage and the results were most likely 
spurious. Subsequently, the ExAC database was released in which the variant has an 
allele frequency of 3 in 22692 but with only a relatively small number of individuals 
covered. Finally, the variant was found in a single allele only of a control group of 2000 
exomes (UCL consortium). 
6.4 Discussion 
The classical description of Knobloch syndrome includes myopia, retinal detachment 
and occipital encephalocele, but more recent publications have described an 
increasingly variable ocular and systemic phenotype.275, 280, 291 This series with detailed 
retinal imaging, ERGs and neuroradiology in all patients, has allowed a detailed 
assessment of the clinical phenotype.  
All patients presented in infancy with nystagmus and had high myopia in at least 1 eye. 
Three patients had inferotemporal lens subluxation consistent with a previous report.275 
Iris abnormalities were also common. Absence of iris crypts and a single case of iris 
atrophy have been described previously.273-275, 291 In a knockout mouse model 
COL18a1-/-, there was disruption of the posterior iris pigment epithelial cell layer and 
release of melanin granules that resembled the human pigment dispersion 
syndrome.292 Three patients in this series had clinical features of pigment dispersion 
syndrome with 1 associated glaucoma.293 This suggests potential increased risk of 
pigmentary glaucoma in Caucasian patients with Knobloch syndrome.  
Many of the retinal changes noted in this series are consistent with high myopia and 
are not specific to the syndrome.294 These include peripapillary atrophy and the 
tessellated fundus appearance with prominent choroidal vessels. Although vitreous 
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abnormalities are seen in high myopia, the collapsed abnormal vitreous present in 
these patients from a young age may relate to the underlying disorder. Macular atrophy 
was identified in all patients. This can also occur in high myopia with diffuse atrophy or 
focal areas of atrophy; the latter shown to develop in the 5th decade in a large natural 
history study.295 The young age of the present patients suggest the atrophic lesions, 
are likely to be a consequence of mutations in COL18A1. Macular atrophic lesions and 
abnormal vitreous condensations have been previously reported and may be key 
features of the disorder.275, 277, 291  
Previous electrophysiology reports in Knobloch syndrome are limited; delayed and 
depressed photopic and scotopic ERGs were reported in 2 children in one report but 
few details on technique or amplitude of responses were given; an undetectable ERG 
was described in one patient in another report.275, 276 This series with detailed 
electrophysiology of all affected patients, demonstrates both cone and rod dysfunction. 
Repeat ERG in patient 1.2 showed deterioration but with stable visual acuity. It 
therefore remains unclear whether this disorder represents a progressive dystrophy of 
photoreceptors or a stable dysfunction but progression, if present, appears 
asymptomatic and slow.  In our patients with long term follow up, there was little 
deterioration in visual acuity unless complicated by retinal detachment.  
COL18A1 encodes collagen alpha-1(XVIII) chain, highly expressed throughout the 
human eye including the iris, ciliary body, trabecular meshwork, Schlemm’s canal, the 
inner limiting membrane (ILM), retinal vessels, basement membrane of the retinal 
pigment epithelium (RPE) and Bruch’s membrane but not in photoreceptors.288 The 
ILM and vitreous body are important regulators of eye size in a chick embryo model 
with disruption of these structures leading to eye enlargement. This could explain the 
high myopia seen in Knobloch syndrome as evidenced by the high axial length 
measured in the myopic eyes of family 1.296 In mice, lack of ColXVIII causes abnormal 
vitreous separation, consistent with the abnormal vitreous and retinal detachment 
found in human disease.297 The underlying pathogenesis of photoreceptor dysfunction 
is not clear from animal models but the abnormal Bruch’s membrane, RPE and ILM 
would be predicted to have secondary effects on the photoreceptors.297 Alternatively 
the distribution and function of ColXVIII may differ in the human eye. 
Occipital encephalocele/meningocele is reported to be common in Knobloch syndrome 
but was only identified in one patient in this series.298 Normal neuroimaging has 
previously been reported in 2 patients; the additional minor abnormality of a subgaleal 
fat pad is a novel observation.277, 282 Four patients had externally observable occipital 
findings, ranging from soft tissue swellings to hair abnormalities, emphasising the 
importance of occipital scalp examination if Knobloch syndrome is suspected. In one 
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patient, a cutaneous scalp abnormality was identified in the absence of 
neuroradiological abnormality. This has been previously reported in a single patient; 
usually there is an associated neuroradiological abnormality when scalp defects are 
present.277, 280, 282, 283, 299  Polymicrogyria was identified on MRI In 3 patients (1.1, 1.2 
and 2.2); a feature now reported in several Knobloch patients.273, 278-280  
Type 18 collagen is found in many different tissues and it is unsurprising that mutations 
in COL18A1 may result in a varied systemic phenotype. Systemic associations in the 
present series include epilepsy, learning difficulties, congenital hydronephrosis and 
unilateral duplex kidney with bifid ureter. There are several reports of epilepsy in 
Knobloch.275, 277, 280, 284, 291, 300 Renal abnormalities in Knobloch are unusual with 2 
previous reports of congenital duplex kidney and bifid ureter.272, 283 Sarcoma, present in 
one subject, has not been previously reported in Knobloch syndrome although there 
has been one case of acute lymphoblastic leukemia.299 Those reports and the present 
series highlight the importance of systemic assessment. 
COL18A1 consists of 43 exons with 3 main alternate isoforms produced.287, 301 There 
have been 22 previously reported, likely pathogenic mutations in COL18A1 leading to 
recessively inherited disease, 17 of which lead to PTCs, 2 large deletions 
encompassing at least a whole exon and 3 splice site mutations, which may indicate 
that this syndrome represents a null phenotype (table 6-4). The c.4063_4064delCT 
mutation is the most common, found in a total of 14 families to date.279, 280, 284, 290, 291, 299, 
300, 302 The diverse ethnic origins of the reported families include Indian, Brazilian, North 
American, Saudi, Irish, Pakistani and Turkish in keeping with a mutational hotspot not a 
founder effect. A further 4 disease causing mutations were identified in the current 
series.  
Knobloch syndrome is a systemic disorder with variable neurological involvement and 
severe visual impairment from early childhood. It may be undiagnosed without careful 
examination of the anterior segment and awareness of the potential lack of scalp 
and/or intracranial occipital abnormalities. The diagnosis might be considered in any 
patient with infantile onset high myopia, developmental abnormalities of the anterior 
segment and evidence of cone-rod dysfunction on ERG. A timely diagnosis not only 
ensures that patients are aware of the potential complications of the disorder, such as 
lens subluxation, retinal detachment and glaucoma, but may facilitate targeted 
molecular sequencing and informed genetic counselling.  
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 Mutation  
NM_030582.3 (AF18081) 
Mutation 
NM_130445.2 (AF18082) 
Exon 
no of 
43 
Reported papers, (no of 
families) 
1 In 5’ UTR (-50,112 nucleotides) c.12-2A>T  Intron 
1 
Sertie 2000
286
                        
Suzuki 2002
284
 
2 c.895delG                   
(p.Val299Serfs* 
c.355delG              
p.Val119Serfs*5 
4 Aldahmesh 2011 
300
 
3 c.1469-2A>G c.929-2A>G Intron 
7 
Suzuki 2009 
290
 
4 c.1604insC          
p.Gly538Argfs*55 
c.1064insC              
p.Gly355Argfs*55 
9 Caglayan 2014
280
 
5 c.1761_2054del, 
p.Asp589_Gly686del 
c.1221_1514del, 
p.Asp409_Gly506del 
9-14 Aldahmesh 2013
291
 
6 c.1778-9insA        
p.Asp593Glufs*58 
c.1238-1239insA, 
p.Asp413Glufs*58 
10 Suzuki 2002 
284
 
7 c.2325_2326delCCinsA, 
p.Pro777Leufs*127 
c.1785_1786delCCinsA 
p.Pro597Leufs*127 
17 Aldahmesh 2011 
300
 
8 c.2416C>T (p.Arg806*) c.1876C>T (p.Arg626*) 18 Passos-Bueno 2006
298
   
Williams 2008
283
 
9 c.2645delT         
p.Leu882Profs*22 
c.2105delT           
p.Leu702Profs*22 
23 Suzuki 2002 
284
 
10 c.2658dupC           
p.Gly887Argfs*23 
c.2118dupC        
p.Gly707Argfs*23 
23 Aldahmesh 2013
291
 
11 c.2797C>T                         
p.Arg933* 
c.2257C>T                         
p.Arg753* 
26 Aldahmesh 2013
291
 
12 c.3213dupC      
(p.Gly1072Argfs*9) 
c.2673dupC        
(p.Gly892Argfs*9) 
33 Suzuki 2009 
290
 (2)                 
Aldahmesh 2013
291
 
13 c.3283C>T                   
(p.Arg1095*) 
c.2743C>T                     
(p.Arg915*) 
35 Aldahmesh 2011 
300
 (2) 
14 c.3363_3364insC, 
(p.Gly1122Argfs*32) 
c.2823_2824insC, 
(p.Gly942Argfs*32) 
35 Menzel 2004 
282
 
15 c.3364_3371delGGCCCCCC 
(p.Gly1125Argfs*142) 
c.2824_2831delGGCCCCCC 
(p.Gly945Argfs*142) 
35 Suzuki 2009 
290
 
16 c.3509-3518delCAGGGCCCCC   
(p.Pro1170Glnfs*38) 
c.2969-2978delCAGGGCCCCC  
(p.Pro990Glnfs*38) 
36 Suzuki 2002
284
 
17 c.3544+3A >C c.3004+3A>C Intron 
36 
Keren 2007 
278
 
18 c.3811C>T (p.Gln1273*) c.3271C>T (p.Gln1091*)                  
c.3277C>T reported 
40 Suzuki 2002
284
 
19 delEx41 delEx41 41 Suzuki 2009 
290
 
20 c.4063_4064delCT 
(p.Leu1355Valfs*72)              
reported as c.4054-4055delCT 
(p.Leu1352Valfs*72) 
c.3523-3524delCT 
(p.Leu1175Valfs*72) 
41 Suzuki 2002 (3)
284
, Paisan-
Ruiz 2008
279
, Suzuki 
2009
290
, Joyce 2010 
302
, 
Mahajan 2010
299
, 
Aldahmesh 2011 
300
, 
Aldahmesh 2013 (3)
291
, 
Caglayan 2014 (2)
280
 
21 
c.4374_4387del 
(p.Ser1459Alafs*9) 
c.3834_3847del 
(p.Ser1279Alafs*9)            
reported as p.Ser1276Alafs*9 
43 Haghighi 2014
276
 
22 
c.4494_4497insTGCC 
(p.Ala1499Cysfs*14) 
c.3954_3957insTGCC 
(p.Ala1319Cysfs*14) 
43 Caglayan 2014
280
 
Table 6-4: Previously reported mutations in COL18A1 
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7 Preserved visual function in retinal dystrophy due to 
hypomorphic RPE65 mutations 
7.1 Introduction 
RPE65 (Retinal Pigment Epithelium-Specific Protein, MIM# 180069), located on 
1p31.3-p31.2, encodes a retina-specific, 65kD visual cycle protein, retinoid 
isomerohydrolase, a vital component of the visual cycle.42 Recessive mutations in 
RPE65 are associated with severe EORD including LCA and account for approximately 
11% of early onset RCD.43, 44 Patients usually present in infancy or early childhood with 
reduced central vision, with or without nystagmus. Nyctalopia is a prominent feature 
and some patients also demonstrate photoattraction.303 Myopia is found in at least half 
of patients.304 Visual acuity, although significantly reduced in childhood is usually 
sufficient to enable a sighted education.303, 305 The fundus appearance is usually normal 
in infancy but small subretinal white dots may appear later in childhood, possibly as a 
result of abnormal accumulation of retinyl esters.53, 306 Retinal imaging reveals a 
variable thinning of the outer nuclear layer on OCT and a characteristically low signal 
on FAF imaging. 101 Electrophysiology demonstrates absent rod function but there may 
be residual cone function in childhood.305 This may reflect the alternative source of 11-
cis retinol that cones obtain from Müller cells.31 Gene therapy trials using subretinally 
administered recombinant adeno-associated viral vectors expressing RPE65 have so 
far achieved promising, albeit largely unsustained improvements in retinal function.307-
309 
Recessive RPE65 related disease may present atypically with mild phenotypes due to 
presumed hypomorphic alleles; a single patient with a fundus albipunctatus phenotype 
has also been reported.8, 303, 310-312 Dominant disease resembling choroideraemia with 
variable penetrance has also been reported in 2 families.8 I identified 4 patients (4 
families) who were known to have early onset retinal dystrophy with preserved visual 
function in to adulthood. Molecular screening including RPE65 had already been 
performed and likely pathogenic variants identified. This group of patients were further 
analysed and the underlying molecular mechanisms explored in this study.  
7.2 Methods 
7.2.1 Ascertainment of patients 
Patients had been recruited from the inherited retinal clinics of Moorfields based on a 
diagnosis of EORD. Molecular screening had been completed by colleagues prior to 
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my investigation of the patients. Probands 1 and 2 with some features of retinal 
dystrophy due to RPE65, but better visual acuity than previously reported, were 
screened for RPE65 mutations by Sanger sequencing. Subsequent to the discovery of 
a putative hypomorphic allele (p.Arg515Trp) in patient 2 and the finding of the same 
allele in a previous report, a panel of 190 unrelated probands with adult-onset 
recessive RCD were Sanger sequenced for exon 14 of RPE65.311 This yielded one 
further proband (patient 3), heterozygous for this mutation. Sanger sequencing of all 
exons and intron-exon boundaries was undertaken in this patient to determine a 
second allele. Finally, Sanger sequencing of RPE65 was performed in patient 4, with a 
retinal appearance similar to fundus albipunctatus, following a report of this phenotypic 
appearance being associated with RPE65; mutations in both RLBP1 and RDH5 had 
already been excluded.313 Segregation to establish bi-allelic mutations was not possible 
for families 2 and 3 in whom family DNA was unavailable. 
7.2.2 Clinical assessment 
Each patient had undergone full clinical examination by one of my supervisors within 
the retinal genetics clinics. Electroretinography was obtained in 3 patients using gold 
foil electrodes to incorporate the ISCEV standards; ERG recording in patient 3 was 
performed elsewhere at age 3 years with surface electrodes. Suprathreshold binocular 
(driving) Esterman visual fields and uniocular Humphrey 24-2 and 30-2 threshold visual 
fields were performed using the Humphrey Field Analyzer II (Carl Zeiss Meditec AG). 
A control group of 5 patients with typical RPE65 related early onset retinal dystrophy, 
and a recorded visual acuity age 18 years, were selected from the genetics database 
in order to statistically compare the median visual acuities in the better eye between 
the hypomorphic group and the control group. Statistical analysis was performed using 
IBM© SPSS© Statistics version 22. 
7.2.3 Molecular investigations 
Molecular screening had been performed as described above and the identified 
variants further analysed as part of this study. Mutation nomenclature was assigned in 
accordance with GenBank Accession number NM_000329.2. Protein modelling of the 
crystalline structure of RPE65 was performed using Visual Molecular Dynamics with 
Protein Data Bank number 4F3A.314 Mutations were plotted on this model including 
hypomorphic mutations from this paper, previously reported hypomorphic mutations, 
and non-hypomorphic missense mutations in order to investigate any potential pattern 
for position of mutations. 
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7.3 Results 
Four patients from 4 families were investigated (figure 7-1). Clinical data are 
summarised in table 7-1. 
 
Figure 7-1: Pedigrees and segregation of RPE65 variants 
Patient 1 presented with mild nyctalopia without nystagmus in early childhood; there 
was no subjective deterioration over time. VA was 0.2 logMAR each eye at age 13 
years, R 0.2 logMAR and L 0.3 logMAR at age 22 years with a highly myopic 
correction. Fundus examination demonstrated myopic changes with peripapillary 
atrophy and visible choroidal vasculature. There were a few white dots in the posterior 
pole and extensive granularity of the retinal mid-periphery that had a white flecked 
appearance. OCT imaging revealed a normal ISe band at the macula with para-foveal 
disruption and temporal retinal thinning in both eyes consequent upon thinning of the 
ONL (figure 7-2). On FAF imaging, there was generalised hypofluorescence with 
irregular almost radial bands of relative hyperfluorescence in the macula which did not 
correspond to the disrupted ISe band on OCT. Binocular Esterman visual fields age 18 
years were full except for an extreme left scotoma outside 70 degrees eccentricity 
(figure 7-3). Uniocular 24-2 Humphrey visual fields age 22 years demonstrated central 
scotoma. ERG at age 13 years showed generalized retinal dysfunction, with cone 
ERGs more affected than rod ERGs (figure 7-4). PERG showed marked macular 
involvement. Repeat ERG age 20 years demonstrated no deterioration. 
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Pt, 
(gender) 
family 
A
g
e
 o
n
s
e
t 
 (
y
rs
) 
A
g
e
 l
a
s
t 
rv
 (
y
rs
) 
L
e
n
g
th
 f
-u
p
 (
y
rs
) Fundus Age at last EDTs, 
key findings 
Latest VA, logMAR 
(Snellen) and 
refractive error 
Other findings 
Pt 1 
(m) 
GC16768 
2 22  9  Peripheral 
small white 
dots level of 
RPE, later 
mid-
peripheral 
RPE atrophy 
19 yrs: cone-rod 
dysfunction; 
marked macular 
involvement; no 
deterioration over 
7 yrs 
R 0.2 (6/9.5)           
L 0.3 (6/12) 
R -15.50/-3.50 x169 
L -16.50/-3.75 x30 
Binocular Esterman 
visual fields well-
preserved age 18, 
Humphrey 24-2 central 
scotoma age 22 
Pt 2 
(m) 
GC14577 
3 19  0  Mild 
peripheral 
RPE 
hypopigment
ation  
17 yrs: rod-cone 
dysfunction with 
severe macular 
involvement 
R 0.0 (6/6)               
L 0.0 (6/6)      
R -0.50/-3.00 x175   
L -0.50/-3.25 x175 
Minimal exophoria with 
good recovery 
Binocular Esterman 
fields well-preserved 
age 17 
Pt 3 
(m) 
GC130 
3 35  13  Widespread 
pigmentary 
change with 
attenuated 
vessels, pale 
discs 
3 yrs: severe 
generalised rod-
cone dysfunction 
R CF                       
L 1.0 (6/60) 
Myopic 
Central visual loss in 
20’s 
Pt 4 
 (f) 
GC15862 
 
7 26  15  Extensive 
round white-
yellow dots 
26 yrs: rod-cone 
dysfunction, 
partial recovery 
after prolonged 
dark adaptation; 
mild worsening of 
rod function and 
PERG over 12 yrs 
R 0.0 (6/6)               
L 0.1 (6/7.5) 
R -4.50 DS              
L +1.00/-1.25 
Intermittent left 
exotropia          
Ishihara age 22, 17/17 
each eye, age 26, R 
12/17 L 16/17  
Binocular Esterman 
fields full age 18,  
Humphrey 30-2 age 26 
paracentral scotomas 
Table 7-1: Summary of clinical data 
Patient 2 presented with mild nyctalopia and photophilia before the age of 5 years with 
no nystagmus and no deterioration in symptoms over time. When reviewed, age 18 
years, VA was 0.0 logMAR in each eye with low myopic correction. Fundus 
examination revealed mild mid-peripheral RPE hypopigmentation and white dots. 
Time-domain OCT demonstrated a normal ISe band throughout the macula. There was 
a ring of relatively increased autofluorescence in the macula on FAF imaging with the 
background signal otherwise markedly reduced. This ring did not correspond to any 
ISe band abnormalities on OCT and as such likely represents relative preservation of 
normal autofluorescence rather than abnormally increased autofluorescence. Binocular 
Esterman visual fields were full age 17 years except for bilateral extreme scotoma 
outside of 70 degrees eccentricity (figure 7-3). ERG demonstrated undetectable rod 
responses but small cone responses in keeping with a RCD. PERG was undetectable 
indicating severe macular involvement (figure 7-4). 
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Figure 7-2: Retinal imaging in hypomorphic RPE65 related dystrophy 
(a) colour fundus 
photographs, (b) FAF 
imaging, (c) OCT.  
Patient 1, right eye, age 19 
years, (a) mid-peripheral 
retinal pigment epithelial 
(RPE) granularity, (b) reduced 
FAF with patchy radial 
relatively preserved FAF in 
the macula, (c) para-foveal 
disrupted ISe band.  
 
Patient 2, right eye, age 18 
years, (a) mild mid-peripheral 
RPE atrophy and white dots, 
(b) relatively preserved 
macula FAF, (c) preserved 
ISe band.  
Patient 3, left eye, age 35 
years, (a) pale disc, 
attenuated vessels, mid-
peripheral intra-retinal 
pigment migration and RPE 
atrophy, macular atrophy     
(b) residual autofluorescence 
in macula, (c) loss of outer 
retina and ISe band.  
Patient 4, right eye, (a) 
extensive white dots around 
arcades, (b) generalized 
reduced FAF (c.i) disrupted 
ISe band, (c.ii) eccentric OCT, 
white dots extend from RPE 
to external limiting membrane. 
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Figure 7-3: Visual fields for patients 1, 2 and 4 
Binocular Esterman suprathreshold fields and Humphrey uniocular threshold fields: patient 1, 
well-preserved Esterman field age 18 years, central scotoma on uniocular Humphrey 24-2 age 
22 years; patient 2 well-preserved Esterman field age 17 years; patient 4 well-preserved 
Esterman field age 18 years, arcuate defects on uniocular Humphrey 30-2 age 26 years. 
The third patient also described nyctalopia at a young age with reported good visual 
acuity into his 20s and onset of central blur from his late 20’s only. Visual acuity age 30 
was R 0.6 logMAR and L 1.0 logMAR but at last review age 44 was R HM, L CF with 
irregular nystagmoid like movements. On fundus examination, there was disc pallor, 
attenuated vessels, mid-peripheral intraretinal pigment migration, and RPE atrophy of 
both macula and mid-periphery (figure 7-2). There was loss of the ISe band and outer 
retina on OCT particularly centrally and temporally. FAF imaging demonstrated loss of 
autofluorescence para-foveally and throughout the peripheral retina with  a ring of 
preserved autofluorescence in the macula. ERG age 3 years was reported to 
demonstrate severe rod-cone dysfunction (performed elsewhere). 
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Figure 7-4: Electrophysiology for patients 1 and 2.  
RE of patients 1 (age 19 years) and 2 (age 18 years) with N for comparison: patient 1 rod 
specific ERG (DA 0.01) markedly subnormal with DA 11.0 moderately subnormal, cone specific 
(LA 30Hz and LA 3.0) markedly delayed and subnormal, PERG markedly subnormal, in keeping 
with a CORD of moderate severity; patient 2 undetectable rod function with markedly delayed 
and subnormal cone responses and undetectable PERG, in keeping with a RCD.  
Patient 4 presented with nyctalopia at age 7 years but no nystagmus. Visual acuity was 
R 0.0 logMAR and L 0.1 logMAR at last review age 26 years with deterioration of 
nyctalopia and colour vision. Fundus examination revealed widespread discrete white 
dots both round and ovoid in shape throughout the mid-periphery of both eyes 
predominantly around the arcades reminiscent of fundus albipunctatus (figure 7-2). The 
number and distribution of the dots remained stable over 12 years of imaging although 
occasional dots were observed to fade in size. On OCT the white dots extended from 
the RPE to the level of the ELM. The ISe band was disrupted but present throughout 
the macula. FAF imaging demonstrated generalised reduction of autofluorescence with 
a discrete area of further reduction infero-nasal to the optic disc in the right eye only, 
suggestive of RPE atrophy (55 degree FAF imaging, not shown). The white dots were 
not hyperautofluorescent. Binocular Esterman visual field age 18 years was full (figure 
7-3). Uniocular, Humphrey 30-2 visual fields age 26 years demonstrated paracentral 
scotoma in both eyes with MD -7.65 DB right and -6.80 DB left. Electrophysiology age 
21 years demonstrated a generalised rod more than cone pattern of abnormality with 
severe rod-system dysfunction (figure 7-5). There was some recovery of rod-dominated 
ERGs after prolonged dark adaptation but they did not normalise. The ERG showed 
mild worsening of rod function over 12 years of testing. PERG was normal age 15 
years with deterioration indicating macular dysfunction evident at age 21 years.  
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Figure 7-5: Electrophysiology for patient 4 
RE (dark adapted, DA, overnight) and left eye (LE, DA for 20 minutes) of patient 4 (age 27 
years) with N for comparison (DA 20 minutes); rod specific ERG is detectable from the RE but 
not from the LE, cone specific responses are profoundly reduced and delayed with the PERG 
from the LE markedly subnormal, PERG age 15 years normal both eyes. Findings are in 
keeping with marked retinal dysfunction of both rod and cones with partial recovery of rod 
function after prolonged dark adaptation. 
Molecular screening of RPE65 in the first patient identified a homozygous variant in 
RPE65, c.746A>G (p.Tyr249Cys), predicted to be damaging in silico. This patient’s 
molecular result has been previously reported.315 Segregation was confirmed in the 
family with an affected brother (unavailable for clinical assessment) also homozygous 
for this variant and their parents and sisters heterozygous. Two mutations in RPE65 
were found in the second patient; c.1067dupA (p.Asn365Lysfs*9), a novel PTC, and 
c.1543C>T (p.Arg515Trp) which has been previously reported as a hypomorphic 
allele.311 This allele was also identified in patient 3 as well as a second mutation, 
c.11+5G>A, previously reported as one of the commonest variants found in RPE65 
related disease.303 Screening of RPE65 in patient 4 identified compound heterozygous 
mutations, c.433G>A (p.Ala145Thr, paternal), not previously associated with disease, 
predicted to be tolerated in silico (SIFT 0.13, Polyphen2 0.41) and found in 15 of 
121,334 alleles on ExAC and c.886dupA (p.Arg296Lysfs*7, maternal) which has been 
previously reported.316  
Two groups were assessed for a significant difference in visual acuities at age 18 
years, the first comprising patients 1,2 and 4 (VA age 18 unavailable for patient 3) and 
the second group of 5 molecularly proven RPE65 patients without known hypomorphic 
alleles. A comparison of the median visual acuity of the two groups was made, and 
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tested for significance using the Mann-Whitney test. There was a significant difference, 
p=0.024 (figure 7-6). 
 
Figure 7-6: Comparison of VA age 18 years for 3 hypomorphes and 5 controls 
 
Figure 7-7: Conservation of RPE65 homologues throughout the species.  
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A review of a further 26 molecularly-confirmed RPE65 families attending the clinics 
found no other cases harbouring the missense changes reported here. Analysis of the 
conservation of missense residues throughout a broad range of vertebrate and 
invertebrate classes was performed with Clustal Omega; all arose in completely 
conserved residues (figure 7-7).  
Assessment of the position of mutations on the 3 dimensional crystalline structure of 
RPE65 did not demonstrate an observable difference between hypomorphic and non-
hypomorphic residues (figure 7-8). 
 
Figure 7-8: Crystalline structure of RPE65 labelled with mutations 
Hypomorphic missense mutations both from this series and previously reported (red), and non-
hypomorphic missense mutations (black). This image was made with VMD software support 
and PDB number 4F3A. 
7.4 Discussion 
Although the majority of patients with mutations in RPE65 have severe visual 
impairment, this series of 4 patients with RPE65 mutations have good visual acuity and 
preserved visual fields into adulthood. Compared to other patients with typical RPE65 
related EORD, visual acuity is statistically better at age 18 years.   
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Four hypomorphic patients with homozygous or compound heterozygous missense 
mutations in RPE65 have previously been reported with nyctalopia from early 
childhood, but normal visual acuity until 6 to 24 years.303, 310-312 The first with reduced 
central vision in the 2nd decade carried 2 missense variants, p.Leu22Pro and 
p.His68Tyr.312 He had end-stage disease with a barely detectable photopic ERG and 
undetectable scotopic ERGs when examined age 40 years. The 2nd was still able to 
read age 40 years and had 2 missense variants, p.Tyr79His and p.Glu95Gln; no further 
information was given on the retinal appearance or ERG.303 The 3rd homozygous for 
p.Arg515Trp, developed central vision loss age 24 years and had end-stage disease 
with an undetectable ERG when examined age 54 years.311 The 4th homozygous for 
p.Pro25Leu had good visual acuity when last reviewed at age 7 years.310 He had 
blonde fundi, residual rod function and relatively well preserved cone function on ERG 
and a low but detectable FAF. Apart from the 4th report, limited phenotypic data have 
been published. 
In contrast, the patients reported herein had detailed phenotyping of both retinal 
structure and function. All patients had good visual acuity until at least age 19 years, 
with only mild visual field loss. Three have lengthy follow-up with evidence of a slow 
but definite progression based on visual acuity (patients 1 and 3), colour vision testing 
(patient 4) and ERG/PERG (patient 4). Patients 1 and 2 had minimal fundus changes 
at last review, similar to the previously reported young patient. In contrast, patient 3 
showed the typical features of advanced photoreceptor degeneration age 35 years 
similar to the end-stage disease in 2 previously reported patients.310-312 OCT imaging in 
patients 1, 2 and 4 demonstrated preserved para-foveal retinal thickness and minimally 
disrupted or intact ISe band; in patient 3 with advanced disease the OCT was markedly 
thinned.317 Fundus autofluorescence was reduced but detectable in all patients.310  
Most patients with RPE65 deficiency have undetectable rod function on ERG but may 
have residual cone function until late in the disease.318 Patient 2 had absent rod 
function but patients 1 and 4 had residual rod function in keeping with milder disease 
with similarities to the previously reported 7 year old patient.310 Unusually, patient 1 
demonstrated relatively greater cone than rod dysfunction on ERG examination with no 
evidence of deterioration between ages 12 and 19 years.   
Patient 4 had widespread white dots that extended from RPE to ELM. Fundus 
albipunctatus due to compound heterozygous RPE65 mutations (IVS1+5G>A and 
p.Ile115Thr) was previously reported in a patient who had deterioration of visual acuity 
by age 18 years.313 Electroretinography was similar to that found in RDH5 mutations 
with normalization of rod-system ERGs after prolonged dark adaptation. The patient in 
the present series has a similar retinal appearance but only partial recovery of rod 
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function following extended dark adaptation and excellent visual acuity at age 26 years. 
The dots in the previously reported patient were demonstrated on OCT to extend 
throughout the RPE up to the level of the ELM, similar to the patient in this report and 
to a previous report of OCT findings in an RPE65 related severe EORD patient.306 
Molecular analysis in patient 1 identified a homozygous p.Tyr249Cys variant, predicted 
to be pathogenic in silico. Patients 2 and 3 carried 2 variants including the p.Arg515Trp 
allele that has been previously reported in a similarly mildly affected patient.311 Patient 
4 had a missense change, p.Ala145Thr, tolerated in silico and not previously reported 
in disease, but arising in a highly conserved residue. This was combined with a PTC 
mutation, previously reported in a patient with LCA and assumed to be null.316 The 
analysis of mutations in this series of patients would indicate that p.Tyr249Cys, 
p.Arg515Trp and p.Ala145Thr are all hypomorphic alleles. One weakness of this study 
has been the lack of other family member DNA samples for segregation in families 2 
and 3 but the finding of a previously reported hypomorphic mutation on one allele 
consistent with their phenotype would support likely pathogenicity.   
RPE65 is a membrane-bound, iron-dependent enzyme that converts all-trans-retinyl 
esters to 11-cis-retinol, most likely in a dimeric state.319 A previously reported in vitro 
assay system using purified RPE65 confirmed its isomerase function in the visual cycle 
and permitted quantitative analysis of enzymatic activity.320 Some hypomorphic RPE65 
alleles have been shown in vitro to produce RPE65 protein with sufficient residual 
activity for good photopic visual function in childhood. For example, p.Pro25Leu was 
found to have 7.75% residual isomerase activity in vitro, sufficient to maintain good 
visual acuity in a patient age 4.5 years.310 In contrast, p.His68Tyr, associated with a 
severe phenotype, had less than 2% activity.  
Investigation of the location of hypomorphic residues in the crystalline RPE65 structure 
revealed no apparent difference when compared to non-hypomorphic residues; the 
hypomorphic residues are surface located as are the majority of non-hypomorphic 
residues (figure 7-8). Previously, in an analysis of a parologue of RPE65, it was 
suggested that surface residues would have little effect on enzyme activity but residues 
located centrally near the substrate binding site would have a greater effect.41 However 
mutations of the surface residues in RPE65 clearly do have an effect on protein 
function. An investigation of RPE65 residues that are frequently affected in retinal 
dystrophy (Arg91, His182 and Tyr368) demonstrated that the amino acid side chains 
make specific interactions with surrounding residues and that the substituted residues 
are not structurally tolerated leading to misfolding.319 In compound heterozygous 
patients with one hypomorphic allele and one severe mutant allele, the overall residual 
activity appears sufficient to regenerate physiologically significant levels of 
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chromophore, perhaps as the structural change in the hypomorphic residues are better 
tolerated. Further in vitro assessment would determine the precise impact on 
isomerase activity for the presumed hypomorphic alleles reported in our subjects. 
It appears from the study of patients with hypomorphic alleles that low levels of 
isomerase activity are sufficient to maintain good foveal cone function in to adulthood 
despite ERG evidence of poor rod and cone function and marked macular dysfunction 
on PERG.310 It is therefore surprising that improvement in visual acuity in RPE65 gene 
replacement therapy trials have been limited despite good rescue of rod and 
extrafoveal cone function.307-309 In the patients in this series, low levels of RPE65 
activity from birth is associated with normal visual acuity but markedly reduced rod and 
cone function.  This suggests that the efficiency of transduction in human gene 
replacement trials may not be the limiting factor in improving visual acuity post 
treatment, but rather that gene replacement therapy should be given very early in 
childhood for optimal recovery of visual acuity.307 
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8 Familial exudative vitreoretinopathy and 
microcephaly 
8.1 Introduction 
Familial exudative vitreoretinopathy (FEVR) is a disorder of abnormal vasculogenesis 
with variable manifestations including incomplete peripheral vascularisation, retinal 
folds and total retinal detachment.126 Approximately 50% of cases can be molecularly 
solved due to mutations in LRP5 (AD, AR), FZD4 (AD, AR), NDP (X-linked 
recessive),TSPAN12 (AD, AR) and ZNF408.125, 321-327 Most of these are genes involved 
in the canonical Wnt signalling pathway, a transmembrane pathway that activates β-
catenin/TCF transcription, involved in retinal development/angiogenesis.328, 329 The 
exception, ZNF408 is a zinc finger transcription factor identified in 3 families to date.125, 
327 There is variable severity within families but complete penetrance.126 
Rarely, FEVR has been reported in association with microcephaly.330-332 KIF11 has 
been reported as one cause of this association, allelic with microcephaly with or 
without chorioretinopathy, lymphedema or mental retardation (MCLMR, 
MIM#152950).333, 334 In addition, one patient with bi-allelic mutations in TUBGCP6 has 
been reported with microcephaly, retinopathy and retinal folds.335 The aim of this study 
was to characterise a series of 12 children from 10 families with microcephaly and 
FEVR and investigate the extent of any genetic heterogeneity. Additionally, the 
potential benefits of a molecular diagnosis in informing both genetic counselling and 
relevant systemic investigations were studied. 
8.2 Methods 
8.2.1 Ascertainment of patients 
Patients were all known to the paediatric genetic clinic at Moorfields, under the care of 
one of my supervisors. One patient was already molecularly solved. Patients were 
identified from the genetics database and from my supervisor as having FEVR and 
microcephaly. In 2 patients, microcephaly was only apparent after further review in 
clinic and measurement of the occipito-frontal circumference (OFC). 
8.2.2 Clinical assessment 
In total, 10 probands and 2 siblings were ascertained for detailed phenotyping including 
growth parameters. I was able to examine 8 patients, my supervisor the remaining 
patients. All patients had retinal imaging and systemic assessment by paediatric 
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colleagues. Systemic assessment included growth parameters of OFC, height and 
weight. Microcephaly was defined as an OFC more than 2 standard deviation (SD) 
below the mean (≤ -2 SD) for gender, age and ethnicity.336 Based on the growth charts 
used within UK practice, this corresponds to ≤ the 2nd centile.337 When necessary, 
patients were referred for further specialist opinion such as endocrinology if LRP5 
mutations were identified which is known to be associated with reduced bone mass.338 
Available parents were examined and FFA performed if indicated. 
8.2.3 Molecular investigations 
Six probands underwent WES, 5 screened by colleagues (Pia Ostergaard and Sahar 
Mansour) at St George’s Hospital as part of a project investigating microcephalic 
patients and one as part of a trio with his parents (AROS). This latter proband was 
solved by WES. WES (St Georges) had initially also identified a novel, heterozygous 
variant in LRP5, c.2116G>A (p.Gly706Arg), in patient 7. Segregation found this variant 
to be homozygous in her unaffected mother making it likely to be a polymorphism. It 
had nevertheless prompted a screen of a series of FEVR microcephaly patients for 
LRP5 variants. 
In total, 8 probands had candidate gene Sanger sequencing including LRP5 (n=7, by 
me), KIF11 (n=7, St George’s hospital colleagues), FZD4 (n=1, by me), NR2E3 (n=6 by 
me), TSPAN12 (n=1, Carmel Toomes in Leeds), NDP (n=3, Leeds), and TUBGCP6 
(n=1, Prof Jackson, Edinburgh). This identified causative mutations in 4 probands. All 
identified mutations were segregated with available affected and unaffected family 
members. I designed primer pairs for screening of LRP5 and FZD4 (table 8-1). 
Mutation nomenclature was assigned in accordance with GenBank Accession numbers 
NM_2335.3 for LRP5, NM_012193.3 for FZD4, NM_004523.3 for KIF11 and 
NM_020431.3 for TUBGCP6. 
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Exon Primer forward 5’ → 3’ Primer reverse 5’ → 3’ Enzyme 
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p
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LRP5 
1 TTCCGCTCCCGCGCGCCCAGCT GCGGGGCCGCCCGGGCCATT MYTAQ 
+DMSO 
70 311 
2 GCAGTACCAGGAGTGCTCTG TGGGCTCATGCAAATTCGAG BIOTAQ 65 572 
3 AGGGCAAGTTCACTGTCTGT GAACGCCTTCAAAAGCCCTG BIOTAQ 65 364 
4 GGTCAGCAGCAATGACTGACG CCCACGCCCCCGCATC MYTAQ 65 355 
5 ATGAGGCAGGTGGAATGGTG  ACCCGCCAAGTGGATCATTT BIOTAQ 65 432 
6 TGAGTATTTCCCTTGCCCGG  TCCGGGTTCTGATGCAAGAC BIOTAQ 65 599 
7 CTCTTGGCACTGGGGATGC  TGGCCAAATAGCAGAGCACA BIOTAQ 65 355 
8 TCTTGTTTGGGGCAGCTCAG GGCACCTGAGCTCAACACTT BIOTAQ 65 414 
9 ACGGCAGCATTCATTGTGTG TTTGAGGCAGGAACAGAGGC BIOTAQ 65 447 
10 TGGGCAAGAAGAGCGAAACT CTCTAATCACCGAGGGCCAC BIOTAQ 65 427 
11 GAAGAGGTGGGGACAGTTGC TTGCAGGCCACAGGGTATG BIOTAQ 65 373 
12 GTTGAACCCTGGCTCACCC  AGAAGCTCCTTTCAGCGTCA BIOTAQ 61 494 
13 TTGTCGAGTGGCGTGCTATC GCCATCCTCTGTTTCCTCCC BIOTAQ 65 392 
14 TTGAGAAGTGTGGCCTCTGC ATCCCCAGGGTGGAAAGTCT BIOTAQ 65 495 
15 AATGTGACCTGTCAGCCTCG TCACTCAGAACCCCAGCCTA BIOTAQ 65 494 
16 AAAGCATGGAATCCCCCAGG CTCGGGACATTCGGACATGT BIOTAQ 65 494 
17 CAGGAGGGCCAGTTCTCATG GAAACTGGATGCCACAGGGA BIOTAQ 65 347 
18 CTTTGAAGCCCAGTCACGC AGAGCCCCTACTCCTGTGAG BIOTAQ 65 413 
19 CGCTGGTCCTAGAAAGGGTC GCACGTCTCCTCCCCTAAAC BIOTAQ 65 318 
20 CAAAGCCAGCCCCTTCAGG TGTCTGCCACATGTGCAAGA BIOTAQ 65 449 
21 GGTAGTGGGAGCAGAGGAGA AGCAGAAGGGTTTGAAAAGGGA BIOTAQ 65 385 
22 GAAGCCCTCTCTGCAAGGAA TAGTGTGGTTGGCAGAGCAG BIOTAQ 65 354 
23 GACAGGCCTTTCCCGTTCA CATCACAGTTCACATTTCTCATGTT BIOTAQ 65 492 
FZD4 
1 GCATCACACTCCCGTCCC TGTCTCCTTCGGGCTAGGAT MYTAQ 64 509 
2a AACTCAGCTTTGTGGGAGCA TGACCCCATTTGAGTCCTGC MYTAQ 64 805 
2b TGAAGAGGCAGCAGAACCTG CAAAATGCTGGCATTCCCCC MYTAQ 64 818 
Table 8-1: Primer pairs for sequencing LRP5 and FZD4 
8.3 Results 
Twelve patients (8 male, 4 female) from 10 families were investigated (table 8-2, figure 
8-1). All had FEVR of variable severity with visual impairment and nystagmus. In 
patients 4 and 10, there was a retinal fold in 1 eye, chorioretinal dysplasia in the other. 
Visual acuity was worse for patients with retinal folds and detachment, and mildest for 
peripheral retinal vascularisation (table 8-3). Age ranged from 4 months to 16 years at 
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last review. OFC ranged from far below the 0.4th centile to on the 2nd centile. 
Developmental delay was present in 8/12 patients.  
Patient, 
gender, 
family 
Gene/ 
assay 
Age 
last 
rv 
Latest 
VA  
logMAR 
(Snellen) 
Fundus features Growth parameters, 
centile 
Other 
findings 
OFC Ht Wt 
Pt 1 (M) 
GC16755 
LRP5 9  yrs R CF      
L NPL 
RE tractional RD, 
nasally avascular, LE 
total RD with no 
fundal view 
<<0.4
th
  0.4
th
-2
nd
  
2
nd
-
9
th
  
Normal DEXA 
scan          
Normal MRI 
brain 
Pt 2 (F) 
GC19160 
LRP5 5  yrs R 1.3 
(6/120) L 
1.4 
(6/150) 
BE retinal folds with 
partial retinal vascular 
preservation on FFA 
<0.4
th
 95
th
 95
th
 Reduced bone 
mass on 
DEXA scan, 
maternal OFC 
95
th
 centile 
Pt 3 (M) 
GC21489 
KIF11 4 
mths 
Fixing 
and 
following 
BE retinal folds with 
partial retinal vascular 
preservation on FFA. 
Rod-cone dysfunction 
on ERG 
<0.4
th
 9
th
 2
nd
 Normal MRI 
brain 
Pt 4 (M) 
GC20377 
 
KIF11 8  yrs R 0.6 
(6/24)     
L 1.6 
(6/240) 
RE chorioretinopathy 
with focal atrophy, LE 
retinal fold. Rod-cone 
dysfunction 
<0.4th N/A N/A Developmental 
delay 
Pt 5 (M) 
GC21033 
TUBGCP6 17 yrs R 0.56 
(6/24)     
L 0.52 
(6/19) 
Loss of 
photoreceptors 
outside of fovea on 
OCT, lack of 
peripheral 
vascularisation with 
fibrotic ridge. Rod-
cone dysfunction 
<<0.4
th
  2
nd
 9-
25
th
 
Moderate 
learning 
difficulties 
Pt 6 (F) 
GC21033 
TUBGCP6 14 yrs R&L 0.7 
(6/30) 
Lack of peripheral 
vascularisation on 
FFA with fibrotic 
ridge. Rod-cone 
dysfunction 
<<0.4
th
 9-
25
th
 
2
nd
-
9
th
  
Moderate 
learning 
difficulties 
Pt 7 (F) 
GC19713 
WES 
negative, 
LRP5 SNP 
 
4  yrs Fixing 
and 
following 
RE Large temporal 
retinal fold, LE Large 
retinal fold with partial 
RD 
<<0.4
th
 N/A N/A Developmental 
delay 
Maternal OFC 
9
th
 centile 
Pt 8 (M) 
GC18797 
NDP & 
LRP5 
negative 
4 yrs BEO 1.0 
(6/60) 
BE retinal folds. 
Reduced ERG 
responses R>L, 
tested age 6 weeks 
2
nd
 N/A N/A Normal MRI 
brain 
Pt 9 (F) 
GC19208 
WES, 
LRP5 
negative 
11 yrs R 1.0 
(6/60)     
L NPL 
RE macular atrophy, 
temporal peripheral 
non-perfusion, 
telangiectasia with 
shallow exudative 
RD, LE total RD 
N/A N/A N/A Developmental 
delay, learning 
difficulties 
Pt 10 (M) 
GC19303 
WES, 
LRP5 
negative 
11 yrs R NPL            
L 0.78 
(6/38) 
RE retinal fold with 
peripheral 
chorioretinal atrophy 
and pigment, LE focal 
chorioretinopathy 
<<0.4
th
 25
th
 50
th
 Normal MRI 
brain            
ERG R 
undetectable   
L rod-cone 
dysfunction 
Pt 11 (M) 
GC20924 
WES, 
NDP, 
LRP5 
negative 
13 yrs R 1.2 
(6/95)     
L 1.4 
(6/150) 
RE retinal fold with 
exudate, LE retinal 
fold with macular scar 
0.4
th
 N/A N/A Parents 
normal FFAs, 
paternal OFC 
91
st
 centile 
Pt 12 (M) 
GC20924 
Unsolved 9 yrs R NPL   
L 1.6 
(6/240) 
RE total RD no fundal 
view, LE retinal fold, 
tractional RD/exudate 
<0.4
th
 N/A N/A Developmental 
delay 
Table 8-2: Clinical summary for patients with FEVR and microcephaly 
Ht, height; wt, weight; RD, retinal detachment; DEXA, dual energy X-ray absorptiometry 
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Patient 1 presented with eye poking at 2 months of age and was found to have a total 
detachment of the left eye with a retinal fold in the right eye. NDP screen was negative. 
Microcephaly was only identified at 9 years of age in the ophthalmology clinic and was 
then confirmed in the affected younger sister. Family 1 had previously undergone 
autozygosity mapping which identified a region of homozygosity at the EVR1 locus 
which encompasses both FZD4 and LRP5. Screening of FZD4 did not find any 
mutation. Screening of LRP5 with segregation identified a novel homozygous splice 
site variant c.4112-3C>G in the proband and his affected sister, and was heterozygous 
in the unaffected sister and parents. Due to the molecular diagnosis, bone density is 
under monitoring with a normal DEXA scan to date.  
 
Figure 8-1: Pedigrees and mutations segregation for 10 FEVR families 
Table 8-3: Visual acuity based on retinal phenotype 
Patient 2 presented in early infancy with nystagmus, poor vision and bilateral retinal 
folds (figure 8-2). Microcephaly was observed at birth. On Sanger sequencing, a 
heterozygous novel missense mutation in LRP5 was identified, c.3914G>A 
(p.Cys1305Tyr) which is predicted damaging in silico (SIFT 0, Polyphen2 1.0) . This 
was also identified in the mother who had previously had a normal dilated fundus 
examination. Subsequent Optos widefield FFA in the mother identified subtle abnormal 
Retinal abnormality Number of eyes Vision logMAR (Snellen) 
Peripheral non-perfusion 5 0.52-0.70 (6/19-6/30) 
Chorioretinal dysplasia 2 0.50-0.80 (6/19-6/38) 
Retinal fold 12 1.2-NPL (6/95-NPL) 
Retinal detachment 5 1.5-NPL (6/190-NPL) 
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peripheral retinal perfusion (figure 8-2). A bone density scan in the affected 5 year old 
child was abnormal with a z-score of -2.1 indicating osteoporosis and a similar scan is 
planned in the mother. Further family segregation was performed within an accredited 
NHS laboratory which found the proband’s sister was not a carrier, and the 2 maternal 
aunts were not carriers. Further retinal screening for these at risk family members was 
therefore not needed. 
Patient 3 presented in infancy with nystagmus, poor vision and microcephaly. Head 
circumference was reportedly normal at birth. Examination under anaesthesia at 6 
months of age identified bilateral retinal folds, and rod-cone dysfunction with ‘enhanced 
S-cone-like’ features on ERG. These comprised the characteristic features of delayed 
30Hz flicker of lower amplitude than the LA 3.0, the DA 3.0 and LA 3.0 responses 
having the same simplified and markedly delayed waveform.135 This finding prompted 
screening of NR2E3 in this patient and other unsolved FEVR/microcephaly patients 
without identifying any pathogenic variants. WES was subsequently performed on the 
proband and both parents. This identified a novel, de novo, nonsense mutation, 
c.247C>T (p.Arg83*) in KIF11 as the likely causative mutation.  
Patient 4 presented in infancy with reduced vision and was found to have a retinal fold 
in the left eye with areas of chorioretinal atrophy in the right eye (figure 8-2). 
Microcephaly was diagnosed in the Ophthalmology clinic at 6 years of age. ERG 
identified rod-cone dysfunction without any features of ESCS as described above. 
Screening of KIF11 by Sanger sequencing identified a novel, heterozygous premature 
truncating codon, c.2910_2914del (p.Glu970Aspfs*17). 
Patients 5 and 6 are siblings with learning difficulties, microcephaly and rod-cone 
dysfunction on ERG. Dilated fundus examination identified abnormal peripheral retinal 
vasculogenesis with peripheral scarred ridges in both eyes (figure 8-2). FFA in patient 
6 identified abnormal vascular malformations anterior to this ridge. Treatment has not 
yet been required. Based on the combination of microcephaly, learning difficulties and 
rod-cone dysfunction, candidate gene sequencing was performed by colleagues in 
Edinburgh. They were found to have bi-allelic novel, mutations in TUBGCP6, c.2066-
6A>G and c.4485-21A>C with RNA analysis confirming abnormal splicing (performed 
in Edinburgh). 
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Figure 8-2: Retinal imaging in FEVR with microcephaly 
Patient 2, LE RetCam colour 
and FFA images 
demonstrating retinal fold from 
optic disc to ora serrata with 
limited retinal vascularisation 
elsewhere 
 
Patient 11, Optos colour 
images of RE retinal fold with 
exudative detachment, LE 
smaller retinal fold with 
macular atrophy 
 
 
Patient 2’s mother, LE Optos 
colour and FFA images, no 
obvious abnormalities on 
colour, but abnormal 
peripheral vascularisation on 
FFA 
 
Patient 4, RetCam images, 
RE inferior, circumscribed 
chorioretinal atrophy lesions, 
LE retinal fold 
 
Patient 5, LE colour montage, 
mid-peripheral RPE 
hypopigmentation, peripheral 
scarred ridge, FAF imaging 
increased autofluorescence 
peri-foveally and in outer 
macular with loss of 
autofluorescence in-between, 
OCT, outer retinal atrophy with 
centrally preserved ISe band 
 
Patient 6, RE Optos colour 
and FFA demonstrating 
macular atrophy, peripheral 
scarred ridge with lack of 
vascularisation anterior to it 
and abnormal vascular 
malformations 
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Six patients (5 families) all with microcephaly and FEVR remain unsolved despite WES 
in all but 1 family. Patient 7 remains unsolved having had a novel, heterozygous variant 
identified on WES in LRP5, c.2116G>A (p.Gly706Arg) which was likely to be a 
polymorphism. Segregation found this variant to be homozygous in her unaffected 
mother who had a normal dilated fundus examination and an OFC on the 9th centile. 
Patient 9 has a retinal fold in one eye and chorioretinal atrophy in the other. His father 
is also microcephalic and on dilated fundus examination has incomplete peripheral 
vascularisation. Screening of the most likely candidate gene, KIF11, has been 
negative. Patients 11 and 12 carry a copy number gain at 4q22.2 (0.68Mb) which is 
paternally inherited. This was found elsewhere by comparative genomic hybridization. 
Within this region are 7 genes (HPGDS, PDLIM5, SMARCAD1, BMPR1B, UNC5C, 
PDHA2, and STPG2). Only one of these has a known retinal developmental role, bone 
morphogenetic protein receptor type 1B (BMPR1B) which has been shown in a mouse 
model to be required for normal ventral ganglion cell axon targeting to the optic nerve 
head as well as controlling inner retinal apoptosis.339 Given the normal fundus 
examination and FFA in the father, it is unlikely that this copy number gain is 
pathogenic. WGS is planned on all unsolved families with available parents to be 
sequenced simultaneously. 
8.4 Discussion 
In this series of 12 patients with FEVR and microcephaly, half of the patients have 
been molecularly solved and half remain under investigation. This reflects a similar 
published solved rate for FEVR alone.125 All patients presented in early childhood with 
nystagmus and visual impairment. Fundus features were variable in keeping with the 
known spectrum of FEVR from incomplete peripheral vascularisation to retinal fold to 
retinal detachment.126 In addition, there were 2 patients with unilateral retinal folds and 
contralateral chorioretinal dysplasia which has been seldom reported in the literature 
before.332, 334 Visual acuity correlated with fundus feature, being most severe in those 
patients with retinal folds or detachment. 
ERG was available in 5 patients, 2 with KIF11 mutations, 2 with TUBGCP6 mutations, 
and 1 unsolved patient and identified rod-cone dysfunction. The TUBGCP6 patients 
have evidence of rod-cone dystrophy on retinal imaging with loss of photoreceptors on 
OCT and abnormal autofluorescence. For the other patients, it is unknown whether 
their ERG features are consistent with a rod-cone dystrophy as there has been limited 
retinal imaging possible due to the severe retinal abnormalities. Interval ERG  would be 
helpful to demonstrate deterioration consistent with a rod-cone dystrophy. Previously 
reported ERG findings in FEVR are limited. A report of 3 patients from one family 
described abnormal ERG in 2 patients with reduced rod and cone responses.340 A 
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detailed characterisation of MCMLR due to KIF11 mutations in 6 patients found rod 
and cone dysfunction with abnormal macular function in those with available PERG 
results.341 It may be anticipated that in the majority of patients with FEVR, there would 
be measureable photoreceptor dysfunction based on abnormal retinal development but 
this hypothesis and determination of progressive retinal dysfunction need to be 
substantiated. 
FEVR with microcephaly has been reported in association with KIF11 and TUBGCP6 
but has not been previously reported with LRP5.333-335, 342 Microcephaly in this series 
ranged from the 2nd centile (-2 SD) to <<0.4th centile (<-5SD). In 2 patients it was only 
observed after measurements in the Ophthalmology clinic and should be specifically 
looked for in patients with FEVR. One drawback in this study is the lack of complete 
data on parental OFC and peripheral retinal examinations which may be helpful in 
filtering whole genome data from the unsolved families if the likely inheritance pattern 
is known.  
LRP5 (MIM 603506) is a 23 exon gene initially found to cause osteoporosis-
pseudoglioma syndrome a recessive disorder of severe retinal dysplasia and juvenile 
osteoporosis presenting with bone fractures in early childhood and subsequently also 
associated with dominant high bone density from missense variants located within the 
N-terminal YWTD-EGF domain.338, 343, 344 LRP5 has been associated with both 
dominant and recessive forms of FEVR with mutations distributed throughout the gene 
and with evidence of non-penetrance in dominant disease.325, 345 In recessive disease, 
carrier parents can also have low bone mass.338 Of the 2 families identified with LRP5 
mutations in this study, one has recessive disease with a novel splice site mutation, 
and the other dominant disease. For patient 2 and her mother, evidence for the 
causality of the novel missense mutation which is predicted to be damaging in silico, 
includes the abnormal peripheral retinal vascular findings in the mother and the 
reduced bone density in the patient at age 5 years. For this family, the molecular 
diagnosis has enabled systemic monitoring of bone density to prevent fractures and 
screening for this mutation in the patients maternal aunts and younger sister, all of 
whom were negative. Given the possibility that a second variant including a copy 
number variant has been missed by Sanger sequencing, or alternatively that there is 
another molecular cause, whole genome sequencing is being performed. 
Kinesin family member 11 (KIF11 MIM 148760) encodes EG5, a microtubule motor 
involved in mitosis.346 Its exact role in retinal development has not yet been elucidated. 
Mutations were first identified in association with MCLMR and later with microcephaly 
and FEVR.346 However, not all patients have microcephaly.334 Patient 3 in this report 
has a de novo, novel, nonsense mutation. Patient 4 has a novel PTC with segregation 
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unavailable to determine if it was de novo. Previously reported mutations include 
missense, nonsense, splice and PTC and are found distributed throughout the gene 
without obvious mutational hotspots and without apparent difference in mutation 
distribution between patients with retinal folds and those with chorioretinal atrophy.333, 
342  At least 40% of mutations arise de novo. Non-penetrance has been reported in 
carrier parents. For family 3, the molecular diagnosis identifying de novo disease has 
allowed accurate genetic counselling on the risk of recurrence in future children. 
TUBGCP6 (MIM 610053) was first reported in a patient with microcephaly and 
chorioretinopathy without further ophthalmic detail provided.347 Subsequently it was 
identified in 4 patients all with extreme microcephaly (-7.2 to -11.1 SD), short stature (-
2.3 to -3.45 SD) and retinopathy with one patient additionally described to have retinal 
folds.335 In one patient, ERG demonstrated absent rod and cone function. The siblings 
in this series have abnormal retinal vascularisation identified in conjunction with a rod-
cone dystrophy but with less severe microcephaly and without short stature. Their 
novel mutations are both predicted to create cryptic splice sites with out of frame 
transcripts then created. Previously reported mutations include splice site, PTC and 
missense.335, 347 Detailed ophthalmic phenotyping of all TUBGCP6 patients would be of 
particular interest to investigate the exact types of retinal involvement. 
WGS in the 5 unsolved families is in progress with probands being sequenced in 
parallel with unaffected and other affected family members to aid interpretation of the 
results. This is particularly relevant when the inheritance can be recessive or dominant, 
with the potential for variable penetrance and de novo mutations. 
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9 Hermansky-Pudlak syndrome 6 
9.1 Introduction 
Oculocutaneous albinism is a recessive disorder of melanogenesis presenting in 
infancy with poor vision and nystagmus.348 It is characterised by iris transillumination, 
foveal hypoplasia, chiasmal misrouting on VEPs and variably reduced pigmentation of 
the fundus, hair and skin. OCA is a feature of certain syndromes including Hermansky-
Pudlak syndrome (HPS, MIM#203300) associated with bleeding diathesis, pulmonary 
fibrosis and granulomatous colitis and Chediak-Higashi syndrome (MIM#214500) with 
immunodeficiency and neurological involvement.349, 350  
HPS is an inherited disorder of lysosomal organelle biogenesis most prevalent in 
Puerto Rico at a rate of 1 in 1800 due to founder mutations in HPS1 and HPS3. 351, 352 
Nine HPS genes have been identified all encoding protein complexes involved in the 
biogenesis of lysosome related organelles (BLOC), including melanosomes in 
melanocytes and delta granules in platelets.353 HPS6 is a subunit of the BLOC2 
complex in addition to HPS3 and HPS5. HPS6 is an integral part of the retrograde 
motor complex for lysosomal transport from cell membrane to the perinuclear region.354 
HPS6 is a very rarely reported subtype with only six families reported to date; their 
HPS6 related disease characterized by OCA with bleeding diatheses.355-357  
There may be a delayed diagnosis of HPS if the systemic disease is mild as has been 
reported in HPS3 related disease and as such the patients may initially have an 
isolated ophthalmic diagnosis of OCA or even ocular albinism.358 Consideration of HPS 
as a differential diagnosis by the ophthalmologist is important due to its systemic 
complications. In this investigation of 2 families with HPS6 related disease, the 
diagnosis was delayed due to a mild systemic phenotype. 
9.2 Methods 
9.2.1 Ascertainment of patients 
Two children from a distantly consanguineous family of Punjabi Afghan descent were 
recruited from the paediatric clinic at Moorfields to the inherited retinal disease study. 
They had both presented in infancy with nystagmus and reduced vision and were 
diagnosed with isolated foveal hypoplasia. WES of the proband when age 10 identified 
a homozygous variant in HPS6 which prompted further investigation of the family by 
myself. I then also investigated an adult patient known to have a diagnosis of HPS and 
a mild systemic phenotype but no molecular diagnosis.  
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9.2.2 Clinical assessment 
All patients were assessed and examined by myself at their most recent visit. All 
underwent full clinical examination and imaging including anterior segment and colour 
fundus photography, FAF and OCT as detailed in methods. ERG was performed using 
eyelid electrodes for the 2 children of family 1 as detailed in methods. In addition, both 
children underwent VEP recording to evaluate chiasmal routing. ERG/VEP recordings 
were not available for patient 3. 
9.2.3 Systemic investigations 
All patients underwent haematological assessment and investigation following referral 
to haematology colleagues. In addition the 2 children of family 1 were under the care of 
general paediatric colleagues. 
9.2.4 Molecular investigations 
The proband of family 1 had previously undergone screening of SLC38A8, which was 
at the time a candidate gene for isolated foveal hypoplasia under investigation by 
colleagues in Leeds.359 This did not identify a mutation. WES was then performed at 
AROS Applied Biotechnology. 
A homozygous variant in HPS6 was identified by colleagues as likely causative. 
Following my own review of the results, a single variant in SLC38A8 was also identified 
and given the patient’s phenotype further investigated. Both patients were clinically 
reviewed by myself and the rest of the family’s blood samples taken for DNA extraction 
and segregation. I designed primers for bi-directional Sanger sequencing of the single 
exon of HPS6 (4 primer pairs required due to size of exon) and the exon-intron 
boundaries as well as the affected exon 7 of SLC38A8 (table 9-1).  
Gene/ 
exon 
Primer forward 5’ → 3’ Primer reverse 5’ → 3’ Enzyme 
A
n
n
e
a
li
n
g
 
te
m
p
 (
°C
) 
A
m
p
li
c
o
n
 
s
iz
e
 (
b
p
) 
HPS6-A GCTGGACCTGGGCAAAGC CAGCAGGACGTGTGTGCG MYTAQ 
+ DMSO 
65 600 
HPS6-B CTTTCAGCCACTGTGTGTGC AAGATTCCCTCGGGTCTCCA BIOTAQ 65 653 
HPS6-C GTACATCTGCTAGAACCGCCA CTTCCACACATCAGGGGGTG MYTAQ 65 597 
HPS6-D CAACACCGTTTTCCAAGCCC CCCTGAGTGTTCTGATGCCT MYTAQ 65 840 
SLC38A8 
exon 7 
AGGACAGGAAAGCTTTGGGC TGTGCCTGTTTCCTCCTGTC BIOTAQ 65 441 
Table 9-1: Primer pairs for sequencing of HPS6 and SLC38A8 
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In the 3rd patient, I performed candidate gene investigation with Sanger sequencing of 
HPS6 based on the mild systemic phenotype. In addition, given a reported history of 
parental consanguinity, autozygosity mapping using a SNP microarray (OmniExpress) 
was performed including all 9 HPS loci (table 9-2). 
HPS subtype Gene Coordinates 
HPS1  HPS1 10q24.2 
HPS2  AP3B1 5q14.1 
HPS3  HPS3 3q24 
HPS4  HPS4 22q12.1 
HPS5  HPS5 11p15.1 
HPS6  HPS6 10q24.32 
HPS7 DTNBP1 6p22.3 
HPS8  BLOC1S3 19q13.32 
HPS9 BLOC1S6 15q21.1 
Table 9-2: Nine HPS genes and loci 
Mutation nomenclature was assigned in accordance with GenBank Accession number 
NM_024747.5. 
9.3 Results 
Clinical details are summarised in table 9-3. Patient 1 was examined at age 12 years. 
She had reduced vision at R 0.48 logMAR, L 0.40 logMAR, fine horizontal nystagmus 
but no iris transillumination. Dilated fundus examination revealed reduced foveal 
reflexes but otherwise appeared normal (figure 9-1). Her younger sibling at  age 4 
years also had reduced vision R0.76 logMAR and L 0.70 logMAR with fine horizontal 
nystagmus and no iris transillumination. His dilated fundus examination also 
demonstrated reduced foveal reflexes and his fundi were noticeably blonder than his 
sisters. On careful comparison of hair and cutaneous pigment in the siblings and their 
parents, the proband’s hair was noted to be slightly lighter than her parents; her 
younger brother on removal of his turban had noticeably lighter hair. Retinal imaging 
confirmed foveal hypoplasia with loss of the foveal pit and persistence of inner retinal 
layers over the expected anatomical position of the fovea (figure 9-1). Both patients 
had previously undergone electrophysiology, in the proband age 1 and repeated age 5 
and in the younger brother at 8 months of age. In both, full field ERG was normal with 
VEPs finding no evidence of chiasmal misrouting.  
 
Subsequent re-evaluation elicited a history of mild bruising at the time of immunisations 
for both children and for patient 1, nose bleeds every 1-2 weeks from the age of 6 
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years. Haematological investigation was consistent with a platelet storage pool 
disorder and HPS was confirmed (table 9-3). 
Pt number,  
age last review, 
family number 
Visual function 
 
Haematology investigations 
Visual 
acuity 
logMAR 
(Snellen) 
Refraction Platelet 
ATP:ADP 
ratio 
(0.9-2.3) 
Platelet Function 
tests 
Electron 
Microscopy 
Pt 1 
12 years 
GC18806 
 
R 0.48 (6/19) 
L 0.40 (6/15) 
R +7.00/-2.00 x 180 
L +6.00/-1.00 x180 
13.9 Normal aggregation    
Significantly 
reduced ATP 
release   
Not done 
Pt 2 
4 years 
GC18806 
 
R 0.76 (6/38) 
L 0.78 (6/38) 
R +5.50/-3.00 x 180 
L +5.50/-3.00 x 180 
31.4 Reduced 
aggregation  
Significantly 
reduced ATP 
release   
Not done 
Pt 3 
29 years 
GC15023 
R 0.82 (6/38)   
L 0.94 (6/48) 
R -1/-1.25 x 180 
L -4/-3 x180 
10.8 Reduced 
aggregation 
Absent ATP release 
Reduced 
platelet 
dense 
granules 
Table 9-3: Key molecular, visual and haematological findings 
ATP, adenosine triphosphate; ADP, adenosine diphosphate  
 
Figure 9-1: Anterior segment and retinal imaging in HPS-6 
(a) anterior segment imaging, (b) colour fundus photographs, (c) FAF imaging, (d) OCT. Patient 
1 and 2, no iris transillumination, peripherally blonde fundi more obvious in patient 2, no fovea 
on FAF or OCT imaging. Patient 3, right Axenfeld anomaly, left posterior embryotoxin, 
transillumination, blonde fundus and no fovea. 
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Patient 3, the second child of parents of Russian-Palestinian origin, presented at 3 
months of age with reduced vision, nystagmus, iris transillumination and blonde fundi. 
In addition right Axenfeld anomaly and left posterior embryotoxin were noted (figure 9-
1). An initial diagnosis of mild ocular albinism was made, amended to oculocutaneous 
albinism age 9 years due to likely inheritance pattern (ie not X-linked) and the 
observation of mildly reduced cutaneous/hair pigmentation.360 There were no 
complications from hernia surgery age 6 years but age 26 years there was prolonged 
bleeding for 3-4 hours following a dental extraction. Haematological investigations 
identified a platelet storage pool disorder consistent with HPS (table 9-3).  
WES in patient 1 identified a novel, homozygous missense variant in HPS6, c.779G>A 
(p.Gly260Glu), predicted to be damaging in silico (SIFT 0.03, Polyphen2 1.00) and a 
novel heterozygous variant in SLC38A8, c.860C>G (p.Ser287Cys) which was 
predicted damaging in silico by Polyphen2 (1.00) but tolerated by SIFT (0.14). 
Sequencing of both variants in patient 2 supported causality of the HPS6 variant with 
the SLC38A8 variant not found. The parents were confirmed to be carriers of the HPS6 
variant (figure 9-2). 
 
Figure 9-2: Pedigree of family 1 (patients 1 and 2) and HPS6 chromatograms 
Patient 3 had a mild systemic phenotype and as this was consistent with previous 
reports of HPS6 related disease, candidate gene sequencing of HPS6 was 
performed.357 This identified bi-allelic PTCs, c.902dupT (p.Thr303Hisfs*64) which was 
novel and c.1083dupC (p.Gly362Argfs*5), not reported in an affected patient before but 
with a very low allele frequency on ExAC (1 in 120260). Both variants resulted in 
predicted truncation of each allele at the same codon (figure 9-3). As both variants 
inserted a base and were within a single exon, they were identified as bi-allelic based 
on Sanger sequencing alone. Autozygosity mapping identified no regions of 
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homozygosity over any of the 9 HPS loci and in general had few regions of 
homozygosity. This meant that the reported consanguinity in the family was unlikely. 
 
Figure 9-3: Pedigree of family 2 (patient 3) and HPS6 chromatograms 
9.4 Discussion 
This study of 3 patients with HPS6 describes novel features including a lack of iris 
transillumination, normal VEPs and 2 novel mutations. Furthermore, it substantiates 
the previous reports of a mild systemic phenotype. 
HPS6 was first reported in a single patient with OCA, bleeding diathesis but no 
pulmonary and gastrointestinal involvement.355 A further report identified HPS6 as a 
cause of OCA with mild bleeding diathesis in an extended Israeli Bedouin pedigree, all 
affected members having classical features of OCA including iris transillumination.356 A 
detailed series of 4 patients with mutations in HPS6 demonstrated variable degrees of 
albinism diagnosed in infancy; all had iris transillumination and bleeding diatheses.357 
There have been no reported complications of pulmonary fibrosis or granulomatous 
colitis. This is similar to the present series of patients and to other BLOC2 subtypes, 
HPS3 and HPS5 which also manifest with milder systemic disease than the other 
forms of HPS.358, 361, 362 Although colitis may present within the first decade of life, the 
onset of pulmonary fibrosis is not until the 4th decade.363, 364 With the limited number of 
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HPS6 patients reported to date, there is the theoretical possibility that these 
complications could still be associated. 
Patients 1 and 2 have an unusual presentation with a lack of iris transillumination and 
no chiasmal misrouting on VEPs which led to an initial diagnosis of isolated foveal 
hypoplasia. Isolated foveal hypoplasia has been reported in association with bi-allelic 
mutations in SLC38A8.359 One variant was found on WES in this gene and assuming a 
second variant was still to be found, this was further investigated. Segregation ruled 
out this variant as it was not present in the affected younger brother. A lack of iris 
transillumination has not been previously reported in HPS although the degree of iris 
defects can range from mild spoke like defects to complete transillumination.365, 366 
Abnormal chiasmal misrouting is regarded as a cardinal feature of OCA and the degree 
of misrouting has been shown to correlate with the loss of pigmentation.140, 367 VEP 
characterisation in HPS is limited; a report of 11 molecularly uncharacterised HPS 
patients identified aberrant chiasmal misrouting in all patients.368 The lack of misrouting 
in the siblings in this report may reflect the mildness of their hypopigmentation. Further 
investigation of VEPs in other HPS patients in particular the BLOC2 subtypes may 
demonstrate similar findings. The visual acuities were significantly reduced most likely 
related to foveal hypoplasia and nystagmus. The vision levels found were similar to 
those reported in other HPS6 patients.357  
Patient 3 in this series has a similar ocular phenotype to previously reported HPS6 
patients with iris transillumination, a blonde fundus and foveal hypoplasia. In addition 
she has features of anterior segment dysgenesis with Axenfeld anomaly and posterior 
embryotoxin, reported in up to a third of patients with HPS.365 Interestingly, she 
underwent abdominal surgery age 6 years without bleeding complications but had 
prolonged bleeding post dental extraction when 10 years of age. 
HPS6 is a single exon gene encoding a 775 amino acid ubiquitously expressed protein 
for which no domain or tertiary/quaternary structure data is available.357 The unbiased 
platform of WES identified a novel missense variant in HPS6 in family 1 (p.Gly260Glu) 
which is predicted to be damaging in silico. This directed further haematological 
assessment and investigation of platelet function. Only 1 of 9 previously reported 
pathogenic variants was missense (p.Thr272Ile).355-357 This was identified in a 
conjunction with a PTC in a patient diagnosed in early childhood with bleeding 
suggestive of HPS and typical ocular phenotypic features.357 Bi-allelic missense 
variants could manifest a milder phenotype as seen in family 1 if the protein function is 
less functionally impaired than truncating variants. However a large series of patients 
would be needed to substantiate this potential correlation. The PTCs identified in 
patient 3 are predicted to produce a truncated protein and not undergo NMD as there is 
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only a single exon of HPS6. 206 This has been substantiated by mRNA investigation in 
the previously reported Bedouin family.356 Neither of these variants has been reported 
in an affected patient before although one variant is present at a very low level on 
ExAC. Both variants would truncate the protein at the same codon of 367 which is the 
same predicted truncation codon of a previously reported variant p.Leu356Argfs*11.356  
This study demonstrates that HPS6 can be associated with mild and late systemic 
manifestations and a diagnosis of HPS should therefore be considered in any patient 
presenting with foveal hypoplasia, ocular albinism or OCA. An accurate diagnosis will 
ensure appropriate precautions during surgical or dental procedures. 369 
 
  
CDH3 related congenital hypotrichosis with juvenile macular dystrophy 
 
 143 
10 CDH3 related congenital hypotrichosis with juvenile 
macular dystrophy  
10.1 Introduction 
CDH3 (Cadherin 3, MIM#114021) encodes P-cadherin, a regulator of both hair, retinal 
and limb development.370, 371 First described in 2 brothers in 1935, hypotrichosis, 
congenital, with juvenile macular dystrophy (HJMD, MIM#601553) presents with 
childhood onset central visual loss with an associated scalp hair abnormality due to bi-
allelic mutations in CDH3.372 The disorder is rare and has been reported in a total of 21 
molecularly confirmed families to date with 15 reported variants.370, 371, 373-381 
Ectodermal dysplasia, ectrodactyly and macular dystrophy syndrome (EEMS) is an 
allelic disorder also arising due to bi-allelic CDH3 variants.382 The disorder is of variable 
severity and phenotype with ectodermal involvement including hypotrichosis, nail 
dysplasia and partial anodontia and limb defects including syndactyly (joined digits), 
campylodactyly (bent digits) or ectrodactyly (missing phalanges with a claw hand 
appearance the most severe manifestation). Only 6 molecularly confirmed patients 
have been reported in the literature, with 5 additional pathogenic variants identified.371, 
376, 382, 383 
Apart from a series of 7 families focusing on electrophysiology characteristics, the 
previous descriptions of CDH3 related macular dystrophy are limited.384 A single 
patient has been published with OCT and FAF imaging with single posterior pole colour 
images on 8 patients otherwise published.370, 373, 375, 376, 381, 384, 385 Following a result from 
WES of a homozygous CDH3 mutation in a patient with macular dystrophy, the 
phenotype was studied and further patients identified with clinically similar 
presentations. A total of 7 patients have been identified and undergone detailed 
phenotyping including serial imaging and electrophysiology. All have bi-allelic CDH3 
mutations including 3 novel mutations. 
10.2 Methods 
10.2.1 Ascertainment of patients 
Patients were identified from adult inherited retinal clinics. Two patients had WES, 1 
patient already had a molecular diagnosis from elsewhere. An additional 9 patients 
were identified by myself and my supervisors as phenotypically similar, and I screened 
this cohort for CDH3 mutations, which identified a further 4 patients.  
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10.2.2 Clinical assessment 
All patients had undergone complete ophthalmic examinations and retinal imaging as 
part of their routine care. Serial imaging was available in patients 1, 3, 5, 6 and 7. 
Thickness of the central subfield region as defined by the Early Treatment Diabetic 
Retinopathy Study (ETDRS) was measured using the automated Heidleberg Spectralis 
viewing module (version 6.3.4.0) with the RPE basement membrane and the ILM 
layers checked for accuracy in each OCT slice and manually corrected if necessary.386 
Size of the atrophic region was mapped for each FAF image with the region first 
highlighted using Adobe Photoshop Elements 14 (Adobe Systems Incorporated, San 
Jose, Ca, USA) and the area then calculated using the Threshold Colour plugin in 
Image J (National Institutes of Health, Bethesda, Md, USA). Only those images in 
which the atrophic region border could be clearly delineated were assessed, which was 
possible for patients 3 and 5.  Five patients underwent EDTs. 
10.2.3 Molecular investigations 
Both WES results (AROS) were confirmed by Sanger sequencing with segregation 
performed in available relatives with specifically designed primers (table 10-1). In 
addition, all 16 exons and intron-exon boundaries of CDH3 were screened in a panel of 
9 patients. Mutation nomenclature was assigned in accordance with GenBank 
Accession number NM_001793.4. 
Exon Primer forward 5’ → 3’ Primer reverse 5’ → 3’ Enzyme 
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1-2 TCAAAGGGGCAAGAGCTGAG CGCGGTCCACACCAAAATG MyTaq 65 507 
3 TCTGCAGCCACTTAGCAGTC CCTCTGAAGGGCTGACTTGG BIOTAQ 65 322 
4 AGGCTCATCTAGGTCTCCTCA CTCTGTGAAGAGGGGCACTG BIOTAQ 65 539 
5-6 CAGTGCCCCTCTTCACAGAG AGCATTTAAGGGTGTGGGCC BIOTAQ 65 545 
7 TGGAGTTGGAACTGGGAGGA GACGTGGGTCCTCACTGTTC MyTaq 65 343 
8 CAGTGCTTCCTGGAGGTCAG GGTCACACAGCCATAGTGCT BIOTAQ 65 329 
9 GACATCCTGCCGCTGTGTAT GGACTTCCCAACACAAGAGTG BIOTAQ 65 506 
10 CTGTTGCTAGTGAGGGCCTC AAATACCTGCCCCCAAACCC BIOTAQ 65 548 
11 TGGTATGAGGAGGCCCTGAA CCGGCCTAGGACCAGTCTTT BIOTAQ 65 403 
12 AGAATGATGGCTCAACTGGCA AGATCATTGTCCCCATGGCC MyTaq 65 501 
13 TCTCTGCATTGCCCACATGT GAGGCTGAGCTGGGAAGATC BIOTAQ 65 549 
14 GCTCTGGCTACTGAGTGAGG GGGCCAAAGAGACTACAGCA BIOTAQ 65 422 
15 TGCTGTAGTCTCTTTGGCCC AAAAGCTGGTTGGTGGTGGA BIOTAQ 65 507 
16 AGAGAGGGGCTCACAGAGAG TGCTGAAGTCAAACTGCCCA BIOTAQ 65 504 
Table 10-1: Primer pairs for CDH3 
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10.3 Results 
Clinical data are summarised in table 10-2. 
Patient, 
family 
number, 
variant 
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Initial VA 
logMAR 
(Snellen) 
Latest 
VA 
logMAR 
(Snellen) 
Latest refractive 
error, dioptres 
Age at 
colour 
vision 
Age at last 
electrophysiology, 
key findings 
Patient 1 
GC18250 
 
11   18 (5) R 0.4 
(6/15) 
L 0.4 
(6/15) 
R 0.80 
(6/36)  
L CF  
R 0/-2.50 x 177  
L -0.25/-2.25 x 162 
13 years 
Ishihara   
R 5/17     
L 6/17 
14 years, subnormal 
PERG P50. Normal 
ERGs 
Patient 2 
GC19726 
 4-5   20 (0) R 1.0 
(6/60) 
L 1.2 
(4/60) 
n/a Not performed 20 years, 
Ishihara 
1/17 BE 
20 years, 
undetectable PERG, 
subnormal rod and 
subnormal and mildly 
delayed cone ERGs 
Patient 3 
GC20690 
5-6 24 (8) R 0.30 
(6/12) 
L 0.30 
(6/12) 
R 0.80 
(6/36) 
L 0.30 
(6/12) 
R +0.50/-2.00 x 5 
L emmetropic 
22 years, 
HRR 
medium 
r/g 
defect, 
b/y 
normal 
Age 22, undetectable 
PERG. Mildly 
subnormal rod ERGs 
on right. Other ERGs 
normal bilaterally.  
Patient 4 
GC22774 
4 25 R 1.0 
(6/60)     
L 1.2 
(4/60) 
n/a Myopic 25 years, 
Ishihara 
R 3/21, L 
0/21 
Not done 
Patient 5 
GC18293 
 8-9  31 (20) R 0.18 
(6/9) 
L 0.18 
(6/9) 
R 0.18 
(6/9)    
L 0.18 
(6/9) 
R -1.00/-1.00 x 170   
L -1.00/-0.50 x 60 
28 years, 
Ishihara   
R 15/17   
L 12/17  
18 years, markedly 
subnormal PERG 
P50. Subnormal rod 
ERGs and subnormal 
and delayed cone 
ERGs. 27 years, 
undetectable PERG; 
stable ERGs.  
Patient 6 
GC19948 
17  36 (3) R 0.6 
(6/24) 
L 1.2 
(4/60) 
R 0.84 
(6/38) 
L 1.20 
(4/60) 
R -0.50/-0.50 x 40  
L +0.50/-2.50 x 180 
33 years, 
Ishihara 
1/17 BE 
33 years, 
undetectable PERG. 
Rod and cone ERGs 
normal on the right; 
marginally subnormal 
on the left due to eye 
closure.  
Patient 7 
GC18996 
10  57 (7) R 1.3 
(3/60) 
L 1.3 
(3/60) 
R 1.20 
(4/60)  
L 1.20 
(4/60) 
Not performed 54 years, 
HRR   
0/24 BE 
Not done 
Table 10-2: Summary of clinical features in CDH3 related macular dystrophy 
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Seven probands from 7 families (6 consanguineous) were identified with bi-allelic 
variants in CDH3 (figure 10-1); 2 from WES, 4 from screening a panel of 9 
phenotypically similar patients and one with an already identified homozygous variant 
found elsewhere by Sanger sequencing.374 All presented in childhood/teenage years, 
age range 4-17 years. Of the 5 patients that screened negative for CDH3, 2 were later 
found to carry likely pathogenic ABCA4 mutations and one was found to have CRB1 
mutations. 
 
Figure 10-1: Pedigrees and chromatograms for patients with CDH3 mutations 
* mutation previously identified
374
 
Vision was universally reduced at presentation. Of the 4 patients with more than one 
review, 3 had documented deterioration of vision, one already having severe vision 
loss at presentation. The mean age at last review was 30.1 years (median 25, range 18 
to 57) with VA ranging from 0.18 logMAR to CF. The best VA was in patient 5 in whom 
VA was 0.18 logMAR each eye at age 31 years. Four patients had reported 
deterioration of central vision. Only patient 2 reported nyctalopia. Fundus abnormalities 
comprised variable degrees of atrophy of the retina, RPE and choroid in the posterior 
pole which extended nasal to the disc (figure 10-2). In 6 patients, the atrophy extended 
outside of the arcades. Patient 7 had severe chorioretinal atrophy with exposed sclera. 
Variable degrees of hyperpigmented spots/clumps in the macula was evident in all 
patients.  
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Figure 10-2: Retinal imaging in patients with HJMD  
(a) Colour fundus photographs, (b) FAF, (c) OCT. Variable extent and severity of outer 
retinal/RPE atrophy, most severe in patient 7 with visible sclera. Pigmented lesions observed in 
all patients within atrophy, correspond to hypertrophy of the RPE (white arrows, patient 3). 
Increasing pigment demonstrated in patient 5. Loss of outer retina on OCT most severe in 
patient 7 who in addition has a serous detachment limited to the area of atrophy. ORTs 
frequently observed (white arrow, patient 6). 
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Serial imaging (available in 5 patients) demonstrated increasing hyperpigmentation 
with time in 3 patients (demonstrated in patient 5 in figure 10-2). FAF imaging 
demonstrated confluent hypofluorescence in areas of atrophy with a surrounding ring 
of relatively increased autofluorescence in 6 of 7 patients tested. In 2 patients within 
the area of confluent atrophy, a speckled hypofluorescence was observed. Patient 5 
had small refractile deposits in both maculae, not noticed in any other patient.  
 
 
Figure 10-3: Serial imaging findings in CDH3 related HJMD 
(A) FAF imaging size of atrophic region, (B) OCT imaging central subfield thickness 
OCT available in all patients, demonstrated variable degrees of atrophy. In patient 7 
there was extensive atrophy of retina, RPE and choroid in addition to a serous retinal 
detachment over the atrophic area in the left eye (figure 10-2). In the remaining 6 
patients there was outer retinal and RPE atrophy with partial preservation of the ISe 
band at the fovea observed in patient 5. Six patients had ORTs, patient 7 having too 
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extensive retinal atrophy for tubulations to be present. Five patients had serial OCT 
and FAF imaging over 2-10 years. The atrophic region on FAF imaging could only be 
accurately measured in 2 patients which demonstrated that the overall size of the 
atrophic region did not increase with time. However, retinal thickness within the 
atrophic region did decrease with time in all patients measured (figure 10-3). 
Electrophysiology demonstrated undetectable PERG in 3 of the 5 patients tested, 
consistent with severe macular dysfunction (figure 10-4). There was a subnormal 
PERG P50 component in patient 3 at age 14 years in keeping with moderate macular 
dysfunction. In patient 5 the PERG was markedly subnormal at the age of 18 years and 
undetectable when examined 9 years later. Bilateral full-field ERG abnormalities were 
evident in patients 2 and 5, indicating mild generalised rod and cone dysfunction. 
There were marginal reductions in the rod-mediated ERGs in the right eye of patient 3 
and rod and cone ERGs in the left eye of patient 6, but likely due to eye closure.  The 
full-field ERGs in patient 5 showed no significant change when re-tested 9 years later. 
 
Figure 10-4: Electroretinography in CDH3 related HJMD 
ERG and PERG features from one eye of patients 1, 3 and 5 and normal control. Patient 1 has 
normal DA ERGs and normal light-adapted LA ERGs; PERG P50 component is subnormal. 
Patient 3 shows mild reduction in the right eye DA ERGs and normal LA ERGs; all left eye 
responses were normal (not shown). Patient 5 shows mild but relatively stable abnormalities of 
all full-field ERGs with evidence of progressive PERG reduction over 9 years.  
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Systemically, all patients had thin scalp hair from at least early childhood, with normal 
hair elsewhere including eyebrows (figure 10-5). All patients had normal limbs.  
 
Figure 10-5: External photographs of patients 1, 6 and 7.  
Head photographs demonstrate thinning of scalp hair with preservation of eyebrows and in 
addition in patient 6 preservation of chest hair. Hand photograph of patient 7 demonstrates 
normal hand morphology. 
Molecular screening identified bi-allelic mutations in CDH3 in all patients including 2 
novel PTCs and 1 novel missense mutation (figure 10-1). The novel missense 
mutation, c.613G>A (p.Val205Met) is predicted damaging in silico (SIFT 0, Polyphen2 
1.0). Only one other mutation was a missense change, R503H which has been 
previously reported in 3 affected families.373, 374 Both missense variants arise in codons 
highly conserved through the species (figure 10-6). All patients had presumed 
homozygote mutations. 
 
Figure 10-6: Conservation of CDH3 missense codons 
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10.4 Discussion 
In this study of CDH3 related retinal dystrophy, detailed phenotyping of molecularly 
confirmed patients has characterised the key ophthalmic and systemic features which 
aided diagnosis and allowed an assessment of the prognosis. The patients all 
presented in childhood with central visual disturbance and sparse scalp hair with a 
predominantly macular dystrophy. The majority of previously reported patients also 
presented with reduced vision in childhood except for one reported family in which the 
eldest child had normal visual acuity at 14 years of age although macular pigmentary 
change was observed.374  
In this series, visual acuity was found to deteriorate over time except for one patient 
with stable and good acuity over 20 years of review and preserved foveal 
photoreceptors visible on OCT. Longitudinal data on visual acuity decline has not been 
previously reported although a trend of decreased vision with patient age has been 
observed.384 Although the majority of previously reported patients have marked 
macular atrophy encompassing the disc, one patient with mild atrophic changes and 
syndactylyl of his left foot has been reported.376 The refractile deposits in patient 5 were 
much smaller than the expected size of refractile drusen and no other cause could be 
elucidated from the patient’s past medical history.387 It remains unclear whether they 
are related to CDH3 as it has not been observed in any other reported patient.  
There has been only one previously published patient with detailed retinal imaging.385 
This 6 year old patient had typical features of posterior pole atrophy with early loss of 
photoreceptors and RPE on OCT. In contrast, all patients in this study underwent 
detailed imaging and 5 had serial OCT investigations. All patients had marked and 
confluent hypofluorescence on FAF imaging which corresponded to the atrophic 
region. This was surrounded by an apparent ring of increased autofluorescence. OCT 
imaging demonstrated loss of outer retina and RPE in all patients with severe atrophy 
in patient 7. ORTs were frequently observed. The posterior pole appears to be 
atrophied from early childhood, with the degree of atrophy within that region 
progressing with time (based on OCT), but the overall area of atrophy (based on FAF 
imaging) not increasing although there were limited numbers available for analysis. 
Serial ERG  available in one patient demonstrated that the full field ERG abnormalities 
did not progress with time although the PERG worsened over the same 9-year period.  
Bilateral ERG abnormalities were evident in 2 of 5 cases and were relatively mild, 
whereas most had PERG evidence of severe macular dysfunction in keeping with the 
retinal imaging; the disorder appears to be largely confined to the posterior pole. 
Previous reports of electroretinography have largely focused on ERG and EOG 
findings with only one report of PERG in HJMD.381 At age 48 years, the patient in this 
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report had very poor vision, an extinguished PERG and reduced cone specific ERG 
responses. ERG findings in previous reports have been either normal or with 
subnormal rod and/or cone responses.370, 373-376, 379, 381, 383-385 One patient was reported 
to have severe retinal dysfunction on ERG but no further details were given.377 
Overall, there is evidence from visual acuities, serial retinal imaging and 
electrophysiology that the condition is progressive but progression is largely limited to 
the posterior pole. The onset of symptoms is not from birth or infancy but 
childhood/adolescence. There is no nystagmus in these patients. The age of onset and 
evidence of progression would indicate that this is a progressive dystrophy and not a 
developmental disorder. 
The most common cause of juvenile-onset macular dystrophy is Stargardt macular 
dystrophy due to bi-allelic mutations in ABCA4.47 This disorder may present with similar 
symptoms to CDH3 related disease with central visual disturbance, macular atrophy, 
and either electrophysiological dysfunction confined to the macula (found in 1/3 of 
children with Stargardt disease) or macular and generalised retinal dysfunction usually 
involving cone and rod systems (found in the remainder).388 Not all patients with 
Stargardt disease have the distinctive yellow-white flecks at presentation. Patients with 
HJMD may initially be misdiagnosed with Stargardt disease but the 2 conditions can be 
distinguished most readily by examination of the scalp hair. In addition, in Stargardt 
disease, the peripapillary region is classically although not universally spared.389 
CDH3 encodes P-cadherin, one of the family of cadherin transmembrane proteins that 
form a major component of adherens junctions important in cell to cell interactions.390 A 
total of 22 mutations in CDH3 have been reported including those from this study, 7 
missense, 2 splice site and the rest PTCs (figure 10-7, table 10-3). 
 
Figure 10-7: Schematic diagram of CDH3 with mutation codon location 
Mutations from this study boxed. EC; extracellular, TM; transmembrane 
All but one of the PTCs identified would be predicted to trigger NMD and lead to 
haploinsufficiency; the exception, p.G786Afs*7 arises after the predicted cut-off for 
NMD.206 Patient 6, homozygous for this variant did not have more severe disease as 
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may be expected if abnormal protein is produced; his onset of visual symptoms was 
later than all other patients in this series. Four of the 7 reported missense variants were 
associated with EEMS which may indicate that abnormally produced protein as 
opposed to a lack of protein has a particularly detrimental effect on limb development.  
Nucleotide Protein Exon ExAC  Phenotype First reported 
c.160+1G>A splice Intron 2 Not present  HJMD/EEMS Indelman 2007 
c.353A>G p.E118G 4 Not present EEMS Shimomura 2008 
c.462delT  p.E155Rfs*6 5 1 in 121084 HJMD Indelman 2003 
c.490dupA (reported as 
c.490insA) 
p.T164Nfs*8 5 1 in 121396 HJMD Shimomura 2008 
c.503T>A p.L168* 5 1 in 121404 HJMD Indelman 2003 
c.613G>A p.V205M 6 Not present HJMD This study 
c.661C>T p.R221* 6 1 in 119728 HJMD Indelman 2007 
c.747C>A p.Y249* 7 Not present HJMD Avitan-Hersh 
2012 
c.830delG (reported as 
c.829delG) 
p.G277Afs*20 7 Not present HJMD/EEMS Indelman 2003 
c.830G>T p.G277V 7 Not present EEMS Basel-Vanagaite 
2011 
c.965A>T p.N322I 8 Not present EEMS Kjaer 2005 
c.981delG p.M327Ifs*23 8 Not present HJMD Sprecher 2001 
c.1425-1G>T Splice Intron 10 1 in 121274 HJMD Shimomura 2008 
c.1508G>A  p.R503H 11 Not present HJMD Indelman 2002 
c.1510G>A p.E504K 11 Not present EEMS Indelman 2007 
c.1568delA p.N523Mfs*14 11 Not present HJMD This study 
Ex12-13 del In-frame del 12-13 Not present HJMD Halford 2012 
c.1724A>G p.H575R 12 Not present HJMD Indelman 2007 
c.1796-2A>G Splice Intron 12 3 in 121250  HJMD Shimomura 2010 
c.1845T>A p.Y615* 13 Not present HJMD Indelman 2005 
c.2117delG (reported 
as c.2112delG) 
p.G706Efs*10 14 Not present HJMD Indelman 2003 
c.2357delG p.G786Afs*7 16 Not present HJMD This study 
Table 10-3: All reported mutations in CDH3 
P-cadherin regulates the development of hair, limbs and the RPE as demonstrated by 
upregulation of its expression in these key locations in mouse embryo studies.371 It is 
not expressed in the neuroretina.371, 391 This would indicate that photoreceptor loss in 
CDH3 related macular dystrophy is secondary to P-cadherin dysfunction in the RPE. 
Cadherin proteins are characterised by 5 calcium binding extracellular (EC) domains, 
critical to protein function. Reported mutations arise throughout the protein but all 
reported missense variants are found within the EC domains which may indicate that 
their functional impact is most significant there. The tertiary protein structure for P-
cadherin has been experimentally proven using X-ray crystallography for EC1 and EC2 
domains only.392  
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The site of disease could be primarily RPE with secondary photoreceptor loss as 
supported by expression studies in animal models.371, 391 In humans, CDH3 mRNA has 
been identified in expressed sequence tags from RPE.393 From this series there is OCT 
evidence for concurrent loss of outer retina and RPE, not with initial photoreceptor loss 
as would be expected in a primary photoreceptor disorder. ORTs on OCT arise in 
regions of outer retinal atrophy  and are typically observed in disorders in which the 
underlying RPE is the primary site of dysfunction such as Stargardt disease and age 
related macular degeneration but have also been reported as late features of 
photoreceptor disorders such as enhanced S-cone syndrome.132 It may be that rather 
than primary RPE dysfunction, the disorder is one of concurrent RPE and 
photoreceptor loss as seen in choroideraemia a condition in which ORTs are also 
frequently identified.394 It is not clear why the retina/RPE in the posterior pole is 
predisposed to degeneration compared to elsewhere in the fundus. The macula is the 
region of highest cone density and has a higher metabolic demand than the rest of the 
retina due to increased phototransduction.395 One possibility is that the increased 
metabolic demand in that region is sufficient to compromise the already abnormal RPE 
cell function. Further understanding of CDH3 protein function in the retina/RPE is 
needed to ultimately define the location and mechanism of disease. 
Although HJMD and EEMS are considered allelic disorders, they may be better 
considered as part of a phenotypic spectrum in which all patients have hypotrichosis 
and macular dystrophy with variable additional limb and ectodermal anomalies.383 
There is no clear genotype-phenotype correlation and the same variant may be 
associated with a variable phenotype. For example the variant p.G277Afs*20 which 
has been associated with both HJMD and EEMS in the homozygous state (figure 10-
7).374, 382 Patient 7 in this study who has no limb or ectodermal abnormalities, was 
found to be homozygous for c.160+1G>A.  This variant has been reported once in a 
compound heterozygous patient in conjunction with a missense change p.E504K.376 
The reported patient had syndactyly of his left foot suggesting an EEMS phenotype, 
although mild. Only 3 other variants have been reported in EEMS, all missense 
changes. Reported limb anomalies include severe split hand/foot malformations but 
may be subtle such as a single nail dysplasia, and should be specifically looked for in 
patients presenting with HJMD.371, 383  
This condition, based on symptoms, visual function, retinal imaging and 
electrophysiological characteristics, is centrally progressive with preserved peripheral 
vision. Its characteristic presentation with marked macular dysfunction in childhood 
with thin, sparse hair are readily recognisable features to aid diagnosis.  
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11 Maculopathy due to mutations in CRB1 
11.1 Introduction 
CRB1 (Crumbs homolog-1, MIM#604210) encodes a subunit of the Crumbs protein, an 
apical protein essential for photoreceptor morphogenesis and protection from light 
induced retinal degeneration.396 Related phenotypes are heterogeneous and include 
LCA, RCD and CORD with CRB1 accounting for an estimated 11% of LCA cases.6, 73, 
397-399 Additional associated features can include exudative telangiectasia and 
nanophthalmos.400, 401 Typical CRB1 related disease manifests as an EORD with 
macular atrophy, generalised nummular pigmentation with para-arteriolar RPE sparing, 
and thickened, disorganised lamination on OCT although these features are variable.6, 
397, 402 In infancy, the full phenotype may not be evident with macular atrophy and 
peripheral white dots early features. There have only been 4 families reported with 
CORD, and in one family this was associated with retinal cysts.6, 399 No correlation has 
been found between genotype and phenotype.403  
A patient with retinal dystrophy localised to the posterior pole and encompassing the 
disc was investigated in this study. Initially, screening of CDH3 was performed which 
was negative for any pathogenic mutation. The patient underwent WES as part of the 
SPEED study which identified a homozygous mutation in CRB1. Whilst further 
investigating this, a report of CRB1 related macular dystrophy in a single family was 
published.404 
11.2 Methods 
11.2.1 Patient ascertainment 
The patient was known to the retinal genetics clinic and was initially prioritised by a 
supervisor for CDH3 screening. This was normal and she was subsequently recruited 
to the SPEED study for further investigation. 
11.2.2 Clinical assessment 
Full examination, imaging and EDTs were performed as part of routine care. Thickness 
of the ETDRS central subfield and temporal inner macula regions were measured 
using the automated Heidleberg Spectralis viewing module (version 6.3.4.0) with the 
RPE basement membrane and the ILM layers checked for accuracy in each OCT slice 
and manually corrected if necessary. OCT thickness over time was measured and 
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compared with normative data.405 Statistical analysis was not possible due to small 
numbers. 
11.2.3 Molecular methods 
WES was performed as part of the SPEED study and 2 CRB1 variants were identified. 
These were confirmed by myself by Sanger sequencing with segregation performed in 
available relatives with specifically designed primers (table 11-1). Mutation 
nomenclature was assigned in accordance with GenBank Accession number 
NM_201253.1. 
Exon Primer forward 5’ → 3’ Primer reverse 5’ → 3’ Enzyme 
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2 GTTGAGGCAGCACAAAGGTCACAA
AG 
GTCACCTCTGCTTCTGCCACTT
AG 
BIOTAQ 60 740 
9.1 CTCAACTTCTTCTTCCATAAAATGG
GG 
CCTTGCAGGCCCTTTATATT BIOTAQ 60 659 
9.2 GGCACATGGCACGAAGTGACCCT GTATACCTTGAGGAGAGAGCTT
TCC 
BIOTAQ 60 776 
Table 11-1: Primer pairs for sequencing of CRB1 
11.3 Results 
A patient of Bangladeshi origin developed central visual disturbance at 12 years of age. 
Visual acuity at presentation to Moorfields at age 19 years was R 0.5 and L 0.3 
logMAR with low myopic refractive correction. There was reduced colour vision on 
Ishihara testing (R 5/17, L 3/17). Over 13 years of follow up, visual acuity deteriorated 
to R 1.3, L 1.5 logMAR. In both eyes, there was a confluent, pale chorioretinal atrophy 
encompassing the disc without peripapillary sparing and extending outside of the 
arcades with anterior retina preservation (figure 11-1). Pigmented lesions within the 
atrophy increased over time and on OCT imaging could be observed as localised RPE 
hypertrophy (figure 11-2).  
FAF imaging demonstrated loss of autofluorescence in areas of atrophy which 
increased over time (figure 11-1). Small islands of hyperautofluorescence were 
observed on FAF imaging that corresponded to preserved RPE on OCT (figure 11-3). 
OCT generally demonstrated loss of outer retina and RPE. Disorganisation of retinal 
lamination was identified on peripheral OCT slices (figure 11-2).  
On OCT thickness measurements, the retina was not thicker compared to published 
controls (table 11-2). However, these measurements were in regions of atrophy where 
it may be expected to be thinned. Comparison of OCT thickness over a 4 year interval 
did not find any notable decrease. The observed increase over time in thickness of the 
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central subfield particularly of the right eye may be due to epiretinal membrane 
formation (figure 11-1).  
 
Figure 11-1: Retinal imaging in CRB1 related maculopathy 
2001: fundus 
photographs 
demonstrating confluent, 
speckled atrophy of the 
posterior pole 
2015: FAF and OCT 
imaging demonstrate 
increased size of 
atrophy on FAF imaging 
in both eyes and 
epiretinal membrane on 
R OCT 
2010: fundus 
photographs 
demonstrate more 
marked atrophy with 
increased pigment spots 
2010: fundus 
photographs 
demonstrate more 
marked atrophy with 
increased pigment spots 
 
2011: FAF and OCT 
imaging demonstrate 
confluent loss of 
autofluorescence 
encompassing the disc 
with loss of outer retina 
and RPE on OCT 
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Figure 11-2: Hyperpigmented macular lesions 
R fundus image and OCT with arrows at position of pigmented lesion corresponding to 
thickened RPE on OCT. Peripheral OCT slice also demonstrates disorganised lamination. 
 
Figure 11-3: Preserved islands of RPE and photoreceptors 
R 30 degree FAF imaging and OCT demonstrate small island of increased autofluorescence 
corresponding to preserved RPE/photoreceptors on OCT. 
 Central subfield Temporal inner macula 
RE 2011 105 298 
RE 2015 169 293 
LE 2011 105 271 
LE 2015 124 298 
Controls 270 323 
Table 11-2: Macula thickness in each eye compared with normative data  
EDTs at age 27 years demonstrated undetectable PERG, moderately severe cone 
dysfunction, and milder rod dysfunction. There was mild deterioration from a previous 
ERG at age 20 years. 
WES identified compound heterozygous mutations in CRB1, c.254G>A (p.Cys85Tyr), 
novel, not in ExAC and predicted pathogenic in silico (SIFT 0, Polyphen2 1.0), and 
c.3542dupG (p.Cys1181Trpfs*13) which has been previously reported in the 
homozygous state in a case of LCA.6 Analysis of conservation between species 
demonstrated that the missense variant arose within a highly conserved residue (figure 
11-4). Segregation confirmed the mutations were in trans with the first variant 
maternally inherited ad the second found in both unaffected brothers. Prior Sanger 
sequencing of CDH3 identified a heterozygous variant, c.109A>T (p.Thr37Ser, 
rs374627741) predicted to be tolerated in silico (SIFT 0.49, Polyphen2 0.765). 
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Figure 11-4: Conservation of novel missense residue in CRB1 
11.4 Discussion 
This study of a patient with CRB1 related maculopathy illustrates the differences in 
presentation when compared with more typical CRB1 related retinal dystrophy. The 
patient had central visual involvement as a presenting feature and low myopia. Patients 
with LCA and RCD typically have a low hyperopic refractive error and present either in 
infancy with severe loss of vision or in childhood with nyctalopia and mid-peripheral 
retinal changes.6 Macular atrophy is a common feature of CRB1 related retinal 
dystrophy in general but is not exclusive to this molecular cause, having been reported 
in several other retinal dystrophies including those due to NMNAT1, CRX, LCA5, 
RDH12, and PROM1.6, 92 76, 178, 205, 406 In early stages, the macular atrophy found in this 
series could resemble other conditions such as Stargardt disease but atrophy 
encompassing the disc appears indicative of either CRB1 or CDH3 related disease. 
The retinal appearance differed from other CRB1 related retinal dystrophies by its lack 
of anterior retinal involvement and the large, disc-encompassing atrophy. 
OCT scanning demonstrated disorganised retinal lamination in the peripheral retina 
and a retinal thickening greater than would be expected in a retinal dystrophy 
particularly within a region of atrophy. This thickening and disorganised lamination has 
been previously reported in CRB1 related disease and is a useful clinical characteristic 
for directing molecular investigation.6, 249  
Four families with CRB1 related CORD have been previously reported with central 
visual disturbance as presenting symptoms but without macular atrophy.6, 399 Only one 
other family has been reported with a similar maculopathy to the patient studied.404 
Two siblings presented in their 20s-30s with central visual disturbance and macular 
atrophy that extended nasally to the disc without peripapillary sparing. The anterior 
retina was preserved. Retinal imaging in the sister was strikingly similar to our patient 
with a pale atrophic appearance to the posterior pole, marked loss of autofluorescence 
encompassing the disc with small islands of preserved RPE that were 
hyperautofluorescent and loss of outer retina and RPE structures on OCT. The brother 
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had less marked atrophy and crescents of hypoautofluorescence rather than the 
confluent autofluorescence seen in the sister. OCT was similar with the exception of 
oedema in one eye. At last review vision was much better in these siblings then in our 
patient studied, at 20/40 RE, 20/400 LE for the sister at age 45 years and 20/40 RE, 
20/70 for the brother at age 41 years. This may be related to the foveal islands of 
preserved photoreceptors/RPE observed in both siblings. A trend towards outer 
macular thickening was observed although they had preserved retinal lamination.404 
Marginal cone involvement was identified in the sister on ERG. 
CRB1 is expressed in the retina in both the subapical region of photoreceptors 
adjacent to adherens junctions and in Müller cells.407 It is not expressed in the RPE 
with minimal expression observed in brain and testis.408 It is particularly important in 
retinal development for correct polarity and adhesion of retinal neuroepithelium 
progenitor cells.409 The CRB family of transmembrane proteins are characterised by 
large extracellular epidermal growth factor (EGF) and laminin-globular domains, a 
single transmembrane domain and a 37 amino acid intracellular domain containing 
specific protein-binding motifs.409 The novel missense mutation identified in this study 
arises within the extracellular EGF domain.  
The thickening and disorganised lamination evident in CRB1 related retinal dystrophy 
is thought to be developmental possibly due to the loss of normal retinal remodelling 
and apoptosis in retinal development.249 Although this has been observed at an early 
age it has not yet been proven to be developmental in humans. The Crb1-/- knockout 
mouse develops isolated, small regions of retinal degeneration not the widespread 
retinal degeneration that more resembles the human disease whereas the Crb2-/-  
knockout mice does have a similar phenotype.407, 410 CRB2 also forms part of the 
subapical CRB complex. In the Crb2-/- knockout mouse, there is abnormal lamination of 
the neuroepithelium from embryonic day 18.5 which suggests that in humans this may 
also be developmental.409  
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12 Cone-rod dystrophy due to mutations in ADAM9 
12.1 Introduction 
ADAM9 (A disintegrin and metalloproteinase domain 9, MIM#602713) is a widely 
expressed integral membrane protein with multiple roles that include cell interactions 
with the extracellular matrix and ECM remodelling.411, 412 Bi-allelic loss of function 
mutations in ADAM9  were identified in 4 families with CORD in 2009; all affected 
individuals developed reduced visual acuity in the first decade of life.411 A further paper 
detailed a consanguineous family with early onset CORD due to splice site mutations 
in ADAM9.413 WES identified a homozygous PTC in ADAM9 in a child with CORD with 
the phenotype the focus of this study. 
12.2 Methods 
12.2.1 Patient ascertainment 
A child with CORD was known to the paediatric retinal genetic clinic and recruited for 
genetic investigations. No variants were identified on an APEX microarray (LCA chip). 
Subsequently WES was then performed. 
12.2.2 Clinical assessment 
I assessed and examined the proband and obtained retinal imaging. He had already 
undergone EDTs at 3 years of age as part of his clinical care but I arranged further 
EDTs at age 7 years. 
12.2.3 Molecular investigations 
The homozygous mutation found on WES by colleagues (AROS) was confirmed by 
Sanger sequencing by myself with segregation performed in available relatives with a 
specifically designed primer pair (table 12-1). Mutation nomenclature was assigned in 
accordance with GenBank Accession number NM_003816.2. 
Exon Primer forward 5’ → 3’ Primer reverse 5’ → 3’ Enzyme 
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10 TTGCCATTTTCCTGCCATGT  AAAGAGCTAATAAACACATAGCACA BIOTAQ 65 401 
Table 12-1: Primer pair for sequencing of ADAM9 
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12.3 Results 
A male patient presented at 3 years of age. He was noted in infancy to have a right 
convergent squint with poor vision and eccentric fixation. There was no nystagmus. He 
was otherwise well with normal development. The parents were from Pakistan and 
were first cousins. He had one unaffected younger brother.  
At first review at 3 years of age, VA was R and L 1.0 logMAR (Snellen 6/60). At last 
review, age 7, the vision was R 1.0 logMAR, L 0.88 logMAR (Snellen 6/48) with a 
hyperopic, astigmatic refractive error of R +4.00/-2.50 x 20, L +4.00/-2.00 x 180. There 
was a moderate left divergent squint with eccentric fixation. Early posterior sub-
capsular cataract was noted.  
 
Figure 12-1: Retinal imaging in a patient with ADAM9 related CORD 
A) R Optos photograph showing a hypopigmented, atrophic region of the posterior pole, 
encompassing the disc with no abnormal peripheral pigment; B) R Optos FAF imaging showing 
reduced autofluorescence in area of atrophy with increased autofluorescence temporally at 
edge of atrophy; C) L Optos photograph magnified to demonstrate speckled nature of atrophy; 
D) L OCT showing generalised loss of outer retina 
Fundus examination showed posterior pole atrophy with a white speckled appearance, 
which extended to the arcades and encompassed the optic disc (figure 12-1). Retinal 
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imaging demonstrated reduced autofluorescence in the posterior pole with atrophy of 
the outer retina on OCT (figure 12-1). EDTs performed at the age of 3 years using 
surface electrodes, revealed an undetectable PERG and borderline photopic and 
scotopic ERGs. At the age of 7 years the PERG and full-field ERG were performed 
using corneal electrodes. The PERG was undetectable in keeping with severe macular 
dysfunction. ERGs were mildly abnormal consistent with CORD (figure 12-2). 
 
Figure 12-2: Electrophysiology in ADAM9 related CORD 
ERGs and PERG from the RE and LE of the patient compared with control N 
WES identified a novel, homozygous mutation in ADAM9, c.967delT 
(p.Ser323Glnfs*33) which is not present in ExAC. On direct Sanger sequencing this 
was shown to segregate in the family with both parents heterozygous for this mutation 
(figure 12-3). 
 
Figure 12-3: Pedigree and sequencing results  
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12.4 Discussion 
Non-syndromic, autosomal recessive CORD is rare and usually associated with bi-
allelic mutations in ABCA4.110 In the previous reports of CORD due to ADAM9, 5 
families were identified with mutations leading to either aberrant splicing or premature 
truncation codons.411, 413 Similar to our patient, all had poor vision in their first decade of 
life, no nystagmus and outer retinal atrophy of the macula. Most were also noted to 
have discrete white patches in the posterior pole and around the disc and a peripheral 
pigmentary retinopathy which is not present in our patient. Retinal imaging in a 
previous report of the index family, demonstrated posterior pole atrophy in 2 patients in 
their 40’s with a similar appearance to our patient. 414 Electrophysiology in these 2 
patients demonstrated severe loss of both cone and rod function. In the recent report of 
a single family, the youngest patient assessed was 17 years.413  Posterior pole atrophy 
was noted and in the retinal images this also encompassed the disc. No 
electrophysiology was available. Given the young age of our patient, we have been 
able to demonstrate the electrophysiological phenotype of severe loss of macular 
function in the early stages with relatively mild peripheral retinal dysfunction.  
The ADAM family of proteins are a large group of widely expressed transmembrane 
and secreted proteins with multiple roles in cell adhesion, cell signalling and 
ectodomain proteolysis of proteins including growth factors.415 Up and down regulation 
of a number of different ADAM proteins has been associated with cancer, 
cardiovascular and neurological syndromes. ADAM9 is expressed in multiple tissues in 
humans including stem cells, renal tubular epithelial cells, placenta, pancreas and 
adipose tissue. It is expressed throughout all layers of the developing retina and RPE 
in chickens.416 There is limited available information on the expression and role of 
ADAM9 in the human eye. 
In both a canine and mouse model, there are cone and rod photoreceptor 
abnormalities on electrophysiology which are not apparent in very young animals but 
develop with time.411, 417 In both models, histopathology localised the primary defect to 
the apical microvilli of the retinal pigment epithelium potentially mediated by failure of 
normal photoreceptor outer segment phagocytosis with a loss of normal contact 
between outer segments and the RPE. These animal models show early preservation 
of photoreceptor structure despite dysfunction. This together with relatively good 
peripheral photoreceptor function in early human disease as illustrated by this case, 
suggest that there is a therapeutic window for gene therapy in patients with mutations 
in ADAM9. 
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13 Somatic mosaic mutation of IKBKG in a male patient 
with incontinentia pigmenti 
13.1 Introduction 
Incontinentia pigmenti (IP, MIM#308300) is a rare, X-linked, dominant genodermatosis, 
normally fatal in utero in males and highly variable in females due to functional 
mosaicism from X-inactivation.418, 419 It manifests in cells of ectodermal origin with a 
characteristic eruption of the skin present at birth that progresses in distinct stages, 
and variable involvement of other systems including neurological, ocular and 
odontological. It arises from mutations in IKBKG (inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase gamma, Xq28) also known as NEMO (nuclear factor 
kappaB (NFkB) essential modulator), a gene involved in the activation of NFkB, a 
transcription factor for inflammatory and apoptotic pathways.67 IKBKG has also been 
shown to inhibit apoptosis in an NFkB independent manner by binding to ubiquitinated 
RIP1.420 In 72% of cases of IP, a recurrent exon 4-10 genomic rearrangement in the 
IKBKG gene is responsible with more than half of cases arising de novo.421, 422 In 
patients with a clinical diagnosis of IP, no mutation is detected in peripheral leukocytes 
in 13% which may be explained by functional mosaicism from X-inactivation in females 
and loss of mutant cells to an undetectable level in peripheral blood leukocytes, 
mutations in regulatory regions or in theory from mutations in other genes.421, 422 
In affected males there are 3 mechanisms that are associated with survival after birth; 
most commonly an abnormal karyotype is identified with 47, XXY (Klinefelter 
syndrome) and skewed X inactivation in favor of expressing wild- type IKBKG, 
secondly hypomorphic mutations that cause IP in females that are associated with a 
syndrome in males of ectodermal dysplasia with immunodeficiency, and finally a post-
zygotic mutation leading to somatic mosaicism.423  
In this study, the mechanism and significance of loss of detectable mutation in 
peripheral blood leukocytes of a somatic mosaic male is discussed and an alternative 
approach to achieving molecular diagnosis presented.  
13.2 Methods 
13.2.1 Patient ascertainment 
The patient was known to the paediatric genetic clinic with a clinical diagnosis of IP 
prior to the molecular diagnosis being made. Following this, the patient was reviewed 
by myself and further investigations planned. 
Somatic mosaic mutation of IKBKG in a male patient with incontinentia pigmenti 
 
 166 
13.2.2 Clinical investigations 
Full ophthalmic examination and imaging was undertaken. The patient was under the 
care of paediatricians and dermatology colleagues from early infancy. Systemic 
investigations included skin biopsy and MRI of the brain.  
13.2.3 Molecular investigations 
13.2.3.1 DNA extraction from multiple tissue sources 
DNA extraction from blood, buccal swab and urine was performed by lab colleagues. I 
performed DNA extraction from the hair root following the QIAGEN protocol using 6 
hairs plucked from the patient’s head to ensure the hair root was included which 
contains the nuclear DNA. A concentration of 22.7ng/µl was obtained.  
13.2.3.2 Sequencing methods 
Initial molecular investigation as an infant included karyotype analysis (North West 
Thames regional genetics service, cytogenetics on lymphocyte culture) and screen for 
the common IKBKG deletion. Further molecular investigations were unavailable until 3 
years of age when fluorescent sequence analysis (Mutation Surveyor) of IKBKG and its 
adjacent highly homologous pseudogene was performed (East Anglian Medical 
Genetics Service, Cambridge). Gene specific, long-range PCR of exon 3-10 of IKBKG 
(to amplify the IKBKG gene rather than its pseudogene) was performed followed by 
NGS of all coding exons and exon/intron boundaries (using Nextera XT library 
construction and the Illumina MiSeq® system, Illumina, San Diego, CA). Mosaicism of a 
variant was calculated based on the estimated allele frequency. Nomenclature was 
assigned using GenBank Accession number NM_003639. A variant was identified as 
novel as previously described in methods and in addition if absent from a locus specific 
database http://IKBKG.lovd.nl. 
DNA from other tissues of variable embryological cell line origin were obtained at age 
5-6 years including blood (mesoderm), buccal cells (ectoderm), hair roots (ectoderm) 
and urine (predominantly epithelial cells of urothelial and renal tubular origin hence 
mixed mesoderm and endoderm).424 Having already established the site of mutation 
and its location within the true gene and not the pseudogene, PCR for exon 8 only was 
performed (table 13-1). 
Exon Primer forward 5’ → 3’ Primer reverse 5’ → 3’ Enzyme 
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8 CTGCTTTGTTCCTGTGGTGC CATCCGTCTCCTGTGGTCAC BIOTAQ 65 348 
Table 13-1: Primer pairs for sequencing exon 8 of IKBKG 
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13.3 Results 
The patient was born to parents of Czech Republic (mother) and Tanzanian Indian 
(father) origin at full term without complication. He presented with a neonatal seizure at 
2 days old and a rash. Local dermatology assessment described the rash as initially 
erythematous, widespread and following Blaschko’s lines. Subsequently, blisters then 
verrucous lesions developed with hypopigmented lines noted at 6 months and 
hyperpigmented streaks in the axillae and groin at 8 months (figure 13-1). He was also 
noted to have small peg-shaped, irregular lower incisors, eczema and dystrophic nails. 
Skin biopsy performed after the initial presentation identified changes consistent with 
IP, specifically; acanthosis of the epidermis with eosinophilic spongiosis, vesicle 
formation and a few necrotic keratinocytes, basal vacuolation and in the dermis, a mild, 
chronic inflammatory infiltrate admixed with eosinophils.  
 
Figure 13-1: Clinical features of incontinentia pigmenti 
a) Right eye anterior segment photograph age 5 years demonstrating nasal retrolental opacity 
visible due to persistent primary hyperplastic vitreous running from optic disc to ora serrata and 
posterior lens capsule; b) RetCam photograph of the right eye taken at examination under 
anaesthesia age 3 months, nasal view of retina demonstrating fold of retina inferonasal to disc 
(arrowed) with hyperplastic vitreous extending anteriorly and associated tractional retinal 
detachment; c) RetCam photograph age 2 years, retina is flat with a pigmented retina pigment 
epithelium line indicating the edge of the previous detachment (arrowed), haze inferotemporal to 
disc arising from the hyperplastic vitreous; d) photograph of lower limbs age 2 weeks 
demonstrating widespread vesicular rash e) photograph of left hand age 6 months 
demonstrating verrucous lesions; f) photograph of left knee age 6 months with subtle 
hypopigmented streaks; g) photograph of right groin age 8 months with hyperpigmented streak. 
MRI performed after the seizure at 3 days of age demonstrated a subtle, low T2 signal 
intensity within the mesial cortex of the right frontal lobe likely to represent acute 
ischemia and when repeated at 5 months identified a mature infarct. Further occasional 
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seizures occurred always associated with fever. Development was normal except for a 
delay in walking (20 months).  
Ophthalmological examination under anesthesia at 3 months demonstrated a total 
retinal detachment of the left eye with nasal funneling to a retrolental mass and 
subretinal hemorrhage. In the right eye there was a fovea sparing, tractional retinal 
detachment (figure 13-1). Persistent primary hyperplastic vitreous was noted to run 
from optic disc to ora serrata and the posterior aspect of the lens in the right eye. The 
right detachment settled spontaneously by 20 months of age and at last review at 6 
years of age, vision was 0.76 logMAR (Snellen 6/38) in the right eye, NPL in the left. 
Karyotype analysis was normal (46 XY). Screen for the common IKBKG deletion was 
negative. Fluorescent sequence analysis of IKBKG and its pseudogene detected a 
sequence variant in exon 8 at a low level. Gene specific, long-range PCR of exon 3-10 
of IKBKG followed by NGS identified a novel, nonsense mutation, c.937C>T 
(p.Gln313*) at an approximate level of 15%.  
The initial analysis which identified the mutation at a level of 15% was performed on a 
blood sample taken when the patient was 10 days old. A second sample from when the 
patient was 3 years, did not detect the mutation. Genotyping at multiple loci was 
performed and confirmed that the sample came from the same individual ruling out any 
potential sample mix-up.  Analysis of maternal DNA did not identify the mutation 
consistent with a de novo event.  
 
Figure 13-2: DNA chromatograms from Sanger sequencing of different tissue 
types 
Blood 2008 and 2013, (mesoderm); hair root 2013 and buccal 2013, (ectoderm); urine 2014, 
(mesoderm/endoderm), arrow points to site of mutation. c.937C>T visible in blood 2008, hair 
root 2013 and urine 2014. 
To further investigate the level of somatic mosaicism in other tissues of variable 
embryological cell line origin, sequencing of samples obtained at age 5-6 years was 
performed in addition to a blood sample from 3 months of age. This identified the 
mutation at low levels in the blood sample from 3 months of age, hair root from 5 years 
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and urine from 6 years with no detectable mutation in the blood or buccal samples 
obtained at 5 years of age (figure 13-2). 
13.4 Discussion 
In this study, the widespread clinical manifestations of IP including the classic skin 
eruption have been observed in a male patient. Severe ocular abnormalities were 
identified with bilateral retinal detachment, worse in the left eye than the right. Ocular 
abnormalities in IP are variable with the most frequent complication an ischaemic 
retinopathy leading to tractional retinal detachment, with marked asymmetry observed 
between eyes, similar to our patient.127, 425 IP is usually fatal in-utero for males but a 
post-zygotic mutation resulting in somatic mosaicism permitted survival. The extent of 
mosaicism has been investigated with detection of the mutation in cells derived from all 
germ layers indicating early occurrence of the mutation embryologically. 426 Molecular 
diagnosis was achieved age 3 years but may have missed the mutation if DNA from 
infancy had not been tested. Somatic mosaicism permitting survival of males has also 
been described in other X-linked dominant disorders. The severe, neurodevelopmental 
Rett syndrome arises due to a mutation in MECP2, with survival in males attributed to 
47, XXY karyotype or somatic mosaicism. 427  
The novel nonsense mutation c.937C>T (p.Gln313*) reported here arises in exon 8 of 
the IKBKG gene. It is predicted to lead to a truncated mRNA transcript that would 
undergo NMD according to the classical rules for this phenomenon.206 More than 70% 
of reported patients have the recurrent exon 4-10 rearrangement, with just under 4% a 
nonsense mutation.422 The high rate of de novo aberrant recombination (approximately 
2/3) is due to the IKBKG locus arising within a region of genomic instability, 
characterised by multiple micro/macro homologies, repeat sequences and tandem 
repeats.428, 429 Missense mutations are rare and can lead to a mild or severe phenotype 
depending on which protein pathway interactions are disrupted. For instance 
p.Ala323Pro is associated with a severe phenotype as it majorly disrupts NF-kB 
activation for all downstream pathways whereas p.Gly57Lys, associated with mild IP, 
disrupts interleukin-1 signalling only.422 A male IP patient has not been previously 
reported with a nonsense mutation. However, there have been case reports of male 
patients with the allelic syndrome of ectodermal dysplasia and immunodeficiency in 
whom nonsense mutations were identified in exon 10 of IKBKG.430, 431 The resulting 
mRNA transcript would be predicted to avoid NMD and produce a protein that partially 
functions.  
In a series of 18 male patients with IP, mosaic IKBKG deletions were identified in 3 
patients with no mutations identified in the peripheral blood leukocytes of the other 
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15.432 This finding was attributed to post-zygotic mosaicism. The lack of detectable 
mutation in 15 patients was thought to arise from uncontrolled apoptosis of mutant cells 
with evidence for this from the marked skewing of X-inactivation observed in the blood 
leukocytes of female carriers, indicating a major selective advantage for cells that 
express wild- type IKBKG. Further evidence for uncontrolled apoptosis was 
demonstrated in a male IP patient in whom the detectable levels of the common exon 
4-10 rearrangement were much higher in a neonatal fibroblast sample than a blood 
sample age 9 years.423 
In this study, the loss of detectable mutation in blood with age provides further 
evidence for the hypothesis that the leukocytes carrying the mutation undergo selective 
apoptosis. In this situation, molecular confirmation may not be possible from blood and 
it would be reasonable to then recommend testing of other readily accessible tissue 
types such as hair root or urine to enable informed genetic counselling of affected 
families
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14 Conclusions 
This thesis documents the results of the investigation of some of the rarest forms of 
EORD, with detailed phenotypical analysis and molecular characterisation of conditions 
previously unreported or with limited data. The vast molecular heterogeneity of 
inherited retinal disease has been demonstrated as well as the variable phenotypic 
expression within a specific disorder. In total, 73 patients from 52 families have been 
characterised in detail with an additional 66 probands molecularly screened. Thirty 
novel mutations in 13 genes were discovered. 
Detailed phenotypic characterisation identified a number of novel features including 
progression of fundal changes in ESCS due to mutations in NR2E3; pigmentary 
glaucoma in Caucasian patients with Knobloch syndrome due to mutations in 
COL18A1 and characterisation of the photoreceptor dysfunction as cone-rod; and 
evidence that CDH3 related macular dystrophy is a centrally progressive disorder with 
minimal peripheral involvement.  
Novel phenotype-genotype correlations included macular dystrophy due to mutations in 
CRX; non-syndromic retinal dystrophy due to mutations in IFT140; and the association 
of LRP5 with FEVR and microcephaly. In addition a patient with retinal features 
resembling fundus albipunctatus due to RPE65 mutation was characterised, this 
association only having been identified once in the literature before. I was able to 
investigate a very rare case of a male patient with IP and demonstrate an alternative 
approach to achieving molecular diagnosis in a mosaic patient.  
Molecular diagnosis enabled accurate prognostic and inheritance risk counselling to 
families including a number of CRX families in whom recessive inheritance had been 
thought most likely and for families with LRP5 and KIF11 related disease in whom de 
novo disease could be proven giving a minimal risk for further children. In addition, a 
molecular diagnosis enabled appropriate targeted systemic investigations such as 
renal screening in patients with IFT140 related disease, bone density scanning in LRP5 
disease and platelet function in HPS6 related disease.  
Of particular interest from this group of patients has been the occurrence of isolated 
ocular disease in genes thought to be associated with syndromic disease such as 
IFT140 and COL18A1 as well as the recognition of syndromic features only once a 
molecular diagnosis had been achieved. This occurred in HPS6, CDH3 and LRP5. This 
highlights not only the variability in phenotypic expression of genes, the reason for 
which is largely poorly understood, but also the importance of continued systemic 
appraisal and suspicion of syndromic features. 
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There should be caution on interpreting results based on single gene screening or on 
assigning pathogenicity to novel mutations without functional evidence. Within this 
thesis, a family with FEVR and microcephaly is undergoing WGS despite a likely 
pathogenic variant in LRP5 partly due to the extremely mild phenotype in the mother. 
WES and WGS are in theory unbiased methods of interrogating a patient’s genome, 
assuming that the interpretation of identified variants is approached in an unbiased 
manner. Confirmation of variants by Sanger sequencing is important to ensure no 
sample/data mix-up has occurred. In addition, with novel variants of uncertain 
pathogenicity, segregation may not fit with disease as found in one unsolved 
FEVR/microcephaly patient initially found to have a heterozygous LRP5 variant that 
was then found to be homozygous in her mother. 
14.1 Future directions  
Many questions and challenges have been raised from this work including why 
frequent genetic pleiotropy exists, how ubiquitously expressed proteins can cause 
isolated retinal disease, the exact mechanisms of disease and how WES negative 
patients can be molecularly solved. 
Firstly, the reason for variable phenotypic expression of disease within families with 
CRX, NR2E3 and COL18A1 remains unclear as does the variable expression between 
families with no clear genotype-phenotype correlation found. In vitro studies of protein 
function can demonstrate differences such as the residual isomerase activity of 
hypomorphic RPE65 mutations compared with non-hypomorphic mutations.310 
However, protein localisation studies in transiently transfected hTERT-RPE1 cells 
found no difference in mislocalisation between syndromic and non-syndromic IFT140 
mutations.  
It is unknown why a number of ubiquitously expressed proteins including IFT140 can 
cause isolated retinal disease. It may be that these mutations arise in a functional 
region of the protein that is critical for retinal function but is tolerated or compensated 
for elsewhere. These could be a retinal specific protein interaction as postulated for 
IMPDH1 related RCD. IMPDH1 encodes an ubiquitously expressed protein for guanine 
nucleotide synthesis but may also have a role in post-transcriptional regulation of 
rhodopsin mRNA.87 In CEP290 related disease, the common c.2991+1655A>G 
mutation leads to a cryptic exon insertion. Fibroblast studies have demonstrated that 
as much as 50% of normal protein is still expressed, which appears to be sufficient for 
normal cilial function in other organs.268 It is still unknown why photoreceptors are 
specifically vulnerable. RNA-sequencing (RNA-seq) data from human retina has the 
potential to answer some of these questions although the interpretation of 
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transcriptome data is challenging. DNA and RNA analysis is typically performed on 
peripheral blood or skin sources with the assumption that the retinal expression will be 
similar. However, RNA-seq data has indicated that splicing in the retina is particularly 
diverse with alternate splicing events and alternate exons identified which may explain 
both phenotypic variability and retinal isolated disease.433, 434 RNA-seq has also been 
used to identify microexons, exons less than 51 nucleotides in length.435 Microexons 
are produced in 1% of all alternate splicing events and have a pivotal role in 
modulating protein interactions in neurogenesis. They may have a critical and as yet 
undefined role in retinal development.   
Molecular mechanisms of disease have been reasonably well characterised for some 
retinal dystrophies including RPE65 in which the protein function is understood and the 
tertiary structure has been experimentally proven.436 Much is still to be elucidated about 
the structure and function of other proteins such as IFT140.23 Understanding 
mechanisms of disease is vital in developing novel therapies. 
One of the biggest difficulties remains in interpreting whole genome data to solve 
patients in whom there are none or only one obvious mutation in known retinal 
dystrophy genes. They may have mutations in novel genes, in regulatory regions or in 
intronic regions critical for splicing. In WES negative patients such as 4 of the 
FEVR/microcephaly families studied in this thesis, interpretation of WGS data will be 
additionally challenging given the variable inheritance patterns possible. Sequencing 
multiple family members who have been clinically characterised should be helpful in 
this regard. The importance of intronic variants and their impact on splicing is being 
increasingly recognised. The common CEP290 mutation is deeply intronic as are 
recently recognised deep intronic ABCA4 variants.12, 437  
Whilst the cost of WGS has now become low enough to make it readily accessible as a 
tool for investigating patients, the challenge of interpreting the vast quantity of data 
remains. Approaches that utilise series of phenotypically similar patients, multiple 
family members and additional data such as RNA-seq are likely to have the greatest 
success in achieving a molecular diagnosis. For the patients and their families, an 
accurate molecular diagnosis, detailed phenotypic data and natural history studies are 
essential for providing prognostic information and counselling and for recruitment to 
clinical trials. Since the initial RPE65 gene therapy trials, there are an increasing 
number of novel therapies being investigated and it is hoped that these will lead to a 
new era of treatment options for patients with these blinding disorders.307-309, 438-440
  
References 
 
 174 
15 References 
1. Mitry D, Bunce C, Wormald R, et al. Causes of certifications for severe 
sight impairment (blind) and sight impairment (partial sight) in children in 
England and Wales. Br J Ophthalmol 2013;97:1431-1436. 
2. Bertelsen M, Jensen H, Larsen M, Lorenz B, Preising MN, Rosenberg T. 
Prevalence and diagnostic spectrum of generalized retinal dystrophy in Danish 
children. Ophthalmic Epidemiol 2013;20:164-169. 
3. Sherwin JC, Hewitt AW, Ruddle JB, Mackey DA. Genetic isolates in 
ophthalmic diseases. Ophthalmic Genet 2008;29:149-161. 
4. Dryja TP, McGee TL, Reichel E, et al. A point mutation of the rhodopsin 
gene in one form of retinitis pigmentosa. Nature 1990;343:364-366. 
5. Wang X, Wang H, Sun V, et al. Comprehensive molecular diagnosis of 179 
Leber congenital amaurosis and juvenile retinitis pigmentosa patients by 
targeted next generation sequencing. J Med Genet 2013;50:674-688. 
6. Henderson RH, Mackay DS, Li Z, et al. Phenotypic variability in patients 
with retinal dystrophies due to mutations in CRB1. Br J Ophthalmol 
2011;95:811-817. 
7. Hull S, Arno G, Plagnol V, et al. The phenotypic variability of retinal 
dystrophies associated with mutations in CRX, with report of a novel macular 
dystrophy phenotype. Invest Ophthalmol Vis Sci 2014;55:6934-6944. 
8. Bowne SJ, Humphries MM, Sullivan LS, et al. A dominant mutation in 
RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with 
choroidal involvement. Eur J Hum Genet 2011;19:1074-1081. 
9. Gregory-Evans K, Kelsell RE, Gregory-Evans CY, et al. Autosomal 
dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of 
GUCY2D, which encodes retinal guanylate cyclase. Ophthalmology 2000;107:55-
61. 
10. Wang F, Wang H, Tuan HF, et al. Next generation sequencing-based 
molecular diagnosis of retinitis pigmentosa: identification of a novel genotype-
phenotype correlation and clinical refinements. Hum Genet 2014;133:331-345. 
11. Estrada-Cuzcano A, Koenekoop RK, Senechal A, et al. BBS1 mutations in a 
wide spectrum of phenotypes ranging from nonsyndromic retinitis pigmentosa 
to Bardet-Biedl syndrome. Arch Ophthalmol 2012;130:1425-1432. 
12. den Hollander AI, Koenekoop RK, Yzer S, et al. Mutations in the CEP290 
(NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum 
Genet 2006;79:556-561. 
References 
 
 175 
13. Glöckle N, Kohl S, Mohr J, et al. Panel-based next generation sequencing 
as a reliable and efficient technique to detect mutations in unselected patients 
with retinal dystrophies. Eur J Hum Genet 2014;22:99-104. 
14. O'Sullivan J, Mullaney BG, Bhaskar SS, et al. A paradigm shift in the 
delivery of services for diagnosis of inherited retinal disease. J Med Genet 
2012;49:322-326. 
15. Audo I, Bujakowska KM, Léveillard T, et al. Development and application 
of a next-generation-sequencing (NGS) approach to detect known and novel 
gene defects underlying retinal diseases. Orphanet J Rare Dis 2012;7:8. 
16. Eisenberger T, Neuhaus C, Khan AO, et al. Increasing the yield in targeted 
next-generation sequencing by implicating CNV analysis, non-coding exons and 
the overall variant load: the example of retinal dystrophies. PLoS One 
2013;8:e78496. 
17. Wang Y, Macke JP, Merbs SL, et al. A locus control region adjacent to the 
human red and green visual pigment genes. Neuron 1992;9:429-440. 
18. Nishiguchi KM, Tearle RG, Liu YP, et al. Whole genome sequencing in 
patients with retinitis pigmentosa reveals pathogenic DNA structural changes 
and NEK2 as a new disease gene. Proc Natl Acad Sci U S A 2013;110:16139-
16144. 
19. Fariss RN, Li ZY, Milam AH. Abnormalities in rod photoreceptors, 
amacrine cells, and horizontal cells in human retinas with retinitis pigmentosa. 
Am J Ophthalmol 2000;129:215-223. 
20. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of cone 
photoreceptors restores visual responses in retinitis pigmentosa. Science 
2010;329:413-417. 
21. Masland RH. The neuronal organization of the retina. Neuron 
2012;76:266-280. 
22. Tsujikawa M, Malicki J. Intraflagellar transport genes are essential for 
differentiation and survival of vertebrate sensory neurons. Neuron 2004;42:703-
716. 
23. Crouse JA, Lopes VS, Sanagustin JT, Keady BT, Williams DS, Pazour GJ. 
Distinct functions for IFT140 and IFT20 in opsin transport. Cytoskeleton 
(Hoboken) 2014;71:302-310. 
24. Burgoyne T, Meschede IP, Burden JJ, Bailly M, Seabra MC, Futter CE. Rod 
disc renewal occurs by evagination of the ciliary plasma membrane that makes 
cadherin-based contacts with the inner segment. Proc Natl Acad Sci U S A 
2015;112:15922-15927. 
25. Mazzoni F, Safa H, Finnemann SC. Understanding photoreceptor outer 
segment phagocytosis: use and utility of RPE cells in culture. Exp Eye Res 
2014;126:51-60. 
References 
 
 176 
26. Curcio CA, Sloan KR, Kalina RE, Hendrickson AE. Human photoreceptor 
topography. J Comp Neurol 1990;292:497-523. 
27. Sakurai M, Mullen KT. Cone weights for the two cone-opponent systems 
in peripheral vision and asymmetries of cone contrast sensitivity. Vision Res 
2006;46:4346-4354. 
28. Shirzad-Wasei N, DeGrip WJ. Heterologous Expression of Melanopsin: 
Present, Problems and Prospects. Prog Retin Eye Res 2016. 
29. Lucas RJ, Lall GS, Allen AE, Brown TM. How rod, cone, and melanopsin 
photoreceptors come together to enlighten the mammalian circadian clock. 
Prog Brain Res 2012;199:1-18. 
30. Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC. Glia-neuron 
interactions in the mammalian retina. Prog Retin Eye Res 2015. 
31. Kaylor JJ, Cook JD, Makshanoff J, Bischoff N, Yong J, Travis GH. 
Identification of the 11-cis-specific retinyl-ester synthase in retinal Müller cells 
as multifunctional O-acyltransferase (MFAT). Proc Natl Acad Sci U S A 
2014;111:7302-7307. 
32. Gariano RF, Gardner TW. Retinal angiogenesis in development and 
disease. Nature 2005;438:960-966. 
33. Ohsawa R, Kageyama R. Regulation of retinal cell fate specification by 
multiple transcription factors. Brain Res 2008;1192:90-98. 
34. Wallace VA. Concise review: making a retina--from the building blocks to 
clinical applications. Stem Cells 2011;29:412-417. 
35. Hendrickson A. Development of Retinal Layers in Prenatal Human Retina. 
Am J Ophthalmol 2016;161:29-35.e21. 
36. Vajzovic L, Hendrickson AE, O'Connell RV, et al. Maturation of the human 
fovea: correlation of spectral-domain optical coherence tomography findings 
with histology. Am J Ophthalmol 2012;154:779-789.e772. 
37. Ye X, Wang Y, Cahill H, et al. Norrin, frizzled-4, and Lrp5 signaling in 
endothelial cells controls a genetic program for retinal vascularization. Cell 
2009;139:285-298. 
38. Palczewski K. Chemistry and biology of the initial steps in vision: the 
Friedenwald lecture. Invest Ophthalmol Vis Sci 2014;55:6651-6672. 
39. Chen C, Thompson DA, Koutalos Y. Reduction of all-trans-retinal in 
vertebrate rod photoreceptors requires the combined action of RDH8 and 
RDH12. J Biol Chem 2012;287:24662-24670. 
40. Jin M, Li S, Moghrabi WN, Sun H, Travis GH. Rpe65 is the retinoid 
isomerase in bovine retinal pigment epithelium. Cell 2005;122:449-459. 
41. Redmond TM, Poliakov E, Yu S, Tsai JY, Lu Z, Gentleman S. Mutation of 
key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the 
visual cycle. Proc Natl Acad Sci U S A 2005;102:13658-13663. 
References 
 
 177 
42. Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma JX. RPE65 is the 
isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A 
2005;102:12413-12418. 
43. Marlhens F, Bareil C, Griffoin JM, et al. Mutations in RPE65 cause Leber's 
congenital amaurosis. Nat Genet 1997;17:139-141. 
44. Gu SM, Thompson DA, Srikumari CR, et al. Mutations in RPE65 cause 
autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet 
1997;17:194-197. 
45. Thompson DA, Li Y, McHenry CL, et al. Mutations in the gene encoding 
lecithin retinol acyltransferase are associated with early-onset severe retinal 
dystrophy. Nat Genet 2001;28:123-124. 
46. den Hollander AI, McGee TL, Ziviello C, et al. A homozygous missense 
mutation in the IRBP gene (RBP3) associated with autosomal recessive retinitis 
pigmentosa. Invest Ophthalmol Vis Sci 2009;50:1864-1872. 
47. Allikmets R. A photoreceptor cell-specific ATP-binding transporter gene 
(ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 
1997;17:122. 
48. Perrault I, Hanein S, Gerber S, et al. Retinal dehydrogenase 12 (RDH12) 
mutations in leber congenital amaurosis. Am J Hum Genet 2004;75:639-646. 
49. Kohl S, Coppieters F, Meire F, et al. A nonsense mutation in PDE6H 
causes autosomal-recessive incomplete achromatopsia. Am J Hum Genet 
2012;91:527-532. 
50. Perrault I, Rozet JM, Calvas P, et al. Retinal-specific guanylate cyclase 
gene mutations in Leber's congenital amaurosis. Nat Genet 1996;14:461-464. 
51. Little JA, Woodhouse JM, Lauritzen JS, Saunders KJ. Vernier acuity in 
Down syndrome. Invest Ophthalmol Vis Sci 2009;50:567-572. 
52. Brémond-Gignac D, Copin H, Lapillonne A, Milazzo S, Development 
ENoSaRiE. Visual development in infants: physiological and pathological 
mechanisms. Curr Opin Ophthalmol 2011;22 Suppl:S1-8. 
53. Galvin JA, Fishman GA, Stone EM, Koenekoop RK. Evaluation of 
genotype-phenotype associations in leber congenital amaurosis. Retina 
2005;25:919-929. 
54. Forrester JV, Dick AD, McMenamin PG, Lee WR. The Eye, Basic Sciences in 
Practice. 2nd ed. Philadelphia, USA: Elsevier Limited; 2002. 
55. Kay H. New method of assessing visual acuity with pictures. Br J 
Ophthalmol 1983;67:131-133. 
56. Ferris FL, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for 
clinical research. Am J Ophthalmol 1982;94:91-96. 
References 
 
 178 
57. Thiadens AA, Hoyng CB, Polling JR, Bernaerts-Biskop R, van den Born LI, 
Klaver CC. Accuracy of four commonly used color vision tests in the 
identification of cone disorders. Ophthalmic Epidemiol 2013;20:114-121. 
58. McCulley TJ, Golnik KC, Lam BL, Feuer WJ. The effect of decreased visual 
acuity on clinical color vision testing. Am J Ophthalmol 2006;141:194-196. 
59. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen 
visual acuity measurements. Retina 2010;30:1046-1050. 
60. Oishi A, Ogino K, Makiyama Y, Nakagawa S, Kurimoto M, Yoshimura N. 
Wide-field fundus autofluorescence imaging of retinitis pigmentosa. 
Ophthalmology 2013;120:1827-1834. 
61. Liew G, Moore AT, Webster AR, Michaelides M. Efficacy and prognostic 
factors of response to carbonic anhydrase inhibitors in management of cystoid 
macular edema in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2015;56:1531-
1536. 
62. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of 
the human mitochondrial genome. Nature 1981;290:457-465. 
63. Consortium IHGS. Finishing the euchromatic sequence of the human 
genome. Nature 2004;431:931-945. 
64. Hayden EC. Technology: The $1,000 genome. Nature 2014;507:294-295. 
65. Strachan T, Read A. Human Molecular Genetics. 4th ed. New York: 
Garland Science; 2011. 
66. Rose AM, Bhattacharya SS. Variant haploinsufficiency and phenotypic 
non-penetrance in PRPF31-associated retinitis pigmentosa. Clin Genet 2016. 
67. Smahi A, Courtois G, Vabres P, et al. Genomic rearrangement in NEMO 
impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The 
International Incontinentia Pigmenti (IP) Consortium. Nature 2000;405:466-472. 
68. Grover S, Fishman GA, Anderson RJ, Lindeman M. A longitudinal study of 
visual function in carriers of X-linked recessive retinitis pigmentosa. 
Ophthalmology 2000;107:386-396. 
69. Taylor D, Hoyt C. Paediatric Ophthalmology and Strabismus: Elselvier Ltd; 
2013. 
70. Leber T. Ueber Retinitis pigmentosa und angeborene Amaurose. Albrecht 
von Graefes Archiv für klinische und experimentelle Ophthalmologie 1869;15:1-
25. 
71. Chung DC, Traboulsi EI. Leber congenital amaurosis: clinical correlations 
with genotypes, gene therapy trials update, and future directions. J AAPOS 
2009;13:587-592. 
72. Cremers FP, van den Hurk JA, den Hollander AI. Molecular genetics of 
Leber congenital amaurosis. Hum Mol Genet 2002;11:1169-1176. 
References 
 
 179 
73. Stone EM. Leber congenital amaurosis - a model for efficient genetic 
testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am 
J Ophthalmol 2007;144:791-811. 
74. Bowne SJ, Sullivan LS, Mortimer SE, et al. Spectrum and frequency of 
mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa 
and leber congenital amaurosis. Invest Ophthalmol Vis Sci 2006;47:34-42. 
75. Chen Y, Zhang Q, Shen T, et al. Comprehensive mutation analysis by 
whole-exome sequencing in 41 Chinese families with Leber congenital 
amaurosis. Invest Ophthalmol Vis Sci 2013;54:4351-4357. 
76. Janecke AR, Thompson DA, Utermann G, et al. Mutations in RDH12 
encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset 
severe retinal dystrophy. Nat Genet 2004;36:850-854. 
77. Freund CL, Wang QL, Chen S, et al. De novo mutations in the CRX 
homeobox gene associated with Leber congenital amaurosis. Nat Genet 
1998;18:311-312. 
78. den Hollander AI, Koenekoop RK, Mohamed MD, et al. Mutations in 
LCA5, encoding the ciliary protein lebercilin, cause Leber congenital amaurosis. 
Nat Genet 2007;39:889-895. 
79. Dryja TP, Adams SM, Grimsby JL, et al. Null RPGRIP1 alleles in patients 
with Leber congenital amaurosis. Am J Hum Genet 2001;68:1295-1298. 
80. Hagstrom SA, Watson RF, Pauer GJ, Grossman GH. Tulp1 is involved in 
specific photoreceptor protein transport pathways. Adv Exp Med Biol 
2012;723:783-789. 
81. Kolandaivelu S, Singh RK, Ramamurthy V. AIPL1, A protein linked to 
blindness, is essential for the stability of enzymes mediating cGMP metabolism 
in cone photoreceptor cells. Hum Mol Genet 2014;23:1002-1012. 
82. Eblimit A, Nguyen TM, Chen Y, et al. Spata7 is a retinal ciliopathy gene 
critical for correct RPGRIP1 localization and protein trafficking in the retina. 
Hum Mol Genet 2015;24:1584-1601. 
83. Zulliger R, Naash MI, Rajala RV, Molday RS, Azadi S. Impaired association 
of retinal degeneration-3 with guanylate cyclase-1 and guanylate cyclase-
activating protein-1 leads to leber congenital amaurosis-1. J Biol Chem 
2015;290:3488-3499. 
84. Stone EM, Cideciyan AV, Aleman TS, et al. Variations in NPHP5 in patients 
with nonsyndromic leber congenital amaurosis and Senior-Loken syndrome. 
Arch Ophthalmol 2011;129:81-87. 
85. Estrada-Cuzcano A, Koenekoop RK, Coppieters F, et al. IQCB1 mutations 
in patients with leber congenital amaurosis. Invest Ophthalmol Vis Sci 
2011;52:834-839. 
References 
 
 180 
86. Sergouniotis PI, Davidson AE, Mackay DS, et al. Recessive mutations in 
KCNJ13, encoding an inwardly rectifying potassium channel subunit, cause leber 
congenital amaurosis. Am J Hum Genet 2011;89:183-190. 
87. Mortimer SE, Xu D, McGrew D, et al. IMP dehydrogenase type 1 
associates with polyribosomes translating rhodopsin mRNA. J Biol Chem 
2008;283:36354-36360. 
88. Roman AJ, Cideciyan AV, Schwartz SB, Olivares MB, Heon E, Jacobson SG. 
Intervisit variability of visual parameters in Leber congenital amaurosis caused 
by RPE65 mutations. Invest Ophthalmol Vis Sci 2013;54:1378-1383. 
89. Wang H, den Hollander AI, Moayedi Y, et al. Mutations in SPATA7 cause 
Leber congenital amaurosis and juvenile retinitis pigmentosa. Am J Hum Genet 
2009;84:380-387. 
90. Sohocki MM, Bowne SJ, Sullivan LS, et al. Mutations in a new 
photoreceptor-pineal gene on 17p cause Leber congenital amaurosis. Nat Genet 
2000;24:79-83. 
91. Lotery AJ, Jacobson SG, Fishman GA, et al. Mutations in the CRB1 gene 
cause Leber congenital amaurosis. Arch Ophthalmol 2001;119:415-420. 
92. Falk MJ, Zhang Q, Nakamaru-Ogiso E, et al. NMNAT1 mutations cause 
Leber congenital amaurosis. Nat Genet 2012;44:1040-1045. 
93. Perrault I, Hanein S, Zanlonghi X, et al. Mutations in NMNAT1 cause Leber 
congenital amaurosis with early-onset severe macular and optic atrophy. Nat 
Genet 2012;44:975-977. 
94. Chiang PW, Wang J, Chen Y, et al. Exome sequencing identifies NMNAT1 
mutations as a cause of Leber congenital amaurosis. Nat Genet 2012;44:972-
974. 
95. Koenekoop RK, Wang H, Majewski J, et al. Mutations in NMNAT1 cause 
Leber congenital amaurosis and identify a new disease pathway for retinal 
degeneration. Nat Genet 2012;44:1035-1039. 
96. Friedman JS, Chang B, Kannabiran C, et al. Premature truncation of a 
novel protein, RD3, exhibiting subnuclear localization is associated with retinal 
degeneration. Am J Hum Genet 2006;79:1059-1070. 
97. Hagstrom SA, North MA, Nishina PL, Berson EL, Dryja TP. Recessive 
mutations in the gene encoding the tubby-like protein TULP1 in patients with 
retinitis pigmentosa. Nat Genet 1998;18:174-176. 
98. Banerjee P, Kleyn PW, Knowles JA, et al. TULP1 mutation in two extended 
Dominican kindreds with autosomal recessive retinitis pigmentosa. Nat Genet 
1998;18:177-179. 
99. Scholl HP, Chong NH, Robson AG, Holder GE, Moore AT, Bird AC. Fundus 
autofluorescence in patients with leber congenital amaurosis. Invest 
Ophthalmol Vis Sci 2004;45:2747-2752. 
References 
 
 181 
100. Wabbels B, Demmler A, Paunescu K, Wegscheider E, Preising MN, Lorenz 
B. Fundus autofluorescence in children and teenagers with hereditary retinal 
diseases. Graefes Arch Clin Exp Ophthalmol 2006;244:36-45. 
101. Lorenz B, Wabbels B, Wegscheider E, Hamel CP, Drexler W, Preising MN. 
Lack of fundus autofluorescence to 488 nanometers from childhood on in 
patients with early-onset severe retinal dystrophy associated with mutations in 
RPE65. Ophthalmology 2004;111:1585-1594. 
102. Traboulsi EI. The Marshall M. Parks memorial lecture: making sense of 
early-onset childhood retinal dystrophies--the clinical phenotype of Leber 
congenital amaurosis. Br J Ophthalmol 2010;94:1281-1287. 
103. Schuil J, Meire FM, Delleman JW. Mental retardation in amaurosis 
congenita of Leber. Neuropediatrics 1998;29:294-297. 
104. Petraglia AL, Chengazi HU, Chung MM, Silberstein HJ. Leber congenital 
amaurosis associated with Chiari I malformation: Two cases and a review of the 
literature. Surg Neurol Int 2012;3:4. 
105. Marshall JD, Hinman EG, Collin GB, et al. Spectrum of ALMS1 variants and 
evaluation of genotype-phenotype correlations in Alström syndrome. Hum 
Mutat 2007;28:1114-1123. 
106. Otto EA, Loeys B, Khanna H, et al. Nephrocystin-5, a ciliary IQ domain 
protein, is mutated in Senior-Loken syndrome and interacts with RPGR and 
calmodulin. Nat Genet 2005;37:282-288. 
107. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 
2006;368:1795-1809. 
108. Bertelsen M, Jensen H, Bregnhøj JF, Rosenberg T. Prevalence of 
generalized retinal dystrophy in denmark. Ophthalmic Epidemiol 2014;21:217-
223. 
109. Sandberg MA, Rosner B, Weigel-DiFranco C, Dryja TP, Berson EL. Disease 
course of patients with X-linked retinitis pigmentosa due to RPGR gene 
mutations. Invest Ophthalmol Vis Sci 2007;48:1298-1304. 
110. Bocquet B, Lacroux A, Surget MO, et al. Relative frequencies of inherited 
retinal dystrophies and optic neuropathies in Southern France: assessment of 
21-year data management. Ophthalmic Epidemiol 2013;20:13-25. 
111. Rosenfeld PJ, Cowley GS, McGee TL, Sandberg MA, Berson EL, Dryja TP. A 
null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and 
autosomal recessive retinitis pigmentosa. Nat Genet 1992;1:209-213. 
112. Xu Y, Guan L, Shen T, et al. Mutations of 60 known causative genes in 157 
families with retinitis pigmentosa based on exome sequencing. Hum Genet 
2014. 
113. Littink KW, van den Born LI, Koenekoop RK, et al. Mutations in the EYS 
gene account for approximately 5% of autosomal recessive retinitis pigmentosa 
References 
 
 182 
and cause a fairly homogeneous phenotype. Ophthalmology 2010;117:2026-
2033, 2033.e2021-2027. 
114. Vithana EN, Abu-Safieh L, Pelosini L, et al. Expression of PRPF31 mRNA in 
patients with autosomal dominant retinitis pigmentosa: a molecular clue for 
incomplete penetrance? Invest Ophthalmol Vis Sci 2003;44:4204-4209. 
115. Audo I, Mohand-Saïd S, Dhaenens CM, et al. RP1 and autosomal 
dominant rod-cone dystrophy: novel mutations, a review of published variants, 
and genotype-phenotype correlation. Hum Mutat 2012;33:73-80. 
116. Webb TR, Parfitt DA, Gardner JC, et al. Deep intronic mutation in OFD1, 
identified by targeted genomic next-generation sequencing, causes a severe 
form of X-linked retinitis pigmentosa (RP23). Hum Mol Genet 2012;21:3647-
3654. 
117. Sharon D, Sandberg MA, Rabe VW, Stillberger M, Dryja TP, Berson EL. 
RP2 and RPGR mutations and clinical correlations in patients with X-linked 
retinitis pigmentosa. Am J Hum Genet 2003;73:1131-1146. 
118. Demirci FY, Rigatti BW, Wen G, et al. X-linked cone-rod dystrophy (locus 
COD1): identification of mutations in RPGR exon ORF15. Am J Hum Genet 
2002;70:1049-1053. 
119. Roosing S, Thiadens AA, Hoyng CB, Klaver CC, den Hollander AI, Cremers 
FP. Causes and consequences of inherited cone disorders. Prog Retin Eye Res 
2014. 
120. Thiadens AA, Phan TM, Zekveld-Vroon RC, et al. Clinical course, genetic 
etiology, and visual outcome in cone and cone-rod dystrophy. Ophthalmology 
2012;119:819-826. 
121. Michaelides M, Hunt DM, Moore AT. The genetics of inherited macular 
dystrophies. J Med Genet 2003;40:641-650. 
122. Zahid S, Jayasundera T, Rhoades W, et al. Clinical phenotypes and 
prognostic full-field electroretinographic findings in Stargardt disease. Am J 
Ophthalmol 2013;155:465-473.e463. 
123. Querques G, Zerbib J, Santacroce R, et al. Functional and clinical data of 
Best vitelliform macular dystrophy patients with mutations in the BEST1 gene. 
Mol Vis 2009;15:2960-2972. 
124. Borman AD, Davidson AE, O'Sullivan J, et al. Childhood-onset autosomal 
recessive bestrophinopathy. Arch Ophthalmol 2011;129:1088-1093. 
125. Salvo J, Lyubasyuk V, Xu M, et al. Next-generation sequencing and novel 
variant determination in a cohort of 92 familial exudative vitreoretinopathy 
patients. Invest Ophthalmol Vis Sci 2015;56:1937-1946. 
126. Gilmour DF. Familial exudative vitreoretinopathy and related 
retinopathies. Eye (Lond) 2015;29:1-14. 
References 
 
 183 
127. O'Doherty M, Mc Creery K, Green AJ, Tuwir I, Brosnahan D. Incontinentia 
pigmenti--ophthalmological observation of a series of cases and review of the 
literature. Br J Ophthalmol 2011;95:11-16. 
128. Dulz S, Wagenfeld L, Nickel M, et al. Novel morphological macular 
findings in juvenile CLN3 disease. Br J Ophthalmol 2015. 
129. Delori F. Lipofuscin: The Origin of the Autofluorescence Signal. In: Lois N, 
Forrester JV (eds), Fundus autofluorescence. Philadelphia, USA: Wolters Kluwer; 
2016. 
130. Smith RT. The Normal Distribution of Fundus Autofluorescence. In: Lois 
N, Forrester JV (eds), Fundus autofluorescence. Philadelphia, USA: Wolters 
Kluwer; 2016. 
131. Robson AG, Audo I, Webster AR. Fundus Autofluorescence in Inherited 
Retinal Dystrophies, Retinitis Pigmentosa. In: Lois N, Forrester JV (eds), Fundus 
Autofluorescence. Philadelphia, USA: Wolters Kluwer; 2016. 
132. Goldberg NR, Greenberg JP, Laud K, Tsang S, Freund KB. Outer retinal 
tubulation in degenerative retinal disorders. Retina 2013;33:1871-1876. 
133. Sujirakul T, Lin MK, Duong J, Wei Y, Lopez-Pintado S, Tsang SH. 
Multimodal Imaging of Central Retinal Disease Progression in a 2-Year Mean 
Follow-up of Retinitis Pigmentosa. Am J Ophthalmol 2015;160:786-798.e784. 
134. Kaneko Y, Moriyama M, Hirahara S, Ogura Y, Ohno-Matsui K. Areas of 
nonperfusion in peripheral retina of eyes with pathologic myopia detected by 
ultra-widefield fluorescein angiography. Invest Ophthalmol Vis Sci 
2014;55:1432-1439. 
135. Vincent A, Robson AG, Holder GE. Pathognomonic (diagnostic) ERGs. A 
review and update. Retina 2013;33:5-12. 
136. McCulloch DL, Marmor MF, Brigell MG, et al. ISCEV Standard for full-field 
clinical electroretinography (2015 update). Doc Ophthalmol 2015;130:1-12. 
137. Bach M, Brigell MG, Hawlina M, et al. ISCEV standard for clinical pattern 
electroretinography (PERG): 2012 update. Doc Ophthalmol 2013;126:1-7. 
138. Holder G, Robson A. Paediatric Electrophysiology: a practical approach. 
In: Pediatric Ophthalmology, Neuro-Ophthalmology, Genetics. Berlin: Springer; 
2006. 
139. Holder GE. Pattern electroretinography (PERG) and an integrated 
approach to visual pathway diagnosis. Prog Retin Eye Res 2001;20:531-561. 
140. Dorey SE, Neveu MM, Burton LC, Sloper JJ, Holder GE. The clinical 
features of albinism and their correlation with visual evoked potentials. Br J 
Ophthalmol 2003;87:767-772. 
141. Holder GE. Electrophysiological assessment of optic nerve disease. Eye 
(Lond) 2004;18:1133-1143. 
References 
 
 184 
142. McBain VA, Robson AG, Hogg CR, Holder GE. Assessment of patients with 
suspected non-organic visual loss using pattern appearance visual evoked 
potentials. Graefes Arch Clin Exp Ophthalmol 2007;245:502-510. 
143. Strien J, Sanft J, Mall G. Enhancement of PCR amplification of moderate 
GC-containing and highly GC-rich DNA sequences. Mol Biotechnol 2013;54:1048-
1054. 
144. Flicek P, Amode MR, Barrell D, et al. Ensembl 2014. Nucleic Acids Res 
2014;42:D749-755. 
145. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating 
inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-5467. 
146. Lindberg P, Stjernström M, Roeraade J. Gel electrophoresis of DNA 
fragments in narrow-bore capillaries. Electrophoresis 1997;18:1973-1979. 
147. Gnirke A, Melnikov A, Maguire J, et al. Solution hybrid selection with 
ultra-long oligonucleotides for massively parallel targeted sequencing. Nat 
Biotechnol 2009;27:182-189. 
148. Meienberg J, Zerjavic K, Keller I, et al. New insights into the performance 
of human whole-exome capture platforms. Nucleic Acids Res 2015;43:e76. 
149. Raczy C, Petrovski R, Saunders CT, et al. Isaac: ultra-fast whole-genome 
secondary analysis on Illumina sequencing platforms. Bioinformatics 
2013;29:2041-2043. 
150. Li H, Durbin R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 2009;25:1754-1760. 
151. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a 
MapReduce framework for analyzing next-generation DNA sequencing data. 
Genome Res 2010;20:1297-1303. 
152. Sund KL, Zimmerman SL, Thomas C, et al. Regions of homozygosity 
identified by SNP microarray analysis aid in the diagnosis of autosomal recessive 
disease and incidentally detect parental blood relationships. Genet Med 
2013;15:70-78. 
153. Zernant J, Külm M, Dharmaraj S, et al. Genotyping microarray (disease 
chip) for Leber congenital amaurosis: detection of modifier alleles. Invest 
Ophthalmol Vis Sci 2005;46:3052-3059. 
154. van Huet RA, Pierrache LH, Meester-Smoor MA, et al. The efficacy of 
microarray screening for autosomal recessive retinitis pigmentosa in routine 
clinical practice. Mol Vis 2015;21:461-476. 
155. Benson DA, Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW. 
GenBank. Nucleic Acids Res 2015;43:D30-35. 
156. Abecasis GR, Altshuler D, Auton A, et al. A map of human genome 
variation from population-scale sequencing. Nature 2010;467:1061-1073. 
References 
 
 185 
157. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat Protoc 
2009;4:1073-1081. 
158. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for 
predicting damaging missense mutations. Nat Methods 2010;7:248-249. 
159. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site 
detection in Genie. J Comput Biol 1997;4:311-323. 
160. Desmet FO, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, 
Béroud C. Human Splicing Finder: an online bioinformatics tool to predict 
splicing signals. Nucleic Acids Res 2009;37:e67. 
161. Sievers F, Wilm A, Dineen D, et al. Fast, scalable generation of high-
quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 
2011;7:539. 
162. Chen F, Ng PS, Faull KF, Lee RH. Cone photoreceptor betagamma-
transducin: posttranslational modification and interaction with phosducin. 
Invest Ophthalmol Vis Sci 2003;44:4622-4629. 
163. Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein 
Data Bank. Nat Struct Biol 2003;10:980. 
164. Consortium U. UniProt: a hub for protein information. Nucleic Acids Res 
2015;43:D204-212. 
165. M W. The zebrafish book. A guide for the laboratory use of zebrafish 
(Danio rerio). 4th ed: University of Oregon Press, Eugene. ; 1993. 
166. Walker MB, Kimmel CB. A two-color acid-free cartilage and bone stain for 
zebrafish larvae. Biotech Histochem 2007;82:23-28. 
167. Gerety SS, Wilkinson DG. Morpholino artifacts provide pitfalls and reveal 
a novel role for pro-apoptotic genes in hindbrain boundary development. Dev 
Biol 2011;350:279-289. 
168. Sullivan-Brown J, Bisher ME, Burdine RD. Embedding, serial sectioning 
and staining of zebrafish embryos using JB-4 resin. Nat Protoc 2011;6:46-55. 
169. Parichy DM, Elizondo MR, Mills MG, Gordon TN, Engeszer RE. Normal 
table of postembryonic zebrafish development: staging by externally visible 
anatomy of the living fish. Dev Dyn 2009;238:2975-3015. 
170. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of 
image analysis. Nat Methods 2012;9:671-675. 
171. Freund CL, Gregory-Evans CY, Furukawa T, et al. Cone-rod dystrophy due 
to mutations in a novel photoreceptor-specific homeobox gene (CRX) essential 
for maintenance of the photoreceptor. Cell 1997;91:543-553. 
172. Furukawa T, Morrow EM, Cepko CL. Crx, a novel otx-like homeobox gene, 
shows photoreceptor-specific expression and regulates photoreceptor 
differentiation. Cell 1997;91:531-541. 
References 
 
 186 
173. Chen S, Wang QL, Nie Z, et al. Crx, a novel Otx-like paired-homeodomain 
protein, binds to and transactivates photoreceptor cell-specific genes. Neuron 
1997;19:1017-1030. 
174. Peng GH, Ahmad O, Ahmad F, Liu J, Chen S. The photoreceptor-specific 
nuclear receptor Nr2e3 interacts with Crx and exerts opposing effects on the 
transcription of rod versus cone genes. Hum Mol Genet 2005;14:747-764. 
175. Evans K, Fryer A, Inglehearn C, et al. Genetic linkage of cone-rod retinal 
dystrophy to chromosome 19q and evidence for segregation distortion. Nat 
Genet 1994;6:210-213. 
176. Sohocki MM, Sullivan LS, Mintz-Hittner HA, et al. A range of clinical 
phenotypes associated with mutations in CRX, a photoreceptor transcription-
factor gene. Am J Hum Genet 1998;63:1307-1315. 
177. Kitiratschky VB, Nagy D, Zabel T, et al. Cone and cone-rod dystrophy 
segregating in the same pedigree due to the same novel CRX gene mutation. Br 
J Ophthalmol 2008;92:1086-1091. 
178. Swain PK, Chen S, Wang QL, et al. Mutations in the cone-rod homeobox 
gene are associated with the cone-rod dystrophy photoreceptor degeneration. 
Neuron 1997;19:1329-1336. 
179. Li L, Xiao X, Li S, et al. Detection of variants in 15 genes in 87 unrelated 
Chinese patients with Leber congenital amaurosis. PLoS One 2011;6:e19458. 
180. Lotery AJ, Namperumalsamy P, Jacobson SG, et al. Mutation analysis of 3 
genes in patients with Leber congenital amaurosis. Arch Ophthalmol 
2000;118:538-543. 
181. Jin ZB, Mandai M, Yokota T, et al. Identifying pathogenic genetic 
background of simplex or multiplex retinitis pigmentosa patients: a large scale 
mutation screening study. J Med Genet 2008;45:465-472. 
182. Sankila EM, Joensuu TH, Hämäläinen RH, et al. A CRX mutation in a 
Finnish family with dominant cone-rod retinal dystrophy. Hum Mutat 
2000;16:94. 
183. Huang L, Xiao X, Li S, et al. CRX variants in cone-rod dystrophy and 
mutation overview. Biochem Biophys Res Commun 2012;426:498-503. 
184. Nichols LL, Alur RP, Boobalan E, et al. Two novel CRX mutant proteins 
causing autosomal dominant Leber congenital amaurosis interact differently 
with NRL. Hum Mutat 2010;31:E1472-1483. 
185. Swaroop A, Wang QL, Wu W, et al. Leber congenital amaurosis caused by 
a homozygous mutation (R90W) in the homeodomain of the retinal 
transcription factor CRX: direct evidence for the involvement of CRX in the 
development of photoreceptor function. Hum Mol Genet 1999;8:299-305. 
References 
 
 187 
186. Zou X, Yao F, Liang X, et al. De novo Mutations in the Cone-rod 
Homeobox Gene Associated with Leber Congenital Amaurosis in Chinese 
Patients. Ophthalmic Genet 2013. 
187. Lines MA, Hébert M, McTaggart KE, Flynn SJ, Tennant MT, MacDonald 
IM. Electrophysiologic and phenotypic features of an autosomal cone-rod 
dystrophy caused by a novel CRX mutation. Ophthalmology 2002;109:1862-
1870. 
188. Ziviello C, Simonelli F, Testa F, et al. Molecular genetics of autosomal 
dominant retinitis pigmentosa (ADRP): a comprehensive study of 43 Italian 
families. J Med Genet 2005;42:e47. 
189. Kohl S, Kitiratschky V, Papke M, Schaich S, Sauer A, Wissinger B. Genes 
and mutations in autosomal dominant cone and cone-rod dystrophy. Adv Exp 
Med Biol 2012;723:337-343. 
190. Perrault I, Hanein S, Gerber S, et al. Evidence of autosomal dominant 
Leber congenital amaurosis (LCA) underlain by a CRX heterozygous null allele. J 
Med Genet 2003;40:e90. 
191. Nakamura M, Ito S, Miyake Y. Novel de novo mutation in CRX gene in a 
Japanese patient with leber congenital amaurosis. Am J Ophthalmol 
2002;134:465-467. 
192. Koenekoop RK, Loyer M, Dembinska O, Beneish R. Visual improvement in 
Leber congenital amaurosis and the CRX genotype. Ophthalmic Genet 
2002;23:49-59. 
193. Zhang Q, Li S, Guo X, et al. Screening for CRX gene mutations in Chinese 
patients with Leber congenital amaurosis and mutational phenotype. 
Ophthalmic Genet 2001;22:89-96. 
194. Rivolta C, Peck NE, Fulton AB, Fishman GA, Berson EL, Dryja TP. Novel 
frameshift mutations in CRX associated with Leber congenital amaurosis. Hum 
Mutat 2001;18:550-551. 
195. Itabashi T, Wada Y, Sato H, Kawamura M, Shiono T, Tamai M. Novel 
615delC mutation in the CRX gene in a Japanese family with cone-rod 
dystrophy. Am J Ophthalmol 2004;138:876-877. 
196. Silva E, Yang JM, Li Y, Dharmaraj S, Sundin OH, Maumenee IH. A CRX null 
mutation is associated with both Leber congenital amaurosis and a normal 
ocular phenotype. Invest Ophthalmol Vis Sci 2000;41:2076-2079. 
197. Paunescu K, Preising MN, Janke B, Wissinger B, Lorenz B. Genotype-
phenotype correlation in a German family with a novel complex CRX mutation 
extending the open reading frame. Ophthalmology 2007;114:1348-1357.e1341. 
198. Preising MN, Paunescu K, Friedburg C, Lorenz B. [Genetic and clinical 
heterogeneity in LCA patients. The end of uniformity]. Ophthalmologe 
2007;104:490-498. 
References 
 
 188 
199. Arcot Sadagopan K, Battista R, Keep RB, Capasso JE, Levin AV. Autosomal-
dominant Leber Congenital Amaurosis Caused by a Heterozygous CRX Mutation 
in a Father and Son. Ophthalmic Genet 2013. 
200. Neveu MM, Dangour A, Allen E, et al. Electroretinogram measures in a 
septuagenarian population. Doc Ophthalmol 2011;123:75-81. 
201. Vincent A, Robson AG, Neveu MM, et al. A phenotype-genotype 
correlation study of X-linked retinoschisis. Ophthalmology 2013;120:1454-1464. 
202. Sohocki MM, Daiger SP, Bowne SJ, et al. Prevalence of mutations causing 
retinitis pigmentosa and other inherited retinopathies. Hum Mutat 2001;17:42-
51. 
203. Vallespin E, Cantalapiedra D, Riveiro-Alvarez R, et al. Mutation screening 
of 299 Spanish families with retinal dystrophies by Leber congenital amaurosis 
genotyping microarray. Invest Ophthalmol Vis Sci 2007;48:5653-5661. 
204. Baker SA, Chen L, Wilkins AD, Yu P, Lichtarge O, Zoghbi HY. An AT-hook 
domain in MeCP2 determines the clinical course of Rett syndrome and related 
disorders. Cell 2013;152:984-996. 
205. Michaelides M, Gaillard MC, Escher P, et al. The PROM1 mutation 
p.R373C causes an autosomal dominant bull's eye maculopathy associated with 
rod, rod-cone, and macular dystrophy. Invest Ophthalmol Vis Sci 2010;51:4771-
4780. 
206. Lejeune F, Maquat LE. Mechanistic links between nonsense-mediated 
mRNA decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol 
2005;17:309-315. 
207. Furukawa T, Morrow EM, Li T, Davis FC, Cepko CL. Retinopathy and 
attenuated circadian entrainment in Crx-deficient mice. Nat Genet 1999;23:466-
470. 
208. Roger JE, Hiriyanna A, Gotoh N, et al. OTX2 loss causes rod differentiation 
defect in CRX-associated congenital blindness. J Clin Invest 2014. 
209. Tran NM, Zhang A, Zhang X, Huecker JB, Hennig AK, Chen S. 
Mechanistically Distinct Mouse Models for CRX-Associated Retinopathy. PLoS 
Genet 2014;10:e1004111. 
210. Marmor MF, Jacobson SG, Foerster MH, Kellner U, Weleber RG. 
Diagnostic clinical findings of a new syndrome with night blindness, 
maculopathy, and enhanced S cone sensitivity. Am J Ophthalmol 1990;110:124-
134. 
211. Sohn EH, Chen FK, Rubin GS, Moore AT, Webster AR, MacLaren RE. 
Macular function assessed by microperimetry in patients with enhanced S-cone 
syndrome. Ophthalmology 2010;117:1199-1206.e1191. 
212. Audo I, Michaelides M, Robson AG, et al. Phenotypic variation in 
enhanced S-cone syndrome. Invest Ophthalmol Vis Sci 2008;49:2082-2093. 
References 
 
 189 
213. Milam AH, Rose L, Cideciyan AV, et al. The nuclear receptor NR2E3 plays 
a role in human retinal photoreceptor differentiation and degeneration. Proc 
Natl Acad Sci U S A 2002;99:473-478. 
214. Khan AO, Aldahmesh M, Meyer B. The enhanced S-cone syndrome in 
children. Br J Ophthalmol 2007;91:394-396. 
215. Wang NK, Fine HF, Chang S, et al. Cellular origin of fundus 
autofluorescence in patients and mice with a defective NR2E3 gene. Br J 
Ophthalmol 2009;93:1234-1240. 
216. Pichi F, Morara M, Veronese C, Nucci P, Ciardella AP. Multimodal imaging 
in hereditary retinal diseases. J Ophthalmol 2013;2013:634351. 
217. Cheng H, Khan NW, Roger JE, Swaroop A. Excess cones in the retinal 
degeneration rd7 mouse, caused by the loss of function of orphan nuclear 
receptor Nr2e3, originate from early-born photoreceptor precursors. Hum Mol 
Genet 2011;20:4102-4115. 
218. Haider NB, Jacobson SG, Cideciyan AV, et al. Mutation of a nuclear 
receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal 
cell fate. Nat Genet 2000;24:127-131. 
219. Neveling K, Collin RW, Gilissen C, et al. Next-generation genetic testing 
for retinitis pigmentosa. Hum Mutat 2012;33:963-972. 
220. Khan AO, Aldahmesh MA, Al-Harthi E, Alkuraya FS. Helicoid subretinal 
fibrosis associated with a novel recessive NR2E3 mutation p.S44X. Arch 
Ophthalmol 2010;128:344-348. 
221. Kuniyoshi K, Hayashi T, Sakuramoto H, et al. Novel mutations in 
enhanced S-cone syndrome. Ophthalmology 2013;120:431.e431-436. 
222. Kannabiran C, Singh H, Sahini N, Jalali S, Mohan G. Mutations in TULP1, 
NR2E3, and MFRP genes in Indian families with autosomal recessive retinitis 
pigmentosa. Mol Vis 2012;18:1165-1174. 
223. Coppieters F, Leroy BP, Beysen D, et al. Recurrent mutation in the first 
zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant 
retinitis pigmentosa. Am J Hum Genet 2007;81:147-157. 
224. Udar N, Small K, Chalukya M, Silva-Garcia R, Marmor M. Developmental 
or degenerative--NR2E3 gene mutations in two patients with enhanced S cone 
syndrome. Mol Vis 2011;17:519-525. 
225. Park SP, Hong IH, Tsang SH, et al. Disruption of the human cone 
photoreceptor mosaic from a defect in NR2E3 transcription factor function in 
young adults. Graefes Arch Clin Exp Ophthalmol 2013. 
226. Pachydaki SI, Klaver CC, Barbazetto IA, et al. Phenotypic features of 
patients with NR2E3 mutations. Arch Ophthalmol 2009;127:71-75. 
References 
 
 190 
227. Rocha-Sousa A, Hayashi T, Gomes NL, et al. A novel mutation (Cys83Tyr) 
in the second zinc finger of NR2E3 in enhanced S-cone syndrome. Graefes Arch 
Clin Exp Ophthalmol 2011;249:201-208. 
228. Wright AF, Reddick AC, Schwartz SB, et al. Mutation analysis of NR2E3 
and NRL genes in Enhanced S Cone Syndrome. Hum Mutat 2004;24:439. 
229. Hayashi T, Gekka T, Goto-Omoto S, Takeuchi T, Kubo A, Kitahara K. Novel 
NR2E3 mutations (R104Q, R334G) associated with a mild form of enhanced S-
cone syndrome demonstrate compound heterozygosity. Ophthalmology 
2005;112:2115. 
230. Yang Y, Zhang X, Chen LJ, et al. Association of NR2E3 but not NRL 
mutations with retinitis pigmentosa in the Chinese population. Invest 
Ophthalmol Vis Sci 2010;51:2229-2235. 
231. Collin RW, van den Born LI, Klevering BJ, et al. High-resolution 
homozygosity mapping is a powerful tool to detect novel mutations causative of 
autosomal recessive RP in the Dutch population. Invest Ophthalmol Vis Sci 
2011;52:2227-2239. 
232. Bandah D, Merin S, Ashhab M, Banin E, Sharon D. The spectrum of retinal 
diseases caused by NR2E3 mutations in Israeli and Palestinian patients. Arch 
Ophthalmol 2009;127:297-302. 
233. Lam BL, Goldberg JL, Hartley KL, Stone EM, Liu M. Atypical mild enhanced 
S-cone syndrome with novel compound heterozygosity of the NR2E3 gene. Am J 
Ophthalmol 2007;144:157-159. 
234. Abu-Safieh L, Alrashed M, Anazi S, et al. Autozygome-guided exome 
sequencing in retinal dystrophy patients reveals pathogenetic mutations and 
novel candidate disease genes. Genome Res 2013;23:236-247. 
235. Siemiatkowska AM, Arimadyo K, Moruz LM, et al. Molecular genetic 
analysis of retinitis pigmentosa in Indonesia using genome-wide homozygosity 
mapping. Mol Vis 2011;17:3013-3024. 
236. Bernal S, Solans T, Gamundi MJ, et al. Analysis of the involvement of the 
NR2E3 gene in autosomal recessive retinal dystrophies. Clin Genet 2008;73:360-
366. 
237. Nakamura Y, Hayashi T, Kozaki K, et al. Enhanced S-cone syndrome in a 
Japanese family with a nonsense NR2E3 mutation (Q350X). Acta Ophthalmol 
Scand 2004;82:616-622. 
238. Cima I, Brecelj J, Sustar M, et al. Enhanced S-cone syndrome with 
preserved macular structure and severely depressed retinal function. Doc 
Ophthalmol 2012;125:161-168. 
239. L B-T, T D, C A, F-X B, Munier FL, DF S. A heterozygous mutation in the 
NR2E3 Gene is associated with an autosomal dominant Retinitis Pigmentosa., 
Annual Meeting of the Association forResearch in Vision and Ophthalmology. 
Fort Lauderdale, Florida, USA; 2006. 
References 
 
 191 
240. von Alpen D, Tran HV, Guex N, et al. Differential dimerization of variants 
linked to enhanced S-cone sensitivity syndrome (ESCS) located in the NR2E3 
ligand-binding domain. Hum Mutat 2015;36:599-610. 
241. Arden G, Wolf J, Berninger T, Hogg CR, Tzekov R, Holder GE. S-cone ERGs 
elicited by a simple technique in normals and in tritanopes. Vision Res 
1999;39:641-650. 
242. Koh AH, Hogg CR, Holder GE. The incidence of negative ERG in clinical 
practice. Doc Ophthalmol 2001;102:19-30. 
243. Vaclavik V, Chakarova C, Bhattacharya SS, et al. Bilateral giant macular 
schisis in a patient with enhanced S-cone syndrome from a family showing 
pseudo-dominant inheritance. Br J Ophthalmol 2008;92:299-300. 
244. Sharon D, Sandberg MA, Caruso RC, Berson EL, Dryja TP. Shared 
mutations in NR2E3 in enhanced S-cone syndrome, Goldmann-Favre syndrome, 
and many cases of clumped pigmentary retinal degeneration. Arch Ophthalmol 
2003;121:1316-1323. 
245. Yzer S, Barbazetto I, Allikmets R, et al. Expanded Clinical Spectrum of 
Enhanced S-Cone Syndrome. JAMA Ophthalmol 2013. 
246. Wang NK, Lai CC, Liu CH, et al. Origin of fundus hyperautofluorescent 
spots and their role in retinal degeneration in a mouse model of Goldmann-
Favre syndrome. Dis Model Mech 2013. 
247. Kellner U, Zrenner E, Sadowski B, Foerster M. Enhanced S Cone 
Sensitivity Syndrome: Long-term Follow-up, Electrophysiological and 
Psychophysical Findings. Clin Vision Sci 1993;8:425-434. 
248. Jacobson SG, Sumaroka A, Aleman TS, et al. Nuclear receptor NR2E3 gene 
mutations distort human retinal laminar architecture and cause an unusual 
degeneration. Hum Mol Genet 2004;13:1893-1902. 
249. Jacobson SG, Cideciyan AV, Aleman TS, et al. Crumbs homolog 1 (CRB1) 
mutations result in a thick human retina with abnormal lamination. Hum Mol 
Genet 2003;12:1073-1078. 
250. Chen J, Rattner A, Nathans J. The rod photoreceptor-specific nuclear 
receptor Nr2e3 represses transcription of multiple cone-specific genes. J 
Neurosci 2005;25:118-129. 
251. Escher P, Gouras P, Roduit R, et al. Mutations in NR2E3 can cause 
dominant or recessive retinal degenerations in the same family. Hum Mutat 
2009;30:342-351. 
252. Roduit R, Escher P, Schorderet DF. Mutations in the DNA-binding domain 
of NR2E3 affect in vivo dimerization and interaction with CRX. PLoS One 
2009;4:e7379. 
References 
 
 192 
253. Mukhopadhyay S, Wen X, Chih B, et al. TULP3 bridges the IFT-A complex 
and membrane phosphoinositides to promote trafficking of G protein-coupled 
receptors into primary cilia. Genes Dev 2010;24:2180-2193. 
254. Wei Q, Zhang Y, Li Y, Zhang Q, Ling K, Hu J. The BBSome controls IFT 
assembly and turnaround in cilia. Nat Cell Biol 2012;14:950-957. 
255. Perrault I, Saunier S, Hanein S, et al. Mainzer-Saldino syndrome is a 
ciliopathy caused by IFT140 mutations. Am J Hum Genet 2012;90:864-870. 
256. Schmidts M, Frank V, Eisenberger T, et al. Combined NGS approaches 
identify mutations in the intraflagellar transport gene IFT140 in skeletal 
ciliopathies with early progressive kidney Disease. Hum Mutat 2013;34:714-724. 
257. Khan AO, Bolz HJ, Bergmann C. Early-onset severe retinal dystrophy as 
the initial presentation of IFT140-related skeletal ciliopathy. J AAPOS 
2014;18:203-205. 
258. Online Mendelian Inheritance in Man. www.omim.org/entry/204000: 
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University 
School of Medicine, under the direction of Dr. Ada Hamosh. 
259. Mainzer F, Saldino RM, Ozonoff MB, Minagi H. Familial nephropathy 
associatdd with retinitis pigmentosa, cerebellar ataxia and skeletal 
abnormalities. Am J Med 1970;49:556-562. 
260. Xu M, Yang L, Wang F, et al. Mutations in human IFT140 cause non-
syndromic retinal degeneration. Hum Genet 2015. 
261. Bifari IN, Elkhamary SM, Bolz HJ, Khan AO. The ophthalmic phenotype of 
IFT140-related ciliopathy ranges from isolated to syndromic congenital retinal 
dystrophy. Br J Ophthalmol 2015. 
262. Le Quesne Stabej P, Saihan Z, Rangesh N, et al. Comprehensive sequence 
analysis of nine Usher syndrome genes in the UK National Collaborative Usher 
Study. J Med Genet 2012;49:27-36. 
263. Beals RK, Weleber RG. Conorenal dysplasia: a syndrome of cone-shaped 
epiphysis, renal disease in childhood, retinitis pigmentosa and abnormality of 
the proximal femur. Am J Med Genet A 2007;143A:2444-2447. 
264. Janssen S, Ramaswami G, Davis EE, et al. Mutation analysis in Bardet-
Biedl syndrome by DNA pooling and massively parallel resequencing in 105 
individuals. Hum Genet 2011;129:79-90. 
265. Bachmann-Gagescu R, Dempsey JC, Phelps IG, et al. Joubert syndrome: a 
model for untangling recessive disorders with extreme genetic heterogeneity. J 
Med Genet 2015;52:514-522. 
266. Bujakowska KM, Zhang Q, Siemiatkowska AM, et al. Mutations in IFT172 
cause isolated retinal degeneration and Bardet-Biedl syndrome. Hum Mol Genet 
2014. 
References 
 
 193 
267. Abu Safieh L, Aldahmesh MA, Shamseldin H, et al. Clinical and molecular 
characterisation of Bardet-Biedl syndrome in consanguineous populations: the 
power of homozygosity mapping. J Med Genet 2010;47:236-241. 
268. Drivas TG, Wojno AP, Tucker BA, Stone EM, Bennett J. Basal exon 
skipping and genetic pleiotropy: A predictive model of disease pathogenesis. Sci 
Transl Med 2015;7:291ra297. 
269. Jonassen JA, SanAgustin J, Baker SP, Pazour GJ. Disruption of IFT complex 
A causes cystic kidneys without mitotic spindle misorientation. J Am Soc Nephrol 
2012;23:641-651. 
270. Miller KA, Ah-Cann CJ, Welfare MF, et al. Cauli: a mouse strain with an 
Ift140 mutation that results in a skeletal ciliopathy modelling Jeune syndrome. 
PLoS Genet 2013;9:e1003746. 
271. Knobloch W, Layer I. Retinal detachment and encephalocele. J Pediat 
Ophthal 1971;8:181-184. 
272. Czeizel AE, Göblyös P, Kustos G, Mester E, Paraicz E. The second report of 
Knobloch syndrome. Am J Med Genet 1992;42:777-779. 
273. Passos-Bueno MR, Marie SK, Monteiro M, et al. Knobloch syndrome in a 
large Brazilian consanguineous family: confirmation of autosomal recessive 
inheritance. Am J Med Genet 1994;52:170-173. 
274. Duh EJ, Yao YG, Dagli M, Goldberg MF. Persistence of fetal vasculature in 
a patient with Knobloch syndrome: potential role for endostatin in fetal vascular 
remodeling of the eye. Ophthalmology 2004;111:1885-1888. 
275. Khan AO, Aldahmesh MA, Mohamed JY, Al-Mesfer S, Alkuraya FS. The 
distinct ophthalmic phenotype of Knobloch syndrome in children. Br J 
Ophthalmol 2012;96:890-895. 
276. Haghighi A, Tiwari A, Piri N, et al. Homozygosity mapping and whole 
exome sequencing reveal a novel homozygous COL18A1 mutation causing 
Knobloch syndrome. PLoS One 2014;9:e112747. 
277. Kliemann SE, Waetge RT, Suzuki OT, Passos-Bueno MR, Rosemberg S. 
Evidence of neuronal migration disorders in Knobloch syndrome: clinical and 
molecular analysis of two novel families. Am J Med Genet A 2003;119A:15-19. 
278. Keren B, Suzuki OT, Gérard-Blanluet M, et al. CNS malformations in 
Knobloch syndrome with splice mutation in COL18A1 gene. Am J Med Genet A 
2007;143A:1514-1518. 
279. Paisán-Ruiz C, Scopes G, Lee P, Houlden H. Homozygosity mapping 
through whole genome analysis identifies a COL18A1 mutation in an Indian 
family presenting with an autosomal recessive neurological disorder. Am J Med 
Genet B Neuropsychiatr Genet 2009;150B:993-997. 
References 
 
 194 
280. Caglayan AO, Baranoski JF, Aktar F, et al. Brain malformations associated 
with Knobloch syndrome--review of literature, expanding clinical spectrum, and 
identification of novel mutations. Pediatr Neurol 2014;51:806-813.e808. 
281. Seaver LH, Joffe L, Spark RP, Smith BL, Hoyme HE. Congenital scalp 
defects and vitreoretinal degeneration: redefining the Knobloch syndrome. Am J 
Med Genet 1993;46:203-208. 
282. Menzel O, Bekkeheien RC, Reymond A, et al. Knobloch syndrome: novel 
mutations in COL18A1, evidence for genetic heterogeneity, and a functionally 
impaired polymorphism in endostatin. Hum Mutat 2004;23:77-84. 
283. Williams TA, Kirkby GR, Williams D, Ainsworth JR. A phenotypic variant of 
Knobloch syndrome. Ophthalmic Genet 2008;29:85-86. 
284. Suzuki OT, Sertié AL, Der Kaloustian VM, et al. Molecular analysis of 
collagen XVIII reveals novel mutations, presence of a third isoform, and possible 
genetic heterogeneity in Knobloch syndrome. Am J Hum Genet 2002;71:1320-
1329. 
285. Sertié AL, Quimby M, Moreira ES, et al. A gene which causes severe 
ocular alterations and occipital encephalocele (Knobloch syndrome) is mapped 
to 21q22.3. Hum Mol Genet 1996;5:843-847. 
286. Sertié AL, Sossi V, Camargo AA, Zatz M, Brahe C, Passos-Bueno MR. 
Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor 
growth, plays a critical role in the maintenance of retinal structure and in neural 
tube closure (Knobloch syndrome). Hum Mol Genet 2000;9:2051-2058. 
287. Seppinen L, Pihlajaniemi T. The multiple functions of collagen XVIII in 
development and disease. Matrix Biol 2011;30:83-92. 
288. Määttä M, Heljasvaara R, Pihlajaniemi T, Uusitalo M. Collagen 
XVIII/endostatin shows a ubiquitous distribution in human ocular tissues and 
endostatin-containing fragments accumulate in ocular fluid samples. Graefes 
Arch Clin Exp Ophthalmol 2007;245:74-81. 
289. Francis P, Robson AG, Holder G, Moore A, Kaushal S. Inherited retinal 
dystrophy and asymmetric axial length. Br J Ophthalmol 2003;87:503-504. 
290. Suzuki O, Kague E, Bagatini K, et al. Novel pathogenic mutations and skin 
biopsy analysis in Knobloch syndrome. Mol Vis 2009;15:801-809. 
291. Aldahmesh MA, Khan AO, Mohamed JY, et al. No evidence for locus 
heterogeneity in Knobloch syndrome. J Med Genet 2013;50:565-566. 
292. Marneros AG, Olsen BR. Age-dependent iris abnormalities in collagen 
XVIII/endostatin deficient mice with similarities to human pigment dispersion 
syndrome. Invest Ophthalmol Vis Sci 2003;44:2367-2372. 
293. Scott A, Kotecha A, Bunce C, et al. YAG laser peripheral iridotomy for the 
prevention of pigment dispersion glaucoma a prospective, randomized, 
controlled trial. Ophthalmology 2011;118:468-473. 
References 
 
 195 
294. Chang L, Pan CW, Ohno-Matsui K, et al. Myopia-related fundus changes 
in Singapore adults with high myopia. Am J Ophthalmol 2013;155:991-999.e991. 
295. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of 
progression of myopic maculopathy: a natural history study. Ophthalmology 
2010;117:1595-1611, 1611.e1591-1594. 
296. Halfter W, Winzen U, Bishop PN, Eller A. Regulation of eye size by the 
retinal basement membrane and vitreous body. Invest Ophthalmol Vis Sci 
2006;47:3586-3594. 
297. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin 
results in eye abnormalities. EMBO J 2002;21:1535-1544. 
298. Passos-Bueno MR, Suzuki OT, Armelin-Correa LM, et al. Mutations in 
collagen 18A1 and their relevance to the human phenotype. An Acad Bras Cienc 
2006;78:123-131. 
299. Mahajan VB, Olney AH, Garrett P, et al. Collagen XVIII mutation in 
Knobloch syndrome with acute lymphoblastic leukemia. Am J Med Genet A 
2010;152A:2875-2879. 
300. Aldahmesh MA, Khan AO, Mohamed JY, et al. Identification of 
ADAMTS18 as a gene mutated in Knobloch syndrome. J Med Genet 
2011;48:597-601. 
301. Aikio M, Hurskainen M, Brideau G, et al. Collagen XVIII short isoform is 
critical for retinal vascularization, and overexpression of the Tsp-1 domain 
affects eye growth and cataract formation. Invest Ophthalmol Vis Sci 
2013;54:7450-7462. 
302. Joyce S, Tee L, Abid A, Khaliq S, Mehdi SQ, Maher ER. Locus 
heterogeneity and Knobloch syndrome. Am J Med Genet A 2010;152A:2880-
2881. 
303. Thompson DA, Gyürüs P, Fleischer LL, et al. Genetics and phenotypes of 
RPE65 mutations in inherited retinal degeneration. Invest Ophthalmol Vis Sci 
2000;41:4293-4299. 
304. Walia S, Fishman GA, Jacobson SG, et al. Visual acuity in patients with 
Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa. 
Ophthalmology 2010;117:1190-1198. 
305. Lorenz B, Gyürüs P, Preising M, et al. Early-onset severe rod-cone 
dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci 
2000;41:2735-2742. 
306. Weleber RG, Michaelides M, Trzupek KM, Stover NB, Stone EM. The 
phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) from 
mutation of RPE65 and differentiation from Leber congenital amaurosis. Invest 
Ophthalmol Vis Sci 2011;52:292-302. 
References 
 
 196 
307. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene 
therapy for Leber congenital amaurosis shows advancing retinal degeneration 
despite enduring visual improvement. Proc Natl Acad Sci U S A 2013;110:E517-
525. 
308. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral 
subretinal delivery of adeno-associated virus in patients with Leber congenital 
Amaurosis type 2. Ophthalmology 2013;120:1283-1291. 
309. Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene 
therapy on Leber's congenital amaurosis. N Engl J Med 2015;372:1887-1897. 
310. Lorenz B, Poliakov E, Schambeck M, Friedburg C, Preising MN, Redmond 
TM. A comprehensive clinical and biochemical functional study of a novel RPE65 
hypomorphic mutation. Invest Ophthalmol Vis Sci 2008;49:5235-5242. 
311. Kondo H, Qin M, Mizota A, et al. A homozygosity-based search for 
mutations in patients with autosomal recessive retinitis pigmentosa, using 
microsatellite markers. Invest Ophthalmol Vis Sci 2004;45:4433-4439. 
312. Marlhens F, Griffoin JM, Bareil C, Arnaud B, Claustres M, Hamel CP. 
Autosomal recessive retinal dystrophy associated with two novel mutations in 
the RPE65 gene. Eur J Hum Genet 1998;6:527-531. 
313. Schatz P, Preising M, Lorenz B, Sander B, Larsen M, Rosenberg T. Fundus 
albipunctatus associated with compound heterozygous mutations in RPE65. 
Ophthalmology 2011;118:888-894. 
314. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J 
Mol Graph 1996;14:33-38, 27-38. 
315. Henderson RH, Waseem N, Searle R, et al. An assessment of the apex 
microarray technology in genotyping patients with Leber congenital amaurosis 
and early-onset severe retinal dystrophy. Invest Ophthalmol Vis Sci 
2007;48:5684-5689. 
316. Coppieters F, Casteels I, Meire F, et al. Genetic screening of LCA in 
Belgium: predominance of CEP290 and identification of potential modifier 
alleles in AHI1 of CEP290-related phenotypes. Hum Mutat 2010;31:E1709-1766. 
317. Jacobson SG, Cideciyan AV, Aleman TS, et al. Photoreceptor layer 
topography in children with leber congenital amaurosis caused by RPE65 
mutations. Invest Ophthalmol Vis Sci 2008;49:4573-4577. 
318. Jacobson SG, Aleman TS, Cideciyan AV, et al. Defining the residual vision 
in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol 
Vis Sci 2009;50:2368-2375. 
319. Kiser PD, Golczak M, Lodowski DT, Chance MR, Palczewski K. Crystal 
structure of native RPE65, the retinoid isomerase of the visual cycle. Proc Natl 
Acad Sci U S A 2009;106:17325-17330. 
References 
 
 197 
320. Nikolaeva O, Takahashi Y, Moiseyev G, Ma JX. Purified RPE65 shows 
isomerohydrolase activity after reassociation with a phospholipid membrane. 
FEBS J 2009;276:3020-3030. 
321. Nikopoulos K, Gilissen C, Hoischen A, et al. Next-generation sequencing 
of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial 
exudative vitreoretinopathy. Am J Hum Genet 2010;86:240-247. 
322. Poulter JA, Ali M, Gilmour DF, et al. Mutations in TSPAN12 cause 
autosomal-dominant familial exudative vitreoretinopathy. Am J Hum Genet 
2010;86:248-253. 
323. Poulter JA, Davidson AE, Ali M, et al. Recessive mutations in TSPAN12 
cause retinal dysplasia and severe familial exudative vitreoretinopathy (FEVR). 
Invest Ophthalmol Vis Sci 2012;53:2873-2879. 
324. Robitaille J, MacDonald ML, Kaykas A, et al. Mutant frizzled-4 disrupts 
retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet 
2002;32:326-330. 
325. Toomes C, Bottomley HM, Jackson RM, et al. Mutations in LRP5 or FZD4 
underlie the common familial exudative vitreoretinopathy locus on 
chromosome 11q. Am J Hum Genet 2004;74:721-730. 
326. Chen ZY, Battinelli EM, Fielder A, et al. A mutation in the Norrie disease 
gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nat 
Genet 1993;5:180-183. 
327. Collin RW, Nikopoulos K, Dona M, et al. ZNF408 is mutated in familial 
exudative vitreoretinopathy and is crucial for the development of zebrafish 
retinal vasculature. Proc Natl Acad Sci U S A 2013;110:9856-9861. 
328. Ke J, Harikumar KG, Erice C, et al. Structure and function of Norrin in 
assembly and activation of a Frizzled 4-Lrp5/6 complex. Genes Dev 
2013;27:2305-2319. 
329. Zhou Y, Wang Y, Tischfield M, et al. Canonical WNT signaling components 
in vascular development and barrier formation. J Clin Invest 2014;124:3825-
3846. 
330. Jarmas AL, Weaver DD, Ellis FD, Davis A. Microcephaly, microphthalmia, 
falciform retinal folds, and blindness. A new syndrome. Am J Dis Child 
1981;135:930-933. 
331. Young ID, Fielder AR, Simpson K. Microcephaly, microphthalmos, and 
retinal folds: report of a family. J Med Genet 1987;24:172-174. 
332. Fryns JP, Smeets E, Van den Berghe H. On the nosology of the "primary 
true microcephaly, chorioretinal dysplasia, lymphoedema" association. Clin 
Genet 1995;48:131-133. 
References 
 
 198 
333. Jones GE, Ostergaard P, Moore AT, et al. Microcephaly with or without 
chorioretinopathy, lymphoedema, or mental retardation (MCLMR): review of 
phenotype associated with KIF11 mutations. Eur J Hum Genet 2014;22:881-887. 
334. Robitaille JM, Gillett RM, LeBlanc MA, et al. Phenotypic overlap between 
familial exudative vitreoretinopathy and microcephaly, lymphedema, and 
chorioretinal dysplasia caused by KIF11 mutations. JAMA Ophthalmol 
2014;132:1393-1399. 
335. Martin CA, Ahmad I, Klingseisen A, et al. Mutations in PLK4, encoding a 
master regulator of centriole biogenesis, cause microcephaly, growth failure 
and retinopathy. Nat Genet 2014;46:1283-1292. 
336. Passemard S, Kaindl AM, Verloes A. Microcephaly. Handb Clin Neurol 
2013;111:129-141. 
337. Wright CM, Booth IW, Buckler JM, et al. Growth reference charts for use 
in the United Kingdom. Arch Dis Child 2002;86:11-14. 
338. Qin M, Hayashi H, Oshima K, Tahira T, Hayashi K, Kondo H. Complexity of 
the genotype-phenotype correlation in familial exudative vitreoretinopathy with 
mutations in the LRP5 and/or FZD4 genes. Hum Mutat 2005;26:104-112. 
339. Liu J, Wilson S, Reh T. BMP receptor 1b is required for axon guidance and 
cell survival in the developing retina. Dev Biol 2003;256:34-48. 
340. Ohkubo H, Tanino T. Electrophysiological findings in familial exudative 
vitreoretinopathy. Doc Ophthalmol 1987;65:461-469. 
341. Balikova I, Robson AG, Holder GE, Ostergaard P, Mansour S, Moore AT. 
Ocular manifestations of microcephaly with or without chorioretinopathy, 
lymphedema or intellectual disability (MCLID) syndrome associated with 
mutations in KIF11. Acta Ophthalmol 2016;94:92-98. 
342. Hu H, Xiao X, Li S, Jia X, Guo X, Zhang Q. KIF11 mutations are a common 
cause of autosomal dominant familial exudative vitreoretinopathy. Br J 
Ophthalmol 2016;100:278-283. 
343. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) 
affects bone accrual and eye development. Cell 2001;107:513-523. 
344. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in 
LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-1521. 
345. Jiao X, Ventruto V, Trese MT, Shastry BS, Hejtmancik JF. Autosomal 
recessive familial exudative vitreoretinopathy is associated with mutations in 
LRP5. Am J Hum Genet 2004;75:878-884. 
346. Ostergaard P, Simpson MA, Mendola A, et al. Mutations in KIF11 cause 
autosomal-dominant microcephaly variably associated with congenital 
lymphedema and chorioretinopathy. Am J Hum Genet 2012;90:356-362. 
References 
 
 199 
347. Puffenberger EG, Jinks RN, Sougnez C, et al. Genetic mapping and exome 
sequencing identify variants associated with five novel diseases. PLoS One 
2012;7:e28936. 
348. Gargiulo A, Testa F, Rossi S, et al. Molecular and clinical characterization 
of albinism in a large cohort of Italian patients. Invest Ophthalmol Vis Sci 
2011;52:1281-1289. 
349. Masliah-Planchon J, Darnige L, Bellucci S. Molecular determinants of 
platelet delta storage pool deficiencies: an update. Br J Haematol 2013;160:5-
11. 
350. Desai N, Weisfeld-Adams JD, Brodie SE, et al. Optic neuropathy in late-
onset neurodegenerative Chédiak-Higashi syndrome. Br J Ophthalmol 2015. 
351. Oh J, Bailin T, Fukai K, et al. Positional cloning of a gene for Hermansky-
Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet 1996;14:300-
306. 
352. Anikster Y, Huizing M, White J, et al. Mutation of a new gene causes a 
unique form of Hermansky-Pudlak syndrome in a genetic isolate of central 
Puerto Rico. Nat Genet 2001;28:376-380. 
353. Cullinane AR, Curry JA, Carmona-Rivera C, et al. A BLOC-1 mutation 
screen reveals that PLDN is mutated in Hermansky-Pudlak Syndrome type 9. Am 
J Hum Genet 2011;88:778-787. 
354. Li K, Yang L, Zhang C, Niu Y, Li W, Liu JJ. HPS6 interacts with dynactin 
p150Glued to mediate retrograde trafficking and maturation of lysosomes. J Cell 
Sci 2014;127:4574-4588. 
355. Zhang Q, Zhao B, Li W, et al. Ru2 and Ru encode mouse orthologs of the 
genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nat Genet 
2003;33:145-153. 
356. Schreyer-Shafir N, Huizing M, Anikster Y, et al. A new genetic isolate with 
a unique phenotype of syndromic oculocutaneous albinism: clinical, molecular, 
and cellular characteristics. Hum Mutat 2006;27:1158. 
357. Huizing M, Pederson B, Hess RA, et al. Clinical and cellular 
characterisation of Hermansky-Pudlak syndrome type 6. J Med Genet 
2009;46:803-810. 
358. Huizing M, Anikster Y, Fitzpatrick DL, et al. Hermansky-Pudlak syndrome 
type 3 in Ashkenazi Jews and other non-Puerto Rican patients with 
hypopigmentation and platelet storage-pool deficiency. Am J Hum Genet 
2001;69:1022-1032. 
359. Poulter JA, Al-Araimi M, Conte I, et al. Recessive mutations in SLC38A8 
cause foveal hypoplasia and optic nerve misrouting without albinism. Am J Hum 
Genet 2013;93:1143-1150. 
References 
 
 200 
360. Charles SJ, Green JS, Grant JW, Yates JR, Moore AT. Clinical features of 
affected males with X linked ocular albinism. Br J Ophthalmol 1993;77:222-227. 
361. Huizing M, Hess R, Dorward H, et al. Cellular, molecular and clinical 
characterization of patients with Hermansky-Pudlak syndrome type 5. Traffic 
2004;5:711-722. 
362. Tsilou ET, Rubin BI, Reed GF, et al. Milder ocular findings in Hermansky-
Pudlak syndrome type 3 compared with Hermansky-Pudlak syndrome type 1. 
Ophthalmology 2004;111:1599-1603. 
363. Gahl WA, Brantly M, Kaiser-Kupfer MI, et al. Genetic defects and clinical 
characteristics of patients with a form of oculocutaneous albinism (Hermansky-
Pudlak syndrome). N Engl J Med 1998;338:1258-1264. 
364. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the 
pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 
2002;76:234-242. 
365. Izquierdo NJ, Townsend W, Hussels IE. Ocular findings in the Hermansky-
Pudlak syndrome. Trans Am Ophthalmol Soc 1995;93:191-200; discussion 200-
192. 
366. Iwata F, Reed GF, Caruso RC, Kuehl EM, Gahl WA, Kaiser-Kupfer MI. 
Correlation of visual acuity and ocular pigmentation with the 16-bp duplication 
in the HPS-1 gene of Hermansky-Pudlak syndrome, a form of albinism. 
Ophthalmology 2000;107:783-789. 
367. von dem Hagen EA, Houston GC, Hoffmann MB, Morland AB. 
Pigmentation predicts the shift in the line of decussation in humans with 
albinism. Eur J Neurosci 2007;25:503-511. 
368. Summers CG, Knobloch WH, Witkop CJ, King RA. Hermansky-Pudlak 
syndrome. Ophthalmic findings. Ophthalmology 1988;95:545-554. 
369. Minkin P, Bertetti R, Lindsey S, Bovino B. Management of tooth 
extraction in a patient with a rare bleeding disorder associated with Hermansky-
Pudlak syndrome: a case report. J Oral Maxillofac Surg 2015;73:219-223. 
370. Sprecher E, Bergman R, Richard G, et al. Hypotrichosis with juvenile 
macular dystrophy is caused by a mutation in CDH3, encoding P-cadherin. Nat 
Genet 2001;29:134-136. 
371. Shimomura Y, Wajid M, Shapiro L, Christiano AM. P-cadherin is a p63 
target gene with a crucial role in the developing human limb bud and hair 
follicle. Development 2008;135:743-753. 
372. Wagner H. Maculaaffektion, vergesellschaftet mit Haarabnormitiit 
yon Lanugotypus, beide vielleicht angeboren bei zweiGeschwistern. Albrecht 
von Graefes Archiv für Ophthalmologie 1935;134:74-81. 
References 
 
 201 
373. Indelman M, Bergman R, Lurie R, et al. A missense mutation in CDH3, 
encoding P-cadherin, causes hypotrichosis with juvenile macular dystrophy. J 
Invest Dermatol 2002;119:1210-1213. 
374. Indelman M, Hamel CP, Bergman R, et al. Phenotypic diversity and 
mutation spectrum in hypotrichosis with juvenile macular dystrophy. J Invest 
Dermatol 2003;121:1217-1220. 
375. Indelman M, Leibu R, Jammal A, Bergman R, Sprecher E. Molecular basis 
of hypotrichosis with juvenile macular dystrophy in two siblings. Br J Dermatol 
2005;153:635-638. 
376. Indelman M, Eason J, Hummel M, et al. Novel CDH3 mutations in 
hypotrichosis with juvenile macular dystrophy. Clin Exp Dermatol 2007;32:191-
196. 
377. Jelani M, Salman Chishti M, Ahmad W. A novel splice-site mutation in the 
CDH3 gene in hypotrichosis with juvenile macular dystrophy. Clin Exp Dermatol 
2009;34:68-73. 
378. Shimomura Y, Wajid M, Kurban M, Christiano AM. Splice site mutations 
in the P-cadherin gene underlie hypotrichosis with juvenile macular dystrophy. 
Dermatology 2010;220:208-212. 
379. Kamran-ul-Hassan Naqvi S, Azeem Z, Ali G, Ahmad W. A novel splice-
acceptor site mutation in CDH3 gene in a consanguineous family exhibiting 
hypotrichosis with juvenile macular dystrophy. Arch Dermatol Res 
2010;302:701-703. 
380. Avitan-Hersh E, Indelman M, Khamaysi Z, Leibu R, Bergman R. A novel 
nonsense CDH3 mutation in hypotrichosis with juvenile macular dystrophy. Int J 
Dermatol 2012;51:325-327. 
381. Halford S, Holt R, Németh AH, Downes SM. Homozygous deletion in 
CDH3 and hypotrichosis with juvenile macular dystrophy. Arch Ophthalmol 
2012;130:1490-1492. 
382. Kjaer KW, Hansen L, Schwabe GC, et al. Distinct CDH3 mutations cause 
ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome). J Med 
Genet 2005;42:292-298. 
383. Basel-Vanagaite L, Pasmanik-Chor M, Lurie R, Yeheskel A, Kjaer KW. 
CDH3-Related Syndromes: Report on a New Mutation and Overview of the 
Genotype-Phenotype Correlations. Mol Syndromol 2010;1:223-230. 
384. Leibu R, Jermans A, Hatim G, Miller B, Sprecher E, Perlman I. 
Hypotrichosis with juvenile macular dystrophy: clinical and electrophysiological 
assessment of visual function. Ophthalmology 2006;113:841-847.e843. 
385. Mason JO, Patel SA. A case of hypotrichosis with juvenile macular 
dystrophy. Retin Cases Brief Rep 2015;9:164-167. 
References 
 
 202 
386. Early Treatment Diabetic Retinopathy Study design and baseline patient 
characteristics. ETDRS report number 7. Ophthalmology 1991;98:741-756. 
387. Suzuki M, Curcio CA, Mullins RF, Spaide RF. REFRACTILE DRUSEN: Clinical 
Imaging and Candidate Histology. Retina 2015;35:859-865. 
388. Fujinami K, Zernant J, Chana RK, et al. Clinical and molecular 
characteristics of childhood-onset Stargardt disease. Ophthalmology 
2015;122:326-334. 
389. Hwang JC, Zernant J, Allikmets R, Barile GR, Chang S, Smith RT. 
Peripapillary atrophy in Stargardt disease. Retina 2009;29:181-186. 
390. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture 
and morphogenesis. Cell 1996;84:345-357. 
391. Xu L, Overbeek PA, Reneker LW. Systematic analysis of E-, N- and P-
cadherin expression in mouse eye development. Exp Eye Res 2002;74:753-760. 
392. Dalle Vedove A, Lucarelli AP, Nardone V, Matino A, Parisini E. The X-ray 
structure of human P-cadherin EC1-EC2 in a closed conformation provides 
insight into the type I cadherin dimerization pathway. Acta Crystallogr F Struct 
Biol Commun 2015;71:371-380. 
393. Boguski MS, Lowe TM, Tolstoshev CM. dbEST--database for "expressed 
sequence tags". Nat Genet 1993;4:332-333. 
394. Roosing S, Collin RW, den Hollander AI, Cremers FP, Siemiatkowska AM. 
Prenylation defects in inherited retinal diseases. J Med Genet 2014;51:143-151. 
395. Khandhadia S, Lotery A. Oxidation and age-related macular degeneration: 
insights from molecular biology. Expert Rev Mol Med 2010;12:e34. 
396. Chartier FJ, Hardy É, Laprise P. Crumbs limits oxidase-dependent 
signaling to maintain epithelial integrity and prevent photoreceptor cell death. J 
Cell Biol 2012;198:991-998. 
397. den Hollander AI, ten Brink JB, de Kok YJ, et al. Mutations in a human 
homologue of Drosophila crumbs cause retinitis pigmentosa (RP12). Nat Genet 
1999;23:217-221. 
398. den Hollander AI, Heckenlively JR, van den Born LI, et al. Leber congenital 
amaurosis and retinitis pigmentosa with Coats-like exudative vasculopathy are 
associated with mutations in the crumbs homologue 1 (CRB1) gene. Am J Hum 
Genet 2001;69:198-203. 
399. Khan AO, Aldahmesh MA, Abu-Safieh L, Alkuraya FS. Childhood Cone-rod 
Dystrophy with Macular Cystic Degeneration from Recessive CRB1 Mutation. 
Ophthalmic Genet 2013. 
400. Zenteno JC, Buentello-Volante B, Ayala-Ramirez R, Villanueva-Mendoza 
C. Homozygosity mapping identifies the Crumbs homologue 1 (Crb1) gene as 
responsible for a recessive syndrome of retinitis pigmentosa and 
nanophthalmos. Am J Med Genet A 2011;155A:1001-1006. 
References 
 
 203 
401. Paun CC, Pijl BJ, Siemiatkowska AM, et al. A novel crumbs homolog 1 
mutation in a family with retinitis pigmentosa, nanophthalmos, and optic disc 
drusen. Mol Vis 2012;18:2447-2453. 
402. Lotery AJ, Malik A, Shami SA, et al. CRB1 mutations may result in retinitis 
pigmentosa without para-arteriolar RPE preservation. Ophthalmic Genet 
2001;22:163-169. 
403. Bujakowska K, Audo I, Mohand-Saïd S, et al. CRB1 mutations in inherited 
retinal dystrophies. Hum Mutat 2012;33:306-315. 
404. Tsang SH, Burke T, Oll M, et al. Whole Exome Sequencing Identifies CRB1 
Defect in an Unusual Maculopathy Phenotype. Ophthalmology 2014. 
405. Grover S, Murthy RK, Brar VS, Chalam KV. Normative data for macular 
thickness by high-definition spectral-domain optical coherence tomography 
(spectralis). Am J Ophthalmol 2009;148:266-271. 
406. Mackay DS, Borman AD, Sui R, et al. Screening of a large cohort of leber 
congenital amaurosis and retinitis pigmentosa patients identifies novel LCA5 
mutations and new genotype-phenotype correlations. Hum Mutat 
2013;34:1537-1546. 
407. Pellissier LP, Lundvig DM, Tanimoto N, et al. CRB2 acts as a modifying 
factor of CRB1-related retinal dystrophies in mice. Hum Mol Genet 
2014;23:3759-3771. 
408. Kantardzhieva A, Gosens I, Alexeeva S, et al. MPP5 recruits MPP4 to the 
CRB1 complex in photoreceptors. Invest Ophthalmol Vis Sci 2005;46:2192-2201. 
409. Alves CH, Pellissier LP, Wijnholds J. The CRB1 and adherens junction 
complex proteins in retinal development and maintenance. Prog Retin Eye Res 
2014;40:35-52. 
410. van de Pavert SA, Kantardzhieva A, Malysheva A, et al. Crumbs 
homologue 1 is required for maintenance of photoreceptor cell polarization and 
adhesion during light exposure. J Cell Sci 2004;117:4169-4177. 
411. Parry DA, Toomes C, Bida L, et al. Loss of the metalloprotease ADAM9 
leads to cone-rod dystrophy in humans and retinal degeneration in mice. Am J 
Hum Genet 2009;84:683-691. 
412. Mahimkar RM, Visaya O, Pollock AS, Lovett DH. The disintegrin domain of 
ADAM9: a ligand for multiple beta1 renal integrins. Biochem J 2005;385:461-
468. 
413. El-Haig WM, Jakobsson C, Favez T, Schorderet DF, Abouzeid H. Novel 
ADAM9 homozygous mutation in a consanguineous Egyptian family with severe 
cone-rod dystrophy and cataract. Br J Ophthalmol 2014. 
414. Danciger M, Hendrickson J, Lyon J, et al. CORD9 a new locus for arCRD: 
mapping to 8p11, estimation of frequency, evaluation of a candidate gene. 
Invest Ophthalmol Vis Sci 2001;42:2458-2465. 
References 
 
 204 
415. Edwards DR, Handsley MM, Pennington CJ. The ADAM 
metalloproteinases. Mol Aspects Med 2008;29:258-289. 
416. Yan X, Lin J, Rolfs A, Luo J. Differential expression of the ADAMs in 
developing chicken retina. Dev Growth Differ 2011;53:726-739. 
417. Goldstein O, Mezey JG, Boyko AR, et al. An ADAM9 mutation in canine 
cone-rod dystrophy 3 establishes homology with human cone-rod dystrophy 9. 
Mol Vis 2010;16:1549-1569. 
418. Landy SJ, Donnai D. Incontinentia pigmenti (Bloch-Sulzberger syndrome). 
J Med Genet 1993;30:53-59. 
419. Parrish JE, Scheuerle AE, Lewis RA, Levy ML, Nelson DL. Selection against 
mutant alleles in blood leukocytes is a consistent feature in Incontinentia 
Pigmenti type 2. Hum Mol Genet 1996;5:1777-1783. 
420. O'Donnell MA, Hase H, Legarda D, Ting AT. NEMO inhibits programmed 
necrosis in an NFκB-independent manner by restraining RIP1. PLoS One 
2012;7:e41238. 
421. Fusco F, Bardaro T, Fimiani G, et al. Molecular analysis of the genetic 
defect in a large cohort of IP patients and identification of novel NEMO 
mutations interfering with NF-kappaB activation. Hum Mol Genet 2004;13:1763-
1773. 
422. Conte MI, Pescatore A, Paciolla M, et al. Insight into IKBKG/NEMO locus: 
report of new mutations and complex genomic rearrangements leading to 
incontinentia pigmenti disease. Hum Mutat 2014;35:165-177. 
423. Kenwrick S, Woffendin H, Jakins T, et al. Survival of male patients with 
incontinentia pigmenti carrying a lethal mutation can be explained by somatic 
mosaicism or Klinefelter syndrome. Am J Hum Genet 2001;69:1210-1217. 
424. Dörrenhaus A, Müller JI, Golka K, Jedrusik P, Schulze H, Föllmann W. 
Cultures of exfoliated epithelial cells from different locations of the human 
urinary tract and the renal tubular system. Arch Toxicol 2000;74:618-626. 
425. Goldberg MF. The blinding mechanisms of incontinentia pigmenti. Trans 
Am Ophthalmol Soc 1994;92:167-176; discussion 176-169. 
426. Roehl AC, Mussotter T, Cooper DN, et al. Tissue-specific differences in the 
proportion of mosaic large NF1 deletions are suggestive of a selective growth 
advantage of hematopoietic del(+/-) stem cells. Hum Mutat 2012;33:541-550. 
427. Clayton-Smith J, Watson P, Ramsden S, Black GC. Somatic mutation in 
MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 
2000;356:830-832. 
428. Fusco F, Paciolla M, Napolitano F, et al. Genomic architecture at the 
Incontinentia Pigmenti locus favours de novo pathological alleles through 
different mechanisms. Hum Mol Genet 2012;21:1260-1271. 
References 
 
 205 
429. Aradhya S, Woffendin H, Jakins T, et al. A recurrent deletion in the 
ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority 
of incontinentia pigmenti mutations. Hum Mol Genet 2001;10:2171-2179. 
430. Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell 
cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest 
2002;109:1501-1509. 
431. Zonana J, Elder ME, Schneider LC, et al. A novel X-linked disorder of 
immune deficiency and hypohidrotic ectodermal dysplasia is allelic to 
incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum 
Genet 2000;67:1555-1562. 
432. Fusco F, Fimiani G, Tadini G, Michele D, Ursini MV. Clinical diagnosis of 
incontinentia pigmenti in a cohort of male patients. J Am Acad Dermatol 
2007;56:264-267. 
433. Farkas MH, Grant GR, White JA, Sousa ME, Consugar MB, Pierce EA. 
Transcriptome analyses of the human retina identify unprecedented transcript 
diversity and 3.5 Mb of novel transcribed sequence via significant alternative 
splicing and novel genes. BMC Genomics 2013;14:486. 
434. Braun TA, Mullins RF, Wagner AH, et al. Non-exomic and synonymous 
variants in ABCA4 are an important cause of Stargardt disease. Hum Mol Genet 
2013;22:5136-5145. 
435. Irimia M, Weatheritt RJ, Ellis JD, et al. A highly conserved program of 
neuronal microexons is misregulated in autistic brains. Cell 2014;159:1511-
1523. 
436. Kiser PD, Zhang J, Badiee M, et al. Catalytic mechanism of a retinoid 
isomerase essential for vertebrate vision. Nat Chem Biol 2015;11:409-415. 
437. Bax NM, Sangermano R, Roosing S, et al. Heterozygous deep-intronic 
variants and deletions in ABCA4 in persons with retinal dystrophies and one 
exonic ABCA4 variant. Hum Mutat 2015;36:43-47. 
438. Gerard X, Garanto A, Rozet JM, Collin RW. Antisense Oligonucleotide 
Therapy for Inherited Retinal Dystrophies. Adv Exp Med Biol 2016;854:517-524. 
439. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-
derived retinal pigment epithelium in patients with age-related macular 
degeneration and Stargardt's macular dystrophy: follow-up of two open-label 
phase 1/2 studies. Lancet 2015;385:509-516. 
440. Stingl K, Bartz-Schmidt KU, Besch D, et al. Subretinal Visual Implant Alpha 
IMS--Clinical trial interim report. Vision Res 2015;111:149-160. 
Appendix: publications during research 
 
 206 
16 Appendix: publications during research 
1st author published: 
Hull S, Owen N, Islam F, Tracey-White D, Plagnol V, Holder GE, Michaelides M, Carss 
K, Raymond FL, Rozet JM, Ramsden SC, Black GCM, Perrault I, Sarkar A, Moosajee 
M, Webster AR, Arno G, Moore AT. Non-syndromic retinal dystrophy due to bi-allelic 
mutations in the ciliary transport gene IFT140. Invest Ophthalmol Vis Sci. 
2016;57(3):1053-62  
Hull S, Holder GE, Robson AG, Mukherjee R, Michaelides M, Webster AR, Moore AT. 
Preserved visual function in retinal dystrophy due to hypomorphic RPE65 mutations. Br 
J Ophthalmol. 2016; Feb 23. doi: 10.1136/bjophthalmol-2015-308019. [Epub ahead of 
print]  
Hull S, Arno G, Holder GE, Plagnol V, Gomez K, Liesner R, Webster AR, Moore 
AT. The ophthalmic presentation of Hermansky-Pudlak syndrome 6. Br J Ophthalmol.  
2016 Jan 28. doi:10.1136/bjophthalmol-2015-308067. [Epub ahead of print] 
Hull S, Arno G, Sergouniotis PI, Tiffin P, Borman AD, Chandra A, Robson AG, Holder 
GE, Webster AR, Moore AT. Clinical and Molecular Characterization of Enhanced S-
Cone Syndrome in Children. JAMA Ophthalmol. 2014;132(11):1341-9 
Hull S, Arno G, Plagnol V, Chamney S, Russell-Eggitt I, Thompson D, Ramsden SC, 
Black GC, Robson AG, Holder GE, Moore AT, Webster AR. The phenotypic variability 
of retinal dystrophies associated with mutations in CRX, with report of a novel macular 
dystrophy phenotype. Invest Ophthalmol Vis Sci. 2014;30;55(10):6934-44 
Hull S, Arno G, Thomson P, Mutch S, Webster AR, Rai H, Hill V, Moore AT. Somatic 
mosaicism of a novel IKBKG mutation in a male patient with incontinentia pigmenti. Am 
J Med Genet A. 2015 Jul;167(7):1601-4.  
Hull S, Arno G, Plagnol V, Robson A, Webster A, Moore AT.  Exome sequencing 
reveals ADAM9 mutations in a child with cone-rod dystrophy. Acta Ophthalmol. 
2015:93(5);e392-3 
Hull S, Kalhoro A, Marr J et al. Congenital high myopia and central macular atrophy: a 
report of 3 families. Eye (Lond). 2015 Jul;29(7):936-42 
Appendix: publications during research 
 
 207 
Hull S, Moore AT. Gyrate atrophy. In Lois N, Forrester JV (eds). Fundus 
autofluorescence, 2nd edition, Lippincott, Williams & Wilkins, 2015 
1st author in press: 
Hull S*, Malik ANJ*, Arno G, Mackay DS, Plagnol V, Michaelides M, Mansour S, 
Albanese A, Tatton Brown K, Holder GE, Webster AR, Heath PT, Moore AT. 
Expanding the phenotype of TRNT1 related immunodeficiency to include childhood 
cataract and inner retinal dysfunction. JAMA Ophthalmol. *joint first authors 
Hull S, Webster AR. Ophthalmic Manifestations of Inherited Metabolic Disease. In 
Hollak CEM, Lachmann R (eds). Inherited Metabolic Disease in Adults: A Clinical 
Guide, Oxford University Press, 2016 
Hull S, Arno G, Ku CA, Ge Z, Waseem N, Chandra A, Webster A, Robson AG, 
Michaelides M, Weleber RG, Davagnanam I, Chen R, Holder GE, Pennesi ME, Moore 
AT.  Novel molecular and clinical findings in Knobloch syndrome. JAMA Ophthalmol 
1st author in submission: 
Hull S, Arno G, Robson AG, Broadgate S, Plagnol V, McKibbin M, Halford S, 
Michaelides M, Holder GE, Moore AT, Khan K, Webster AR. Detailed characterization 
of CDH3 related congenital hypotrichosis with juvenile macular dystrophy, a centrally 
progressive disorder with limited peripheral retinal involvement. JAMA Ophthalmol  
Hull S*, Mukherjee R*, Holder GE, Moore AT, Webster AR. The clinical features of 
retinal disease due to a dominant mutation in RPE65. Mol Vis. *joint first authors 
Co-author published: 
Scheidecker S, Hull S, Perdomo Y, Studer F, Pelletier V, Muller J, Stoetzel C, 
Schaefer E, Defoort-Dhellemmes S, Drumare I, Holder GE, Hamel CP, Webster AR, 
Moore AT, Puech B, Dollfus HJ. Predominantly Cone-System Dysfunction as Rare 
Form of Retinal Degeneration in Patients With Molecularly Confirmed Bardet-Biedl 
Syndrome. Am J Ophthalmol. 2015;160(2):364-372 
Scheidecker S, Etard C, Haren L, Stoetzel C, Hull S, Arno G, Plagnol V, Drunat 
S, Passemard S, Toutain A, Obringer C, Koob M, Geoffroy V, Marion V, Strähle U, 
Ostergaard P, Verloes A, Merdes A, Moore AT, Dollfus H. Mutations in TUBGCP4 
Appendix: publications during research 
 
 208 
alter microtubule organization via the γ-tubulin ring complex in autosomal-recessive 
microcephaly with chorioretinopathy. Am J Hum Genet. 2015;96(4):666-74. 
Arno G, Hull S, Robson AG, Holder GE, Cheetham ME, Webster AR, Plagnol V, 
Moore AT. Lack of Interphotoreceptor Retinoid Binding Protein Caused by 
Homozygous Mutation of RBP3 Is Associated With High Myopia and Retinal 
Dystrophy. Invest Ophthalmol Vis Sci. 2015;56(4):2358-65 
Hufnagel RB, Arno G, Hein ND, Hersheson J, Prasad M, Anderson Y, Krueger LA, 
Gregory LC, Stoetzel C, Jaworek TJ, Hull S, Li A, Plagnol V, Willen CM, Morgan TM, 
Prows CA, Hegde RS, Riazuddin S, Grabowski GA, Richardson RJ, Dieterich K, Huang 
T, Revesz T, Martinez-Barbera JP, Sisk RA, Jefferies C, Houlden H, Dattani MT, Fink 
JK, Dollfus H, Moore AT, Ahmed ZM. Neuropathy target esterase impairments cause 
Oliver-McFarlane and Laurence-Moon syndromes. J Med Genet. 2015;52(2):85-94. 
Onoufriadis A, Shoemark A, Munye MM, James CT, Schmidts M, Patel M, Rosser EM, 
Bacchelli C, Beales PL, Scambler PJ, Hart SL, Danke-Roelse JE, Sloper JJ, 
Hull S, Hogg C, Emes RD, Pals G, Moore AT, Chung EM; UK10K, Mitchison HM. 
Combined exome and whole-genome sequencing identifies mutations in ARMC4 as a 
cause of primary ciliary dyskinesia with defects in the outer dynein arm. J Med 
Genet. 2014;51(1):61-7. 
Co-author in press: 
Parfitt DA, Lane A, Ramsden CM, Carr AJF, Munro PM, Jovanovic K, Schwarz N, 
Kanuga N, Muthiah MN, Hull S,  Gallo JM, da Cruz L, Moore AT, Hardcastle AJ, Coffey 
PJ, Cheetham ME. Patient-derived iPSC three-dimensional optic cups to test disease 
mechanisms and RNA therapy for inherited blindness. Cell Stem Cell. 
Islam F, Hull S, Quereshi N, Mansfield DC, Moore AT, Bird A. Unusual Retinal 
Vascular proliferation in von Hippel-Lindau disease. JAMA Ophthalmol. 
 
